<SEC-DOCUMENT>0001144204-18-058039.txt : 20181107
<SEC-HEADER>0001144204-18-058039.hdr.sgml : 20181107
<ACCEPTANCE-DATETIME>20181107171930
ACCESSION NUMBER:		0001144204-18-058039
CONFORMED SUBMISSION TYPE:	1-A/A
PUBLIC DOCUMENT COUNT:		9
FILED AS OF DATE:		20181107
DATE AS OF CHANGE:		20181107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Glucose Biosensor Systems (Greater China) Holdings, Inc.
		CENTRAL INDEX KEY:			0001725430
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				821512711
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		1-A/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	024-10911
		FILM NUMBER:		181167410

	BUSINESS ADDRESS:	
		STREET 1:		733 THIRD AVENUE
		STREET 2:		FLOOR 15
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		646-790-5756

	MAIL ADDRESS:	
		STREET 1:		733 THIRD AVENUE
		STREET 2:		FLOOR 15
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
</SEC-HEADER>
<DOCUMENT>
<TYPE>1-A/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?>
<edgarSubmission xmlns="http://www.sec.gov/edgar/rega/oneafiler" xmlns:ns1="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>1-A/A</submissionType>
    <filerInfo>
      <liveTestFlag>LIVE</liveTestFlag>
      <filer>
        <issuerCredentials>
          <cik>0001725430</cik>
          <ccc>XXXXXXXX</ccc>
        </issuerCredentials>
        <offeringFileNumber>024-10911</offeringFileNumber>
      </filer>
      <flags>
        <sinceLastFiling>true</sinceLastFiling>
      </flags>
    </filerInfo>
  </headerData>
  <formData>
    <employeesInfo>
      <issuerName>Glucose Biosensor Systems (Greater China) Holdings, Inc.</issuerName>
      <jurisdictionOrganization>DE</jurisdictionOrganization>
      <yearIncorporation>2016</yearIncorporation>
      <cik>0001725430</cik>
      <sicCode>3829</sicCode>
      <irsNum>82-1512711</irsNum>
      <fullTimeEmployees>1</fullTimeEmployees>
      <partTimeEmployees>2</partTimeEmployees>
    </employeesInfo>
    <issuerInfo>
      <street1>733 Third Avenue</street1>
      <street2>Floor 15</street2>
      <city>New York</city>
      <stateOrCountry>NY</stateOrCountry>
      <zipCode>10017</zipCode>
      <phoneNumber>646-790-5756</phoneNumber>
      <connectionName>Gary Simon</connectionName>
      <industryGroup>Other</industryGroup>
      <cashEquivalents>418420.00</cashEquivalents>
      <investmentSecurities>0.00</investmentSecurities>
      <accountsReceivable>0.00</accountsReceivable>
      <propertyPlantEquipment>0.00</propertyPlantEquipment>
      <totalAssets>2495923.00</totalAssets>
      <accountsPayable>5559617.00</accountsPayable>
      <longTermDebt>0.00</longTermDebt>
      <totalLiabilities>5559617.00</totalLiabilities>
      <totalStockholderEquity>-3063694.00</totalStockholderEquity>
      <totalLiabilitiesAndEquity>2495923.00</totalLiabilitiesAndEquity>
      <totalRevenues>564.00</totalRevenues>
      <costAndExpensesApplToRevenues>5057339.00</costAndExpensesApplToRevenues>
      <depreciationAndAmortization>0.00</depreciationAndAmortization>
      <netIncome>-5056775.00</netIncome>
      <earningsPerShareBasic>-0.61</earningsPerShareBasic>
      <earningsPerShareDiluted>-0.61</earningsPerShareDiluted>
      <nameAuditor>BDO East Coast Partnership</nameAuditor>
    </issuerInfo>
    <commonEquity>
      <commonEquityClassName>Common Stock</commonEquityClassName>
      <outstandingCommonEquity>8250000</outstandingCommonEquity>
      <commonCusipEquity>0000000NA</commonCusipEquity>
      <publiclyTradedCommonEquity>0000000NA</publiclyTradedCommonEquity>
    </commonEquity>
    <preferredEquity>
      <preferredEquityClassName>Series A Preferred</preferredEquityClassName>
      <outstandingPreferredEquity>1222506</outstandingPreferredEquity>
      <preferredCusipEquity>0000000NA</preferredCusipEquity>
      <publiclyTradedPreferredEquity>0000000NA</publiclyTradedPreferredEquity>
    </preferredEquity>
    <debtSecurities>
      <debtSecuritiesClassName>Convertible Notes</debtSecuritiesClassName>
      <outstandingDebtSecurities>7036075</outstandingDebtSecurities>
      <cusipDebtSecurities>0000000NA</cusipDebtSecurities>
      <publiclyTradedDebtSecurities>0000000NA</publiclyTradedDebtSecurities>
    </debtSecurities>
    <issuerEligibility>
      <certifyIfTrue>true</certifyIfTrue>
    </issuerEligibility>
    <applicationRule262>
      <certifyIfNotDisqualified>true</certifyIfNotDisqualified>
    </applicationRule262>
    <summaryInfo>
      <indicateTier1Tier2Offering>Tier2</indicateTier1Tier2Offering>
      <financialStatementAuditStatus>Audited</financialStatementAuditStatus>
      <securitiesOfferedTypes>Equity (common or preferred stock)</securitiesOfferedTypes>
      <offerDelayedContinuousFlag>Y</offerDelayedContinuousFlag>
      <offeringYearFlag>N</offeringYearFlag>
      <offeringAfterQualifFlag>N</offeringAfterQualifFlag>
      <offeringBestEffortsFlag>Y</offeringBestEffortsFlag>
      <solicitationProposedOfferingFlag>N</solicitationProposedOfferingFlag>
      <resaleSecuritiesAffiliatesFlag>N</resaleSecuritiesAffiliatesFlag>
      <securitiesOffered>2083334</securitiesOffered>
      <outstandingSecurities>8250000</outstandingSecurities>
      <pricePerSecurity>12.0000</pricePerSecurity>
      <issuerAggregateOffering>25000000.00</issuerAggregateOffering>
      <securityHolderAggegate>0.00</securityHolderAggegate>
      <qualificationOfferingAggregate>0.00</qualificationOfferingAggregate>
      <concurrentOfferingAggregate>0.00</concurrentOfferingAggregate>
      <totalAggregateOffering>25000000.00</totalAggregateOffering>
      <underwritersServiceProviderName>Cuttone &amp; Co., LLC</underwritersServiceProviderName>
      <underwritersFees>1750000.00</underwritersFees>
      <auditorServiceProviderName>BDO East Coast Partnership</auditorServiceProviderName>
      <auditorFees>100000.00</auditorFees>
      <legalServiceProviderName>Hughes Hubbard &amp; Reed LLP</legalServiceProviderName>
      <legalFees>250000.00</legalFees>
      <brokerDealerCrdNumber>33038</brokerDealerCrdNumber>
      <estimatedNetAmount>22500000.00</estimatedNetAmount>
      <clarificationResponses>Based on maximum offering of $25,000,000 and includes sales commissions, audit, legal and miscellaneous other expenses totaling $2,500,000.</clarificationResponses>
    </summaryInfo>
    <juridictionSecuritiesOffered>
      <jurisdictionsOfSecOfferedSame>true</jurisdictionsOfSecOfferedSame>
      <issueJuridicationSecuritiesOffering>AL</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>AK</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>AZ</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>AR</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>CA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>CO</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>CT</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>DE</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>FL</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>GA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>HI</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>ID</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>IL</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>IN</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>IA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>KS</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>KY</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>LA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>ME</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MD</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MI</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MN</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MS</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MO</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>MT</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NE</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NV</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NH</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NJ</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NM</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NY</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>NC</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>ND</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>OH</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>OK</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>OR</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>PA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>RI</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>SC</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>SD</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>TN</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>TX</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>UT</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>VT</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>VA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>WA</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>WV</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>WI</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>WY</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>DC</issueJuridicationSecuritiesOffering>
      <issueJuridicationSecuritiesOffering>PR</issueJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>AL</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>AK</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>AZ</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>AR</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>CA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>CO</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>CT</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>DE</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>FL</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>GA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>HI</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>ID</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>IL</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>IN</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>IA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>KS</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>KY</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>LA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>ME</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MD</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MI</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MN</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MS</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MO</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>MT</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NE</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NV</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NH</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NJ</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NM</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NY</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>NC</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>ND</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>OH</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>OK</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>OR</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>PA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>RI</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>SC</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>SD</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>TN</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>TX</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>UT</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>VT</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>VA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>WA</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>WV</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>WI</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>WY</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>DC</dealersJuridicationSecuritiesOffering>
      <dealersJuridicationSecuritiesOffering>PR</dealersJuridicationSecuritiesOffering>
    </juridictionSecuritiesOffered>
    <securitiesIssued>
      <securitiesIssuerName>Glucose Biosensor Systems (Greater China) Holdings, Inc.</securitiesIssuerName>
      <securitiesIssuerTitle>Series A Convertible Preferred Stock $0.01 par value</securitiesIssuerTitle>
      <securitiesIssuedTotalAmount>1222506</securitiesIssuedTotalAmount>
      <securitiesPrincipalHolderAmount>0</securitiesPrincipalHolderAmount>
      <securitiesIssuedAggregateAmount>$8,715,793</securitiesIssuedAggregateAmount>
    </securitiesIssued>
    <securitiesIssued>
      <securitiesIssuerName>Glucose Biosensor Systems (Greater China) Pty Ltd.</securitiesIssuerName>
      <securitiesIssuerTitle>Convertible Notes (Convertible into shares of common stock of Glucose Biosensor Systems (Greater China) Holdings, Inc.)</securitiesIssuerTitle>
      <securitiesIssuedTotalAmount>7036075</securitiesIssuedTotalAmount>
      <securitiesPrincipalHolderAmount>0</securitiesPrincipalHolderAmount>
      <securitiesIssuedAggregateAmount>$5,277,056</securitiesIssuedAggregateAmount>
    </securitiesIssued>
    <unregisteredSecuritiesAct>
      <securitiesActExcemption>Regulation S</securitiesActExcemption>
    </unregisteredSecuritiesAct>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>PART II AND III
<SEQUENCE>2
<FILENAME>tv506394_partiiandiii.htm
<DESCRIPTION>PART II AND III
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify"><B>&nbsp;</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PART II PRELIMINARY OFFERING CIRCULAR - FORM
1-A: TIER 2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: red"><B>An offering statement pursuant
to Regulation A relating to these securities has been filed with the United States Securities and Exchange Commission. Information
contained in this Preliminary Offering Circular is subject to completion or amendment. These securities may not be sold nor may
offers to buy be accepted before the offering statement filed with the United States Securities and Exchange Commission is qualified.
This Preliminary Offering Circular shall not constitute an offer to sell or the solicitation of an offer to buy nor may there be
any sales of these securities in any state in which such offer, solicitation or sale would be unlawful before registration or qualification
under the laws of any such state. We may elect to satisfy our obligation to deliver a Final Offering Circular by sending you a
notice within two business days after the completion of our sale to you that contains the URL where the Final Offering Circular
or the offering statement in which such Final Offering Circular was filed may be obtained.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: red"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0"> <FONT STYLE="font-size: 10pt; color: red"><B>Preliminary
                                         Offering Circular</B></FONT> </P>
                                            <P STYLE="margin-top: 0; margin-bottom: 0"> <FONT STYLE="font-size: 10pt; color: red"><B>(Subject
                                         to Completion)</B></FONT> </P></TD>
    <TD STYLE="width: 50%; font-size: 10pt; text-align: right"> <FONT STYLE="font-size: 10pt; color: red"><B>Dated: November
    7, 2018</B></FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>GLUCOSE BIOSENSOR
SYSTEMS<BR>
(GREATER CHINA) HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$9,000,000 MINIMUM OFFERING AMOUNT
(750,000 SHARES OF COMMON STOCK)&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>$25,000,000 MAXIMUM OFFERING AMOUNT (2,083,334
SHARES OF COMMON STOCK)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This is the initial public offering
of securities of Glucose Biosensor Systems (Greater China) Holdings, Inc., a Delaware corporation (the &ldquo;Company,&rdquo;
 &ldquo;we,&rdquo; &ldquo;our&rdquo; and &ldquo;us&rdquo;). We are offering a minimum of 750,000 and a maximum of 2,083,334 shares
(the &ldquo;Shares&rdquo;) of our common stock, par value $0.01 (&ldquo;Common Stock&rdquo;), at an offering price of $12.00 per
share for a minimum offering amount of $9,000,000 and a maximum offering amount of $25,000,000 (the &ldquo;Offering&rdquo;). The
Offering will terminate on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018, subject to extension by us for up to
thirty (30) days; provided that, if we have received and accepted subscriptions for the minimum number of Shares on or before
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018, or the end of the thirty (30) day extension, if exercised, then
the Company will close on the minimum offering amount (the &ldquo;Initial Closing&rdquo;) and this offering will continue until
the earlier of (i) the date which is sixty (60) days after the Initial Closing, or (ii) the date on which the maximum offering
amount is sold (such earlier date, the &ldquo;Termination Date&rdquo;). If, on the Initial Closing date, we have sold less than
the maximum number of Shares, then we may hold one or more additional closings to sell additional Shares (each, an &ldquo;Additional
Closing&rdquo;), until the earlier of: (i) the sale of the maximum number of Shares or (ii) the Termination Date.</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Until we achieve the minimum offering
amount, the proceeds for the Offering will be kept in an escrow account. Upon achievement of the minimum offering amount and the
closing on such amount, the proceeds from the minimum offering amount will be distributed to the Company and the associated Shares
will be issued to the investors in the Initial Closing. If the Offering does not close on or before &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2018 for any reason, the proceeds for the Offering will be promptly returned to investors, without deduction and without interest.
Prime Trust, LLC (&ldquo;Prime Trust&rdquo; or &ldquo;Escrow Agent&rdquo;), 2300 West Sahara, Suite 1170, Las Vegas, NV 89102,
will serve as the escrow agent. Prime Trust is a &ldquo;bank&rdquo; under SEC Rule 15c2-4. The minimum purchase requirement per
investor is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares $(&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;);
however, we can waive the minimum purchase requirement on a case-by-case basis in our sole discretion.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have engaged Cuttone &amp; Co., LLC
as our placement agent (the &ldquo;Placement Agent&rdquo;) to offer the Shares to prospective investors on a &ldquo;best efforts
basis, minimum-maximum&rdquo; basis, and our Placement Agent will have the right to engage such other Financial Industry Regulatory
Authority, Inc. (&ldquo;FINRA&rdquo;) member firms as it deems appropriate to assist in the offering. We expect to commence the
sale of the Shares as of the date on which the offering statement of which this Offering Circular is a part (the &ldquo;Offering
Statement&rdquo;), is qualified by the United States Securities and Exchange Commission (the &ldquo;SEC&rdquo;). Prior to this
offering, there has been no public market for our Common Stock. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have applied to list our Common Stock on
The Nasdaq Stock Market (&ldquo;Nasdaq&rdquo;) under the symbol &ldquo;GBSG&rdquo;. We expect our Common Stock to begin trading
on Nasdaq upon consummation of the Offering; provided that we have met the minimum listing criteria of Nasdaq. There is no assurance
that this application will be approved, or that a market for our Shares will develop. Our Common Stock will not commence trading
on Nasdaq, however, unless and until (i) this Offering is closed in an amount sufficient to meet the minimum listing criteria of
Nasdaq, including having a market value of shares sold in this Offering of at least $15 million in accordance with Nasdaq rules;
(ii) this Offering is terminated and (iii) we have filed a post-qualification amendment to the Offering Statement, and a registration
statement on Form 8-A (&ldquo;Form 8-A&rdquo;) under the Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), and
such post-qualification amendment is qualified by the SEC and the Form 8-A has become effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 5, 2017, the Company effected
a stock split of one to 90,000 shares resulting in 9,000,000 issued and outstanding shares of common stock as of that date and
the date hereof. On August 9, 2018, the Company effected a reverse stock split of approximately one
to 0.9167 shares that resulted in the Company having 8,250,000 issued and outstanding shares of common stock. Share and per
share amounts set forth herein (except in any historical financial information) give effect to the reverse split, unless indicated
otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following this offering, we will be a &ldquo;controlled
company&rdquo; within the meaning of the corporate governance rules of Nasdaq. See &ldquo;Management.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are an &ldquo;emerging growth company&rdquo;
as defined in the Jumpstart Our Business Startups Act, or the JOBS Act, and, as such, may elect to comply with certain reduced
reporting requirements for this Offering Circular and future filings after this Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Investing in our Common Stock involves
a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page 17 for a discussion of certain risks that you should carefully
consider in connection with an investment in our Common Stock. An investment in this company should only be made if you are capable
of evaluating the risks and merits of this investment and if you have sufficient resources to bear the entire loss of your investment.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: justify; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross Proceeds</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Placement Agent<BR>
    Commissions (1)(2)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Proceeds to the<BR>
    Company (3)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; font-weight: bold; text-align: justify">Total Minimum(4)</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 15%; font-weight: bold; text-align: right">9,000,000</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 15%; font-weight: bold; text-align: right">630,000</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 15%; font-weight: bold; text-align: right">7,620,000</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">Total Maximum</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">25,000,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">1,750,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">22,500,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">(1)&nbsp;Represents
placement agent commissions equal to 7.0% per share (or $0.84 per share) payable to the Placement Agent in connection with this
offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">(2) Does
not include a non-accountable expense allowance equal to 0.75% of the gross proceeds of this offering, payable to the Placement
Agent, nor does it include the reimbursement of up to $150,000 in expenses incurred by the Placement Agent in connection with
this offering. We have agreed to issue to the Placement Agent warrants to purchase shares of common stock equal to 5% of the total
number of Shares sold in this offering, and to grant the Placement Agent certain indemnification and advancement rights. See &ldquo;Plan
of Distribution&rdquo; beginning on page  52 of this Offering Circular for additional information regarding total Placement
Agent compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">(3) Includes estimated
total offering expenses, which are expected to be approximately $750,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">(4) Sales of
Shares, if any, to affiliates of, and persons associated with, the Underwriter, the Dealers and the Company will be included
for purposes of satisfying the Minimum Offering Amount. See &ldquo;Plan of Distribution.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Generally, no sale may be made to you in
this offering if the aggregate purchase price you pay is more than 10% of the greater of your annual income or your net worth.
Different rules apply to accredited investors and non-natural persons. Before making any representation that your investment does
not exceed applicable thresholds, we encourage you to review Rule 251(d)(2)(i)(C) of Regulation A. For general information on investing,
we encourage you to refer to investor.gov.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>THE UNITED STATES SECURITIES AND EXCHANGE
COMMISSION DOES NOT PASS UPON THE MERITS OF OR GIVE ITS APPROVAL TO ANY SECURITIES OFFERED OR THE TERMS OF THE OFFERING, NOR DOES
IT PASS UPON THE ACCURACY OR COMPLETENESS OF ANY OFFERING CIRCULAR OR OTHER SELLING LITERATURE. THESE SECURITIES ARE OFFERED PURSUANT
TO AN EXEMPTION FROM REGISTRATION WITH THE COMMISSION; HOWEVER, THE COMMISSION HAS NOT MADE AN INDEPENDENT DETERMINATION THAT THE
SECURITIES OFFERED HEREUNDER ARE EXEMPT FROM REGISTRATION.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">This Offering Circular follows the disclosure
format prescribed by Part I of Form S-1 pursuant to the general instructions of Part II(a)(1)(ii) of Form 1-A.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Cuttone &amp;
Co., LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The date of this Offering Circular is&nbsp;_____,
2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>AN OFFERING STATEMENT PURSUANT TO REGULATION
A RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. INFORMATION CONTAINED IN THIS PRELIMINARY
OFFERING CIRCULAR IS SUBJECT TO COMPLETION OR AMENDMENT. THESE SECURITIES MAY NOT BE SOLD NOR MAY OFFERS TO BUY BE ACCEPTED BEFORE
THE OFFERING STATEMENT FILED WITH THE COMMISSION IS QUALIFIED. THIS PRELIMINARY OFFERING CIRCULAR SHALL NOT CONSTITUTE AN OFFER
TO SELL OR THE SOLICITATION OF AN OFFER TO BUY NOR MAY THERE BE ANY SALES OF THESE SECURITIES IN ANY STATE IN WHICH SUCH OFFER,
SOLICITATION OR SALE WOULD BE UNLAWFUL BEFORE REGISTRATION OR QUALIFICATION UNDER THE LAWS OF ANY SUCH STATE. WE MAY ELECT TO SATISFY
OUR OBLIGATION TO DELIVER A FINAL OFFERING CIRCULAR BY SENDING YOU A NOTICE WITHIN TWO BUSINESS DAYS AFTER THE COMPLETION OF OUR
SALE TO YOU THAT CONTAINS THE URL WHERE THE FINAL OFFERING CIRCULAR OR THE OFFERING STATEMENT IN WHICH SUCH FINAL OFFERING CIRCULAR
WAS FILED MAY BE OBTAINED.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>THIS OFFERING CIRCULAR DOES NOT CONSTITUTE
AN OFFER OR SOLICITATION IN ANY JURISDICTION IN WHICH SUCH AN OFFER OR SOLICITATION WOULD BE UNLAWFUL. NO PERSON HAS BEEN AUTHORIZED
TO GIVE ANY INFORMATION OR TO MAKE ANY REPRESENTATIONS CONCERNING THE COMPANY OTHER THAN THOSE CONTAINED IN THIS OFFERING CIRCULAR,
AND IF GIVEN OR MADE, SUCH OTHER INFORMATION OR REPRESENTATION MUST NOT BE RELIED UPON.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>PROSPECTIVE INVESTORS ARE NOT TO CONSTRUE
THE CONTENTS OF THIS OFFERING CIRCULAR, OR OF ANY PRIOR OR SUBSEQUENT COMMUNICATIONS FROM THE COMPANY OR ANY OF ITS EMPLOYEES,
AGENTS OR AFFILIATES, AS INVESTMENT, LEGAL, FINANCIAL OR TAX ADVICE.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>BEFORE INVESTING IN THIS OFFERING, PLEASE
REVIEW ALL DOCUMENTS CAREFULLY, ASK ANY QUESTIONS OF THE COMPANY&rsquo;S MANAGEMENT THAT YOU WOULD LIKE ANSWERED AND CONSULT YOUR
OWN COUNSEL, ACCOUNTANT AND OTHER PROFESSIONAL ADVISORS AS TO LEGAL, TAX AND OTHER RELATED MATTERS CONCERNING THIS INVESTMENT.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NASAA UNIFORM LEGEND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>FOR RESIDENTS OF ALL STATES: THE PRESENCE
OF A LEGEND FOR ANY GIVEN STATE REFLECTS ONLY THAT A LEGEND MAY BE REQUIRED BY THAT STATE AND SHOULD NOT BE CONSTRUED TO MEAN AN
OFFER OR SALE MAY BE MADE IN A PARTICULAR STATE. IF YOU ARE UNCERTAIN AS TO WHETHER OR NOT OFFERS OR SALES MAY BE LAWFULLY MADE
IN ANY GIVEN STATE, YOU ARE HEREBY ADVISED TO CONTACT THE COMPANY. THE SECURITIES DESCRIBED IN THIS OFFERING CIRCULAR HAVE NOT
BEEN REGISTERED UNDER ANY STATE SECURITIES LAWS (COMMONLY CALLED &ldquo;BLUE SKY&rdquo; LAWS).</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>IN MAKING AN INVESTMENT DECISION INVESTORS
MUST RELY ON THEIR OWN EXAMINATION OF THE PERSON OR ENTITY CREATING THE SECURITIES AND THE TERMS OF THE OFFERING, INCLUDING THE
MERITS AND RISKS INVOLVED. THESE SECURITIES HAVE NOT BEEN RECOMMENDED BY ANY FEDERAL OR STATE SECURITIES COMMISSION OR REGULATORY
AUTHORITY. FURTHERMORE, THE FOREGOING AUTHORITIES HAVE NOT CONFIRMED THE ACCURACY OR DETERMINED THE ADEQUACY OF THIS DOCUMENT.
ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTICE TO FOREIGN INVESTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>IF THE PURCHASER LIVES OUTSIDE THE UNITED
STATES, IT IS THE PURCHASER&rsquo;S RESPONSIBILITY TO FULLY OBSERVE THE LAWS OF ANY RELEVANT TERRITORY OR JURISDICTION OUTSIDE
THE UNITED STATES IN CONNECTION WITH ANY PURCHASE OF THE SECURITIES, INCLUDING OBTAINING REQUIRED GOVERNMENTAL OR OTHER CONSENTS
OR OBSERVING ANY OTHER REQUIRED LEGAL OR OTHER FORMALITIES. THE COMPANY RESERVES THE RIGHT TO DENY THE PURCHASE OF THE SECURITIES
BY ANY FOREIGN PURCHASER.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_009" TITLE="Forward Looking Statement"></A>Forward Looking Statement Disclosure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Form 1-A, Offering
Circular, and any documents incorporated by reference herein or therein contain forward-looking statements and are subject to risks
and uncertainties. All statements other than statements of historical fact or relating to present facts or current conditions included
in this Form 1-A, Offering Circular, and any documents incorporated by reference are forward-looking statements. Forward-looking
statements give the Company&rsquo;s current reasonable expectations and projections relating to its financial condition, results
of operations, plans, objectives, future performance and business. You can identify forward- looking statements by the fact that
they do not relate strictly to historical or current facts. These statements may include words such as &lsquo;&lsquo;anticipate,&rdquo;
 &lsquo;&lsquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;project,&rdquo; &ldquo;plan,&rdquo; &ldquo;intend,&rdquo; &ldquo;believe,&rdquo;
 &ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;can have,&rdquo; &ldquo;likely&rdquo; and other words and terms of similar meaning
in connection with any discussion of the timing or nature of future operating or financial performance or other events. The forward-looking
statements contained in this Form 1-A, Offering Circular, and any documents incorporated by reference herein or therein are based
on reasonable assumptions the Company has made in light of its industry experience, perceptions of historical trends, current conditions,
expected future developments and other factors it believes are appropriate under the circumstances. As you read and consider this
Form 1-A, Offering Circular, and any documents incorporated by reference, you should understand that these statements are not guarantees
of performance or results. They involve risks, uncertainties (many of which are beyond the Company&rsquo;s control) and assumptions.
Although the Company believes that these forward-looking statements are based on reasonable assumptions, you should be aware that
many factors could affect its actual operating and financial performance and cause its performance to differ materially from the
performance anticipated in the forward-looking statements. Should one or more of these risks or uncertainties materialize, or should
any of these assumptions prove incorrect or change, the Company&rsquo;s actual or uncertainties materialize, or should any of these
assumptions prove incorrect or change, the Company&rsquo;s actual operating and financial performance may vary in material respects
from the performance projected in these forward-looking statements. Any forward-looking statement made by the Company in this Form
1-A, Offering Circular or any documents incorporated by reference herein speaks only as of the date of this Form 1-A, Offering
Circular or any documents incorporated by reference herein. Factors or events that could cause our actual operating and financial
performance to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company
undertakes no obligation to update any forward-looking statement, whether as a result of new information, future developments or
otherwise, except as may be required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>About This Form 1-A and Offering Circular</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In making an investment
decision, you should rely only on the information contained in this Form 1-A and Offering Circular. The Company has not authorized
anyone to provide you with information different from that contained in this Form 1-A and Offering Circular. We are offering to
sell, and seeking offers to buy the Shares only in jurisdictions where offers and sales are permitted. You should assume that the
information contained in this Form 1-A and Offering Circular is accurate only as of the date of this Form 1-A and Offering Circular,
regardless of the time of delivery of this Form 1-A and Offering Circular. Our business, financial condition, results of operations,
and prospects may have changed since that date. Statements contained herein as to the content of any agreements or other documents
are summaries and, therefore, are necessarily selective and incomplete and are qualified in their entirety by the actual agreements
or other documents. The Company will provide the opportunity to ask questions of and receive answers from the Company&rsquo;s management
concerning terms and conditions of the Offering, the Company or any other relevant matters and any additional reasonable information
to any prospective investor prior to the consummation of the sale of the Shares. This Form 1-A and Offering Circular do not purport
to contain all of the information that may be required to evaluate the Offering and any recipient hereof should conduct its own
independent analysis. The statements of the Company contained herein are based on information believed to be reliable. No warranty
can be made as to the accuracy of such information or that circumstances have not changed since the date of this Form 1-A and Offering
Circular. The Company does not expect to update or otherwise revise this Form 1-A, Offering Circular or other materials supplied
herewith. The delivery of this Form 1-A and Offering Circular at any time does not imply that the information contained herein
is correct as of any time subsequent to the date of this Form 1- A and Offering Circular. This Form 1-A and Offering Circular are
submitted in connection with the Offering described herein and may not be reproduced or used for any other purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are offering to sell,
and seeking offers to buy, the Shares only in jurisdictions where such offers and sales are permitted. You should rely only on
the information contained in this Offering Circular. We have not authorized anyone to provide you with any information other than
the information contained in this Offering Circular. The information contained in this Offering Circular is accurate only as of
its date, regardless of the time of its delivery or of any sale or delivery of our securities. Neither the delivery of this Offering
Circular nor any sale or delivery of our securities shall, under any circumstances, imply that there has been no change in our
affairs since the date of this Offering Circular. This Offering Circular will be updated and made available for delivery to the
extent required by the federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated,
data contained in this Offering Circular concerning the glucose monitoring market and the other markets relevant to our operations
are based on information from various public sources. Although we believe that this data is generally reliable, such information
is inherently imprecise, and our estimates and expectations based on these data involve a number of assumptions and limitations.
As a result, you are cautioned not to give undue weight to such data, estimates or expectations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>TABLE OF CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 92%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORWARD
    LOOKING STATEMENT DISCLOSURE</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_009">4</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#partii_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OFFERING
    SUMMARY AND RISK FACTORS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#partii_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#partii_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OFFERING
    SUMMARY</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#partii_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#partii_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE
    OFFERING</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#partii_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#partii_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK
    FACTORS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#partii_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#partii_0022">CAPITALIZATION</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#partii_0022">49</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#partii_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DILUTION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#partii_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN
    OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_007">52</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#partii_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE
    OF PROCEEDS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#partii_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#partii_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION
    OF BUSINESS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#partii_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#partii_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MANAGEMENT&rsquo;S
    DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#partii_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#partii_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MANAGEMENT</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#partii_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#partii_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECURITY
    OWNERSHIP OF MANAGEMENT AND CERTAIN SECURITYHOLDERS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#partii_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#partii_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INTEREST
    OF MANAGEMENT AND OTHERS IN CERTAIN TRANSACTIONS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#partii_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">91</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#partii_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION
    OF OUR SECURITIES</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#partii_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">92</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#partii_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIVIDEND
    POLICY</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#partii_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#partii_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SHARES
    ELIGIBLE FOR FUTURE SALE</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#partii_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#partii_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DISQUALIFYING
    EVENTS DISCLOSURE</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#partii_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#partii_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ERISA
    CONSIDERATIONS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#partii_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#partii_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INVESTOR
    ELIGIBILITY STANDARDS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#partii_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#partii_018"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL
    MATTERS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#partii_018"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#partii_019"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#partii_019"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#partii_020"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE
    YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#partii_020"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#partii_021">FINANCIAL
    STATEMENTS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#partii_021">F-1</A></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: center; text-indent: -0.3in"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_001"></A>OFFERING
SUMMARY AND RISK FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_002"></A>OFFERING
SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>The following summary
is qualified in its entirety by the more detailed information appearing elsewhere in this Offering Circular and/or incorporated
by reference in this Offering Circular. For full offering details, please (1) thoroughly review this Form 1-A filed with the Securities
and Exchange Commission (2) thoroughly review this Offering Circular and (3) thoroughly review any attached documents to or documents
referenced in, this Form 1-A and Offering Circular.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>This summary highlights
information contained in other parts of this Offering Circular. Because it is a summary, it does not contain all of the information
that you should consider in making your investment decision. Before investing in our securities, you should read the entire Offering
Circular carefully, including our consolidated financial statements and the related notes included in this Offering Circular and
the information set forth under the headings &ldquo;Risk Factors&rdquo; and &ldquo;Management&rsquo;s Discussion and Analysis
of Financial Condition and Results of Operations.&rdquo; When used herein, unless the context requires otherwise, references to
the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;our&rdquo; and &ldquo;us&rdquo; refer to Glucose Biosensor Systems (Greater
China) Holdings, Inc., a Delaware corporation, collectively with its subsidiaries, Glucose Biosensor Systems (Greater China),
Inc., a Delaware corporation and Glucose Biosensor Systems (Greater China) Pty Ltd, an Australian corporation.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>On November 5, 2017,
the Company effected a stock split of one to 90,000 shares resulting in 9,000,000 issued and outstanding shares of common stock
as of that date and the date hereof. On August 9, 2018, the Company effected a reverse
stock split of approximately one to 0.9167 shares that resulted in the Company having 8,250,000 issued and outstanding shares
of common stock. Share and per share amounts set forth herein (except in any historical financial information) give effect to
the reverse split, unless indicated otherwise.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Our Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="tv506394_img01.jpg" ALT="" STYLE="width: 657px; height: 197px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">For illustrative purposes only &ndash; not
Company products</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>General</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are a development stage
medical device company with licensed rights to commercialize a novel &ldquo;smart&rdquo; biosensor salivary glucose monitoring
system (the &ldquo;GBS System&rdquo;) in the greater China region (the &ldquo;China Region&rdquo;), comprised of Mainland China,
Hong Kong, Vietnam and Bangladesh. We were formed on December 5, 2016, as a Delaware corporation with headquarters in New York
City.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are a wholly-owned subsidiary
of Life Science Biosensor Diagnostics Pty Ltd (&ldquo;LSBD&rdquo;), an Australian company that acquired the worldwide intellectual
property rights to the biosensor platform from the University of Newcastle, Australia. LSBD has licensed to us that technology
for us to commercialize the GBS System in the China Region.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>The GBS System</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The basic components of
the GBS System are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>The Biosensor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The technology in development
is a single-use organic biosensor that reacts with saliva and initiates an electrochemical reaction, producing a detectable electrical
signal that is proportional to the glucose present in the sample and converted by a smart device into a real-time saliva glucose
reading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Dedicated digital health care application</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our digital health care
application will be designed to enable user interaction, data interface, storage, analytics and patient support programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A major feature of the
GBS System will be its ability to detect glucose in saliva, obviating the need for patients or consumers to perform frequent finger
punctures as required by conventional blood glucose measurement techniques.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The GBS System is being
designed such that when the GBS System&rsquo;s single-use organic biosensor interacts with saliva it initiates an electrochemical
reaction, producing a measurable electrical signal directly correlated to the amount of glucose present in the saliva. This measurement
is then converted into a real-time saliva glucose reading, by a smartphone or a dedicated reading &ldquo;smart&rdquo; device.
This data set would then be securely stored, in analyzed and/or raw form, in a non-relational database in the cloud, for further
evaluation and processing. This digital platform, combined with the clinically-relevant data, is designed to enable diabetics
to achieve better glucose control, including through an accumulation of lifestyle data, thereby helping prevent or delay long
term medical complications. This is summarized below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="tv506394_img02.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The GBS System is currently
in the development stage following feasibility work. The GBS System will require regulatory approval in the various jurisdictions
comprising the China Region. We believe that the GBS System&rsquo;s fabrication method will allow for printing at high volume
and low cost using existing technology. Certain proprietary components of the digital infrastructure required to support the GBS
System are in design and development planning stage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We contemplate that
the use of saliva-based sampling will make glucose monitoring more accessible to patients, as no painful intervention is necessary.
The intuitive interface with smart devices would enable analytical capabilities accessed through the data generated. These attributes
would be designed to unlock a broader opportunity in the personalized medicine sector of the healthcare industry in the China
Region, as illustrated below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="tv506394_img03.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We believe the methodology
of the GBS System will represent a breakthrough in glucose monitoring as it is a non-invasive, painless, scientifically valid
and cost-effective saliva-based method of measuring glucose levels. A number of reports over recent years have shown that there
is a direct relationship between blood glucose levels and the concentration of glucose in saliva. Glucose is present in saliva
at a concentration range of approximately 0.008 to 0.20 mM, which is considerably lower than the range of concentration for glucose
in blood, which is typically 3.3&ndash;8.3mM. The goal and our expectation for the GBS System is to use the technology to detect
those low concentrations of glucose, making it possible to measure the level of glucose and offer a path towards glucose monitoring
that is comparable to existing blood-based measurement. The biosensor exhibits linear glucose sensing at significantly greater
sensitivity than commercial blood glucose sensors, offering potential for the prospect of a saliva-based test for diabetic monitoring.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We intend to engage local
distributors in the China Region that will agree to stock, market, distribute and sell the GBS System across the region.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>Diabetes and The Importance of Glucose Monitoring</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Diabetes is the condition
in which the body does not properly process food for use as energy. Most of the food we eat is turned into glucose, or sugar, for
our bodies to use for energy. The pancreas, an organ that lies near the stomach, makes a hormone called insulin to help glucose
get into the cells of our bodies. When a person has diabetes, the body either does not make enough insulin or cannot use its own
insulin as well as it should. This causes sugars to build up in blood. Diabetes can cause serious health complications including
heart disease, blindness, kidney failure, and lower-extremity amputations. Self-monitoring of blood glucose is an important component
of modern therapy for diabetes and is recommended for people with diabetes by their health care professionals in order to achieve
normal levels of glycemia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Self-monitoring should
be part of a regular management plan for patients with diabetes. Self-monitoring provides information regarding an individual&rsquo;s
dynamic blood glucose profile. This information can help with the appropriate scheduling of food, activity, and medication. It
is also required for understanding of the timing of blood glucose variations. Lack of regular self-monitoring predicts hospitalization
for diabetes-related complications. Self-monitoring of blood glucose is an essential tool for people with diabetes who are taking
insulin or for those who experience fluctuations in their blood glucose levels, especially hypoglycemia. For patients taking insulin
and adjusting their dose, self-monitoring is needed for self-management. For others receiving oral medication, profiling glucose
trends and the confirmation of high or low blood glucose can be a useful addendum to successful management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>The Diabetes Market</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The economic growth of
China has had a major impact on the incidence of diabetes. China accounts for the fastest growing global market segment and has,
by a significant number, the largest diabetic population. In 2015, China alone had a similar number of people with diabetes as
the next 3 largest diabetes markets combined (India, USA and Brazil). China alone had 1.3 million deaths due to diabetes in 2015
(26% of total global deaths), with 41% of those deaths occurring in people under 60. The Journal of the American Medical Association
identified that out of 99,000 people surveyed in China, half had pre-diabetes blood glucose levels &ndash; abnormally high but
not high enough for a diagnosis of diabetes. The projections suggest that there are 493 million people with pre-diabetes in China.
Diabetes related health expenditure in China was $51 billion in 2015 and is expected to reach $72 billion by 2040.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The healthcare industry
in China is undergoing significant change, driven by ongoing healthcare reforms, the review of government policies and the introduction
and adoption of new technologies; in some cases even leading to the shift of screening for disease or symptoms of disease, from
health care providers to consumers, through wearable devices and software applications. Combined with China&rsquo;s aging population
and a healthcare infrastructure that has struggled to keep up with the pace of socioeconomic change, these changes create significant
opportunity in China to enhance efficiency through innovation. In the Chinese digital healthcare market alone, investment in 2020
in general disease management is expected to be $35 billion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>Our Technology</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>(Below &ndash; image of prototype)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="tv506394_img04.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The core innovation
of our business will be the ability to measure glucose in saliva non-invasively. The core technology is the biosensor that enables
the wider glucose management system. The biosensor technology is being built into a medical device that we expect to conform with
global medical device standards. The biosensor is based on a modified organic thin film transistor architecture incorporating
glucose oxidase as the recognition element. Through prototypes, the biosensor exhibits linear glucose sensing at concentrations
with greater sensitivity than commercial blood glucose sensors, offering potential for the prospect of a saliva-based test for
diabetic monitoring. It has been demonstrated that the biosensor exhibits sensitivity in the saliva glucose region of 8-200 uM.
The mechanism by which the glucose sensing occurs involves the diffusion of protons (generated by the enzymatic oxidation of glucose)
to, and subsequent doping of, the poly (3-hexythiophene) transistor channel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Through the deployment
of our digital ecosystem, we propose to enable an entire patient/user community providing educational resources, enabling patient
support groups and taking patient care beyond the health care provider&rsquo;s office. This would create a tool extending beyond
a simple stand-alone device, in essence a system that enables the patient to take greater control of their levels of glucose. This
would all be possible due to the following attributes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">No more multiple daily routine finger prick testing.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Programmable notifications and reminders.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Insight and practical understanding of factors that affect patient/user glucose levels.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The non-invasive attributes
of our technology, including the ability for real-time measurement and remote monitoring, could make it easier for a patient to
monitor their glucose levels. This means that we would have the potential to collect a greater amount of information from a larger
proportion of patients. This increased data flow would enable significant disease management opportunities to improve the way diabetes
is controlled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>The License Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In August 2017, the
Company entered into the Technology License Agreement with LSBD, as amended by the Variation Agreement to Technology License Agreement,
dated as December 8, 2017, the Second Variation Agreement to Technology License Agreement, dated as of April 18, 2018, and the
Third Variation Agreement to Technology License Agreement dated July 10, 2018 (as so amended to date, cumulatively, the &ldquo;License
Agreement&rdquo;), setting forth our contractual rights in and responsibilities relating to the saliva glucose biosensor system
for the China Region. The License Agreement includes the following summary terms:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">an exclusive license is granted to the Company covering certain glucose sensor intellectual property scheduled in the License Agreement and other data owned by LSBD, but solely to (i) hold regulatory marketing authorizations in the China Region, (ii) promote, market and import specific licensed products in the China Region, (iii) provide customer support on the licensed products in the China Region, (iv) use the licensed products in the China Region, and &nbsp;(v) collect data for LSBD regarding the use of the licensed products in the China Region;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the licensed products covered by the License Agreement are only those products that are procured
by the Company from authorized suppliers in the China Region under rights owned by LSBD;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the licensed rights do not cover digital or online use to users not physically in the China Region;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the licensed rights are limited to those expressly set forth in the License Agreement and are non-transferable,
non-assignable and non-sub-licensable, except that LSBD will in good faith consider any Company request for any sub-license;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         Company is required to meet specified performance milestones, including conducting clinical
                                         studies; obtaining regulatory approvals in the China Region within two years after the
                                         commencement of trading of the Shares on Nasdaq and within two years thereof placing
                                         orders with LSBD for a minimum number of products based on market growth, with annual
                                         increases; annually agree with LSBD as to that market growth; achieve annually that market
                                         share growth plus a minimum fixed percentage and quarterly orders with LSBD for products
                                         in quantities at that quarterly market share growth plus a minimum fixed percentage;
                                         conduct minimum marketing on standards reasonably determined by LSBD; and convert all
                                         glucose monitoring sales by the Company into glucose monitoring sales of the biosensor
                                         strip within five years; provided that (i) LSBD must supply all licensed product in accordance
                                         with the License Agreement, (ii) such product must be of merchantable quality and in
                                         accordance with local law, and (iii) certain end user data must be accessible to the
                                         Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">upon failure of any of these requirements, LSBD may require the Company to make cash payment of
the value of any shortfall and the failure to pay this amount within 14 business days will subject it to monthly compounding interest
at a rate of LIBOR plus 4%;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Company must notify LSBD of infringements of any licensed intellectual property and cooperate
with and as instructed by LSBD, at LSBD&rsquo;s expense, in preventing such infringement, but may take no other action regarding
infringement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Company must market, sell and distribute the licensed products in accordance with law and distribution
requirements set forth in the License Agreement, including delivering licensed products without inclusion of any other product,
only as supplied by LSBD, without changing LSBD&rsquo;s packaging or branding thereof and only in quantities as directed by LSBD;
complying with all regulations; and keeping specified records and batch samples relating to its activities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Company must file for and obtain all legal permits for marketing and selling the licensed products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Company must pay LSBD, subject to a monthly late charge, a one-time fixed license fee within
14 days of the obtaining of required regulatory approvals in China; fixed royalty percentages on the sale of specified licensed
products on sales of commercial units and certain other devices; application license fees and fees for patient education services,
all as determined from time to time by LSBD;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Company must obtain, retain and provide to LSBD certain end user and other data and notify
LSBD as to a variety of matters relating to the data, almost all of which data will be solely owned by LSBD, provided that the
Company will have rights to certain of the data during the term of the License Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">LSBD will own all of the right, title and interest in substantially all of the intellectual property
covered by the License Agreement and LSBD shall have the right to control the protection of that licensed intellectual property
as assisted by the Company, which shall have no rights to control or otherwise conduct protective activities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the parties generally agree to keep confidential, subject to customary exceptions, all confidential
information of the other party, subject to express exceptions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">except with respect to LSBD&rsquo;s ownership of all intellectual property rights in respect of
the licensed property and the non-infringement by the Company&rsquo;s exercise of those rights, LSBD provides no, and disclaims
all, representations, warranties or covenants relating to the licensed intellectual property or any other matters under the License
Agreement and in particular disclaims any fitness of the property for any purpose;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">LSBD
                                         is indemnified by the Company for any losses that may be incurred relating to any conduct,
                                         including any data collection or retention, by the Company under or relating to the License
                                         Agreement or the intellectual property under it, or any negligent or willful misconduct
                                         or violation of law by the Company, with no reciprocal indemnity; provided that LSBD
                                         indemnifies the Company for any losses arising that may be incurred related to (i) any
                                         third party claim that the exercise by the Company of its rights in respect of a licensed
                                         product violates its property or rights, and (ii) any regulatory or quality recall or
                                         any consumer or user claims or liability in relation to a licensed product (regardless
                                         of any contributory or comparative negligence of any Licensee Indemnitee), subject to
                                         contributory negligence; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                         term of the License Agreement runs until the final date of protection afforded to the
                                         patent portfolio covered by the License Agreement, which is currently until 2033, provided
                                         that either party may terminate the License Agreement earlier following any uncured material
                                         breach by the other party of it, the discontinuation of the other party&rsquo;s operations
                                         or an actual or prospective change in control of the other party, where change in control
                                         means, among other things, (i) any change of 50% ownership of outstanding common stock
                                         or voting rights, (ii) a merger resulting in a party&rsquo;s pre-merger voting securities
                                         failing to represent at least 50% of all voting power immediately post-merger, (iii)
                                         a sale of substantially all assets, (iv) solely with respect to the Company, without
                                         LSBD&rsquo;s prior approval a majority change in the composition of our board of directors
                                         (unless such change was pre-approved by our board, a nominating or other independent
                                         committee thereof) or (v) the dissolution or liquidation of the other party. In the event
                                         of a change in control of LSBD, LSBD must pay the Company an amount equal to the greater
                                         of the five-year projected net sales and five times the prior year&rsquo;s actual net
                                         sales of the Company, as adjusted depending on how much of the term of the License Agreement
                                         remains. No similar payment is required by the Company in the event of a change in control
                                         of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Upon
                                         the expiration, termination or cancellation of the License Agreement in any way, the following consequences are required (i) the cessation of substantially all
                                         of the Company&rsquo;s operations, (ii) the forfeiture to LSBD of substantially all of
                                         the Company&rsquo;s intellectual property, and (iii) the payment of due amounts, effectively
                                         threatening the Company&rsquo;s viability and otherwise having a material adverse effect
                                         on the Company and its business, assets and prospects.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preceding summary and
all other references to the License Agreement in this Offering Circular is subject to and you are encouraged to read the complete
text of the License Agreement, including variations, which are filed as exhibits to the Offering Statement of which this Offering
Circular is a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Risks We Face</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">An investment in our securities
involves a high degree of risk. You should carefully consider the risks summarized below. The risks are discussed more fully in
the &ldquo;Risk Factors&rdquo; section of this Offering Circular immediately following this Offering Circular summary. These risks
include, but are not limited to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We are controlled by our parent, LSBD, which owns the intellectual property rights to the biosensor platform that we license and is responsible for much of the development of the biosensor platform as well as the GBS System. The terms of the License Agreement present significant risks and payment and other obligations by us to LSBD.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Given our lack of revenue, we expect to need to raise additional capital, the availability to us of which on acceptable terms, if any, cannot be assured.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We may not generate revenue in the manner in which we anticipate. Further, we expect to incur losses for the foreseeable future.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The regulatory clearance processes in the China Region that we must navigate may be expensive, time-consuming, and uncertain and may prevent us from obtaining clearance for the commercialization of the GBS System or future product candidates, if any.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Our revenue is highly dependent on our principal product, which is yet to be approved, and, if approved, market acceptance of our product.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We are subject to the risk of reliance on third parties to manufacture and supply our product.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We are subject to the risk of reliance on third parties to distribute our product.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Our relationships with LSBD are related party transactions and include commercial and capital arrangements and obligations. Our intellectual property primarily will consist of the license, rather than the outright ownership, of intellectual property rights from LSBD, so that we may commercialize the GBS System in the China Region.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If we or LSBD are unable to successfully protect our intellectual property and proprietary rights, our competitive position will be harmed.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If others claim we or LSBD infringes on their intellectual property rights, we may be subject to costly and time-consuming litigation.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We face competition from companies that have greater resources than we do and we may not be able to effectively compete against these companies.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Commercialization Hurdles</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are a development
stage company formed in December 2016 as a new business and have not yet begun to commercialize our licensed technology or any
products. Our efforts to date have been organizational and formational, have depended on LSBD and its affiliates and have not
generated revenue, and it is still too early to predict if we will ever be able to generate revenues. Therefore, we are, and expect
for the foreseeable future to be, subject to all the risks and uncertainties inherent in a new business and the development and
sale of new medical devices and related software applications. We may be unable to fully develop, obtain regulatory approval for,
manufacture, market, sell and derive revenues from the GBS System and our inability to do so would materially and adversely impact
our viability. In addition, we still must establish many functions necessary to operate a business, including finalizing our managerial
and administrative structure, continuing product and technology development, assessing and commencing our marketing activities,
implementing financial systems and controls and personnel recruitment. This discussion of commercialization hurdles is subject
to and must be considered in the context of &ldquo;Risk Factors&rdquo; below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The GBS System is in
the development stage with the core biosensor within the GBS System having developed a functioning laboratory prototype of the
core biosensor (sensor strip and readout device). The development for the full GBS System, comprised of the sensor strip, dedicated
 &lsquo;smart&rsquo; reader device and smartphone application as a commercial grade medical device is in process. This Offering
is for preliminary financing toward pursuing further development and, if such development is successful, commercialization of
the GBS System. There are numerous hurdles required before commercialization will be possible, as to which there can be no assurances.
Those hurdles include, but are not limited to, and are not necessarily set forth in chronological order:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Additional Capital</U>. We expect that we will require more capital than is contemplated in
this Offering to reach commercialization of the GBS System. Such need for capital is an over-riding condition to the achievement
of many of the other hurdles to commercialization.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Regulatory Approvals</U>. The research, design, testing, manufacturing, labeling, selling, marketing
and distribution of medical devices are subject to extensive regulation by country-specific regulatory authorities, which regulations
differ from country to country. We have not yet obtained any regulatory approvals in any jurisdiction. We must obtain all regulatory
approvals as will permit the commercialization of the GBS System as well as any eligible protection of any intellectual property.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Clinical Studies</U>. To date, we have not conducted clinical studies and trials on the GBS
System. These studies and trials will be required prior to and in connection with obtaining all regulatory approvals. These studies
and trials will have to be successfully completed to obtain requisite regulatory approvals.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Manufacture and Supply</U>. Neither we nor LSBD own or operate manufacturing facilities or maintain
the resources for the production of the GBS System and its components on a commercial scale. Therefore, we will have to rely on
outsourcing in this regard. We must identify and reach agreements with manufacturers and suppliers before we can commence commercialization
of the GBS System.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Marketing</U>. We are looking for and will depend in large part on qualified distributors for
the marketing and selling of our products. While we will depend on these distributors&rsquo; efforts, we will be unable to control
their efforts completely. We have not yet executed any distribution agreements in this regard.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Software Compatibility</U>. We must conduct software work to make the GBS System application
compatible with existing and potential future smart device platforms. This software work remains to be done.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Personnel</U>.
                                         In order to commercialize our GBS System, we will need to attract and retain highly skilled
                                         managerial, sales, scientific and technical personnel to advance the product beyond its
                                         current development stage. To date we have utilized certain employees of our parent LSBD,
                                         which arrangement will not be sufficient to move toward commercialization of the GBS
                                         System.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Intellectual
                                         Property</U>. Before commencing any commercialization, we will need to assess the eligibility
                                         of our intellectual property for suitable protections in the jurisdictions of the China
                                         Region and if possible implement measures to achieve that protection. This will require
                                         significant work in each of those jurisdictions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; text-transform: uppercase">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Experts</U>. For purposes of most of the foregoing steps, including in particular regulatory
and intellectual property hurdles, we will need to engage third party experts, including in particular specialized local counsel
in certain jurisdictions.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; text-transform: uppercase">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Status
                                         of Product</U>. The GBS System is only in the development stage with the core biosensor
                                         within the GBS System having completed the proof of the concept stage. Significant work
                                         remains to move from the current stages of the product toward commercialization.</TD></TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>



<P STYLE="margin-top: 0; margin-bottom: 0"></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_003"></A>THE
OFFERING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28%; padding-left: 0.15in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.15in"><B>Issuer:</B></P></TD>
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 70%; text-align: justify"><FONT STYLE="font-size: 10pt">Glucose Biosensor Systems (Greater China) Holdings, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in"><FONT STYLE="font-size: 10pt"><B>Number of Shares of Common Stock
    Outstanding before the Offering:<SUP>1</SUP></B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">8,250,000 shares as the date hereof.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in"><FONT STYLE="font-size: 10pt"><B>Common Stock Offered by us:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0">A minimum of 750,000 and a maximum of 2,083,334 shares of our
                                    common stock, par value $0.01 (&ldquo;Common Stock&rdquo;), at an offering price of $12.00
                                    per share (the &ldquo;Shares&rdquo;).</P>


</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in"><FONT STYLE="font-size: 10pt"><B>Common Stock to be Outstanding
    after this Offering:<SUP>1</SUP></B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0">10,739,864 shares, if the minimum amount of Shares is sold, and
12,079,198 shares, if the maximum amount of Shares are sold.</P> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in"><FONT STYLE="font-size: 10pt"><B>Gross Proceeds to be Received in this Offering:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">$9,000,000, if the minimum amount of Shares is sold, and
    $25,000,000, if the maximum amount of Shares are sold.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in"><FONT STYLE="font-size: 10pt"><B>Use of Proceeds:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We intend to use the net proceeds received from this offering to pursue the early stages of regulatory approvals processes and compliance with obligations under the License Agreement, and secondarily, to the extent available, for development of our software platform, sales and marketing efforts to penetrate the markets in the China Region, production arrangements, funding our working capital and for general corporate purposes. See &ldquo;Use of Proceeds.&rdquo;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in"><FONT STYLE="font-size: 10pt"><B>Controlled Company:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0">LSBD currently beneficially owns 100% of our
                                    Common Stock. Upon the completion of this offering, LSBD will own 76.8% of our Common Stock
                                    if the minimum number of Shares is sold and 68.3% if the maximum number of Shares is sold.
                                    Since immediately following completion of this offering LSBD will control more than a majority
                                    of the total voting power of our outstanding Common Stock, LSBD will be able to control the
                                    outcome of all matters submitted to a vote of our stockholders, including, for example, the
                                    election of directors, amendments to our certificate of incorporation and mergers or other
                                    business combinations. See &ldquo;Description of Capital Stock&rdquo;. In addition, we currently
                                    intend to utilize the controlled company exemption under the Nasdaq corporate governance rules,
                                    and so you will not have the same protections afforded to stockholders of companies that are
                                    subject to such requirements.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in; text-align: justify; text-indent: -2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><SUP>1</SUP>Excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; width: 90%"><FONT STYLE="font-size: 10pt">1,222,506 shares issuable upon the exercise of outstanding
    warrants issued in connection with the placement of our Series A Convertible Preferred Stock, at an exercise price of $12.00
    per share, which warrants are exercisable only during the one-year period commencing on the second anniversary of the closing
    of this Offering;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">500,000 shares that will become available for future issuance
    under our 2017 Equity Incentive Plan; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">conversion of the warrants (the &ldquo;Placement Agent Warrants&rdquo;)
    to purchase shares of Common Stock equal to 5.0% of the aggregate Shares sold in this Offering, which Placement Agent Warrants
    will be for the purchase of 37,500 shares in the event the minimum number of Shares  is sold and 104,167 shares in the event
    the maximum number of Shares  is sold.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Unless expressly indicated or the context requires
otherwise, all information in this Offering Circular:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font-size: 10pt">assumes the automatic conversion of 1,222,506 outstanding shares of our Series A Convertible Preferred Stock as of the date hereof into 1,222,506 shares of Common Stock in connection with this Offering;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">assumes the automatic conversion of an aggregate amount of
    $5,277,056 (including principal and accrued but unpaid interest) of convertible notes issued by the Company&rsquo;s 98%-owned
    subsidiary, Glucose Biosensor Systems (Greater China) Pty Ltd (&ldquo;GBS Pty Ltd&rdquo;) as of the date hereof into 517,358
    shares of Common Stock at a price per share equal to $10.20 in connection with this Offering; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">presents share and per share amounts (except in historical
    financial information) reflecting the reverse stock split effected on August 9, 2018, of approximately one to 0.9167 shares
    that     resulted in     8,250,000 shares     of common stock being issued and outstanding as of the date
    hereof.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28%; padding-left: 0.15in; text-indent: -0.15in"><FONT STYLE="font-size: 10pt"><B>Proposed Listing:</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 70%; text-align: justify"><FONT STYLE="font-size: 10pt">We have applied to list our Common Stock on The Nasdaq Stock Market (&ldquo;Nasdaq&rdquo;) under the symbol &ldquo;GBSG&rdquo;. There is no assurance that this application will be approved and investors may not know at the time that their investment becomes irrevocable whether this application will be approved or whether the Shares will ever be listed. Nonetheless, our Common Stock will not commence trading on Nasdaq unless and until (i) the minimum amount of this Offering is closed; (ii) this Offering is terminated and (iii) we have filed a post-qualification amendment to the Offering Statement, and a registration statement on Form 8-A (&ldquo;Form 8-A&rdquo;) under the Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), and such post-qualification amendment is qualified by the SEC and the Form 8-A has become effective. Pursuant to applicable rules under Regulation A, the Form 8-A will not become effective until the SEC qualifies the post-qualification amendment. We intend to file the post-qualification amendment and request its qualification immediately prior to the termination of the Offering in order that the Form 8-A may become effective as soon as practicable. Even if we meet the minimum requirements for listing on Nasdaq, we may wait before terminating the Offering and commencing the trading of our Common Stock on Nasdaq in order to raise additional proceeds. As a result, you may experience a delay between the closing of your purchase of shares of our Common Stock and the commencement of exchange trading of our Common Stock on Nasdaq. See &ldquo;Risk Factors &ndash; Our shares of Common Stock are not and may not be listed for trading on a national securities exchange.&rdquo;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in"><FONT STYLE="font-size: 10pt"><B>Risk Factors:</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">An investment in our company is highly speculative and involves a significant degree of risk.&nbsp;&nbsp;See &ldquo;Risk Factors&rdquo; and other information included in this Offering Circular for a discussion of factors you should carefully consider before deciding to invest in our securities.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_004"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The purchase of the Company&rsquo;s
Common Stock involves substantial risks. You should carefully consider the following risk factors in addition to any other risks
associated with this investment. The Shares offered by the Company constitute a highly speculative investment and you should be
in an economic position to lose your entire investment. The risks listed do not necessarily comprise all those associated with
an investment in the Shares and are not set out in any particular order of priority. Additional risks and uncertainties may also
have an adverse effect on the Company&rsquo;s business and your investment in the Shares. An investment in the Company may not
be suitable for all recipients of this Offering Circular. You are advised to consult an independent professional adviser or attorney
who specializes in investments of this kind before making any decision to invest. You should consider carefully whether an investment
in the Company is suitable in the light of your personal circumstances and the financial resources available to you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The discussions and information
in this Offering Circular may contain both historical and forward-looking statements. To the extent that the Offering Circular
contains forward-looking statements regarding the financial condition, operating results, business prospects, or any other aspect
of the Company&rsquo;s business, please be advised that the Company&rsquo;s actual financial condition, operating results, and
business performance may differ materially from that projected or estimated by the Company in forward-looking statements. The Company
has attempted to identify, in context, certain of the factors it currently believes may cause actual future experience and results
may differ from the Company&rsquo;s current expectations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Before investing, you should
carefully read and carefully consider the following risk factors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to Our Financial Position
and Capital Requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We were formed in December 2016 and are
thus subject to the risks associated with new businesses.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We were formed in December
2016 as a new business and have not yet begun to commercialize our licensed technology or any products. As such, this limited
operating history may not be adequate to enable you to fully assess our ability to develop and commercialize the GBS System, achieve
market acceptance of the GBS System and respond to competition. Our efforts to date have been organizational and formational,
have depended on LSBD and its affiliates and have not generated revenue, and it is still too early to predict if we will ever
be able to generate revenues. Therefore, we are, and expect for the foreseeable future to be, subject to all the risks and uncertainties,
inherent in a new business and the development and sale of new medical devices and related software applications. As a result,
we may be unable to fully develop, obtain regulatory approval for, commercialize, manufacture, market, sell and derive revenues
from the GBS System and our inability to do so would materially and adversely impact our viability. In addition, we still must
establish many functions necessary to operate a business, including finalizing our managerial and administrative structure, continuing
product and technology development, assessing and commencing our marketing activities, implementing financial systems and controls
and personnel recruitment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Accordingly, you should
consider our prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by companies in their
initial revenue generating stages, particularly those in the medical device and digital heath fields. In particular, potential
investors should consider that there is a significant risk that we will not be able to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">implement or execute our current business plan, or that our business plan is sound;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">maintain our management team and Board of Directors;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">raise sufficient funds in the capital markets or otherwise to effectuate our business plan;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">determine that the technologies that have been developed are commercially viable; and/or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">attract, enter into or maintain contracts with, and retain customers.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In the event that we do
not successfully address these risks, our business, prospects, financial condition, and results of operations could be materially
and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Given our lack of revenue and our negative
cash flow, we expect to need to raise additional capital, which may be unavailable to us or, even if consummated, may cause dilution
or place significant restrictions on our ability to operate.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to our
management&rsquo;s estimates, based on our budget and proposed schedules of development, approvals and organization, we believe,
although there can be no assurances, that if we raise the minimum amount of this Offering then we will have sufficient capital
resources to enable us to continue to implement our business plan and remain in operation for at least the next 12 months, but
there can be no assurances how long, if at all, after such 12 months we might be able to continue as such without raising additional
capital. We do not anticipate generating any revenues within 24 months from the date of this Offering. We believe, although there
can be no assurances, that raising more than the minimum and less than the maximum amount of this Offering will enable us to continue
to implement our business plan and remain in operation for an indeterminate amount of time longer than just raising the minimum
amount, with the amount raised in excess over that minimum amount generally allowing for more additional time, but we will still
be required to promptly seek and obtain additional sources of capital. Even if we raise the maximum amount of this Offering, we
will need additional capital before we are able to fully implement our business plan and commercialize our products for public
sale, as to which there can be no assurances as to success. In any event, there can be assurances that we will ever be able to
raise additional capital.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Since we might be unable
to generate revenue or cash flow to fund our operations for the foreseeable future, we expect to need to seek additional equity
or debt financing to provide the capital required to maintain or expand our operations. We may also need additional funding for
developing products and services, increasing our sales and marketing capabilities, and promoting brand identity, as well as for
working capital requirements and other operating and general corporate purposes. Moreover, the regulatory compliance arising out
of being a publicly registered company will increase our costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We do not currently have
any arrangements or credit facilities in place as a source of funds, and there can be no assurance that we will be able to raise
sufficient additional capital on acceptable terms, or at all. If such financing is not available on satisfactory terms, or is not
available at all, we may be required to delay, scale back or eliminate the development of business opportunities and our operations
and financial condition may be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If we raise additional
capital by issuing equity securities, the percentage ownership of our existing stockholders may be reduced, and accordingly these
stockholders may experience substantial dilution. We may also issue equity securities that provide for rights, preferences and
privileges senior to those of our Common Stock. Given our need for cash and that equity-based offerings are the most common type
of fundraising, the risk of dilution is particularly significant for our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Debt financing, if obtained,
may involve agreements that include liens on our assets, covenants limiting or restricting our ability to take specific actions,
such as incurring additional debt, could increase our expenses and require that our assets be provided as a security for such debt.
Debt financing would also be required to be repaid regardless of our operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If we raise additional
funds through collaborations and licensing arrangements, we may be required to relinquish some rights to our technologies or candidate
products, or to grant licenses on terms that are not favorable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have incurred significant losses since
inception. As such, you cannot rely upon our historical operating performance to make an investment decision regarding our company.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Since our inception,
we have engaged primarily in formational activities and have not yet entered the commercialization stage. We have financed our
operations primarily through financing from pre-IPO capital raising and have incurred losses since inception, including a net
loss of $5,020,383 for the period from July 1, 2017 through June 30, 2018. We do not know whether or when we will become profitable.
Our ability to generate revenue and achieve profitability depends upon our ability, alone or with others, to launch the GBS System
in the China Region and manufacture, market and sell the GBS System where approved. We may be unable to achieve any or all of
these goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The directors have
expressed in the notes to the financial statements that the Company will continue as a going concern dependent on its ability to
raise additional capital.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company is an early
stage and emerging growth company and has not generated any revenues to date. As such, the Company is subject to all of the risks
associated with early stage and emerging growth companies. Since inception, the Company has incurred losses and negative cash
flows from operating activities. The Company does not expect to generate positive cash flows from operating activities in the
near future until such time, if at all, the Company completes the development process of its products, including regulatory approvals,
and thereafter, begins to commercialize and achieve substantial acceptance in the marketplace for the first of a series of products
in its medical device portfolio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company incurred
a net loss of $5,020,383 for the period from July 1, 2017 through June 30, 2018. At June 30, 2018, the Company had an accumulated
deficit of $5,332,055, negative working capital of $3,063,694, $5,559,617, in current liabilities of which $5,277,056 are convertible
notes issued by our 98%-owned subsidiary GBS Pty Ltd that will convert to Common Stock upon the proposed IPO, and cash of $418,420.
In the near future, the Company anticipates incurring operating losses and does not expect to experience positive cash flows from
operating activities and may continue to incur operating losses until it completes the development of its products and seeks regulatory
approvals to market such products. These factors may raise doubt about the Company&rsquo;s ability to continue as a going concern
without sufficient capital. See Note 1 to Consolidated Financial Statements for the period from July 1, 2017 through June 30,
2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A failure to raise sufficient
capital, obtain regulatory approvals for the Company&rsquo;s products, generate sufficient product revenues, or control expenditures,
among other factors, may adversely impact the Company&rsquo;s ability to meet its financial obligations as they become due and
payable and to achieve its intended business objectives, and therefore, raises substantial doubt of the Company&rsquo;s ability
to continue as a going concern. The Company&rsquo;s consolidated financial statements have been prepared on a going concern basis
which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business.
The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded
asset amounts or the amounts and classification of liabilities should the Company be unable to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our License Agreement with our wholly-owning
parent, LSBD, which relates to the Company&rsquo;s principal asset consisting of licensed intellectual property, contains numerous
significant performance, payment, liability, compliance, termination and intellectual property risks that may threaten the Company&rsquo;s
viability or otherwise have a material adverse effect on the Company and its business, assets and its prospects.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The License Agreement is
limited to the China Region and includes the terms and related risks set forth below The Company has no contractual rights to the
intellectual property covered in the License Agreement other than as expressly set forth therein. The Company&rsquo;s plans, business,
prospects and viability are substantially dependent on that intellectual property and subject to the limitations relating thereto
as set forth in the License Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Under the License Agreement an exclusive license is granted to the Company covering certain glucose sensor intellectual property scheduled in the License Agreement and other data owned by LSBD, but solely to (i) hold regulatory marketing authorizations in the China Region, (ii) promote, market and import specific licensed products in the China Region, (iii) provide customer support on the licensed products in the China Region, (iv) use the licensed products in the China Region, and (v) collect data for LSBD regarding the use of the licensed products in the China Region. As granted solely for the specified purposes, the Company will be unable to use the license beyond the specified products for the specified purposes, thus limiting the potential commercialization of the applicable intellectual property, even as such commercialization might be appropriate, related, synergistic or enhanced by the Company&rsquo;s operations for the benefit of a third party, including LSBD. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The licensed products under the License Agreement are only those products that are procured by the Company from suppliers authorized by LSBD in the China Region under rights owned by LSBD. Accordingly, the Company will not have unfettered right to select its suppliers, regardless of whether unauthorized suppliers would provide products on better pricing, delivery, quality or other terms, thus potentially materially and adversely impacting those aspects of the Company&rsquo;s business, economies, profitability and prospects and making the Company subject to the terms offered by the authorized suppliers. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The licensed rights under the License Agreement do not cover digital or online use to users not physically in the China Region. Accordingly, to the extent that such users are prohibited, the Company will be unable to realize any commercialization from such users and ensure that such users do not do business with the Company, even as such commercialization and business might be appropriate, related, synergistic or enhanced by the Company&rsquo;s operations. In addition, the Company may be responsible for costs and other liabilities that might arise to the extent that users outside the China Region obtain such access, and may incur costs to comply with these prohibitions. Further, the non-coverage of digital or online use for users not physically in the China Region may constitute a material limitation on the ability of the Company to freely conduct business digitally, online or through any other medium that may reach outside of the China Region. This limitation may have a material adverse effect on the Company&rsquo;s marketing, sales, operational and other business efforts.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The distribution license contained in the License Agreement is expressly limited by certain terms, which include the Company providing customer support on licensed products and collecting data for LSBD regarding the use thereof. The customer service and data collection and retention may be expensive in cost, resources, legal and regulatory compliance and other ways, none of which costs can be quantified at this time. Further, changing regulations with respect to medical and similar such data may make such compliance beyond the scope of the Company&rsquo;s capabilities. There can be no assurances that the costs and limited capabilities regarding these matters will not have a material adverse effect on the ability of the Company to comply with these distribution requirements on an economical basis, if at all.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Company is required to meet specified performance milestones,
    including conducting clinical studies; obtaining regulatory approvals in the China Region within two years after the commencement
    of trading of the Shares on Nasdaq and within two years thereof placing orders with LSBD for a minimum number of products
    based on market growth, with annual increases; annually agree with LSBD as to that market growth; achieve annually that market
    share growth plus a minimum fixed percentage and quarterly orders with LSBD for products in quantities at that quarterly market
    share growth plus a minimum fixed percentage; conduct minimum marketing on standards reasonably determined by LSBD; and convert
    all glucose monitoring sales by the Company into glucose monitoring sales of the biosensor strip within five years; provided
    that (i) LSBD must supply all licensed product in accordance with the License Agreement, (ii) such product must be of merchantable
    quality and in accordance with local law, and (iii) certain end user data must be accessible to the Company. These milestones
    represent significant performance and other hurdles that may not be achievable. In addition, the parties must agree as to
    market share growth and then the Company must exceed that growth by the specified minimum fixed percentage each quarter and
    annually. There can be no assurances that agreement can be reached each quarter or that if reached it can be exceeded by the
    specified minimum percentage each time required. Failure to meet any such performance milestone or satisfy any related requirement
    under the License Agreement would create significant liabilities that would have a material adverse effect on our business,
    financial condition, prospects and assets.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Upon failure of any of these requirements, LSBD may require the Company to make cash payment of the value of any shortfall. These failure provisions may have a material adverse effect on the Company and its operations and may not be sustainable by the Company. Each failure requires a full cash payment for the shortfall, effectively guaranteeing to LSBD a return regardless of the performance by the Company. There can be no assurances that the Company will have or be able to obtain sufficient cash to make the required shortfall payments. In particular, the failure to pay the amount of any shortfall within 14 business days of being due will subject the amount due to monthly compounding interest at the rate of LIBOR plus 4%, without any relief or defenses set forth in the License Agreement, which amounts may significantly increase and be or become unbearable or unsustainable to the Company. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the licensed rights in general are limited to those expressly set forth in the License Agreement and are non-transferable, non-assignable and non-sub-licensable, with the only exception that LSBD will in good faith consider any Company request for any sub-license, which consideration does not imply any commitment to agree to any such sub-license, the absence of all of which may have a material adverse effect on the Company and its business, assets and prospects. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The non-exclusive, non-transferable use of specified trademarks for marketing the licensed products is subject to certain limitations that may limit the ability of the Company to develop its own branding, trade name and other intangible value, which may have a material adverse effect on the Company and its business, assets and prospects.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">LSBD may require or make any changes to licensed products at no cost to LSBD. This right of LSBD may create material expense, relationship, practical, reputational and other adverse harm to the Company, its business and its prospects without any control over these changes by the Company. Further, there are no material limitations, indemnities or cost-sharing provisions imposed on LSBD that would ameliorate the impact on the Company of these changes.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Company must notify LSBD of infringements of any licensed intellectual property and cooperate with and as instructed by LSBD, at LSBD&rsquo;s expense, in preventing such infringement, but may take no other action regarding infringement. These provisions leave the Company little control over whether, to what extent and at what consequences any infringement protection may be undertaken, thus potentially resulting in protective conduct that may have a material adverse effect on the Company, its business and its prospects without any control or even input by the Company over these protective actions.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Company must market, sell and distribute the licensed products in accordance with law and distribution requirements set forth in the License Agreement, including delivering licensed products without inclusion of any other product, only as supplied by LSBD, without changing LSBD&rsquo;s packaging or branding thereof and only in quantities as directed by LSBD; complying with all regulations; and keeping specified records and batch samples relating to its activities. These limitations expose the Company to a breach to the extent it fails to comply with marketing, sales and distribution requirements and further limits the ability of the Company to expand its business or strategy by linking or bundling licensed products with other Company products as may become strategically indicated or perceived as beneficial to the Company. Likewise, the Company may be limited in its ability to realize marketing or other synergies from any marketing, distribution or sales platforms or networks that it may develop or design, thereby having a material adverse effect on the Company, its operations or its prospects.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Company must file for and obtain all legal permits for marketing and selling licensed products. There can be no assurances that the Company will be able to obtain or maintain any or all required permits.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Company must pay LSBD, subject to a monthly late charge, a one-time fixed license fee within 14 days of the obtaining of required regulatory approvals in China; fixed royalty percentages on the sale of specified licensed products on sales of commercial units and certain other devices; application license fees and fees for patient education services, all as determined from time to time by LSBD. These payment requirements may have a material adverse effect on the Company, its operations or its prospects, since the Company may not be able to make these substantial payments as and when incurred, which payments are required based on milestones unrelated to the Company&rsquo;s cash flow, liquidity, profitability or other set-offs.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Company must obtain, retain and provide to LSBD certain end user and other data and notify LSBD as to a variety of matters relating to the data, all of which data shall be solely owned by LSBD, provided that the Company will own certain of the data during the term of the License Agreement. There can be no assurances that the Company will have the resources or that it will be economical for the Company to comply with these data requirements or that it will be able to do so in complete compliance with all applicable regulations and law. Further, the ownership of the data as noted represents a limitation on the ability of the Company to fully exploit for its own legally permissible purposes customer and other data that it may obtain in the course of its operations, which data may have intrinsic, intangible or other value that will result from the Company&rsquo;s efforts. Further, the rights of the Company to use the data do not survive the License Agreement and thus do not necessarily represent a reliable future asset of the Company. These limitations on the ownership and use of data may have a material adverse effect on the Company, its operations and its prospects.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">LSBD will own all of the right, title and interest in substantially all of the intellectual property covered by the License Agreement and LSBD shall have the right to control the protection of that licensed intellectual property as assisted by the Company, which shall have no rights to control or otherwise conduct protective activities. The full ownership by LSBD of the licensed intellectual property as noted represents a limitation on the ability and incentives of the Company to fully exploit for its own legally permissible purposes that property. The licensed rather than owned nature of the property also represent a significant limitation on the ability of the Company to realize returns on investments made in, or the increase in the value of, that property. These limitations may have a material adverse effect on the Company, its operations and its prospects.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The parties generally agree to keep confidential, subject to customary exceptions, all confidential information of the other party, subject to express exceptions. There can be no assurances that these confidentiality provisions will not have a limitation on the ability of the Company to exploit for its own benefit certain information that it learns in the course of its business or that it will not inadvertently violate the terms of that confidentiality, with material adverse consequences to the Company, its business or its prospects.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Except with respect to LSBD&rsquo;s ownership of all intellectual property rights in respect of the licensed property and the non-infringement by the Company&rsquo;s exercise of those rights, LSBD provides no, and disclaims all, representations, warranties or covenants relating to the licensed intellectual property or any other matters under the License Agreement and in particular disclaims any fitness of the property for any purpose.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">LSBD is indemnified by the Company for any losses that may be incurred relating to any conduct, including any data collection or retention, by the Company under or relating to the License Agreement or the intellectual property under it, or any negligent or willful misconduct or violation of law by the Company, with no reciprocal indemnity; provided that LSBD indemnifies the Company for any losses arising that may be incurred related to (i) any third party claim that the exercise by the Company of its rights in respect of a licensed product violates its property or rights, and (ii) any regulatory or quality recall or any consumer or user claims or liability in relation to a licensed product (regardless of any contributory or comparative negligence of any Licensee Indemnitee, subject to contributory negligence.. These provisions effectively give the Company limited recourse the event that the licensed intellectual property is flawed, defective, inadequate, incomplete, uncommercial, wrongly described or otherwise not useful for purposes of the Company&rsquo;s expectations, plans or strategies. The Company has not independently verified any of the technical, scientific, commercial, legal, medical or other circumstances or nature of the licensed intellectual property and therefore there can be no assurances that any of the foregoing risks have been reduced or eliminated. These provisions represent a significant risk of a material adverse impact on the Company, its business or its prospects.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">The term of the License Agreement runs until the final date of protection afforded to the
    patent portfolio covered by the License Agreement, which is currently until 2033, provided that either party may terminate
    the License Agreement earlier following any uncured material breach by the other party of it, the discontinuation of the other
    party&rsquo;s operations or an actual or prospective change in control of the other party, where change in control means,
    among other things, (i) any change of 50% ownership of outstanding common stock or voting rights, (ii) a merger resulting
    in a party&rsquo;s pre-merger voting securities failing to represent at least 50% of all voting power immediately post-merger,
    (iii) a sale of substantially all assets, (iv) solely with respect to the Company, without LSBD&rsquo;s prior approval a majority
    change in the composition of our board of directors (unless such change was pre-approved by our board, a nominating or other
    independent committee thereof) or (v) the dissolution or liquidation of the other party. In the event of a change in control
    of LSBD, LSBD must pay the Company an amount equal to the greater of the five-year projected net sales or five times the prior
    year&rsquo;s actual net sales of the Company, as adjusted depending on how much of the term of the License Agreement remains.
    No similar payment is required by the Company in the event of a change in control of the Company. These termination provisions
    represent a significant risk that the License Agreement may be terminated by LSBD or by way of certain transactions, which
    termination would have an immediate, material and existential adverse impact on the Company and its operations, assets and
    prospects.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Notwithstanding the change of control risks described above, the License Agreement imposes severe consequences upon the Company upon the expiration, termination or cancellation of the License Agreement in any way. These consequences would require (i) the cessation of substantially all of the Company&rsquo;s operations, (ii) the forfeiture to LSBD of substantially all of the Company&rsquo;s intellectual property, and (iii) the payment of due amounts, effectively threatening the Company&rsquo;s viability and otherwise having a material adverse effect on the Company and its business, assets and prospects.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preceding risks are
subject to, and you are encouraged to read, the complete text of the License Agreement, including variations, which are filed as
exhibits to the Offering Statement of which this Offering Circular is a part. These risks are not exclusive and any one or more
thereof have the risks described above or elsewhere herein and may otherwise materially and adversely affect, or represent existential
risks to, the Company, its business and it prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Neither we nor LSBD have yet begun commercializing
the GBS System and the ability to do so will depend on the acceptance of the GBS System in the Chinese healthcare market.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Neither we nor LSBD have
yet begun commercializing the GBS System and it has not yet received regulatory approvals in China or elsewhere. We have limited
experience engaging in commercial activities and limited established relationships with physicians and hospitals as well as third-party
suppliers on whom we will depend for the manufacture of our product. We are faced with the risk that the China Region marketplace
will not be receptive to the GBS System over competing products and that we will be unable to enter the marketplace or compete
effectively. Factors that could affect our ability to establish the GBS System or any potential future product include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the development of products or devices which could result in a shift of customer preferences away from our device and services and significantly decrease revenue;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the increased use of improved diabetes drugs that could encourage certain diabetics to test less often, resulting in less usage of self-monitoring (saliva-based, blood-based or otherwise) test device for certain types of diabetics;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the challenges of developing (or acquiring externally-developed) technology solutions that are adequate and competitive in meeting the requirements of next-generation design challenges;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the significant number of current competitors in the glucose monitoring market who have significantly greater brand recognition and more recognizable trademarks and who have established relationships with diabetes healthcare providers and payors; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">intense competition to attract acquisition targets, which may make it more difficult for us to acquire companies or technologies at an acceptable price or at all.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We cannot assure you that
the GBS System or any future product will gain market acceptance. If the market for the GBS System or any future product fails
to develop or develops more slowly than expected, or if any of the technology and standards supported by us do not achieve or sustain
market acceptance, our business and operating results would be materially and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We cannot accurately predict the volume
or timing of any sales, making the timing of any revenues difficult to predict.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may be faced with lengthy
and unpredictable customer evaluation and approval processes associated with the GBS System. Consequently, we may incur substantial
expenses and devote significant management effort and expense in developing customer adoption of the GBS System, which may not
result in revenue generation. We must also obtain regulatory approvals of the GBS System in each respective jurisdiction, which
is subject to risk and potential delays, and may actually occur. As such, we cannot accurately predict the volume, if any, or timing
of any future sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If the GBS System fails to satisfy current
or future customer requirements, we may be required to make significant expenditures to redesign the product, and we may have insufficient
resources to do so.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The GBS System is being
designed to address an existing marketplace and must comply with current and evolving customer requirements in order to gain market
acceptance. There is a risk that the GBS System will not meet anticipated customer requirements or desires. If we are required
to redesign our products to address customer demands or otherwise modify our business model, we may incur significant unanticipated
expenses and losses, and we may be left with insufficient resources to engage in such activities. If we are unable to redesign
our products, develop new products or modify our business model to meet customer desires or any other customer requirements that
may emerge, our operating results would be materially adversely affected and our business might fail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We expect to derive substantially all
of our revenues from a principal technology, which we license from LSBD and which leaves us subject to the risk of reliance on
LSBD and its technology.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We expect to derive substantially
all of our revenues from sales of products derived from a principal technology, which we license exclusively from LSBD. Our initial
product utilizing this technology is the GBS System. As such, any factor adversely affecting sales of the GBS System, including
the product development and release cycles, regulatory issues, market acceptance, product competition, performance and reliability,
reputation, price competition and economic and market conditions, would likely harm our operating results. We may be unable to
fully develop the GBS System or other products utilizing our technology, which would likely lead to the failure of our business.
Moreover, in spite of our efforts related to the registration of our technology, if intellectual property protection is not available
for our principal technology, the viability of the GBS System and any other products that may be derived from such technology would
likely be adversely impacted to a significant degree, which would materially impair our prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We will be dependent upon third-party
manufacturers and suppliers making us vulnerable to contractual relationships and market forces, supply shortages and problems
and price fluctuations, which could harm our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Neither we nor LSBD own
or operate manufacturing facilities or maintain the resources for the production of the GBS System and its components on a commercial
scale. Therefore, we will have to rely on outsourcing in this regard. Third party manufacturers and suppliers may encounter problems
for a variety of reasons, including, for example, failure to follow specific protocols and procedures, failure to comply with applicable
legal and regulatory requirements, equipment malfunction and environmental factors, failure to properly conduct their own business
affairs, and infringement of third-party intellectual property rights, any of which could delay or impede their ability to meet
our requirements. Reliance on these third-party suppliers also subjects us to other risks where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">we may not be able to obtain an adequate manufacture or supply in a timely manner or on commercially reasonable terms;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">third party manufacturers or suppliers make errors that could adversely affect the efficacy or safety of the GBS System or cause delays in shipment;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">we may have difficulty locating and qualifying alternative suppliers;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">switching components or suppliers may require product redesign and possibly submission to Chinese or other regulatory bodies, which could significantly impede or delay our commercial activities;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">sole-source suppliers fail to supply components of the GBS System; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">third party manufacturers or suppliers encounter financial or other business hardships unrelated to us, interfering with their fulfillment of our orders and requirements.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may not be able
to quickly establish additional or alternative suppliers if necessary, in part because we may need to undertake additional activities
to establish such suppliers as required by the regulatory approval process. Any interruption or delay in obtaining products from
our third-party suppliers, or our inability to obtain products from qualified alternate sources at acceptable prices in a timely
manner, could impair our ability to meet the demand of our customers and cause them to switch to competing products. Given our
potential reliance on certain single-source suppliers, we may well be susceptible to supply shortages because we would not have
alternate suppliers readily available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We are looking for and expect to rely
in part on third-party distributors to effectively distribute our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are looking for and
will depend in part on qualified distributors for the marketing and selling of our products. We will depend on these distributors&rsquo;
efforts to market our products, yet we will be unable to control their efforts completely. We have not yet executed any distribution
agreements in this regard and there can be no assurances that suitable distributors will be engaged on terms acceptable to us.
These distributors typically would sell a variety of other, non-competing products that may limit the resources they dedicate to
selling the GBS System. In addition, we are unable to ensure that our distributors will comply with all applicable laws regarding
the sale of our products. If our distributors fail to effectively market and sell the GBS System in full compliance with applicable
laws, our operating results and business may suffer. Recruiting and retaining qualified third-party distributors and training them
in our technology and product offering will require significant time and resources. To develop and expand our distribution, we
will be required to scale and improve our processes and procedures that support our distributors. Further, if our relationship
with a successful distributor terminates, we may be unable to replace that distributor without disruption to our business. If we
fail to develop or maintain positive relationships with our distributors, including in new markets, fail to manage, train or incentivize
these distributors effectively, or fail to provide distributors with competitive products on attractive terms, or if these distributors
are not successful in their sales efforts, we may not achieve or may have a reduction in revenue and our operating results, reputation
and business would be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Failure in our conventional, online and
digital marketing efforts could significantly impact our ability to generate sales.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We intend to engage in
conventional marketing strategies and also may utilize online and digital marketing in order to create awareness to the GBS System.
Our management believes that using a wide variety of marketing strategies, including online advertisement and a variety of other
pay-for-performance methods may be effective for marketing and generating sales of the GBS System as opposed to relying exclusively
on traditional, expensive retail channels. In any event, there is a risk that any or all of our marketing strategies could fail.
We cannot predict whether the use of traditional or non-traditional retail sales tools and reliance on healthcare providers to
educate our customers about the GBS System will be successful or if we may achieve any successful marketing of the GBS System.
The failure of our marketing efforts could significantly and negatively impact our ability to generate sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The GBS System may utilize a smart device
platform and maybe in the future other platforms. If we are unable to achieve or maintain a good relationship with these platforms,
or if the platform store or any other applicable platform were unavailable for any prolonged period of time, our business will
suffer.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A key component of the
GBS System is a smart device application that includes tools to help diabetic patients manage their disease. This application will
be compatible with various operating platforms. If we are unable to make the GBS System application compatible with these platforms,
or if there is any deterioration in our relationship with either platform providers or others after our application is available,
our business would be materially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are subject to each
of the standard terms and conditions for application developers, which govern the promotion, distribution and operation of games
and other applications on their respective storefronts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>As we intend to conduct business internationally,
we are susceptible to risks associated with international relationships.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We expect to operate our
business in the China Region and initially in China. The international operation of our business requires significant management
attention, which could negatively affect our business if it diverts their attention from their other responsibilities. In the event
that we are unable to manage the complications associated with international operations, our business prospects could be materially
and adversely affected. In addition, doing business with foreign customers subjects us to additional risks that we do not generally
face in the United States. These risks and uncertainties include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">management, communication and integration problems resulting from cultural differences and geographic dispersion;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">localization of products and services, including translation of foreign languages;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">delivery, logistics and storage costs;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">longer accounts receivable payment cycles and difficulties in collecting accounts receivable;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">difficulties supporting international operations;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">difficulties supporting customer services;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">changes in economic and political conditions;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">impact of trade protection measures;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">complying with import or export licensing requirements;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">exchange rate fluctuations;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">competition from companies with international operations, including large international competitors and entrenched local companies;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">potentially adverse tax consequences, including foreign tax systems and restrictions on the repatriation of earnings;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">maintaining and servicing computer hardware in distant locations;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">keeping current and complying with a wide variety of foreign laws and legal standards, including local labor laws;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">securing or maintaining protection for our intellectual property; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">reduced or varied protection for intellectual property rights, including the ability to transfer such rights to third parties, in some countries.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The occurrence of any or
all of these risks could adversely affect our international business and, consequently, our results of operations and financial
condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Failure to make adequate contributions
to various employee benefit plans as required by Chinese regulations may subject us to penalties.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Companies operating in
China are required to participate in various government-sponsored employee benefit plans, including certain social insurance, housing
funds and other welfare-oriented payment obligations, and contribute to the plans in amounts equal to certain percentages of salaries,
including bonuses and allowances, of their employees up to a maximum amount specified by the local government from time to time
at locations where they operate their businesses. While we intend to comply with all material aspects of relevant regulations,
the requirements governing employee benefit plans have not been implemented consistently by the local governments in China given
the different levels of economic development in different locations. If we are subject to late fees or fines in relation to the
underpaid employee benefits, our financial condition and results of operations may be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Non-U.S. governments often impose strict
price controls, which may adversely affect our future profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If successfully developed,
we intend to seek approval to market the GBS System in the China Region. If we obtain approval in one or more of the jurisdictions
within our License Agreement, we will be subject to rules and regulations in those jurisdictions relating to our products. In some
countries, each of which may have developed its own rules and regulations, pricing may be subject to governmental control under
certain circumstances. In these countries, pricing negotiations with governmental authorities can take considerable time after
the receipt of requisite marketing approval. To obtain reimbursement or pricing approval in some countries, we may be required
to conduct a clinical trial that compares the cost-effectiveness of our product to other available products. If reimbursement of
our product candidates is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable
to achieve or sustain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The software application and associated
business processes of the GBS System may contain undetected errors, which could limit our ability to provide our services and diminish
the attractiveness of our service offerings.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The GBS System may contain
undetected errors, defects or bugs. As a result, our customers or end users may discover errors or defects in our products, software
or the systems we design, or the products or systems incorporating our designs and intellectual property may not operate as expected.
We may discover significant errors or defects in the future that we may not be able to fix. Our inability to fix any of those errors
could limit our ability to provide our products, impair the reputation of our brand and diminish the attractiveness of our product
offerings to our customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, we may utilize
third party technology or components in our products and we rely on those third parties to provide support services to us. Failure
of those third parties to provide necessary support services could materially adversely impact our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our future performance will depend on
the continued engagement of key members of our management team.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our future performance
depends to a large extent on the continued services of members of our current management including, in particular, our President.
In the event that we lose the continued services of such key personnel for any reason, this could have a material adverse effect
on our business, operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we are not able to attract and retain
highly skilled managerial, scientific and technical personnel, we may not be able to implement our business model successfully.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We believe that our management
team must be able to act decisively to apply and adapt our business model in the markets in which we will compete. In addition,
we will rely upon technical and scientific employees or third-party contractors to effectively establish, manage and grow our business.
Consequently, we believe that our future viability will depend largely on our ability to attract and retain highly skilled managerial,
sales, scientific and technical personnel. In order to do so, we may need to pay higher compensation or fees to our employees or
consultants than we currently expect and such higher compensation payments would have a negative effect on our operating results.
Competition for experienced, high-quality personnel is intense and we cannot assure that we will be able to recruit and retain
such personnel. We may not be able to hire or retain the necessary personnel to implement our business strategy. Our failure to
hire and retain such personnel could impair our ability to develop new products and manage our business effectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to Product Development and
Regulatory Approval</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The regulatory clearance process which
we may be required to navigate may be expensive, time-consuming, and uncertain and may prevent us from obtaining clearance for
the commercialization of the GBS System or our any future product.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We will not be permitted
to market the GBS System until we receive regulatory clearance. To date, we have not received regulatory clearance in any jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The research, design, testing,
manufacturing, labeling, selling, marketing and distribution of medical devices are subject to extensive regulation by country-specific
regulatory authorities, which regulations differ from country to country. There can be no assurance that, even after such time
and expenditures, we will be able to obtain necessary regulatory approvals for clinical testing or for the manufacturing or marketing
of any products. In addition, during the regulatory process, other companies may develop other technologies with the same intended
use as our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We also will be subject
to numerous post-marketing regulatory requirements, which may include labeling regulations and medical device reporting regulations,
which may require us to report to different regulatory agencies if our device causes or contributes to a death or serious injury,
or malfunctions in a way that would likely cause or contribute to a death or serious injury. In addition, these regulatory requirements
may change in the future in a way that adversely affects us. If we fail to comply with present or future regulatory requirements
that are applicable to us, we may be subject to enforcement action by regulatory agencies, which may include, among others, any
of the following sanctions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">customer notification, or orders for repair, replacement or refunds;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">voluntary or mandatory recall or seizure of our current or future products;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">imposing operating restrictions, suspension or shutdown of production;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">refusing our requests for clearance or pre-market approval of new products, new intended uses or modifications to the GBS System or future products;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">rescinding clearance or suspending or withdrawing pre-market approvals that have already been granted; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">criminal prosecution.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The occurrence of any of
these events may have a material adverse effect on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have not conducted clinical studies
of the GBS System. Clinical and pre-clinical data is susceptible to varying interpretations, which could delay, limit or prevent
additional regulatory clearances.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To date, we have not
conducted clinical studies on the GBS System. There can be no assurance that we will successfully complete any clinical studies
necessary to receive regulatory approvals in certain jurisdictions. While preliminary studies conducted by LSBD have produced
results we believe to be encouraging and indicative of the potential efficacy of the GBS System, data already obtained, or in
the future obtained, from pre-clinical studies and clinical studies do not necessarily predict the results that will be obtained
from later pre-clinical studies and clinical studies. Moreover, pre-clinical and clinical data are susceptible to varying interpretations,
which could delay, limit or prevent additional regulatory approvals. The failure to adequately demonstrate the safety and effectiveness
of an intended product under development could delay or prevent regulatory clearance of the device, resulting in delays to commercialization,
and could materially harm our business. There can be no assurance that we will be able to receive approval for any potential applications
of our principal technology, or that we will receive regulatory clearances from targeted regions or countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may be unable to complete required
clinical trials, or we may experience significant delays in completing such clinical trials, which could significantly delay our
targeted product launch timeframe and impair our viability and business plan.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The completion of any future
clinical trials for the GBS System or other trials that we may be required to undertake in the future could be delayed, suspended
or terminated for several reasons, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our failure or inability to conduct the clinical trial in accordance with regulatory requirements;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">sites participating in the trial may drop out of the trial, which may require us to engage new sites for an expansion of the number of sites that are permitted to be involved in the trial;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">patients may not enroll in, remain in or complete, the clinical trial at the rates we expect; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">clinical investigators may not perform our clinical trial on our anticipated schedule or consistent with the clinical trial protocol and good clinical practices.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If our clinical trials
are delayed it will take us longer to ultimately commercialize the GBS System and generate revenues. Moreover, our development
costs will increase if we have material delays in our clinical trial or if we need to perform more or larger clinical trials than
planned. We may be faced with similar risks in connection with future trials we conduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we or our manufacturers fail to comply
with the regulatory quality system regulations or any applicable equivalent regulations, our proposed operations could be interrupted
and our operating results would suffer.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We, our manufacturers and
suppliers will be required, to the extent of applicable regulation, to follow the quality system regulations of each jurisdiction
it will seek to penetrate and also will be subject to the regulations of these jurisdictions regarding the manufacturing processes.
If we, our manufacturers or our suppliers are found to be in significant non-compliance or fail to take satisfactory corrective
action in response to adverse regulatory findings in this regard, regulatory agencies could take enforcement actions against us
and our manufacturers, which could impair or prevent our ability to produce our products in a cost-effective and timely manner
in order to meet customers&rsquo; demands. Accordingly, our operating results would suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We are subject to the risk of reliance
on third parties to conduct our clinical trial work.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We will depend on independent
clinical investigators to conduct our clinical trials. Contract research organizations may also assist us in the collection and
analysis of data. These investigators and contract research organizations will not be our employees and we will not be able to
control, other than by contract, the amount of resources, including time that they devote to products that we develop. If independent
investigators fail to devote sufficient resources to our clinical trials, or if their performance is substandard, it will delay
the approval or clearance and commercialization of any products that we develop. Further, regulatory bodies in the China Region
require that we comply with standards, commonly referred to as good clinical practice, for conducting, recording and reporting
clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality
of trial subjects are protected. If our independent clinical investigators and contract research organizations fail to comply with
good clinical practice, the results of our clinical trials could be called into question and the clinical development of our product
candidates could be delayed. Failure of clinical investigators or contract research organizations to meet their obligations to
us or comply with federal regulations could adversely affect the clinical development of our product candidates and harm our business.
Moreover, we intend to have several clinical trials in order to support our marketing efforts and business development purposes.
Such clinical trials will be conducted by third parties as well. Failure of such clinical trials to meet their primary endpoints
could adversely affect our marketing efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may be subject to healthcare fraud
and abuse laws and regulations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Many international healthcare
laws and regulations apply to the glucose monitoring business and medical devices. We will be subject to certain regulations regarding
commercial practices false claims. The medical device industry worldwide has been under heightened scrutiny as the subject of government
investigations and enforcement actions involving manufacturers who allegedly offered unlawful inducements to potential or existing
customers in an attempt to procure their business, including arrangements with physician consultants. If our operations or arrangements
are found to be in violation of such governmental regulations, we may be subject to civil and criminal penalties, damages, fines
and the curtailment of our operations. All of these penalties could adversely affect our ability to operate our business and our
financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Product liability suits, whether or not
meritorious, could be brought against us due to an alleged defective product or for the misuse of the GBS System. These suits could
result in expensive and time-consuming litigation, payment of substantial damages, and an increase in our insurance rates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If the GBS System are defectively
designed or manufactured, contain defective components or are misused, or if someone claims any of the foregoing, whether or not
meritorious, we may become subject to substantial and costly litigation. Misusing our device or failing to adhere to the operating
guidelines or the device producing inaccurate meter readings could cause significant harm to patients, including death. In addition,
if our operating guidelines are found to be inadequate, we may be subject to liability. Product liability claims could divert management&rsquo;s
attention from our core business, be expensive to defend and result in sizable damage awards against us. While we expect to maintain
product liability insurance, we may not have sufficient insurance coverage for all future claims. Any product liability claims
brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing continuing
coverage, could harm our reputation in the industry and could reduce revenue. Product liability claims in excess of our insurance
coverage would be paid out of cash reserves harming our financial condition and adversely affecting our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we are found to have violated laws
protecting the confidentiality of patient health information, we could be subject to civil or criminal penalties, which could increase
our liabilities and harm our reputation or our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Part of our business plan
includes the storage and potential monetization of data of users of the GBS System. There are a number of laws around the world
protecting the confidentiality of certain patient health information, including patient records, and restricting the use and disclosure
of that protected information. Privacy rules protect medical records and other personal health information by limiting their use
and disclosure, giving individuals the right to access, amend and seek accounting of their own health information and limiting
most use and disclosures of health information to the minimum amount reasonably necessary to accomplish the intended purpose. We
may face difficulties in holding such information in compliance with applicable law. If we are found to be in violation of the
privacy rules, we could be subject to civil or criminal penalties, which could increase our liabilities, harm our reputation and
have a material adverse effect on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to Our Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We depend on intellectual property licensed
from our parent, Life Science Biosensor Diagnostics Pty Ltd (&ldquo;LSBD&rdquo;), and termination of this license could result
in the loss of significant rights, which would significantly harm our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are dependent on know-how
and proprietary technology, both our own and licensed from others, including, in particular, LSBD. Any termination or absence of
legal effect of a license could result in the loss of significant rights and could harm our ability to commercialize the GBS System.
Disputes may also arise between us and our licensors, including LSBD, regarding intellectual property subject to the License Agreement,
including those relating to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the scope of rights, if any, granted under the License Agreement and other interpretation-related issues;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the License Agreement;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">whether our licensor or its licensor had the right to grant the License Agreement;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">whether third parties are entitled to compensation or equitable relief, such as an injunction, for our use of the intellectual property without their authorization;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our right to sublicense intellectual property and other rights to third parties under collaborative development relationships;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">whether we are complying with our obligations with respect to the use of the licensed technology in relation to our development and commercialization of product candidates;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the allocation of ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and by us and our partners; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the amounts of royalties, milestones or other payments due under the License Agreement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If disputes over intellectual
property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms,
or are insufficient to provide us the necessary rights to use the intellectual property, we may be unable to successfully develop
and commercialize the affected product candidates. If we or any such licensors fail to adequately protect this intellectual property,
our ability to commercialize our products could suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We will depend primarily on LSBD to file,
prosecute, maintain, defend and enforce intellectual property that we license from it and that is material to our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The intellectual property
relating to the GBS System is controlled by LSBD and licensed to us. LSBD generally has the right to file, prosecute, maintain
and defend the intellectual property we have licensed from LSBD. If LSBD or any other licensees and in some cases, co-owners from
which we do not yet have licenses, having rights to file, prosecute, maintain, and defend our intellectual property rights fail
to conduct these activities for intellectual property protection covering any of our product candidates, our ability to develop
and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making,
using or selling competing products. We cannot be certain that such activities by LSBD and any other licensors have been or will
be conducted in compliance with applicable laws and regulations or will result in valid and enforceable intellectual property rights.
Pursuant to the terms of the License Agreement with LSBD, it may have the right to control enforcement of our licensed intellectual
property or defense of any claims asserting the invalidity of that intellectual property and, even if we are permitted to pursue
such enforcement or defense, we cannot ensure the cooperation of LSBD. We cannot be certain that LSBD will be able to and effectively
allocate sufficient resources or prioritize their or our enforcement of such intellectual property or defense of such claims to
protect our interests in the licensed intellectual property. Even if we are not a party to these legal actions, an adverse outcome
could harm our business because it might prevent us from continuing to license intellectual property that we may need to operate
our business. In addition, even when we have the right to control prosecution of licensed intellectual property and related applications,
enforcement of licensed intellectual property, or defense of claims asserting the invalidity of that intellectual property, we
may still be adversely affected or prejudiced by actions or inactions of our licensors and their counsel that took place prior
to or after our assuming control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The failure to obtain or maintain licensing
agreements and other intellectual property could materially impact our ability to compete effectively.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In order for our business
to be viable and to compete effectively, we need to develop and maintain, and we will heavily rely on, our proprietary position
with respect to our technologies and intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There are significant risks
associated with our actual or proposed intellectual property. The risks and uncertainties that we face with respect to our proprietary
rights principally include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">pending intellectual property applications, we have filed or will file may not result in acquired intellectual property or may take longer than we expect to result in acquired intellectual property;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">we may be subject to interference proceedings;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">we may be subject to opposition proceedings in foreign countries;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any intellectual property that is acquired by us may not provide meaningful protection;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">we may not be able to develop additional proprietary technologies that is protectable;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">other companies may challenge intellectual property licensed or acquired by us;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">other companies may have independently developed and/or protected (or may in the future independently develop and protect) similar or alternative technologies, or duplicate our technologies;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a freedom-to-operate analysis has not been done to determine the IP rights that third parties may have related to this technology;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">other companies may design their technologies around technologies we have licensed or developed; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">enforcement of intellectual property is complex, uncertain and very expensive.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We cannot be certain that
intellectual property protection will be issued as a result of any of our pending or future applications, or that any of our intellectual
property, once issued, will provide us with adequate protection from competing products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">It is also possible that
others may have or may obtain intellectual property protection that could prevent us from commercializing our products or require
us to obtain licenses requiring the payment of significant fees or royalties in order to enable us to conduct our business. As
to the intellectual property that we have licensed, our rights depend on maintaining our obligations to the licensor under the
applicable license agreement, and we may be unable to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Costly litigation may be necessary to
protect our intellectual property rights and we may be subject to claims alleging the violation of the intellectual property rights
of others.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A freedom-to-operate analysis
will have to be done in China and other Licensed Territories to determine the rights that third parties may have related to this
technology in order to mitigate expensive litigation risks. We may face significant expense and liability as a result of litigation
or other proceedings relating to intellectual property rights of others. In the event that another party has intellectual property
protection relating to an invention or technology claimed by us or LSBD, we may be required to participate in an interference proceeding
declared by the regulatory authorities to determine priority of invention, which could result in substantial uncertainties and
costs for us, even if the eventual outcome was favorable to us. We, or our licensors, also could be required to participate in
interference proceedings involving intellectual property of another entity. An adverse outcome in an interference proceeding could
require us to cease using the technology, substantially modify it or to license rights from prevailing third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The cost to us of any intellectual
property litigation or other proceeding relating to our licensed intellectual property, even if resolved in our favor, could be
substantial, especially given our early stage of development. Our ability to enforce our intellectual property protection could
be limited by our financial resources, and may be subject to lengthy delays. A third party may claim that we are using inventions
claimed by their intellectual property and may go to court to stop us from engaging in our normal operations and activities, such
as research, development and the sale of any future products. Such lawsuits are expensive and would consume significant time and
other resources. There is a risk that a court will decide that we are infringing the third party&rsquo;s intellectual property
and will order us to stop the activities claimed by the intellectual property. In addition, there is a risk that a court will order
us to pay the other party damages for having infringed their intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Moreover, there is no guarantee
that any prevailing intellectual property owner would offer us a license so that we could continue to engage in activities claimed
by the intellectual property, or that such a license, if made available to us, could be acquired on commercially acceptable terms.
In addition, third parties may, in the future, assert other intellectual property infringement claims against us with respect to
our services, technologies or other matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have limited foreign intellectual
property rights and may not be able to protect our intellectual property rights throughout the China Region.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.7pt; text-align: justify; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.7pt; text-align: justify; text-indent: 0.45in">The only trademark
right identified in the Licensing Agreement is a common law trademark to &ldquo;Glucose Biosensor.&rdquo; Common law trademarks
are not recognized in China. Notwithstanding the terms of the Licensing Agreement, we may not be able to register the mark &ldquo;Glucose
Biosensor&rdquo; in China or other territories.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have limited intellectual
property rights, consisting primarily of intellectual property licensed from LSBD. Filing, prosecuting and defending intellectual
property on devices in all countries throughout the China Region would be prohibitively expensive, and our intellectual property
rights in some countries can be less extensive than those in the United States. In addition, the laws of some foreign countries
do not protect intellectual property to the same extent as laws in the United States. Consequently, we may not be able to prevent
third parties from practicing our inventions or from selling or importing products made using our inventions. Competitors may use
our technologies in jurisdictions where we have not obtained intellectual property rights to develop their own products and further,
may export otherwise infringing products to territories where we have intellectual property protection, but enforcement is not
as strong as that in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The legal systems of certain
countries, particularly China and certain other developing countries, do not favor the enforcement of trade secrets and other intellectual
property, particularly those relating to medical device products, which could make it difficult for us to stop the infringement
of our intellectual property or marketing of competing products in violation of our proprietary rights generally. Certain countries
in the China Region and developing countries, including China, have compulsory licensing laws under which an intellectual property
owner may be compelled to grant licenses to third parties. In those countries, we and LSBD may have limited remedies if our intellectual
property is infringed or if we or LSBD are compelled to grant a license to a third party, which could materially diminish the value
of that intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We and our principal licensor, LSBD,
rely on confidentiality agreements that could be breached and may be difficult to enforce, which could result in third parties
using our intellectual property to compete against us.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although we believe that
we and our principal licensor, LSBD, take reasonable steps to protect our intellectual property, including the use of agreements
relating to the non-disclosure of confidential information to third parties, as well as agreements that purport to require the
disclosure and assignment to us of the rights to the ideas, developments, discoveries and inventions of our employees and consultants
while we employ them, the agreements can be difficult and costly to enforce. Although we and LSBD seek to enter into these types
of agreements with contractors, consultants, advisors and research collaborators, to the extent that employees and consultants
utilize or independently develop intellectual property in connection with any of our projects, disputes may arise as to the intellectual
property rights associated with our technology. If a dispute arises, a court may determine that the right belongs to a third party.
In addition, enforcement of our rights can be costly and unpredictable. We and LSBD also rely on trade secrets and proprietary
know-how that we and LSBD may seek to protect in part by confidentiality agreements with employees, contractors, consultants, advisors
or others. Despite the protective measures we employ, we and LSBD still face the risk that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">these agreements may be breached;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">these agreements may not provide adequate remedies for the applicable type of breach;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our proprietary know-how will otherwise become known; or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our competitors will independently develop similar technology or proprietary information.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may be subject to claims challenging
the invention of the intellectual property that we license from LSBD.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">LSBD and we may be subject
to claims that former employees, collaborators or other third parties have an interest in intellectual property as an inventor
or co-inventor. For example, LSBD and we may have inventorship disputes arise from conflicting obligations of consultants or others
who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging
inventorship. If LSBD and we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual
property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a
material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in
substantial costs and be a distraction to management and other employees. As a result, it is unclear whether and, if so, to what
extent employees of LSBD or us may be able to claim compensation with respect to our future revenue. We may receive less revenue
from future products if any of employees of LSBD or us successfully claim compensation for their work in developing our intellectual
property, which in turn could impact our future profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have entered in to the
License Agreement with LSBD for intellectual property essential to us, the terms of which agreement present risks to us and our
business and prospects. In August 2017, the Company entered into the license relating to the saliva glucose biosensor system for
the China Region. The key highlights of the Licensing Agreement are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the Company must
                                    obtain regulatory approval in the China Region</FONT> within 24 months after the engagement
                                    of trading of the Shares on Nasdaq <FONT STYLE="font-size: 10pt">and this approval will flow
                                    through to the platform owned by LSBD;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the Company has certain naming rights to the biosensor and the system;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the Company must execute a Quality of Life clinical study prior to regulatory approval;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">within 24 months following receipt of all required regulatory approvals in China initially, the Company must have placed orders with the Licensor (or Authorised Supplier) for a minimum of commercial units;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">after 24 months, the Company must have placed orders each year with the Licensor (or Authorized Supplier) for the greater of a minimum of commercial units or an amount that is equivalent to the average of all distributors of Licensed Products sales in the previous 12 months multiplied by the Expected Market Growth plus a fixed percentage;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the Company must engage in a marketing campaign and ensure &ldquo;Share of Voice&rdquo; in the Territory must be at a fixed percentage no later than 12 months following receipt of all required regulatory approvals in China. The Share of Voice will be determined by the Licensor acting reasonably and relying on a reputable third-party report as to the applicable Share of Voice; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the Company will have access to the data generated by glucose monitoring but the data will be owned by LSBD.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to Our Industry</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We face intense competition in the self-monitoring
of glucose market, particularly blood-based products, and as a result we may be unable to effectively compete in our industry.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">With our first product,
the GBS System, we expect to compete directly and primarily with large medical device companies, as well as with second and third
tier companies having various levels of sophistication and resources. The large companies have most of the glucose monitoring business
and strong research and development capacity. Their dominant market position over the last few decades and significant control
over markets could significantly limit our ability to introduce the GBS System or effectively market and generate sales of the
product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have not yet entered
the commercial stage and most of our competitors have long histories and strong reputations within the industry. They have significantly
greater brand recognition, financial and human resources than we do. They also have more experience and capabilities in researching
and developing testing devices, obtaining and maintaining regulatory clearances and other requirements, manufacturing and marketing
those products than we do. There is a significant risk that we may be unable to overcome the advantages held by our competition,
and our inability to do so could lead to the failure of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Competition in the glucose
monitoring markets is intense, which can lead to, among other things, price reductions, longer selling cycles, lower product margins,
loss of market share and additional working capital requirements. To succeed, we must, among other critical matters, gain consumer
acceptance for the GBS System, technical solutions, prices and response time, or a combination of these factors, than those of
other competitors. If our competitors offer significant discounts on certain products, we may need to lower our prices or offer
other favorable terms in order to compete successfully. Moreover, any broad-based changes to our prices and pricing policies could
make it difficult to generate revenues or cause our revenues, if established, to decline. Moreover, if our competitors develop
and commercialize products that are more desirable than the GBS System or the other products that we may develop, we may not convince
customers to use our products. Any such changes would likely reduce our commercial opportunity and revenue potential and could
materially adversely impact our operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we or LSBD fail to respond quickly
to technological developments our products may become uncompetitive and obsolete.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The glucose monitoring
market may experience rapid technology developments, changes in industry standards, changes in customer requirements and frequent
new product introductions and improvements. If we or LSBD are unable to respond to these developments, we may lose competitive
position, and the GBS System or any other device or technology may become uncompetitive or obsolete, causing our business and prospects
to suffer. In order to compete, we and LSBD may have to develop, license or acquire new technology on a schedule that keeps pace
with technological developments and the requirements for products addressing a broad spectrum and designers and designer expertise
in our industries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If third-party payors do not provide
coverage and reimbursement for the use of the GBS System, our business and prospects may be negatively impacted.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Third-party payors, whether
foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare
costs. In addition, in certain countries, no uniform policy of coverage and reimbursement for medical device products and services
exists among third-party payors. Therefore, coverage and reimbursement for medical device products and services can differ significantly
from payor to payor. In addition, payors continually review new technologies for possible coverage and can, without notice, deny
coverage for these new products and procedures. As a result, the coverage determination process is often a time-consuming and costly
process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with
no assurance that coverage and adequate reimbursement will be obtained, or maintained if obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Reimbursement systems in
international markets vary significantly by country and by region within some countries, and reimbursement approvals must be obtained
on a country-by-country basis. In many international markets, a product must be approved for reimbursement before it can be approved
for sale in that country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Further, many international
markets have government-managed healthcare systems that control reimbursement for new devices and procedures. For example, no government
in the areas where we hold our license has approved reimbursement of the GBS System in particular. In most markets, there are private
insurance systems as well as government-managed systems. If sufficient coverage and reimbursement is not available for our current
or future products, in any country where our license operates, the demand for our products and our revenues will be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to Our Proposed Operations
in the China Region</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We intend to establish operations and
seek approval to commercialize the GBS System in the China Region, in particular in China, and a number of risks associated with
international operations could materially and adversely affect our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We expect to be subject
to a number of risks related with our international operations, many of which may be beyond our control. These risks include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">different regulatory requirements for medical product approvals in foreign countries;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">different standards of care in various countries that could complicate the evaluation of our product candidates;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">different U.S. and foreign medical product import and export rules;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">reduced protection for intellectual property rights in certain countries;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">unexpected changes in tariffs, trade barriers and regulatory requirements;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">different reimbursement systems and different competitive medical products indicated for glucose testing;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">compliance with the Foreign Corrupt Practices Act (the &ldquo;FCPA&rdquo;), and other anti-corruption and anti-bribery laws;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">foreign taxes, including withholding of payroll taxes;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">workforce uncertainty in countries where labor unrest is more common than in the U.S.;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">potential liability resulting from development work conducted by third party foreign distributors; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The medical device and other medical
product industries in China are highly regulated and such regulations are subject to change.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The medical devices and
other medical product industries in China are subject to comprehensive government regulation and supervision, encompassing the
approval, registration, manufacturing, packaging, licensing and marketing of new products. In recent years, the regulatory framework
in China regarding our industry has undergone significant changes, and we expect that it will continue to undergo significant changes.
Any such changes or amendments may result in increased compliance costs on our business or cause delays in or prevent the successful
development or commercialization of our product candidates in China. Chinese authorities have become increasingly vigilant in enforcing
laws in the medical devices and other medical product industries, in some cases launching industry-wide investigations, oftentimes
appearing to focus on foreign companies. The costs and time necessary to respond to an investigation can be material. Any failure
by us or our partners to maintain compliance with applicable laws and regulations or obtain and maintain required licenses and
permits may result in the suspension or termination of our business activities in China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Even if the GBS System is approved in
China, we may experience difficulties in successfully generating sales of the GBS System in China.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Even if the GBS System
is approved for sale in China, we may experience difficulties in our marketing, commercialization and sales efforts in China, and
our business and operations could be adversely affected. In particular, sales of the GBS System in China may be limited due to
the complex nature of the healthcare system, low average personal income, lack of patient cost reimbursement and pricing controls.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The retail prices of any product that
we develop may be subject to control, including periodic downward adjustment, by Chinese government authorities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The price for medical products
is highly regulated in China, both at the national and provincial level. Price controls may reduce prices to levels significantly
below those that would prevail in less regulated markets or limit the volume of products which may be sold, either of which may
have a material and adverse effect on potential revenues from sales of the GBS System in China. Moreover, the process and timing
for the implementation of price restrictions is unpredictable, which may cause potential revenues from the sales of the GBS System
to fluctuate from period to period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our operations in China would be subject
to restrictions on paying dividends or making other payments to us, which may restrict our ability to satisfy our liquidity requirements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A portion of our operations
may require a corporate presence, but not necessarily any manufacturing, marketing or distribution in China, through a subsidiary
to be located there. This presence is expected to be limited by our arrangements with independent distributors operating in China.
To the extent of any such corporate presence in China, we may rely on dividends and royalties paid by the subsidiary for a portion
of our cash needs, including the funds necessary to service any debt we may incur and to pay our operating expenses. The payment
of dividends by the subsidiary will be subject to limitations. Regulations in China currently permit payment of dividends only
out of accumulated profits as determined in accordance with accounting standards and regulations in China. Our subsidiary would
not be permitted to distribute any profits until losses from prior fiscal years have been recouped and in any event, must maintain
certain minimum capital requirements. Our subsidiary would also be required to set aside at least 10.0% of its after-tax profit
based on Chinese accounting standards each year to its statutory reserve fund until the cumulative amount of such reserves reaches
50.0% of its registered capital. Statutory reserves are not distributable as cash dividends. In addition, if our subsidiary incurs
debt on its own behalf in the future, the agreements governing such debt may restrict its ability to pay dividends or make other
distributions to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Any capital contributions from us to
our operating subsidiary in China must be approved by the Ministry of Commerce in China, and failure to obtain such approval may
materially and adversely affect the liquidity position of the subsidiary.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Ministry of Commerce
in China or its local counterpart must approve the amount and use of any capital contributions from us to any potential subsidiary
in China, and there can be no assurance that we will be able to complete the necessary government registrations and obtain the
necessary government approvals on a timely basis, or at all. If we fail to do so, we may not be able to contribute additional capital
to fund our Chinese operations, and the liquidity and financial position of the subsidiary may be materially and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may be subject to currency exchange
rate fluctuations and currency exchange restrictions with respect to our operations in China, which could adversely affect our
financial performance.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If the GBS System is approved
for sale in China, a portion of our product sales may occur in local Renminbi (&ldquo;RMB&rdquo;) and our operating results may
be subject to volatility from currency exchange rate fluctuations. We have not hedged and do not expect to hedge against the risks
associated with fluctuations in exchange rates and, therefore, exchange rate fluctuations could have an adverse impact on our future
operating results. Currently, the Renminbi is permitted to fluctuate within a narrow and managed band against a basket of certain
foreign currencies. Any significant currency exchange rate fluctuations may have a material adverse effect on our business and
financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, the Chinese
government imposes controls on the convertibility of the Renminbi into foreign currencies and the remittance of foreign currency
out of China for certain transactions. Shortages in the availability of foreign currency may restrict the ability of our operating
subsidiary in China to remit sufficient foreign currency to pay dividends or other payments to us, or otherwise satisfy their foreign
currency-denominated obligations. Under existing Chinese foreign exchange regulations, payments of current account items, including
profit distributions, interest payments and balance of trade, can be made in foreign currencies without prior approval from the
State Administration of Foreign Exchange (&ldquo;SAFE&rdquo;) by complying with certain procedural requirements. However, approval
from SAFE or its local branch is required where Renminbi is to be converted into foreign currency and remitted out of China to
pay capital expenses such as the repayment of loans denominated in foreign currencies. The Chinese government may also at its discretion
restrict access in the future to foreign currencies for current account transactions. If the foreign exchange control system prevents
us from obtaining sufficient foreign currency to satisfy our operational requirements, our liquidity and financial position may
be materially and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Because our China subsidiary&rsquo;s
funds will be held in banks that do not provide insurance, the failure of any bank in which it deposits its funds could adversely
affect our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Banks and other financial
institutions in China do not provide insurance for funds held on deposit. As a result, in the event of a bank failure, our China
subsidiary may not have access to funds on deposit. Depending upon the amount of money the subsidiary maintains in a bank that
fails, its inability to have access to cash could materially impair its operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may be subject to tax inefficiencies
and have not ascertained the impact of the new U.S. tax laws on the Company.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The tax regulations of
the U.S. and other jurisdictions in which we operate are extremely complex and subject to change. New laws, new interpretations
of existing laws, such as the Base Erosion Profit Shifting project initiated by the Organization for Economic Co-operation and
Development and any legislation proposed by the relevant taxing authorities, or limitations on our ability to structure our operations
and intercompany transactions may lead to inefficient tax treatment of our revenue, profits, royalties and distributions, if any
are achieved.&nbsp;&nbsp;In the U.S., in December 2017, comprehensive tax reform was enacted. We have not yet ascertained what
impact the new law will have on our future effective tax rate, corporate structure and the Company in general.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, we and our
foreign subsidiaries, none of which has been formed (other than Glucose Biosensor Systems (Greater China) Pty Ltd), will have various
intercompany transactions. We may not be able to obtain certain benefits under relevant tax treaties to avoid double taxation on
certain transactions among our subsidiaries. If we are not able to avail ourselves of the tax treaties, we could be subject to
additional taxes, which could adversely affect our financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our foreign operations, particularly
those in China, are subject to significant risks involving the protection of intellectual property.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We and LSBD may be required
to seek to protect the products and technology that we consider important to our business by pursuing intellectual property protections
in China and other countries, relying on intellectual property, trade secrets or medical product regulatory protection or employing
a combination of these methods. We note that the application for intellectual property protection does not mean that protection
will be granted, or that any protection eventually granted will be as broad as requested or will be sufficient to protect our technology.
There are a number of factors that could cause our intellectual property, if acquired, to become invalid or unenforceable or that
could cause our intellectual property protections not to be granted. Furthermore, the terms of the intellectual property owned
by LSBD and licensed by us are limited by what has been and/or may be granted under law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Intellectual property rights
and confidentiality protections in China may not be as effective as those in the U.S. or other countries for many reasons, including
lack of procedural rules for discovery and evidence, low damage awards, and lack of judicial independence. Implementation and enforcement
of China intellectual property laws have historically been deficient and ineffective and may be hampered by corruption and local
protectionism. Policing unauthorized use of proprietary technology is difficult and expensive, and we may need to resort to litigation
to enforce or defend our intellectual property or to determine the enforceability and validity of our proprietary rights or those
of others. The experience and capabilities of China courts in handling intellectual property litigation varies and outcomes are
unpredictable. An adverse determination in any such litigation could materially impair our intellectual property rights and may
harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We are subject to laws and regulations
governing business conduct, which will require us to develop and implement costly compliance programs.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We must comply with a wide
range of laws and regulations to prevent corruption, bribery, and other unethical business practices, including the FCPA, anti-bribery
and anti-corruption laws in other countries, particularly China. The creation and implementation of international business practices
compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Anti-bribery laws prohibit
us, our employees, and some of our agents or representatives from offering or providing any personal benefit to covered government
officials to influence their performance of their duties or induce them to serve interests other than the missions of the public
organizations in which they serve. Certain commercial bribery rules also prohibit offering or providing any personal benefit to
employees and representatives of commercial companies to influence their performance of their duties or induce them to serve interests
other than their employers. The FCPA also obligates companies whose securities are listed in the U.S. to comply with certain accounting
provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including
international subsidiaries, and devise and maintain an adequate system of internal accounting controls for international operations.
The anti-bribery provisions of the FCPA are enforced primarily by the Department of Justice. The SEC is involved with enforcement
of the books and records provisions of the FCPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Compliance with these anti-bribery
laws is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the anti-bribery
laws present particular challenges in the medical products industries because in many countries including China, hospitals are
state-owned or operated by the government, and doctors and other hospital employees are considered foreign government officials.
Furthermore, in certain countries (China in particular), hospitals and clinics are permitted to sell medical devices to their patients
and are primary or significant distributors of medical devices. Certain payments to hospitals in connection with clinical studies,
procurement of medical devices and other work have been deemed to be improper payments to government officials that have led to
vigorous anti-bribery law enforcement actions and heavy fines in multiple jurisdictions, particularly in the U.S. and China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">It is not always possible
to identify and deter violations, and the precautions we take to detect and prevent this activity may not be effective in controlling
unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming
from a failure to be in compliance with such laws or regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In the medical products
industries, corrupt practices include, among others, acceptance of kickbacks, bribes or other illegal gains or benefits by the
hospitals and medical practitioners from medical device manufacturers, distributors or their third-party agents in connection with
the prescription of certain medical devices or disposables. If our employees, affiliates, distributors or third-party marketing
firms violate these laws or otherwise engage in illegal practices with respect to their sales or marketing of our products or other
activities involving our products, we could be required to pay damages or heavy fines by multiple jurisdictions where we operate,
which could materially and adversely affect our financial condition and results of operations. The Chinese government has also
sponsored anti-corruption campaigns from time to time, which could have a negative effect on any future marketing efforts by us
to new hospital customers or intermediaries. There have been recent occurrences in which certain hospitals have denied access to
sales representatives from medical device companies because the hospitals wanted to avoid the perception of corruption. If this
attitude becomes widespread among our potential customers, our ability to promote our products to hospitals may be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As we expand our operations
in the China Region, we will need to increase the scope of our compliance programs to address the risks relating to the potential
for violations of the FCPA and other anti-bribery and anti-corruption laws. Our compliance programs will need to include policies
addressing not only the FCPA, but also the provisions of a variety of anti-bribery and anti-corruption laws in multiple jurisdictions,
including China, provisions relating to books and records that apply to us as a public company, and include effective training
for our personnel throughout our organization. The creation and implementation of anti-corruption compliance programs is costly
and such programs are difficult to enforce, particularly where reliance on third parties is required. Violation of the FCPA and
other anti-corruption laws can result in significant administrative and criminal penalties for us and our employees, including
substantial fines, suspension or debarment from government contracting, prison sentences, or even the death penalty in extremely
serious cases in certain countries. The SEC also may suspend or bar us from trading securities on U.S. exchanges for violation
of the FCPA&rsquo;s accounting provisions. Even if we are not ultimately punished by government authorities, the costs of investigation
and review, distraction of company personnel, legal defense costs, and harm to our reputation could be substantial and could limit
our profitability or our ability to develop or commercialize our product candidates. In addition, if any of our competitors are
not subject to the FCPA, they may engage in practices that will lead to their receipt of preferential treatment from foreign hospitals
and enable them to secure business from foreign hospitals in ways that are unavailable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Uncertainties with respect to the China
legal system could have a material adverse effect on us.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The legal system of China
is a civil law system primarily based on written statutes. Unlike in a common law system, prior court decisions may be cited for
reference but are not binding. Because the China legal system continues to rapidly evolve, the interpretations of many laws, regulations
and rules are not always uniform and enforcement of these laws, regulations and rules involve uncertainties, which may limit legal
protections available to us. Moreover, decision makers in the China judicial system have significant discretion in interpreting
and implementing statutory and contractual terms, which may render it difficult for our China subsidiary to enforce the contracts
it has entered into with our business partners, customers and suppliers. Different government departments may have different interpretations
of certain laws and regulations, and licenses and permits issued or granted by one government authority may be revoked by a higher
government authority at a later time. Navigating the uncertainty and change in the China legal system will require the devotion
of significant resources and time, and there can be no assurance that our contractual and other rights will ultimately be enforced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Changes in China&rsquo;s economic, political
or social conditions or government policies could have a material adverse effect on our business and operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Chinese economy and
Chinese society continue to undergo significant change. Adverse changes in the political and economic policies of the Chinese government
could have a material adverse effect on the overall economic growth of China, which could adversely affect our ability to conduct
business in China. The Chinese government continues to adjust economic policies to promote economic growth. Some of these measures
benefit the overall Chinese economy, but may also have a negative effect on us. For example, our financial condition and results
of operations in China may be adversely affected by government control over capital investments or changes in tax regulations.
As the Chinese medical products industries grow and evolve, the Chinese government may also implement measures to change the structure
of foreign investment in this industry. We are unable to predict any such policy changes, any of which could materially and adversely
affect our Chinese subsidiary&rsquo;s liquidity, access to capital and its ability to conduct business in China. Any failure on
our part to comply with changing government regulations and policies could result in the loss of our ability to develop and commercialize
our product candidates in China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our operations in China subject us to
various Chinese labor and social insurance laws, and our failure to comply with such laws may materially and adversely affect our
business, financial condition and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are subject to China
Labor Contract Law. The Labor Contract Law places certain restrictions on the circumstances under which employers may terminate
labor contracts and require economic compensation to employees upon termination of employment, among other things. In addition,
companies operating in China are generally required to contribute to labor union funds and the mandatory social insurance and housing
funds. Any failure by us to comply with Chinese labor and social insurance laws may subject us to late fees, fines and penalties,
or cause the suspension or termination of our ability to conduct business in China, any of which could have a material and adverse
effect on business, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Fluctuation in the value of the RMB may
have a material adverse effect on your investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The conversion of RMB into
foreign currencies, including U.S. dollars, is based on rates set by the People&rsquo;s Bank of China (&ldquo;PBOC&rdquo;). It
is difficult to predict how market forces or Chinese or U.S. government policy may impact the exchange rate between the RMB and
the U.S. dollar in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A substantial portion of
our revenues and costs may be denominated in RMB. Any significant revaluation of the RMB may materially affect our cash flows,
net revenues, earnings and financial position, and the value of, and any dividends payable on, our Common Stock in U.S. dollars.
For example, an appreciation of the RMB against the U.S. dollar would make any new RMB-denominated investments or expenditures
costlier to us, to the extent that we need to convert U.S. dollars into RMB for such purposes. Conversely, a significant depreciation
of the RMB against the U.S. dollar may significantly reduce the U.S. dollar equivalent of our earnings, which in turn could adversely
affect the price of our Common Stock. If we decide to convert RMB into U.S. dollars for the purpose of making payments for dividends
on our Common Stock, strategic acquisitions or investments or other business purposes, appreciation of the U.S. dollar against
the RMB would have a negative effect on the U.S. dollar amount available to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Very few hedging options
are available in China to reduce our exposure to exchange rate fluctuations. In addition, our currency exchange loss may be magnified
by Chinese exchange control regulations that restrict our ability to convert RMB into foreign currency. As a result, fluctuations
in exchange rates and restrictions on exchange may have a material adverse effect on your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to this Offering and the Ownership
of Our Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our parent company may exert significant
influence over our affairs, including the outcome of matters requiring stockholder approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of the date of this
Offering Circular, without giving effect to the recent private placement, our parent company, LSBD, has 100% beneficial ownership
of the Company. Even after the expected dilution on completion of this Offering, such parent will have the ability to control the
election of our directors and the outcome of corporate actions requiring stockholder approval, such as: (i) a merger or a sale
of our company, (ii) a sale of all or substantially all of our assets, and (iii) amendments to our certificate of incorporation
and by-laws. This concentration of voting power and control could have a significant effect in delaying, deferring or preventing
an action that might otherwise be beneficial to our other stockholders and be disadvantageous to our stockholders with interests
different from those individuals. Therefore, you should not invest in reliance on your ability to have any control over our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have broad discretion in the use of
the net proceeds from this offering and may use the net proceeds in ways with which you may not agree.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;Our management will
have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that do not
advance our business plan, achieve proposed objectives, improve our financial condition, generate revenue or enhance the value
of our securities. You will be relying on the judgment of our management with regard to the use of these net proceeds, and you
will not have the opportunity, as part of your investment decision, to assess whether the net proceeds are being used appropriately.
The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse
effect on our business, cause the price of our securities to decline and delay the development of our product candidates. Pending
the application of these funds, we may invest the net proceeds from this offering in a manner that does not produce income or that
loses value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Certain important information may not
be known and events may not have occurred at the time that an investor&rsquo;s investment decision to invest in the Shares becomes
irrevocable, thus creating doubt and related risk as to whether that information will be known and those events will occur as anticipated
if at all.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Certain important information
may not be known and events may not have occurred at the time that an investor&rsquo;s investment decision to invest in the Shares
becomes irrevocable. As noted elsewhere herein, including &ldquo;Risk Factors &ndash; Our shares of Common Stock are not and may
not be listed for trading on a national securities exchange&rdquo; below, an investor may not know whether our Common Stock will
be listed for trading on Nasdaq until after the investor&rsquo;s investment decision has become irrevocable. We will also be, if
we achieve Nasdaq listing for our Common Stock, a &ldquo;controlled company&rdquo; under the corporate governance standards for
Nasdaq listed companies and will be exempt from certain corporate governance requirements of the rules. In the event of such achievement,
we intend to utilize those exemptions. Accordingly, stockholders would not have the same protections afforded to stockholders of
companies that are subject to all of the Nasdaq corporate governance requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We qualify as a &ldquo;controlled
company&rdquo; within the meaning of the Nasdaq rules. As a result, we qualify for, and if Nasdaq listing is achieved intend to
rely on, exemptions from corporate governance requirements that provide protection to stockholders of other companies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Immediately following completion
of this offering, LSBD will control more than a majority of the total voting power of our outstanding Common Stock. As a result,
LSBD will be able to control the outcome of all matters submitted to a vote of our stockholders, including, for example, the election
of directors, amendments to our certificate of incorporation and mergers or other business combinations. See &ldquo;Description
of Capital Stock&rdquo;. In addition, we currently intend to utilize the controlled company exemption under the Nasdaq corporate
governance rules, and so you will not have the same protections afforded to stockholders of companies that are subject to such
requirements, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the requirement that a majority of our Board of Directors consist of &ldquo;independent directors&rdquo;;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the requirement that we have a compensation committee that is composed entirely of independent
directors with a written charter addressing the committee&rsquo;s purpose and responsibilities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the requirement that we have a nominating and corporate governance committee that is composed entirely
of independent directors with a written charter addressing the committee&rsquo;s purpose and responsibilities; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the requirement for an annual performance evaluation of the compensation and nominating and corporate
governance committees.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Accordingly, we will not
have a nominating and corporate governance committee and our compensation committee may not consist entirely of independent directors.
Accordingly, you will not have the same protections afforded to stockholders of companies that are subject to all of the corporate
governance requirements of the Nasdaq rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, Nasdaq has
developed listing standards regarding compensation committee independence requirements and the role and disclosure of compensation
consultants and other advisers to the compensation committee that, among other things, requires:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">compensation committees be composed of independent directors, as determined pursuant to new independence
requirements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">compensation committees be explicitly charged with hiring and overseeing compensation consultants,
legal counsel and other committee advisors; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">compensation committees be required to consider, when engaging compensation consultants, legal
counsel or other advisors, independence factors, including factors that examine the relationship between the consultant or advisor&rsquo;s
employer and us.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a controlled company, we will not be subject
to these compensation committee independence requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Investors in this offering will experience
immediate and substantial dilution in net tangible book value.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> You will incur immediate
and substantial dilution as a result of this offering. After giving effect to the sale by us of up to 2,083,334 shares of Common
Stock at an assumed public offering price of $12.00 per share, and before deducting the commissions and estimated offering expenses,
investors in this offering can expect an immediate dilution to net tangible assets (which excludes a value for the License Agreement)
of a decrease of $10.35 per share down from $12.00 to $1.65 immediately after the offering. See &ldquo;Dilution&rdquo; for a more
complete description of how the value of your investment in our Common Stock will be diluted upon the completion of this offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <B><I>&nbsp;</I></B> </P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Our shares of Common Stock are not and may not be listed for
trading on a national securities exchange.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have submitted an application
to list our Common Stock on The Nasdaq Stock Market (&ldquo;Nasdaq&rdquo;) under the symbol &ldquo;GBSG&rdquo;. There is no assurance
that this application will be approved and investors may not know at the time that their investment becomes irrevocable whether
this application will be approved or whether the Shares will ever be listed. Nonetheless, our Common Stock will not commence trading
on Nasdaq unless and until (i) the minimum amount of this Offering is closed; (ii) this Offering is terminated and (iii) we have
filed a post-qualification amendment to the Offering Statement, and a registration statement on Form 8-A (&ldquo;Form 8-A&rdquo;)
under the Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), and such post-qualification amendment is qualified
by the SEC and the Form 8-A has become effective. Pursuant to applicable rules under Regulation A, the Form 8-A will not become
effective until the SEC qualifies the post-qualification amendment. We intend to file the post-qualification amendment and request
its qualification immediately prior to the termination of the Offering in order that the Form 8-A may become effective as soon
as practicable. Even if we meet the minimum requirements for listing on Nasdaq, we may wait before terminating the Offering and
commencing the trading of our Common Stock on Nasdaq in order to raise additional proceeds. As a result, you may experience a delay
between the closing of your purchase of shares of our Common Stock and the commencement of exchange trading of our Common Stock
on Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Whether we meet Nasdaq&rsquo;s
minimum listing criteria will be determined by Nasdaq in its discretion. If we do not meet the criteria, or Nasdaq does not make
necessary discretionary exceptions, as to which there can be no assurance, then we will not be able to list our Common Stock on
Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There is no assurance that
such listing will ever be obtained. You may not be able to sell your securities at the time desired or at the price desired. The
failure of our securities to be approved for trading on Nasdaq may have the effect of limiting the trading activity of our securities
and reducing the liquidity of an investment in our Common Stock. The effects of not being able to list our securities on a national
exchange include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">limited dissemination of the market price of our securities;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">limited news coverage;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">limited interest by investors in our securities;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">volatility of the prices of our stock and any warrants we may issue, due to low trading volume;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">increased difficulty in selling our securities in certain states due to &ldquo;blue sky&rdquo; restrictions; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">limited ability to issue additional securities or to secure additional financing.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If we fail to meet the
minimum requirements for listing on Nasdaq, we may seek to have our Common Stock quoted over-the-counter, such as on the OTCQX.
The OTCQX is not a stock exchange, and if our Common Stock trades on the OTCQX rather than Nasdaq, there may be significantly less
trading volume and analyst coverage of, and significantly less investor interest in, our Common Stock, which may lead to lower
trading prices for our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If initially listed, we may not be able
to satisfy listing requirements of The Nasdaq Stock Market to maintain a listing of our Common Stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If our Common Stock is
listed on Nasdaq, we must meet certain financial and liquidity criteria to maintain such listing. If we violate the Nasdaq listing
requirements, our Common Stock may be delisted. If we fail to meet any of the Nasdaq&rsquo;s listing standards, our Common Stock
may be delisted. In addition, our board may determine that the cost of maintaining our listing on a national securities exchange
outweighs the benefits of such listing. A delisting of our Common Stock from Nasdaq may materially impair our stockholders&rsquo;
ability to buy and sell our Common Stock and could have an adverse effect on the market price of, and the efficiency of the trading
market for, our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The market price of our Common Stock
may be significantly volatile.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The market price for our
Common Stock may be significantly volatile and subject to wide fluctuations in response to factors including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">actual or anticipated fluctuations in our quarterly or annual operating results;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">changes in financial or operational estimates or projections;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">conditions in markets generally;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">changes in the economic performance or market valuations of companies similar to ours; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">general economic or political conditions in the United States or elsewhere.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In particular, the market
prices for securities of medical device companies have historically been particularly volatile. Some of the factors that may cause
the market price of our Common Stock to fluctuate include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any delay in or the results of our clinical trials;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any delay in manufacturing of our products;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any delay with the approval for reimbursement for the patients from their insurance companies;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our failure to comply with regulatory requirements;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the announcements of clinical trial data, and the investment community&rsquo;s perception of and reaction to those data;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the results of clinical trials conducted by others on products that would compete with ours;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any delay or failure to receive clearance or approval from regulatory agencies or bodies;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our inability to commercially launch products or market and generate sales of our products, including the GBS System;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">failure of the GBS System or any other products, even if approved for marketing, to achieve any level of commercial success;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our failure to obtain intellectual property protection for any of our technologies and products (including those related to the GBS System) or the issuance of third party intellectual property that cover our proposed technologies or products;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">developments or disputes concerning our product&rsquo;s intellectual property rights;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our or our competitors&rsquo; technological innovations;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">general and industry-specific economic conditions that may affect our expenditures;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">changes in market valuations of similar companies;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">announcements by us or our competitors of significant contracts, acquisitions, strategic partnerships, joint ventures, capital commitments, new technologies, or intellectual property;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">failure to adequately manufacture the GBS System or any other products through third parties;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">future sales of our Common Stock or other securities, including shares issuable upon the exercise of outstanding warrants or otherwise issued pursuant to certain contractual rights;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">period-to-period fluctuations in our financial results; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">low or high trading volume of our Common Stock due to many factors, including the terms of our financing arrangements.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, if we fail
to reach an important research, development or commercialization milestone or result by a publicly expected deadline, even if by
only a small margin, there could be significant impact on the market price of our Common Stock. Additionally, as we approach the
announcement of anticipated significant information and as we announce such information, we expect the price of our Common Stock
to be volatile and negative results would have a substantial negative impact on the price of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In some cases, following
periods of volatility in the market price of a company&rsquo;s securities, stockholders have often instituted class action securities
litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management
attention and resources, which could significantly harm our business operations and reputation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Shares eligible for future sale may adversely
affect the market for our Common Stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have a significant
number of shares of Common Stock underlying outstanding preferred stock and the convertible notes of our subsidiary GBS Pty Ltd.,
the future sale of which shares could depress the price of our publicly-traded stock. As of the date of this Offering Circular:
(i) 1,222,506 shares of Common Stock are issuable upon the completion of this Offering by mandatory conversion of such outstanding
preferred stock convertible at a one-to-one ratio; (ii) 517,358 shares of Common Stock are issuable upon the completion of this
Offering by mandatory conversion of $5,277,056 of such debt at an effective exercise price at a 15% discount to the price per
Share in this Offering; and (iii) and 1,222,506 shares of Common Stock are issuable during the one year period commencing on the
second anniversary of the completion of this Offering by exercise of outstanding warrants that were issued in connection with
the issuance of the preferred stock. In addition, from time to time, certain of our stockholders may be eligible to sell all or
some of their shares of Common Stock by means of ordinary brokerage transactions in the open market pursuant to Rule 144, promulgated
under the Securities Act, subject to certain limitations. In general, pursuant to Rule 144, after satisfying a six month holding
period: (i) affiliated stockholder (or stockholders whose shares are aggregated) may, under certain circumstances, sell within
any three month period a number of securities which does not exceed the greater of 1% of the then outstanding shares of Common
Stock or the average weekly trading volume of the class during the four calendar weeks prior to such sale and (ii) non-affiliated
stockholders may sell without such limitations, provided we are current in our public reporting obligations. Rule 144 also permits
the sale of securities by non-affiliates that have satisfied a one year holding period without any limitation or restriction.
Any substantial sale of our Common Stock pursuant to Rule 144 or pursuant to any resale report may have a material adverse effect
on the market price of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>As an &ldquo;emerging growth company&rdquo;
under applicable law, we will be subject to lessened disclosure requirements, which could leave our stockholders without information
or rights available to stockholders of more mature companies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For as long as we remain
an &ldquo;emerging growth company&rdquo; as defined in the JOBS Act, we have elected to take advantage of certain exemptions from
various reporting requirements that are applicable to other public companies that are not &ldquo;emerging growth companies&rdquo;
including, but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">taking advantage of an extension of time to comply with new or revised financial accounting standards;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We expect to take advantage
of these reporting exemptions until we are no longer an &ldquo;emerging growth company&rdquo;. Because of these lessened regulatory
requirements, our stockholders would be left without information or rights available to stockholders of more mature companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Because we have elected to use the extended
transition period for complying with new or revised accounting standards for an &ldquo;emerging growth company&rdquo; our financial
statements may not be comparable to companies that comply with public company effective dates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have elected to use
the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.
This election allows us to delay the adoption of new or revised accounting standards that have different effective dates for public
and private companies until those standards apply to private companies. While we are not currently delaying the implementation
of any relevant accounting standards, in the future we may avail ourselves of these rights, and as a result of this election, our
financial statements may not be comparable to companies that comply with public company effective dates. Because our financial
statements may not be comparable to companies that comply with public company effective dates, investors may have difficulty evaluating
or comparing our business, performance or prospects in comparison to other public companies, which may have a negative impact on
the value and liquidity of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our Common Stock may be considered a
 &ldquo;penny stock&rdquo;, and thereby be subject to additional sale and trading regulations that may make it more difficult to
sell.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Common Stock may be
considered to be a &ldquo;penny stock&rdquo; if it does not qualify for one of the exemptions from the definition of &ldquo;penny
stock&rdquo; under Section 3a51-1 of the Exchange Act. Our Common Stock may be a &ldquo;penny stock&rdquo; if it meets one or more
of the following conditions: (i) the stock trades at a price less than $5 per share; (ii) it is not traded on a &ldquo;recognized&rdquo;
national exchange; or (iii) is issued by a company that has been in business less than three years with net tangible assets less
than $5 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The principal result or
effect of being designated a &ldquo;penny stock&rdquo; is that securities broker-dealers participating in sales of our Common Stock
will be subject to the &ldquo;penny stock&rdquo; regulations set forth in Rules 15g-2 through 15g-9 promulgated under the Exchange
Act. Moreover, Rule 15g-9 requires broker-dealers in penny stocks to approve the account of any investor for transactions in such
stocks before selling any penny stock to that investor. This procedure requires the broker-dealer to: (i) obtain from the investor
information concerning his or her financial situation, investment experience and investment objectives; (ii) reasonably determine,
based on that information, that transactions in penny stocks are suitable for the investor and that the investor has sufficient
knowledge and experience as to be reasonably capable of evaluating the risks of penny stock transactions; (iii) provide the investor
with a written statement setting forth the basis on which the broker-dealer made the determination in (ii) above; and (iv) receive
a signed and dated copy of such statement from the investor, confirming that it accurately reflects the investor&rsquo;s financial
situation, investment experience and investment objectives. Compliance with these requirements may make it more difficult and time
consuming for holders of our Common Stock to resell their shares to third parties or to otherwise dispose of them in the market
or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our compliance with complicated U.S.
regulations concerning corporate governance and public disclosure is expensive. Moreover, our ability to comply with all applicable
laws, rules and regulations is uncertain given our management&rsquo;s relative inexperience with operating U.S. public companies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a publicly reporting
company, we are faced with expensive and complicated and evolving disclosure, governance and compliance laws, regulations and standards
relating to corporate governance and public disclosure, including the Sarbanes-Oxley Act and the Dodd-Frank Act. New or changing
laws, regulations and standards are subject to varying interpretations in many cases due to their lack of specificity, and, as
a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies, which
could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure
and governance practices. As a result, our efforts to comply with evolving laws, regulations and standards of a U.S. public company
are likely to continue to result in increased general and administrative expenses and a diversion of management time and attention
from revenue-generating activities to compliance activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Moreover, our executive
officers have little experience in operating a U.S. public company, which makes our ability to comply with applicable laws, rules
and regulations uncertain. Our failure to company with all laws, rules and regulations applicable to U.S. public companies could
subject us or our management to regulatory scrutiny or sanction, which could harm our reputation and stock price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Anti-takeover provisions in our charter
documents and Delaware law could discourage, delay or prevent a change in control of our company and may affect the trading price
of our Common Stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are a Delaware corporation
and the anti-takeover provisions of the Delaware General Corporation Law may discourage, delay or prevent a change in control
by prohibiting us from engaging in a business combination with an interested stockholder for a period of three years after the
person becomes an interested stockholder, even if a change in control would be beneficial to our existing stockholders. In addition,
our certificate of incorporation and by-laws may discourage, delay or prevent a change in our management or control over us that
stockholders may consider favorable. Our certificate of incorporation and by-laws currently provide for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the issuance of &ldquo;blank check&rdquo; preferred stock
    that could be issued by our Board of Directors to thwart a takeover attempt;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">that vacancies on our Board of Directors, including newly created directorships, may be
    filled only by a majority vote of directors then in office;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">that special meetings of stockholders may only be called
    by our Chief Executive Officer, our Board of Directors or a majority of our stockholders;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">not provide stockholders with the ability to cumulate their votes; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">provide that our Board of Directors or our stockholders may
    amend our by-laws.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We do not currently intend to pay dividends
on our Common Stock in the foreseeable future, and consequently, your ability to achieve a return on your investment will depend
on appreciation in the price of our Common Stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We do not anticipate paying
any cash dividends to holders of our Common Stock in the foreseeable future. Consequently, investors must rely on sales of their
Common Stock after price appreciation, which may never occur, as the only way to realize any future gains on their investments.
There is no guarantee that shares of our Common Stock will appreciate in value or even maintain the price at which our stockholders
have purchased their shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>As a result of becoming a public company,
we will be obligated to develop and maintain a system of effective internal control over financial reporting. We may not complete
our analysis of our internal control over financial reporting in a timely manner, or these internal controls may not be determined
to be effective, which may harm investor confidence in our company and, as a result, the value of our Common Stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We will be required, pursuant
to Section 404 of the Sarbanes-Oxley Act, to furnish a report by management on, among other things, the effectiveness of our internal
control over financial reporting in the second annual report we file with the SEC. This assessment will need to include disclosure
of any material weaknesses identified by our management in our internal control over financial reporting. However, our auditors
will not be required to formally attest to the effectiveness of our internal control over financial reporting pursuant to Section
404 until we are no longer an &ldquo;emerging growth company&rdquo; as defined in the JOBS Act if we take advantage of the exemptions
available to us through the JOBS Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are in the very early
stages of the costly and challenging process of compiling the system and process documentation necessary to perform the evaluation
needed to comply with Section 404. In this regard, we will need to continue to dedicate internal resources, engage outside consultants
and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps
to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement
a continuous reporting and improvement process for internal control over financial reporting. As we transition to the requirements
of reporting as a public company, we may need to add additional finance staff. We may not be able to remediate any future material
weaknesses, or to complete our evaluation, testing and any required remediation in a timely fashion. During the evaluation and
testing process, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable
to assert that our internal controls are effective. If we are unable to assert that our internal control over financial reporting
is effective, or if our auditors are unable to express an opinion on the effectiveness of our internal controls when they are required
to issue such opinion, investors could lose confidence in the accuracy and completeness of our financial reports, which could harm
our stock price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The Company has engaged in certain transactions
with related persons.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Please see the section
of this Offering Circular entitled &ldquo;Interest of Management and Others in Certain Transactions.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The Company may undertake additional
equity or debt financing that may dilute the shares in this offering.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company may undertake
further equity or debt financing which may be dilutive to existing shareholders, including you, or result in an issuance of securities
whose rights, preferences and privileges are senior to those of existing shareholders, including you, and also reducing the value
of shares subscribed for under this Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If the maximum offering is not raised,
it may increase the amount of long-term debt or the amount of additional equity we need to raise.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There is no assurance that
the maximum number of Shares in this offering will be sold. If the maximum Offering amount is not sold, we may need to incur indebtedness
or raise additional equity in order to finance our operations. Incurring debt will create debt service obligations and make less
cash available for operations. Increasing the amount of additional equity that we will have to seek in the future will further
dilute those investors participating in this Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Investor funds will not accrue interest
while in escrow prior to closing.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Until we achieve the minimum
offering amount, the proceeds for the Offering will be kept in an escrow account. Upon achievement of the minimum offering amount
and the closing on such amount, the proceeds from the minimum offering amount will be distributed to the Company and the associated
Shares will be issued to the investors in the Initial Closing. If the Offering does not close for any reason, the proceeds for
the Offering will be promptly returned to investors, without deduction and generally without interest. Prime Trust, LLC will serve
as the escrow agent. Proceeds from investors after the Initial Closing also will be kept in escrow subject to an Additional Closing,
each of which the Company may undertake from time to time on a rolling basis without any minimum amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The Company has made assumptions in its
projections and in forward-looking statements that may not be accurate.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The discussions and information
in this Offering Circular may contain both historical and &ldquo;forward-looking statements&rdquo; which can be identified by the
use of forward-looking terminology including the terms &ldquo;believes,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;continues,&rdquo;
 &ldquo;expects,&rdquo; &ldquo;intends,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; &ldquo;should,&rdquo;
or, in each case, their negative or other variations or comparable terminology. You should not place undue reliance on forward-looking
statements. These forward-looking statements include matters that are not historical facts. Forward-looking statements involve
risk and uncertainty because they relate to future events and circumstances. Forward-looking statements contained in this Offering
Circular, based on past trends or activities, should not be taken as a representation that such trends or activities will continue
in the future. To the extent that the Offering Circular contains forward-looking statements regarding the financial condition,
operating results, business prospects, or any other aspect of the Company&rsquo;s business, please be advised that the Company&rsquo;s
actual financial condition, operating results, and business performance may differ materially from that projected or estimated
by the Company. The Company has attempted to identify, in context, certain of the factors it currently believes may cause actual
future experience and results to differ from its current expectations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The Company has significant discretion
over the net proceeds of this offering.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company has significant
discretion over the net proceeds of this Offering. As is the case with any business, particularly one without a proven business
model, it should be expected that certain expenses unforeseeable to management at this juncture will arise in the future. There
can be no assurance that management&rsquo;s use of proceeds generated through this offering will prove optimal or translate into
revenue or profitability for the Company. Investors are urged to consult with their attorneys, accountants and personal investment
advisors prior to making any decision to invest in the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The offering price for the shares offered
has been determined by the Company.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The price at which the
Shares are being offered has been arbitrarily determined by the Company. There is no relationship between the offering price and
our assets, book value, net worth, or any other economic or recognized criteria of value. Rather, the price of the Shares was derived
as a result of internal decisions based upon various factors including prevailing market conditions, our future prospects and our
capital structure. These prices do not necessarily accurately reflect the actual value of the Shares or the price that may be realized
upon disposition of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The preparation of our financial statements
involves the use of estimates, judgments and assumptions, and our financial statements may be materially affected if such estimates,
judgments or assumptions prove to be inaccurate.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Financial statements prepared
in accordance with accounting principles generally accepted in the United States of America typically require the use of estimates,
judgments and assumptions that affect the reported amounts. Often, different estimates, judgments and assumptions could reasonably
be used that would have a material effect on such financial statements, and changes in these estimates, judgments and assumptions
may occur from period to period over time. Significant areas of accounting requiring the application of management&rsquo;s judgment
include, but are not limited to, determining the fair value of assets and the timing and amount of cash flows from assets. These
estimates, judgments and assumptions are inherently uncertain and, if our estimates were to prove to be wrong, we would face the
risk that charges to income or other financial statement changes or adjustments would be required. Any such charges or changes
could harm our business, including our financial condition and results of operations and the price of our securities. See &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations&rdquo; for a discussion of the accounting estimates, judgments
and assumptions that we believe are the most critical to an understanding of our financial statements and our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If securities industry analysts do not
publish research reports on us, or publish unfavorable reports on us, then the market price and market trading volume of our Common
Stock could be negatively affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any trading market for
our Common Stock will be influenced in part by any research reports that securities industry analysts publish about us. We do not
currently have and may never obtain research coverage by securities industry analysts. If no securities industry analysts commence
coverage of us, the market price and market trading volume of our Common Stock could be negatively affected. In the event we are
covered by analysts, and one or more of such analysts downgrade our securities, or otherwise reports on us unfavorably, or discontinues
coverage or us, the market price and market trading volume of our Common Stock could be negatively affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We will incur increased costs as a result
of operating as a public company and our management will be required to devote substantial time to new compliance initiatives and
corporate governance practices.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a public company, and
particularly after we are no longer an &ldquo;emerging growth company,&rdquo; we will incur significant legal, accounting and other
expenses that we did not incur as a private company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection
Act, the listing requirements of Nasdaq and other applicable securities rules and regulations impose various requirements on public
companies. Our management and other personnel will need to devote a substantial amount of time to compliance with these requirements.
Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more
time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive
for us to obtain directors&rsquo; and officers&rsquo; liability insurance, which could make it more difficult for us to attract
and retain qualified members of our board of directors. We cannot predict or estimate the amount of additional costs we will incur
as a public company or the timing of such costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Future issuances of our Common Stock
or securities convertible into our Common Stock, or the expiration of lock-up agreements that restrict the issuance of new Common
Stock or the trading of outstanding Common Stock, could cause the market price of our Common Stock to decline and would result
in the dilution of your holdings.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Future issuances of
our Common Stock or securities convertible into our Common Stock, or the expiration of lock-up agreements that restrict the issuance
of new Common Stock or the trading of outstanding Common Stock, could cause the market price of our Common Stock to decline. We
cannot predict the effect, if any, of future issuances of our Common Stock or securities convertible into our Common Stock, or
the future expirations of lock-up agreements, on the price of our Common Stock. In all events, future issuances of our Common
Stock would result in the dilution of your holdings. In addition, the perception that new issuances of our Common Stock, or other
securities convertible into our Common Stock, could occur, or the perception that locked-up parties will sell their securities
when the lock-ups expire, could adversely affect the market price of our Common Stock. Further, our directors, officers and more
than 5% stockholders will enter into agreements pursuant to which, subject to certain exceptions, such persons will not sell any
shares of our Common Stock that they own for one year after the date of this Offering Circular, as further described in &ldquo;Plan
of Distribution&rdquo;.&nbsp;Other investors in our outstanding Series A Convertible Preferred Stock and the notes issued by our
98%-owned subsidiary GBS Pty Ltd, all of which automatically convert into shares of Common Stock immediately prior to the initial
closing of this Offering, have agreed to the same lock-up, but for a period of 180 days rather than one year. In addition to any
adverse effects that may arise upon the expiration of these lock-up agreements, the lock-up provisions in these agreements may
be waived, at any time and without notice. If the restrictions under the lock-up agreements are waived, our Common Stock may become
available for resale, subject to applicable law, including without notice, which could reduce the market price for our Common
Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Neither the Offering nor the Shares have
been registered under Federal or State Securities Laws, leading to an absence of certain regulation applicable to the Company.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company also has relied
on exemptions from securities registration requirements under applicable federal securities laws. Investors in the Company, therefore,
will not receive any of the benefits that such registration would otherwise provide. Prospective investors must therefore assess
the adequacy of disclosure and the fairness of the terms of this Offering on their own or in conjunction with their personal advisors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">IN ADDITION TO THE RISKS
LISTED ABOVE, BUSINESSES ARE OFTEN SUBJECT TO RISKS NOT FORESEEN OR FULLY APPRECIATED BY MANAGEMENT. IT IS NOT POSSIBLE TO FORESEE
ALL RISKS THAT MAY AFFECT THE COMPANY. MOREOVER, THE COMPANY CANNOT PREDICT WHETHER THE COMPANY WILL SUCCESSFULLY EFFECTUATE THE
COMPANY&rsquo;S CURRENT BUSINESS PLAN. EACH PROSPECTIVE PURCHASER IS ENCOURAGED TO CAREFULLY ANALYZE THE RISKS AND MERITS OF AN
INVESTMENT IN THE SECURITIES AND SHOULD TAKE INTO CONSIDERATION WHEN MAKING SUCH ANALYSIS, AMONG OTHER FACTORS, THE RISK FACTORS
DISCUSSED ABOVE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="partii_0022"></A><B>CAPITALIZATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table sets forth our capitalization as of June
30, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">on
                                         an actual basis;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">on a pro forma basis, assuming
                                         the sale in this Offering of the minimum amount of shares being offered, at an assumed
                                         offering price to the public of $12.00 per share, resulting in net proceeds to us of
                                         $7,620,000 (after deducting underwriting discount and commissions of $630,000 and our
                                         estimated other offering expenses of $750,000); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">on a pro forma, as adjusted
                                         basis, assuming the sale in this offering of the maximum amount of shares being offered,
                                         at an assumed offering price to the public of $12.00 per share, resulting in net proceeds
                                         to us of $22,500,000 (after deducting underwriting discount and commissions of $1,750,000
                                         and our estimated other offering expenses of $750,000).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">You should read this table together
with our audited consolidated financial statements as of and for the year ended June&nbsp;30, 2017 and the year ended June 30,
2018 and the related notes thereto, included elsewhere in this Offering Circular. Our use of proceeds from this offering is discussed
under &ldquo;Use of Proceeds.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>As&nbsp;of&nbsp;June
    30,&nbsp;2018</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Actual</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Audited)</B></P></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Pro&nbsp;Forma</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Assuming</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Minimum</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Offering</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Amount</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Pro&nbsp;Forma</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Assuming</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Maximum</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Offering</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Amount</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Stockholders&rsquo; equity (deficit):</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 55%; padding-left: 0.25in; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Preferred Shares, $0.01 par
    value, 2,000,000 shares authorized, 1,222,506 shares issued and outstanding as of June 30, 2018<SUP>1</SUP></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">8,715,794</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 0.25in; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Common Shares, $0.01 par value, 20,000,000
    shares authorized, 9,000,000 shares issued and outstanding as of June 30, 2018</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 0.25in; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Ordinary Shares, 2,036,000 shares issued
    and outstanding as of June 30, 2018<SUP>2</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,314,494</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,314,494</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,314,494</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 0.25in; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Additional paid-in capital</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(8,333,033</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;10,476,804</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><SUP>3</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;25,356,804</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><SUP>3</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 0.25in; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Accumulated deficit</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(5,332,055</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(5,332,055</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(5,332,055</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 0.25in; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Accumulated Other comprehensive income</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">571,105</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">571,105</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">571,105</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Total stockholders&rsquo; equity (deficit)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(3,063,694</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7,030,349</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><SUP>4</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">21,909,349</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Total capitalization</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(3,063,694</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7,030,349</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">21,909,349</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><SUP>1</SUP> These shares automatically convert to shares of
our Common Stock in connection with the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><SUP>2</SUP> These ordinary shares are
issued by our 98%-owned subsidiary, GBS Pty Ltd, and remain outstanding following the completion of this Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><SUP>3 </SUP>These amounts equal the net
proceeds raised in the minimum and maximum offerings $(7,620,000 and $22,500,000, respectively), plus the aggregate outstanding
amount of the convertible notes issued by GBS Pty Ltd $(5,277,056) as of June 30, 2018, minus deferred charges and unamortized
debt issuance costs to be written off against share capital in connection with this Offering $(2,420,252).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><SUP>4</SUP> These amounts include the
automatic conversion of the foregoing convertible notes into 517,358 shares of Common Stock at a price per share equal to $10.20
(representing a 15% discount to the $12.00 price per share in this Offering).</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The table above excludes the following
securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,222,506
                                         shares issuable upon the exercise of outstanding warrants issued in connection with the
                                         placement of our Series A Convertible Preferred Stock, at an exercise price of $12.00
                                         per share, which warrants are exercisable only during the one-year period commencing
                                         on the second anniversary of the closing of this Offering;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">500,000
                                         shares that will become available for future issuance under our 2017 Equity Incentive
                                         Plan; and </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">conversion
                                         of the warrants (the &ldquo;Placement Agent Warrants&rdquo;) to purchase shares of Common
                                         Stock equal to 5.0% of the aggregate Shares sold in this Offering, which Placement Agent
                                         Warrants will be for the purchase of&nbsp;37,500 shares in the event the minimum number
                                         of Shares is sold and 104,167 shares in the event the maximum number of Shares is sold.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_005"></A>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term &ldquo;dilution&rdquo;
refers to the reduction (as a percentage of the aggregate Shares outstanding) that occurs for any given share of stock when additional
shares are issued. If all of the Shares in this offering are fully subscribed and sold, the Shares offered herein will constitute
approximately 16.2% of the total Shares of stock of the Company (excluding the impact of outstanding warrants). The Company anticipates
that subsequent to this offering the Company may require additional capital and such capital may take the form of Common Stock,
other stock or securities or debt convertible into stock. Such future fund-raising will further dilute the percentage ownership
of the Shares sold herein in the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The share
and per share amounts set forth below reflects the reverse stock split of approximately one to 0.916 shares that resulted
in 8,250,000 shares of Common Stock being issued and outstanding on August 9, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> If you invest in
our Common Stock, your interest will be diluted immediately to the extent of the difference between the offering price per share
of our Common Stock and the pro forma net tangible book value per share of our Common Stock after this offering. As of June 30,
2018, the net tangible book value of the Company was approximately negative $5,046,817 (including the impact of outstanding convertible
notes issued by our 98%-owned subsidiary GBS Pty Ltd) since the Company has not generated any revenue to date. Based on 8,250,000
shares of Common Stock issued and outstanding as of the date of this Offering Circular, that equates to a net tangible book value
of approximately minus $0.61 per share on a pro forma basis. Net tangible book value per share consists of shareholders&rsquo;
equity adjusted for the intangible assets, divided by the total number of shares outstanding. The pro forma net tangible book
value, assuming full subscription in this Offering, would be $1.65 per share. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Thus, if the Offering
is fully subscribed, the net tangible book value per share owned by our current shareholders will have immediately increased by
approximately $2.23 without any additional investment on their part and the net tangible book value per Share for new investors
will be immediately diluted to $1.65 per Share, which represents a $10.35 dilution per share to new investors. These calculations
do not include the costs of the Offering and dilution from exercising of warrants, will cause further dilution. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
illustrates this per Share dilution:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="border-collapse: collapse; width: 93%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%"> Offering price per Share* </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 10%; text-align: right"> 12.00 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Net Tangible Book Value per Share before Offering (based on 8,250,000 shares) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> (0.61 </TD><TD STYLE="text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Increase in Net Tangible Book Value per Share Attributable to Shares Offered Hereby (based
    on 2,083,334 shares***) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.26 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Net Tangible Book Value per Share after Offering and Conversion of Preferred Stock and Convertible
    Notes (based on 12,073,198 shares) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.65 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Dilution of Net Tangible Book Value per Share to Purchasers in this Offering** </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 10.35 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
</TABLE><BR STYLE="clear: both"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">* Before deduction
of offering expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">** Excludes the value of the
License Agreement due to it being intangible in nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> *** Being total amount of
shares at completion of maximum offering, conversion of convertible notes and convertible preference shares. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is a material
disparity between the price of the Shares in this Offering and the effective cash cost to existing shareholders for Shares acquired
by them in a transaction during the past year. The Company&rsquo;s operations to date have been funded by LSBD as well as by $13,992,849
proceeds from the equivalent of 1,739,864 shares of Common Stock in preferred stock, warrants and convertible note issuances.
As a result, the average effective cash contribution for shares acquired by them in a transaction during the past year was approximately
$8.04 per share, whereas the public contribution under this public offering will be $12.00 per share.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
sets forth, assuming the sale of 2,083,334 shares of our Common Stock offered for sale if the maximum amount is sold in this Offering,
as of the date hereof, the total number of shares previously issued and sold to existing investors including holders of our Series
A Convertible Preferred Stock and holders of our subsidiary&rsquo;s notes convertible into our Common Stock, the total consideration
paid for the foregoing and the average price per share. As the table shows, new investors purchasing shares of Common Stock may
in certain circumstances pay an average price per share substantially higher than the average price per shares paid by our existing
stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Purchased</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Total</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Consideration</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Date Hereof</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percent</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percent</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font-weight: bold; text-align: left">Existing Stockholders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">8,250,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">68.3</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">0.0</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Convertible Note Holders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">517,358</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.3</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,277,056</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13.5</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Convertible Preferred Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,222,506</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10.1</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,715,793</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22.4</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">New Investors (maximum offering)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,083,334</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17.3</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">25,000,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">64.1</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; padding-left: 10pt">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">12,073,198</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">100.00</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">%</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">38,992,850</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">100.00</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">%</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_007" TITLE="Plan of Distribution"></A>PLAN OF DISTRIBUTION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
this offering, we will enter into a placement agency agreement with Cuttone &amp; Co., LLC on or immediately prior to the date
on which the SEC initially qualifies the Offering Statement (the &ldquo;Qualification Date&rdquo;), pursuant to which Cuttone
will offer the Shares on a &ldquo;best efforts, minimum-maximum basis.&rdquo; The minimum offering amount is $9,000,000; and the
maximum offering amount is $25,000,000.&nbsp;Subject to certain conditions, Cuttone &amp; Co., LLC (&ldquo;Cuttone&rdquo;
or the Placement Agent) has agreed to use its best efforts to procure potential purchasers for the Offered Shares. This offering
is being undertaken on a best efforts only basis. The Placement Agent is not required to take or pay for any specific number or
dollar amount of our Common Stock. The Placement Agent will have the right to engage such other FINRA member firms as it determines
to assist in this offering. The Shares will initially be offered at the initial public offering price set forth on the cover of
this Offering Circular by the Placement Agent and by the participating broker-dealers included in the Placement Agent&rsquo;s
selling group syndicate (each a &ldquo;Dealer&rdquo; and collectively the &ldquo;Dealers&rdquo;), who will then sell the Shares
to the public at the initial public offering price. Sales commissions will be paid to the Dealers by the Placement Agent after
closing of the offering. We will not offer any discounts or pay any fees directly to the Dealers. After the initial offering of
the Shares, the offering price and other selling terms may be subject to change. The offering of the Shares is subject to receipt
and acceptance and subject to the right of the Company to reject any subscription in whole or in part, for any reason or no reason.
Neither the Placement Agent, nor any of its affiliates have provided any services to us or our affiliates in the past.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
Shares will be issued in one or more closings. For the Initial Closing and each Additional Closing, all proceeds for such
closing will be kept in an escrow account maintained by the Escrow Agent, Prime Trust, 2300 West Sahara, Suite 1170, Las
Vegas, NV 89102, which is a &quot;bank&quot; under Rule 15c2-4, for the benefit of the investors in accordance with Rule
15c2-4 under the Exchange Act. Upon each closing, the proceeds collected for such closing will be disbursed to the Company
and the Shares for such closing will be issued to investors. The Placement Agent and the participating broker-dealers must
sell the minimum number of shares set forth in this Offering Circular (the &ldquo;Minimum Offering&rdquo;). Neither the
Underwriter nor the Dealers have any obligation to sell any Shares. Sales of Shares to affiliates and persons associated with
the Placement Agent and the Company, if any, will be included for purposes of satisfying the Minimum Offering Amount. The
escrow account will be opened immediately prior to the Qualification Date and will remain open until the offering terminates
without the Minimum Offering having been reached, or if the Initial Closing occurs, until the last Additional Closing date.
All funds received into the escrow account will be held in an account in accordance with Rule 15c2-4 under the Exchange Act.
All funds will be transmitted directly by wire or electronic funds transfer via ACH to the specified bank account maintained
by the Escrow Agent per the instructions in the subscription agreement. The Escrow Agent may accept checks from investors if
such investors meet certain eligibility requirements. The Placement Agent will not accept or handle any funds. The
subscription agreement will be available at <U>________</U>. The Escrow Agent will notify the Placement Agent when the full
amount necessary to purchase the Minimum Offering has been received. If, on the Termination Date, investor funds are not
received in respect of the Minimum Offering, then all investor funds that were deposited into the escrow account will be
returned promptly to investors, without interest and without deduction, and the offering will terminate.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Technology and Escrow Services</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company will
enter into an escrow agreement with Prime Trust, a Nevada registered trust company, under which Prime Trust will hold in escrow
all proceeds of this Offering until gross proceeds of $9,000,000 are realized from the sale of 750,000 shares of Common Stock.
Such escrow account and escrow funds shall be maintained in a manner that is compliant with SEC Rules 10b-9 and 15c2-4 as promulgated
under the Securities Exchange Act of 1934, as amended. In addition, Prime Trust will perform the following administrative functions
in connection with this Offering in addition to acting as the escrow agent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">review the subscription agreements to determine
    whether all of the necessary information has been obtained from the investors, to determine compliance with the investment
    limitation requirement, and to perform anti-money laundering checks;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">contact the investors if necessary to gather
    additional information or clarification;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">provide us with prompt notice for subscriptions
    that cannot be accepted; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">transmit the subscription information data
    to our transfer agent.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company will
also enter into a technology services agreement with Prime Trust, under which Prime Trust will provide certain technology services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As compensation
for the escrow services and administrative functions listed above, we have agreed to pay Prime Trust a fixed amount per each domestic
investor and per each international investor to conduct an anti-money laundering check. In addition, we will pay Prime Trust a
flat fee for account set up, a monthly fee for so long as this Offering is being conducted, and up to a fixed amount per investor
for processing incoming funds. In addition, as compensation for the technology services, we will pay Prime Trust a flat license
fee, a monthly fee for &lsquo;Invest Now&rsquo; button technology, and a fixed fee for each subscription agreement executed via
electronic signature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prime Trust is
not participating as an underwriter or placement agent or sales agent of this Offering and will not solicit any investment in
the Company, recommend the Company&rsquo;s securities or provide investment advice to any prospective investor, and no communication
through any medium, including any website, should be construed as such, or distribute this Offering Circular or other offering
materials to investors. The use of Prime Trust&rsquo;s technology should not be interpreted and is not intended as an endorsement
or recommendation by it of the Company or this Offering. All inquiries regarding this Offering or escrow should be made directly
to the Company.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></P>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Engagement Agreement with the Placement
Agent</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are currently party to an engagement
agreement with Cuttone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Offering Expenses</I>.</B> We
are responsible for all offering fees and expenses, including the following: (i) fees and disbursements of our legal counsel,
accountants, and other professionals we engage; (ii) fees and expenses incurred in the production of offering documents, including
design, printing, photograph, and written material procurement costs; (iii) all filing fees, including FINRA and blue sky filing
fees; (iv) all of the legal fees related to the registration and qualification of the Shares under state securities laws and FINRA
clearance; and (v) our transportation, accommodation, and other roadshow expenses. We are obligated to reimburse the Placement
Agent for reasonable travel expenses and other out-of-pocket expenses including legal fees and diligence costs associated or incurred
in connection with the offering, in an aggregate amount of $150,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Reimbursable Expenses in the
Event of Termination</I>.</B> In the event the offering does not close or the engagement agreement is terminated for any reason
(other than termination due to the Placement Agent&rsquo;s material failure to provide its services), we have agreed to reimburse
the Placement Agent for reasonable travel expenses and other out-of-pocket expenses including legal fees and diligence costs associated
or incurred in connection with the offering, in an aggregate amount of up to $150,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Strategic Transaction Advisory
Services</I></B>. If, during the term of the engagement agreement without consummation of this offering, we enter into a merger,
consolidation, purchase or sale of assets or similar strategic transaction, we have agreed to pay the Placement Agent a fee of
1.5% of the total consideration in the strategic transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Commission</I>.</B> We have agreed
to pay a commission of 7% of the gross offering proceeds to the Placement Agent as compensation immediately upon consummation
of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Non-Accountable Expense Reimbursement.
</I></B>We have agreed to pay a non-accountable expense allowance equal to 0.75% of the gross proceeds to the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Placement Agent&rsquo;s Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Upon each closing of this offering,
we have agreed to issue warrants to the Placement Agent (&ldquo;Placement Agent&rsquo;s Warrants&rdquo;) to purchase a number
of shares of the Common Stock equal to 5.0% of the total Shares sold in such closing. The Placement Agent&rsquo;s Warrants are
exercisable commencing on the Qualification Date, and will be exercisable for five years after the Qualification Date. The Placement
Agent&rsquo;s Warrants are not redeemable by us. The exercise price for the Placement Agent&rsquo;s Warrants will be the amount
that is 10% greater than the initial public offering price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Placement Agent&rsquo;s Warrants
and the Common Stock underlying the Placement Agent&rsquo;s Warrants are deemed compensation by FINRA and therefore are subject
to a 180-day lock-up pursuant to FINRA Rule 5110(g)(1). The Placement Agent, or permitted assignees under such rule, may not exercise,
sell, transfer, assign, pledge, or hypothecate the Placement Agent&rsquo;s Warrants or the Common Stock underlying the Placement
Agent&rsquo;s Warrants, nor will the Placement Agent or permitted assignees engage in any hedging, short sale, derivative, put,
or call transaction that would result in the effective economic disposition of the Placement Agent&rsquo;s Warrants or the underlying
Common Stock for a period of 180 days from the Qualification Date, except that they may be transferred, in whole or in part, by
operation of law or by reason of our reorganization, or to any placement agent or selected dealer participating in the offering
and their officers or partners if the Placement Agent&rsquo;s Warrants or the underlying Common Stock so transferred remain subject
to the foregoing lock-up restrictions for the remainder of the time period. The Underwriter&rsquo;s Warrants will provide
for adjustment in the number and price of the Underwriter&rsquo;s Warrants and the Common Stock underlying such Placement
Agent&rsquo;s Warrants in the event of recapitalization, merger, stock split, or other structural transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Future Services</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have agreed to provide the Placement
Agent with the first option to act as our investment banker for a period of 18 months following the fiscal closing of this Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Lock-Up Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> Our directors, officers
and more than 5% shareholders have agreed, or will agree, with the Placement Agent, subject to certain exceptions, that, without
the prior written consent of the Placement Agent, they will not, directly or indirectly, during the period ending one year after
the date of the Offering Circular (180 days for investors in our Series A Convertible Preferred Stock and the outstanding notes
convertible into shares of our Common Stock): </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 50.55pt; text-align: justify; text-indent: -14.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.9pt"></TD><TD STYLE="width: 14.7pt">&#9679;</TD><TD STYLE="text-align: justify">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option
or contract to sell, grant any option, right or warrant for the sale of, or otherwise dispose of or transfer any shares of the
Common Stock or any securities convertible into or exchangeable or exercisable for the Common Stock, whether now owned or hereafter
acquired by us or each such principal stockholder or with respect to which us or each such principal stockholder has or hereafter
acquires the power of disposition; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: justify; text-indent: -0.2in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36.4pt"></TD><TD STYLE="width: 14.2pt">&#9679;</TD><TD STYLE="text-align: justify">enter into any swap or any other agreement or any transaction that transfers, in whole or in part,
the economic consequence of ownership of the Common Stock, whether any such swap or transaction is to be settled by delivery of
the Common Stock or other securities, in cash or otherwise.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">These agreements do not apply, in our
case, to securities issued pursuant to existing employee benefit plans or securities issued upon exercise of options, and other
exceptions, and in the case of our officers, directors and other holders of our securities, exercise of stock options issued pursuant
to a stock option or similar plans, and other exceptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Listing on a National Securities Exchange</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have applied to
list our Common Stock on The Nasdaq Stock Market (&ldquo;Nasdaq&rdquo;) under the symbol &ldquo;GBSG&rdquo;. Our Common Stock will
not commence trading on Nasdaq, however, unless and until the (i) this Offering is closed in amounts sufficient to meet the minimum
listing criteria of Nasdaq; (ii) this Offering is terminated and (iii) we have filed a post-qualification amendment to the Offering
Statement, and a registration statement on Form 8-A (&ldquo;Form 8-A&rdquo;) under the Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;), and such post-qualification amendment is qualified by the SEC and the Form 8-A has become effective. Pursuant to applicable
rules under Regulation A, the Form 8-A will not become effective until the SEC qualifies the post-qualification amendment. We intend
to file the post-qualification amendment and request its qualification immediately prior to the termination of the Offering in
order that the Form 8-A may become effective as soon as practicable. Even if we meet the minimum requirements for listing on Nasdaq,
we may wait before terminating the Offering and commencing the trading of our Common Stock on Nasdaq in order to raise additional
proceeds. As a result, you may experience a delay between the closing of your purchase of shares of our Common Stock and the commencement
of exchange trading of our Common Stock on Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Whether we meet Nasdaq&rsquo;s
minimum listing criteria will be determined by Nasdaq in its discretion. If we do not meet the criteria, or Nasdaq does not make
necessary discretionary exceptions, as to which there can be no assurance, then we will not be able to list our Common Stock on
Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no assurance
that such listing will ever be obtained and investors may not know at the time that their investment becomes irrevocable whether
the listing application will be approved. If we fail to meet the minimum requirements for listing on Nasdaq, we will seek to have
our Common Stock quoted on an alternative exchange, trading platform or over-the-counter, such as on the OTCQX. The OTCQX is not
a stock exchange, and if our Common Stock trades on the OTCQX rather than Nasdaq, there may be significantly less trading volume
and analyst coverage of, and significantly less investor interest in, our Common Stock, which may lead to lower trading prices
for our Common Stock. See &ldquo;Risk Factors &ndash; Our shares of Common Stock are not and may not be listed for trading on
a national securities exchange.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Pricing of the Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Prior to the offering, there has been
no public market for the Offered Shares. The initial public offering price was determined by negotiation between us and the Placement
Agent. The principal factors considered in determining the initial public offering price include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 50.55pt; text-indent: -14.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.9pt"></TD><TD STYLE="width: 14.7pt">&#9679;</TD><TD>the information set forth in this Offering Circular
                                         and otherwise available to the Placement Agent;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 50.55pt; text-indent: -14.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.9pt"></TD><TD STYLE="width: 14.7pt">&#9679;</TD><TD>our history and prospects and the history of and prospects for the industry in which we compete;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 50.55pt; text-indent: -14.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.9pt"></TD><TD STYLE="width: 14.7pt">&#9679;</TD><TD>our past and present financial performance;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 50.55pt; text-indent: -14.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.9pt"></TD><TD STYLE="width: 14.7pt">&#9679;</TD><TD>our prospects for future earnings and the present state of our development;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 50.55pt; text-indent: -14.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.9pt"></TD><TD STYLE="width: 14.7pt">&#9679;</TD><TD>the general condition of the securities markets at the time of this offering;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 50.55pt; text-indent: -14.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.9pt"></TD><TD STYLE="width: 14.7pt">&#9679;</TD><TD STYLE="text-align: justify">the recent market prices of, and demand for, publicly traded common stock of generally comparable companies; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 50.55pt; text-indent: -14.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.9pt"></TD><TD STYLE="width: 14.7pt">&#9679;</TD><TD>other factors deemed relevant by the Placement Agent
                                         and us.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Indemnification and Control</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have agreed
to indemnify the Placement Agent against certain liabilities, including liabilities under the Securities Act of 1933, as amended
(the &ldquo;Securities Act&rdquo;), and to advance and reimburse its cost of defense of any claims asserted in connection with
the offering. If we are unable to provide this indemnification, we will contribute to the payments the Placement Agent and its
selling agents, affiliates and controlling persons may be required to make in respect of these liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Placement Agent
and its affiliates are engaged in various activities, which may include securities trading, commercial and investment banking,
financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities.
The Placement Agent and its affiliates may in the future perform various financial advisory and investment banking services for
us, for which they have received or will receive customary fees and expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Relationship with the Underwriter</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the ordinary
course of their various business activities, the Placement Agent and its affiliates may make or hold a broad array of investments
and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans)
for their own account and for the accounts of their customers, and such investment and securities activities may involve our securities
and/or instruments. The Placement Agent and its affiliates may also make investment recommendations and/or publish or express
independent research views in respect of such securities or instruments, or recommend to clients that they acquire, long and/or
short positions in such securities and instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investment Limitations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As set forth in Title
IV of the JOBS Act, there are no limits on how many shares an investor may purchase if the Offering results in a listing of our
Common Stock on Nasdaq or other national securities exchange. The following would apply only if we are unable to obtain a listing
on a national securities exchange and we may seek for our Common Stock to trade on a platform of the OTC Markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generally, in the case
of trading on the over-the-counter markets, no sale may be made to you in this Offering if the aggregate purchase price you pay
is more than 10% of the greater of your annual income or net worth (please see under &ldquo;How to calculate your net worth&rdquo;).
Different rules apply to accredited investors and non-natural persons. Before making any representation that your investment does
not exceed applicable thresholds, we encourage you to review Rule 251(d)(2)(i)(C) of Regulation A. For general information on investing,
we encourage you to refer to <U>www.investor.gov</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because this is a Tier
2, Regulation A offering, most investors in the case of trading on the over-the-counter markets must comply with the 10% limitation
on investment in the Offering. The only investor in this Offering exempt from this limitation is an &ldquo;accredited investor&rdquo;
as defined under Rule 501 of Regulation D under the Securities Act (an &ldquo;Accredited Investor&rdquo;). If you meet one of the
following tests you should qualify as an Accredited Investor:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
are a natural person who has had individual income in excess of $200,000 in each of the two most recent years, or joint income
with your spouse in excess of $300,000 in each of these years, and have a reasonable expectation of reaching the same income level
in the current year;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
are a natural person and your individual net worth, or joint net worth with your spouse, exceeds $1,000,000 at the time you purchase
Shares (please see below under &ldquo;How to calculate your net worth&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iii)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You are
an executive officer or general partner of the issuer or a manager or executive officer of the general partner of the issuer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
are an organization described in Section 501(c)(3) of the Internal Revenue Code of 1986, as amended, or the Code, a corporation,
a Massachusetts or similar business trust or a partnership, not formed for the specific purpose of acquiring the Shares, with total
assets in excess of $5,000,000;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
are a bank or a savings and loan association or other institution as defined in the Securities Act, a broker or dealer registered
pursuant to Section 15 of the Exchange Act, an insurance company as defined by the Securities Act, an investment company registered
under the Investment Company Act of 1940 (the &ldquo;Investment Company Act&rdquo;), or a business development company as defined
in that act, any Small Business Investment Company licensed by the Small Business Investment Act of 1958 or a private business
development company as defined in the Investment Advisers Act of 1940;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
are an entity (including an Individual Retirement Account trust) in which each equity owner is an accredited investor;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
are a trust with total assets in excess of $5,000,000, your purchase of Shares is directed by a person who either alone or with
his purchaser representative(s) (as defined in Regulation D promulgated under the Securities Act) has such knowledge and experience
in financial and business matters that he is capable of evaluating the merits and risks of the prospective investment, and you
were not formed for the specific purpose of investing in the Shares; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
are a plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its
political subdivisions, for the benefit of its employees, if such plan has assets in excess of $5,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Date</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This offering will start on or after the Qualification Date
and will terminate if the Minimum Offering is not reached or, if it is reached, on the Termination Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Offering Procedure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are offering
a minimum of 750,000 and a maximum of 2,083,334 shares (the &ldquo;Shares&rdquo;) of our common stock, par value $0.01 (&ldquo;Common
Stock&rdquo;), at an offering price of $12.00 per share for a minimum offering amount of $9,000,000 and a maximum offering amount
of $25,000,000 (the &ldquo;Offering&rdquo;). The Offering will terminate on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2018, subject to extension by us for up to thirty (30) days; provided that, if we have received and accepted subscriptions for
the minimum number of Shares on or before &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018, or the end of the thirty
(30) day extension, if exercised, then the Company will close on the minimum offering amount (the &ldquo;Initial Closing&rdquo;)
and this offering will continue until the earlier of (i) the date which is sixty (60) days after the Initial Closing, or (ii)
the date on which the maximum offering amount is sold (such earlier date, the &ldquo;Termination Date&rdquo;). If, on the Initial
Closing date, we have sold less than the maximum number of Shares, then we may hold one or more additional closings to sell additional
Shares (each, an &ldquo;Additional Closing&rdquo;), until the earlier of: (i) the sale of the maximum number of Shares or (ii)
the Termination Date.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the minimum
offering being raised, we will undertake one or more closings on a rolling basis as funds are received from investors. Funds tendered
by investors will be kept in an escrow account until the next closing after they are received by the escrow agent. At each closing,
funds held in escrow will be distributed to us, and the associated shares will be issued to the investors. All subscribers will
be instructed by us or our agents to transfer funds by wire, credit or debit cards or ACH transfer directly to the escrow account
established for this offering or deliver checks made payable to &ldquo;Prime Trust, LLC as Escrow Agent for Investors in Glucose
Biosensor Systems Offering&rdquo; which the escrow agent shall deposit into such escrow account and release to us at each closing.
Subject to the minimum offering being raised, we intend to close on all funds received from investors that are deposited in the
escrow account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will engage Prime
Trust, LLC, as escrow agent and the escrow agreement will be filed as an exhibit to the Offering Statement of which this Offering
Circular is a part. The escrow agent has not investigated the desirability or advisability of investment in our Common Stock nor
approved, endorsed or passed upon the merits of purchasing the common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will use the
website, https://gbsgreaterchina.com, to provide information on the offering to potential investors. The website will be the exclusive
online means by which prospective investors may subscribe in this offering. This Offering Circular will be furnished to prospective
investors via download 24 hours per day, 7 days per week on the foregoing website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You will be required
to complete a subscription agreement in order to invest. The subscription agreement includes a representation to the effect that,
if you are not an &ldquo;accredited investor&rdquo; as defined under securities law, you are investing an amount that does not
exceed the greater of 10% of your annual income or 10% of your net worth, as described in the subscription agreement. After we
receive your complete, executed subscription agreement (the form of which is attached to the Offering Statement as Exhibit 4.1)
and the funds required under the subscription agreement have been transferred to the escrow account, we have the right to review
and accept or reject your subscription in whole or in part, for any reason or for no reason. We will return all monies from rejected
subscriptions immediately to you, without interest or deduction. Upon our acceptance of a subscription agreement, we will countersign
the subscription agreement and issue the shares subscribed at closing. Once you submit the subscription agreement and it is accepted,
you may not revoke or change your subscription or request your subscription funds. All accepted subscription agreements are irrevocable.
The subscription agreement will be governed and construed in accordance with the laws of the State of New York. By signing the
subscription agreement, you will consent to the jurisdiction of any state or federal court of competent jurisdiction located within
New York and no other place and irrevocably agree that all actions or proceedings relating to the subscription agreement may be
litigated in such courts. The governing law and jurisdictions provisions of the subscription agreement will not apply to
or limit any claims made by you (or any transferee of securities purchased by you) under the federal securities laws and the rules
and regulations thereunder.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_006"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We estimate that
the net proceeds from the sale of the shares of our Common Stock will be approximately $22.50 million if the maximum offering
is completed and approximately $7.62 million if the minimum offering is completed, assuming a public offering price of $12.00
per share, after deducting the estimated placement agency discounts and commissions and estimated offering expenses payable by
us.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we meet the
maximum offering it will enable the Company to better pursue the early stages of the regulatory approval process and comply with
obligations under the License Agreement. To the extent that we raise less than the maximum offering, we will have to raise that
much more capital in the future to pursue our business objectives. Since we have not yet developed detailed priorities for the
use of proceeds, pending our regulatory approvals analysis and other early stage activities, we are unable to describe what uses
of proceeds would be foregone to the extent we raise less than the maximum offering; provided that there can be no assurances
that even if we raise the maximum offering the net proceeds would be sufficient, without additional capital raised, to achieve
all necessary such regulatory approvals or compliance obligations. See &ldquo;Risk Factors &ndash; Given our lack of revenue and
our negative cash flow, we expect to need to raise additional capital, which may be unavailable to us or, even if consummated,
may cause dilution or place significant restrictions on our ability to operate.&rdquo;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that
a substantial portion of the net proceeds used for the purposes described above will be paid to LSBD pursuant to the License Agreement,
pursuant to which LSBD will conduct a substantial portion of the activities that must be performed in the near term to advance
our business plan, including without limitation market data studies, delivery of a finalized field prototype biosensor, delivery
of a manufacture-to-scale plan, delivery of a global regulatory strategy plan, commencing scale manufacturing, commencement of
confidential testing, submitting and finalizing regulatory submissions through final approvals, delivery of a finalized product
for sale, and many other services. Not all of the services to be performed by LSBD under the License Agreement are expected to
be completed within the first year following this Offering. While the payments to LSBD for all such services would exceed net
proceeds in the event only the minimum amount of this Offering is received, the Company expects that it will use such net proceeds
for purposes as are most timely and appropriate in its judgment.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to use the
net proceeds received from this offering as described above and secondarily, if available, for development of our software platform,
sales and marketing efforts to penetrate the markets in the China Region, production arrangements, funding our working capital
and for general corporate purposes. We may find it necessary or advisable to reallocate portions of the net proceeds reserved for
one category to another, or to add additional categories, and we will have broad discretion in doing so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The broad expected
use of net proceeds of this offering represents our current intentions based upon our general plan and business conditions. The
amounts and timing of our use of net proceeds will vary depending on numerous factors. As a result, management will have broad
discretion in the application of the net proceeds, and investors will be relying on our judgment regarding the application of the
net proceeds of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pending the use of
the net proceeds of this offering, we intend to invest the net proceeds in short-term investment-grade, interest-bearing securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A portion of the proceeds
from this Offering may be used to compensate or otherwise make payments to officers or directors of the issuer. The officers and
directors of the Company may be paid salaries and receive benefits that are commensurate with similar companies, and a portion
of the proceeds may be used to pay these ongoing business expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Company reserves the right to change
the use of proceeds set out herein based on the needs of the proposed business of the Company and the discretion of the Company&rsquo;s
management. The Company may reallocate the estimated use of proceeds among the various categories or for other uses if management
deems such a reallocation to be appropriate.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_007"></A>DESCRIPTION
OF BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Glucose Biosensor Systems
(Greater China) Holdings, Inc. (the &ldquo;Company&rdquo;) is a development stage medical device company that owns the license
to the novel and patent-protected biosensor saliva glucose monitoring system (the &ldquo;GBS System&rdquo;) in the region of Mainland
China, Hong Kong, Vietnam and Bangladesh (&ldquo;China Region&rdquo;). We were formed on December 5, 2016, as a Delaware corporation
with headquarters in New York City.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a wholly-owned
subsidiary of Life Science Biosensor Diagnostics Pty Ltd (&ldquo;LSBD&rdquo;), an Australian company that owns the worldwide intellectual
property rights to the biosensor platform invented at the University of Newcastle, Australia. LSBD is responsible for the development
of the biosensor platform and has licensed that technology to us to commercialize the GBS System in the China Region. We have
two subsidiaries: wholly-owned Glucose Biosensor Systems (Greater China), Inc., a Delaware corporation, and 98%-owned Glucose
Biosensor Systems (Greater China) Pty Ltd (&ldquo;GBS Pty Ltd&rdquo;), an Australian corporation. We expect to form and utilize
additional foreign subsidiaries to facilitate our operations in certain jurisdictions and for other purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A major feature of
the GBS System will be its ability to detect glucose in saliva, obviating the need for patients or consumers to perform frequent
finger punctures as required by conventional blood glucose measurement techniques.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once developed, the
basic components of the GBS System will be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The biosensor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The single use
organic biosensor reacts with saliva and initiates an electrochemical reaction, producing a detectable electrical signal that
is proportional to the glucose present in the sample and converted by a smartphone or dedicated reading &lsquo;smart&rdquo; device into a real-time
saliva glucose reading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dedicated digital health care application</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our digital health
care application will be designed to enable user interaction, data interface, storage, analytics and patient support programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tv506394_img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">For illustrative
purposes only &ndash; not Company products</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When the GBS System&rsquo;s
single-use organic biosensor interacts with saliva it initiates an electrochemical reaction, producing a measurable electrical
signal directly correlated to the amount of glucose present in the saliva. This measurement is then converted into a real-time
saliva glucose reading, by a smartphone or a dedicated reading &ldquo;smart&rdquo; device. This data set would then be securely
stored, in analyzed and/or raw form, in a non-relational database in the cloud, for further evaluation and processing. This digital
platform, combined with the clinically-relevant data, is designed to enable diabetics to achieve better glucose control, including
through an accumulation of lifestyle data, thereby helping prevent or delay long term medical complications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe the
core innovation of our business will be the ability to measure glucose in saliva non-invasively. The core technology is the biosensor
that enables the wider glucose management system. While complex in materials, technology and architecture, the biosensor is a
recognized technology that is being transformed into a medical device that we expect to conform with the highest global medical
device standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 59; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The non-invasive
attributes of the technology, the ability for real-time measurement and remote monitoring, could make it easier for a patient
to monitor their glucose levels. This means that we have the potential to collect a greater amount of information from a larger
proportion of patients. This increased data flow, for both the patient and their healthcare professionals, opens significant opportunities
to improve the way diabetes is managed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Through the deployment
of our digital ecosystem, we propose to enable an entire patient/user community providing educational resources, enabling patient
support groups and taking patient care beyond the health care provider&rsquo;s office. This would create a tool extending beyond
a simple stand-alone device, in essence a system that enables the patient to take greater control of their levels of glucose. This
would all be possible due to the following attributes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font-size: 10pt">No more multiple daily routine finger prick testing.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Programmable notifications and reminders.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Insight and practical understanding of factors that affect patient/user glucose levels.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The biosensor is
currently in development and within the next 24 months, the Company intends to advance the technology to conform to the regulatory
requirements of the China Food&nbsp;&amp;&nbsp;Drug Administration (CFDA) with the aim of generating revenue once approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This digital platform,
combined with the clinically-relevant data, is designed to enable diabetics to achieve better glucose control, including through
an accumulation of lifestyle data, thereby helping prevent or delay long term medical complications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Revenue</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The convergence of
the biosensor with the digital networks and non-relational databases, placed within the Chinese diabetes patient community creates
a redefined value chain with projected revenue generated from:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Biosensor sales to patients.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Alternative revenue streams that could potentially be generated from the well stratified patient database and network unified under the digital platform.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company will market,
distribute and sell the product across the geographic region through contracted distributors that already possess significant market
share within the self-testing blood glucose strips market. The Company is aiming to appoint multiple exclusive distributors across
31 territories in Mainland China initially.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The GBS System</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The GBS System consists
of a biosensor component that utilizes saliva to measure glucose, a digital health care application for smart devices and access
to a cloud based non-relational patient database. A major feature of the GBS System is its ability to detect glucose in saliva,
obviating the need for patients or consumers to perform frequent finger punctures as required by conventional blood glucose measurement
techniques.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When the GBS System&rsquo;s
single-use organic biosensor interacts with saliva it initiates an electrochemical reaction, producing a measurable electrical
signal directly correlated to the amount of glucose present in the saliva. This measurement is then converted into a real-time
saliva glucose reading, by a smartphone or other &lsquo;smart&rsquo; reading device. This data set is then securely stored, in analyzed and/or
raw form, in a non-relational database in the cloud, for further evaluation and processing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We contemplate that
the use of saliva-based sampling will make glucose monitoring more accessible to patients as no painful intervention is necessary.
The intuitive interface with smart devices would enable analytical capabilities accessed through the data stored on the non-relational
database. These attributes would be designed to unlock a broader opportunity in the personalized medicine sector of the healthcare
industry in the China Region. Our goals regarding this broader opportunity include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">using revenue generated from biosensor sales for working capital purposes, and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">capitalizing on and leveraging the dedicated, demographically-defined and segmented user network to be created through the institution of the proposed digital platform.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A saliva based glucose
monitoring system appears to be more patient-friendly as it eliminates the need for invasive finger pricks. This leads us to believe
that patients would increase the frequency of sampling saliva, giving them more insight into their glucose levels, resulting in
higher compliance and thus better glycemic control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The digital platform
combined with the clinically relevant data, will enable diabetics to achieve better glucose control through a greater understanding
of lifestyle factors, thereby helping prevent or delay long term medical complications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The convergence of
the biosensor with the digital networks and non-relational databases, placed within the Chinese diabetes patient community, is
designed to create a redefined value chain through:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">revenue generated from biosensor sales to patients;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">revenue generated from sales to consumers who proactively monitor glucose levels (e.g., lifestyle users as part of a wellness, fitness, weight reduction program); and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">revenue generated from the network and the non-relational database.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The smart device application
or dedicated reading device would allow every measurement to be stored locally and online. This data could then be used to improve
the daily management of diabetes. As the database builds knowledge, including by machine learning, and continuously updates with
the patient&rsquo;s activities, such as nutrition, exercise and sleep, and also cross correlates with the data of other users,
the biosensor system would provide intelligent suggestions and automated actions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For example, a patient
who has demonstrated regular high readings of glucose on a particular day of the week may be prompted to reduce intake of carbohydrates
(such as sugar) that day or to increase the frequency of measurements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Saliva-Based Biosensor - The Technology</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Self-testing blood
glucose monitors were introduced to the market in the 1970s and, since then, the method of glucose self-testing has not meaningfully
changed. The methodology of the GBS System represents a breakthrough in glucose monitoring as it represents the potential for a
non-invasive, painless, scientifically valid and cost-effective saliva-based method of measuring glucose levels. The core innovation
that the Company is introducing is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The sampling medium for detection of glucose, saliva.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The detection mechanism of glucose built in the biosensor.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While complex in
materials technology and architecture, the biosensor is built on recognized sensing technology. Through the research conducted
at the University of Newcastle, Australia, this technology is evolving into a medical device in conformity to the required highest
global medical device standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The biosensor is
based on a modified organic thin film transistor architecture incorporating glucose oxidase as the recognition element. Through
prototypes, the biosensor exhibits linear glucose sensing at concentrations with greater sensitivity than commercial blood glucose
sensors, offering potential for the prospect of a saliva-based test for diabetic monitoring and diagnosis. It has been demonstrated
that the biosensor exhibits excellent sensitivity in the saliva glucose region of 8-200 &micro;M. The mechanism by which the glucose
sensing occurs involves the diffusion of protons (generated by the enzymatic oxidation of glucose) to, and subsequent doping of,
the poly (3-hexythiophene) transistor channel. The fundamentals of the biosensor technology have been well-characterized and have
a deep scientific history. Since their invention in 1947, transistors have dominated the mainstream microelectronics industry.
Field Effect Transistors (FETs) are a class of transistor in which the current between a pair of source and drain electrodes separated
by a semiconductor is controlled by a voltage applied to a third electrode known as the gate. The gate electrode is separated
from the source-drain region by a thin (~100 nm) insulating dielectric region and thus is coupled to the semiconductor. By altering
the bias voltage applied to the gate region, the source-drain region can be altered from conducting to insulating and thus the
device can be turned on or off. Importantly, the presence of a relatively small number of charges on the gate electrode alters
the flow of a great many charges between the source and drain electrodes. Accordingly, the FET acts as a switch as well as an
amplifier.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The biosensor makes
use of another scientific discovery known as organic electronic polymers. This work, which was conducted in the 1970s, focused
on the development of doped polyacetylene. Historically conductive polymers can also be traced back to the early 1960s. Conductive
polymers have several advantages over other organic conductors with regard to their processability and hence their use is becoming
increasingly widespread. The polymers that show the most promise in this area are based on the polythiophene structure. The flexible
nature of these polymers allows them to be processed into almost any desired shape or form, making them attractive for the low-cost
production of flexible electronic circuits, such as FETs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The first demonstrated
combination of FETs and organic electronic polymers was in the solid-state organic thin film transistor (OTFT) developed in 1986
using polythiophene (an organic electronic polymer) as the semi-conducting layer, with a similar device being reported in 1988.
The performance of OTFTs in comparison with conventional silicon-based transistors has been considered encouraging and they have
already been used in applications in logic circuits or as the driving elements in active matrix displays. Sensor fabrication based
on organic electronics is also well-established, primarily driven by the appealing features offered by these materials such as
flexible and adjustable chemical properties, and room temperature operation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">One of the most
attractive features of organic electronics is the potential for flexible low-cost fabrication. A common feature of early OTFTs
was the use of silicon as the substrate material, and thus since these hybrid devices are not truly all-polymer-based they do
not offer all the advantages with respect to fabrication. In the world of sensors, the vast majority of previous scientific research
and subsequent technological implementation of organic sensors has involved electrochemically grown films exhibiting performance
levels that are, in most cases, inadequate for real applications. Solution-processed polymers, on the other hand, offer the greatest
potential for the fabrication of low-cost electronics since they can be easily processed as liquids, unlike the organic crystals
and short chain oligomers which are typically vapor deposited. Combining these unique material properties with low-cost techniques,
such as ink-jet printing, offers the ability to rapidly produce disposable printed electronic circuits. The first all-polymer
printed OTFT was reported in 1994. OTFTs are an exciting class of devices within the organic electronics field. The prospect of
low cost organic electronic modules incorporating OTFTs fabricated at low temperatures using low energy techniques is very attractive.
Low temperature solution-based processes, such as ink-jet printing, allow for compatibility with&nbsp;exible substrates, upon
which it would be impossible to fabricate conventional electronics. In addition, conducting polymers can be synthesized in a laboratory
without using rare or expensive materials meaning that they have the potential to be low cost when produced on a large scale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The GBS System leverages
this history of all-polymer printed OTFTs. The organic polymeric semiconductor poly-3-hexylthiophene, which the biosensor is based
upon, is a relatively well understood material. The defining characteristic of our biosensor device is that it is based upon organic
materials that exhibit excellent performance and can be solution processed at low temperatures on flexible substrates via low cost,
high volume but highly sophisticated printing techniques. We believe that this indicates that inexpensive, non-medical waste disposable
biosensors can be easily produced in large quantities. However, as we have yet to manufacture our biosensors on a commercial scale,
there is no assurance that we will be able to manufacture the biosensors cost-effectively in commercial quantities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tv506394_img04.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><B>For illustrative
purposes only &ndash; not a Company product</B></P>


<!-- Field: Page; Sequence: 62; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>License Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2017,
the Company entered into the Technology License Agreement with LSBD, as amended by the Variation Agreement to Technology License
Agreement, dated as December 8, 2017, the Second Variation Agreement to Technology License Agreement, dated as of 18 April 2018,
and the Third Variation Agreement to Technology License Agreement dated July 10, 2018 (as so amended to date, cumulatively, the
 &ldquo;License Agreement&rdquo;), setting forth our contractual rights in and responsibilities relating to the saliva glucose
biosensor system for the China Region. The License Agreement includes the following summary terms:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">an exclusive license is granted to the Company covering certain glucose sensor intellectual property scheduled in the License Agreement and other data owned by LSBD, but solely to (i) hold regulatory marketing authorizations in the China Region, (ii) promote, market and import specific licensed products in the China Region, (iii) provide customer support on the licensed products in the China Region, (iv) use the licensed products in the China Region, and&nbsp;&nbsp;(v) collect data for LSBD regarding the use of the licensed products in the China Region;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the licensed products covered by the License Agreement are only those products that are procured by the Company from authorized suppliers in the China Region under rights owned by LSBD;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the licensed rights do not cover digital or online use to users not physically in the China Region;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the licensed rights are limited to those expressly set forth in the License Agreement and are non-transferable, non-assignable and non-sub-licensable, except that LSBD will in good faith consider any Company request for any sub-license;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the Company is
                                    required to meet specified performance milestones, including conducting clinical studies;
                                    obtaining regulatory approvals in the China Region within two years after the commencement
                                    of trading of the Shares on Nasdaq and within two years thereof placing orders with LSBD for
                                    a minimum number of products based on market growth, with annual increases; annually agree
                                    with LSBD as to that market growth; achieve annually that market share growth plus a minimum
                                    fixed percentage and quarterly orders with LSBD for products in quantities at that quarterly
                                    market share growth plus a minimum fixed percentage; conduct minimum marketing on standards
                                    reasonably determined by LSBD; and convert all glucose monitoring sales by the Company into
                                    glucose monitoring sales of the biosensor strip within five years; provided that (i) LSBD
                                    must supply all licensed product in accordance with the License Agreement, (ii) such product
                                    must be of merchantable quality and in accordance with local law, and (iii) certain end user
                                    data must be accessible to the Company;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">upon failure of any of these requirements, LSBD may require the Company to make cash payment of the value of any shortfall and the failure to pay this amount within 14 business days will subject it to monthly compounding interest at a rate of LIBOR plus 4%;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the Company must notify LSBD of infringements of any licensed intellectual property and cooperate with and as instructed by LSBD, at LSBD&rsquo;s expense, in preventing such infringement, but may take no other action regarding infringement;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the Company must market, sell and distribute the licensed products in accordance with law and distribution requirements set forth in the License Agreement, including delivering licensed products without inclusion of any other product, only as supplied by LSBD, without changing LSBD&rsquo;s packaging or branding thereof and only in quantities as directed by LSBD; complying with all regulations; and keeping specified records and batch samples relating to its activities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 63; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the Company must file for and obtain all legal permits for marketing and selling the licensed products;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the Company must pay LSBD, subject to a monthly late charge, a one-time fixed license fee within 14 days of the obtaining of required regulatory approvals in China; fixed royalty percentages on the sale of specified licensed products on sales of commercial units and certain other devices; application license fees and fees for patient education services, all as determined from time to time by LSBD;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the Company must obtain, retain and provide to LSBD certain end user and other data and notify LSBD as to a variety of matters relating to the data, almost all of which data will be solely owned by LSBD, provided that the Company will have rights to certain of the data during the term of the License Agreement;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">LSBD will own all of the right, title and interest in substantially all of the intellectual property covered by the License Agreement and LSBD shall have the right to control the protection of that licensed intellectual property as assisted by the Company, which shall have no rights to control or otherwise conduct protective activities;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the parties generally agree to keep confidential, subject to customary exceptions, all confidential information of the other party, subject to express exceptions;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">except with respect to LSBD&rsquo;s ownership of all intellectual property rights in respect of the licensed property and the non-infringement by the Company&rsquo;s exercise of those rights, LSBD provides no, and disclaims all, representations, warranties or covenants relating to the licensed intellectual property or any other matters under the License Agreement and in particular disclaims any fitness of the property for any purpose;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">LSBD is indemnified
                                    by the Company for any losses that may be incurred relating to any conduct, including any
                                    data collection or retention, by the Company under or relating to the License Agreement or
                                    the intellectual property under it, or any negligent or willful misconduct or violation of
                                    law by the Company, with no reciprocal indemnity; provided that LSBD indemnifies the Company
                                    for any losses arising that may be incurred related to (i) any third party claim that the
                                    exercise by the Company of its rights in respect of a licensed product violates its property
                                    or rights, and (ii) any regulatory or quality recall or any consumer or user claims or liability
                                    in relation to a licensed product (regardless of any contributory or comparative negligence
                                    of any Licensee Indemnitee, subject to contributory negligence;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0">The term of the License Agreement runs until
                                    the final date of protection afforded to the patent portfolio covered by the License Agreement,
                                    which is currently until 2033, provided that either party may terminate the License Agreement
                                    earlier following any uncured material breach by the other party of it, the discontinuation
                                    of the other party&rsquo;s operations or an actual or prospective change in control of the
                                    other party, where change in control means, among other things, (i) any change of 50% ownership
                                    of outstanding common stock or voting rights, (ii) a merger resulting in a party&rsquo;s pre-merger
                                    voting securities failing to represent at least 50% of all voting power immediately post-merger,
                                    (iii) a sale of substantially all assets, (iv) solely with respect to the Company, without
                                    LSBD&rsquo;s prior approval a majority change in the composition of our board of directors
                                    (unless such change was pre-approved by our board, a nominating or other independent committee
                                    thereof) or (v) the dissolution or liquidation of the other party. In the event of a change
                                    in control of LSBD, LSBD must pay the Company an amount equal to the greater of the five-year
                                    projected net sales and five times the prior year&rsquo;s actual net sales of the Company,
                                    as adjusted depending on how much of the term of the License Agreement remains. No similar
                                    payment is required by the Company in the event of a change in control of the Company; and</P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Upon the expiration, termination or cancellation of the License Agreement in any way, the Company the following consequences are required (i) the cessation of substantially all of the Company&rsquo;s operations, (ii) the forfeiture to LSBD of substantially all of the Company&rsquo;s intellectual property, and (iii) the payment of due amounts, effectively threatening the Company&rsquo;s viability and otherwise having a material adverse effect on the Company and its business, assets and prospects.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preceding summary
and all other references to the License Agreement in this Offering Circular is subject to, and you are encouraged to read, the
complete text of the License Agreement, including variations, which are filed as exhibits to the Offering Statement of which this
Offering Circular is a part. See &ldquo;Risk Factors &ndash; Our License Agreement with our wholly-owning parent, LSBD, which relates
to the Company&rsquo;s principle asset consisting of licensed intellectual property, contains numerous significant performance,
payment, liability, compliance, termination and intellectual property risks that may threaten the Company&rsquo;s viability or
otherwise have a material adverse effect on the Company, its business and its prospects.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 64; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Certain Steps to Commercialization</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a development
stage company formed in December 2016 as a new business and have not yet begun to commercialize our licensed technology or any
products. Our efforts to date have been organizational and formational, have depended on LSBD and its affiliates and have not
generated revenue, and it is still too early to predict if we will ever be able to generate revenues. Therefore, we are, and expect
for the foreseeable future to be, subject to all the risks and uncertainties inherent in a new business and the development and
sale of new medical devices and related software applications. As a result, we may be unable to fully develop, obtain regulatory
approval for, commercialize, manufacture, market, sell and derive revenues from the GBS System and our inability to do so would
materially and adversely impact our viability. In addition, we still must establish many functions necessary to operate a business,
including finalizing our managerial and administrative structure, continuing product and technology development, assessing and
commencing our marketing activities, implementing financial systems and controls and personnel recruitment. This discussion of
commercialization hurdles is subject to and must be considered in the context of &ldquo;Risk Factors&rdquo; below, which you are
directed to read carefully in their entirety.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Offering is for
preliminary financing toward pursuing commercialization of our proposed initial product, the GBS System. There are numerous hurdles
required before commercialization will be possible, as to which there can be no assurances. Those hurdles include, but are not
limited to, and are not necessarily set forth in chronological order:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Additional Capital</U>. We expect that we will require more capital than is contemplated in
this Offering to reach commercialization of the GBS System. Such need for capital is an over-riding condition to the achievement
of many of the other hurdles to commercialization.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Regulatory Approvals</U>. The research, design, testing, manufacturing, labeling, selling, marketing
and distribution of medical devices are subject to extensive regulation by country-specific regulatory authorities, which regulations
differ from country to country. We have not yet obtained any regulatory approvals in any jurisdiction, including in particular
the China Region. We must obtain all regulatory approvals as will permit the commercialization of the GBS System as well as any
eligible protection of any intellectual property.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Clinical Studies</U>. To date, we have not conducted clinical studies and trials on the GBS
System. These studies and trials will be required prior to and in connection with obtaining all regulatory approvals. These studies
and trials will have to be successfully completed to obtain approvals in order to commercialize the GBS System.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Manufacture and Supply</U>. Neither we nor LSBD own or operate manufacturing facilities or maintain
the resources for the production of the GBS System and its components on a commercial scale. Therefore, we will have to rely on
outsourcing in this regard. We must identify and reach agreements with manufacturers and suppliers before we can commence commercialization
of the GBS System.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Marketing</U>. We are looking for and will depend in part on qualified distributors for the
marketing and selling of our products. We will depend on these distributors&rsquo; efforts to market our products, yet we will
be unable to control their efforts completely. We have not yet executed any distribution agreements in this regard.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Software Compatibility</U>. We must conduct software work to make the GBS System application
compatible with existing and potential future smart device platforms. This software work remains to be done.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Personnel</U>.
                                         In order to commercialize our GBS System, we will need to attract and retain highly skilled
                                         managerial, sales, scientific and technical personnel to advance the product beyond its
                                         current development stage. To date we have utilized certain employees of our parent LSBD,
                                         which arrangement will not be sufficient to move toward commercialization of our product.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 65; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Intellectual
                                         Property</U>. Before commencing any commercialization, we will need to assess the eligibility
                                         of our intellectual property for suitable protections in the jurisdictions of the China
                                         Region and if possible implement measures to achieve that protection. This will require
                                         significant work in each of those jurisdictions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Experts</U>. For purposes of most of the foregoing steps, including in particular regulatory
and intellectual property hurdles, we will need to engage third party experts, including in particular specialized local counsel
in each jurisdiction, in order to assess our ability to commercialize our products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><U>Status
                                         of Product</U>. A functioning laboratory prototype of the core biosensor (sensor strip
                                         and readout device) has been developed. The development for the full <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GBS
                                         System, comprised of the sensor strip, dedicated &lsquo;smart&rsquo; reader device and
                                         smartphone application (with cloud storage, database and analytical functionality) as
                                         a commercial grade medical device is in progress.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Manufacturing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The feasibility work
for manufacturing has been completed and is now in development stage. LSBD currently is conducting trials to identify optimal printing
techniques. As new materials and designs are evaluated through the course of continuing development work, it is expected that improved
manufacturing and other processes will develop as well, including the expertise to print all components of the glucose sensor in
the requisite architecture on a small scale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LSBD is working to
identify, negotiate and effectuate manufacturing know-how to mass-produce the biosensor with economies of scale. The manufacturing
methods, locations, and other pertinent terms and details applicable to our manufacturing sources are in the planning process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is anticipated that
the manufacturing process will include a standardization and calibration process that will be automatically initiated with every
new batch of biosensors purchased to ensure requisite, uniformity and performance characteristics. The validation process would
verify that the biosensor is authentic and not an unauthorized copy that might result in erroneous or dubious results. This process
would compare the batch sold against the batch produced, validating authenticity and quality control parameters. This is expected
to be a key component in the manufacturing process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Glucose Monitoring Industry</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The blood glucose self-monitoring
market is currently estimated to reach in excess of $12 billion by 2020. Four companies &ndash; Roche, Abbott, Johnson &amp; Johnson
(LifeScan) and Bayer (recently acquired by Panasonic) &ndash; currently dominate the global market. Although the top four companies
appear to be losing some market share to smaller competitors, they are still believed to hold more than 70% global market share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Self-Monitoring
of Blood Glucose (SMBG)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tv506394_img06.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Self-Monitoring of
blood glucose is the main approach for glucose monitoring and has been used for over 40 years. Currently, SMBG is conducted periodically
by the patient using a blood glucose measuring device. Blood glucometers require pricking a finger with a lancet and applying a
drop of blood on the test strip. The test strip is then inserted into the device which provides a reading of glucose level in blood.
Test strips are supplied by the glucometer manufacturer and are generally device-specific, although generic test strips are also
available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are more than
100 types of blood glucometers currently are commercially available and they differentiate based on size and weight, cost, data
storage capacity, test accuracy, blood sample size and screen visibility (users with poor eyesight may prefer larger screens).
Some glucometers also include high-tech features such as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Bluetooth: some meters
have Bluetooth capabilities, allowing data to be transmitted to a smartphone, tablet or computer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">USB Port: many meters
allow users to download data to a computer with a USB cable. Some meters plug directly into a computer&rsquo;s USB port; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 66; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Bolus Calculator: meters
such as Roche&rsquo;s Accu-Chek Aviva Expert, use a bolus calculator that suggests a dose of meal-time insulin based on blood glucose
reading and specific meals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These systems, however,
still have shortcomings. In addition to the referenced strain on patients, a recent study of commercial blood glucose sensors has
shown that of the 34 systems completely assessed, seven systems did not fulfill the minimal accuracy requirements of the ISO standard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Continuous Glucose
Monitoring (CGM)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Continuous Glucose
Monitoring is an alternative to periodic SMBG. The procedure involves the insertion of a glucose sensor into the subcutaneous tissue
layer or the hypodermis. The sensor, which measures glucose levels in interstitial fluid, is attached to a transmitter that sends
signals to either an insulin pump or a portable meter. These devices are generally worn for about one week and require regular
calibration through conventional blood glucose detection, about twice a day. While the accuracy of these devices has been an issue,
it has improved in recent years. CGM can track a patients&rsquo; glucose throughout the day and night, notifying the patient of
highs and lows so the person can act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subcutaneous glucose
levels change more slowly than plasma glucose, which can be a restriction to their effectiveness, particularly if glucose levels
are changing rapidly. Subcutaneous glucose levels have a time lag compared to blood glucose measurements, and measurements may
not always match blood glucose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CGM is commonly used
in conjunction with continuous subcutaneous insulin infusion (CSII), which involves a patient wearing an insulin pump and infusion
set that infuses insulin into the body. Although pumps are currently manually controlled by the patient, CGM with CSII could potentially
be used as part of a closed-loop. CSII is generally restricted to Type 1 diabetics, where the need for ongoing insulin infusion
is highest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CGM is mainly used
in a limited proportion of diabetics, particularly those concerned about severe, nocturnal hypoglycemia, pregnant women who require
meticulous glucose control or those who may not be able to easily administer an SMBG test (e.g., those living in remote or hostile
environments). However, CGM is more expensive than traditional SMBG and may be less eligible for reimbursement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Developments in
Saliva Glucose Monitoring</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that there
are a limited number of companies developing saliva-based glucose monitoring. In addition, we believe that a number of universities
across the world have a range of saliva based sensors at early stages of development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Emerging approaches
to non-invasive glucose monitoring, none of which have reached widespread application, include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Optical Transducers &ndash; Optical transducers can potentially detect glucose in blood using light of variable frequencies. Different properties of light are used to interact with glucose molecules. The anterior chamber of the eye and the interstitial fluid are two regions where spectroscopic measurement of the reflected or transmitted light can be captured. Some emerging techniques in optical transducers include Kromoscopy, Photoacoustic spectroscopy, OCT, Occlusion spectroscopy, Polarimetry, Thermal infrared, Fluorescence, Raman spectroscopy, MIR spectroscopy, and NIR spectroscopy. Most of these systems are not suitable for point of care testing.</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Transdermal Transducers &ndash; Transdermal transducers can be used to measure glucose. In this case, oxygen supply is not a limiting factor and hence the concentration of glucose can potentially be detected with less interference. Some techniques, such as reverse iontophoresis, demonstrate adequate precision for home-based blood glucose monitoring. The shortcoming of such transducer types is their inability to detect hypoglycemia with a sensitivity of 23% for glucose concentrations. Emerging techniques in transdermal transducers include impedance spectroscopy, skin suction blister, sonophoresis and reverse iontophoresis.</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Use of Wearable Technologies for Diabetes Management &ndash; Several companies are developing wearable devices that are purported to be capable of monitoring glucose and tracking biometrics to monitor health. These devices commonly use the speckle pattern effect, i.e., using changing patterns of scattered light. Some wearable devices also use non-invasive spectrometric process combined with electrical sampling to determine glucose levels in blood using low-cost wavelength specific transmitters and receivers.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 67; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Further technologies in development include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse">
<TR>
    <TD NOWRAP STYLE="width: 35%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Technology</B></FONT></TD>
    <TD NOWRAP STYLE="vertical-align: top; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 64%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Limitations and Impediments</B></FONT></TD></TR>
<TR>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top">&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Lasers</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -20pt"><FONT STYLE="font-family: Symbol">-</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Safety
        concerns with long-term use of lasers on the skin</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -20pt"><FONT STYLE="font-family: Symbol">-</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Concerns
        with lag time between glucose levels in the skin and blood glucose levels</P></TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.25in">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Breath-based measurements</P></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -20pt"><FONT STYLE="font-family: Symbol">-</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Concerns
        that measuring breath does not accurately correlate with blood glucose levels</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -20pt"><FONT STYLE="font-family: Symbol">-</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Potential
        for contamination</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -20pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">-</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not
suitable for young children</FONT></P></TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.25in">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Tear sample</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -20pt"><FONT STYLE="font-family: Symbol">-</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Concerns
        with lag time between glucose levels in tears and blood glucose levels</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -20pt"><FONT STYLE="font-family: Symbol">-</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;May
        be affected by the patient&rsquo;s hydration</P></TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.25in">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Wearable technology to detect glucose through the skin</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -20pt"><FONT STYLE="font-family: Symbol">-</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reliability
        of results due to problems with sweat and body temperature</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -20pt"><FONT STYLE="font-family: Symbol">-</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Usability
        during sporting activities, particularly water sports</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -20pt"><FONT STYLE="font-family: Symbol">-</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Problems
        with skin irritation</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -20pt"><FONT STYLE="font-family: Symbol">-</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not
        suitable or practical for children</P></TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.25in">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Using ear lobe sensors or ear canals</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -20pt"><FONT STYLE="font-family: Symbol">-</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indiscreet
        and impractical</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -20pt"><FONT STYLE="font-family: Symbol">-</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Problems
        with ear wax and reliability of the measurements, especially in children</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Importance of Glucose Monitoring</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">One of the main aims
of diabetes monitoring and management is to maintain blood glucose levels within a specified target range. Self-monitoring of blood
glucose should be part of a regular management plan for patients with diabetes to enable this. Self-monitoring provides information
regarding an individual&rsquo;s dynamic blood glucose profile. This information can help with the appropriate scheduling of food,
activity, and medication. It is also required for understanding of the timing of blood glucose variations. Lack of regular self-monitoring
predicts hospitalization for diabetes-related complications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Self-monitoring of
blood glucose is an essential tool for people with diabetes who are taking insulin or for those who experience fluctuations in
their blood glucose levels, especially hypoglycemia. For patients taking insulin and adjusting their dose, self-monitoring is needed
for self-management. For others receiving oral medication, profiling glucose trends and the confirmation of high or low blood glucose
can be a useful addendum to successful management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Self-monitoring of
blood glucose aids the management of diabetes by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Facilitating the development of an individualized blood glucose profile, which can then guide health care professionals in treatment planning for an individualized diabetic regimen;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Giving people with diabetes and their families the ability to make appropriate day-to-day treatment choices in diet and physical activity as well as administration of insulin or other agents;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Improving patients&rsquo; recognition of hypoglycemia or severe hyperglycemia; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Enhancing patient education and patient empowerment regarding the effects of lifestyle and pharmaceutical intervention on glycemic control.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 68; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The role of blood glucose
control in preventing the development and progression of complications has been proven in both type 1 and type 2 diabetes, with
an especially strong relationship between intensive blood glucose control and complications such as neuropathy (affecting limbs)
and diabetic retinopathy (leading to blindness).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Over time, glucose
measurements are expected to provide the patient and their health care professionals with the information and insights required
to determine the best management strategy for diabetes, potentially minimizing the fluctuations in their glucose levels and resulting
in better health outcomes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The role of blood glucose
monitoring and control in preventing the development and progression of diabetes complications has been well established. Studies
show that those who properly monitored blood glucose levels had better health outcomes (such as reduced complications of diabetes)
compared to those who did not.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a person with diabetes,
however, this daily process is not only painful but can be exhausting, disruptive, frustrating, frightening and consuming, which
often leads to poor compliance and poor health outcomes. People with diabetes have reported that stigma is a significant concern
to them. This causes tension and anxiety and, because the procedure is perceived as inconvenient and difficult, leads to suboptimal
monitoring and poor adherence. Many people with diabetes do not test as often as clinically recommended, increasing the risk of
complications. The reasons for under-compliant testing include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Inconvenience &ndash; patients with single-point finger stick devices must use them several times a day. The patient self-inflicts a painful prick and draws blood to measure blood glucose levels. This process is inconvenient and is often uncomfortable in social situations.</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Pain &ndash; although the fingertip provides a good site to obtain a blood sample, it also is densely populated with highly sensitive nerve endings. As a result, lancing and subsequent manipulation of the finger to draw blood and multiple finger sticks can be painful.</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Risk of infection
 &ndash; the Centers for Disease Control data suggests that Hepatitis B Virus morbidity and mortality may be higher in diabetics
than in non-diabetics.</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Difficulty of use &ndash; to obtain a blood sample with single-point finger stick devices, patients generally prick one of their fingertips and squeeze the area to produce the blood sample, with another prick required if insufficient blood volume is first obtained. The blood sample is then placed on a disposable test strip that is inserted into a blood glucose meter. This task can be difficult for patients who have decreased sense of touch and/or clarity of vision, which is not be uncommon for diabetics.</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Medical Waste &ndash; used needles, lancets and blood strips are medical waste that must be disposed of accordingly.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Diabetes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Diabetes is the condition
in which the body does not properly process food for use as energy. Most of the food we eat is turned into glucose, or sugar, for
our bodies to use for energy. The pancreas, an organ that lies near the stomach, makes a hormone called insulin to help glucose
get into the cells of our bodies. When a person has diabetes, the body either does not make enough insulin or cannot use its own
insulin as well as it should. This causes sugars to build up in blood. Diabetes can cause serious health complications including
heart disease, blindness, kidney failure, and lower-extremity amputations. Self-monitoring of blood glucose is an important component
of modern therapy for diabetes and is recommended for people with diabetes by their health care professionals in order to achieve
normal levels of glycemia. The types of diabetes are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Type 1 Diabetes</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Type 1 diabetes is
caused by an auto-immune reaction where the body&rsquo;s defense system attacks the insulin-producing cells located in a person&rsquo;s
pancreas. The reason why this occurs is not fully understood. People with Type 1 diabetes produce no insulin. The disease can affect
people of any age, but usually occurs in children or young adults. People with this form of diabetes need injections or infusions
of insulin every day to control the levels of glucose in their blood. Type 1 diabetes patients constitute approximately 10% of
the overall number of patients, but are much more extensive users of glucose monitoring systems, as these people with diabetes
need to measure their glucose levels over 6 times a day.</P>


<!-- Field: Page; Sequence: 69; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When a person has lived
with diabetes for many years, a condition known as &ldquo;Hypoglycemia Unawareness&rdquo; can occur, affecting approximately 40%
of people with Type 1 diabetes. As a result, people with this condition monitor their glucose levels more frequently. It is a major
limitation to achieving tight diabetes control and significantly reduces quality of life.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Type 2 Diabetes</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Type 2 diabetes accounts
for at least 90% of all cases of diabetes. It is characterized by insulin resistance and relative insulin deficiency, either of
which may be present at the time that diabetes becomes clinically manifest. The diagnosis of Type 2 diabetes usually occurs after
the age of 40 but can occur earlier, especially in populations with high diabetes incidence. Type 2 diabetes can remain undetected
for many years and the diagnosis is often made from associated complications or incidentally through an abnormal blood or urine
glucose test. It is often, but not always, associated with obesity, which may contribute to insulin resistance and lead to elevated
glucose levels. As Type 2 diabetes is a progressive disease, a growing portion of Type 2 diabetes patients use insulin as part
of their treatment. Trends such as urbanization, unhealthy diets and reduced physical activity are all contributing lifestyle factors
that increase the risk of developing Type 2 diabetes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Gestational Diabetes</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Gestational diabetes
is a form of diabetes consisting of high glucose levels during pregnancy. It develops in one in seven pregnancies worldwide and
is associated with complications in the period immediately before and after birth. Gestational diabetes usually disappears after
pregnancy, but afflicted women and their offspring are at an increased risk of developing Type 2 diabetes later in life. Approximately
half of women with a history of gestational diabetes go on to develop Type 2 diabetes within five to ten years after delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that the
GBS System also will be able to support patients with pre-diabetes, also called metabolic syndrome. Metabolic syndrome is a combination
of medical disorders that increase the risk of developing cardiovascular disease and diabetes. Approximately 493 million people
in China are understood to have pre-diabetes. This population is typically prescribed with periodic lab-based glucose level testing
which requires a doctor visit and typically does not involve the utilization of self-monitoring glucose devices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Diabetes &ndash; The Global Epidemic</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Diabetes is a global
epidemic and it is growing rapidly. Some key statistics include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">In 2017, it was
estimated that one in 11 people across the globe had diabetes. That&rsquo;s 425 million people. Changing lifestyles, diets, and
urbanization has aided this rapid rise in diabetes.</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">By 2045, it is
estimated that one in 10 people will have diabetes, an increase of over 200 million people in 28 years.</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Diabetes can lead
to complications such as heart disease, blindness, kidney failure, and lower-extremity amputations and results in a huge burden
on healthcare infrastructure.</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Every six seconds, a person dies from diabetes.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Diabetes in China</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The International
Diabetes Federation (the &ldquo;IDF&rdquo;) recently noted that China has the world&rsquo;s largest diabetes epidemic, and it
continues to grow at a fearsome pace. Rapidly rising rates of diabetes have been seen in previous studies, and according to the
latest data, 10.9% of Chinese adults have diabetes. The Chinese diabetic population stands at some 114 million people &mdash;
about a third of all people globally with diabetes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The economic growth
of China has had a major impact on the incidence of the disease, such that China accounts for the fastest growing global market
segment. China has, by a significant number, the largest number of people with diabetes. In 2015, China alone had a similar number
of people with diabetes as the next three largest diabetes markets combined (India, USA and Brazil). China had 1.3 million deaths
due to diabetes in 2015 (26% of total global deaths due to diabetes), with 40.8% of those deaths occurring in people under 60.
Diabetes related health expenditure in China was US$51bn in 2015 alone and is expected to reach US$72bn by 2040.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Journal of the
American Medical Association identified that out of 99,000 people surveyed in a study, half had pre-diabetes blood glucose levels
 &ndash; abnormally high but not high enough for a diagnosis of diabetes. Approximately 493 million people in China are understood
to have pre-diabetes. These findings indicate the enormity of diabetes as a public health problem in China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 70; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Diabetes is set to
become the heaviest burden on the Chinese healthcare system, as the IDF estimates diabetes accounts for 13% of all medical expenditures
in China.&nbsp;The number of people affected by diabetes has spiked in recent years and is expected to reach 150 million Chinese
by 2040. The biggest challenge for the Chinese government in this context is to&nbsp;raise public awareness&nbsp;of the symptoms
of diabetes and the benefits of early diagnosis. Adding to this burden is the indirect cost associated with informal care by relatives
or caregivers &ndash; while it is difficult to calculate, some studies suggest this could constitute up to half the cost of diabetes.
Further, lost productivity from diabetes is a drain on the economy, amounting to 0.6% of China&rsquo;s GDP. People with diabetes
in China spend nine times more money on health care than healthy people of the same age and sex without diabetes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A significant portion
of the direct costs of diabetes, and its broader economic impact, arises due to associated complications such as heart disease,
kidney disease, amputations, cerebral conditions and blindness &ndash; over 70% of patients have at least one complication. A recent
study using actual electronic insurance claims data (from 2009-2011) in China found that the average direct cost of treatment (US$1,857
per patient) increased significantly with the number of diabetes-related complications up to over US$3,000. The average annual
cost per patient with at least one hospitalization (about 20% of patients) in a year (US$6,301 in 2009) was more than four-fold
the costs per patient with only outpatient visits. These complications and hospitalizations are far more likely if diabetes is
undiagnosed or poorly monitored and managed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Patent Protection</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 74%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Official Number</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 25%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Status</B></FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">US 9,766,199</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Granted</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">CN 201380022888</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>Notice of Allowance</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">AU2016/050555</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Filed</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The original patent
application, which claims a priority date of March 2012, has been granted in the United States and the Chinese Patent Office has
issued a Notice of Allowance in China (CN 201380022888). A second international patent application (PCT/AU2016/050555) claiming
iterations to the device design has been filed with a priority date of June 2016 and will soon enter national phase in certain
jurisdictions, and further patent applications are in preparation.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Healthcare Industry and the Digital
Effect &ndash; China</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The healthcare industry
in China is undergoing significant change, driven by ongoing healthcare reforms, the review of government policies and the introduction
and adoption of new technologies such as wearable devices and mobile apps. Combined with an aging population and a healthcare infrastructure
that has struggled to keep up with the pace of socioeconomic change, this creates significant opportunity in China to enhance efficiency
through innovation. In 2012, the Ministry of Health invested approximately US$1.4billion (RMB 9.5 billion) to develop electronic
medical records, improve hospital information systems and intensify digital healthcare. These costs may be only the beginning as
the combination of an aging population with long-term inefficiencies and unmet needs within the healthcare system trigger subsequent
reforms to address issues within the Chinese healthcare system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The broad scope of
digital health includes categories such as mobile health (mHealth), health information technology, wearable devices, telehealth
and telemedicine, and personalized medicine. Providers and other stakeholders are using digital health in their efforts to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">reduce inefficiencies;&nbsp;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">improve access;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">reduce cost;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">increase quality; and</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">make medicine more personalized for patients.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 71; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is widely believed
that patients and consumers can use digital health to better manage and track their health and wellness related activities. In
2016, to address challenges presented by demographic change, China&rsquo;s State Council announced a plan for deepening reform
of the country&rsquo;s health-care system. The plan, which aims to guide medical reforms in specific regions, was widely seen as
encouraging the further development of digital health programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This growth in digital
healthcare is expected to be driven in large part by solutions to address current inefficiencies and unmet needs in the Chinese
healthcare system for diabetes sufferers. The promise of digital health &ndash; also termed &lsquo;connected health&rsquo; &ndash;
in this context is to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">allow for remote diagnosis and monitoring;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">facilitate self-managed care;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">deliver care outside traditional settings, with better access at lower cost; and</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">assist chronic disease management to improve population health outcomes.</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Specifically, there
are several diabetes websites in China offering education, information and the potential to connect with health care professionals.
Many of these websites collect patient information using blood glucose monitors that are often provided by major pharmaceutical
companies and not part of one complete ecosystem.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that the
opportunity to unlock substantial savings in the Chinese healthcare value chain is significant. Recently, there appears to have
been a significant increase in Chinese digital healthcare resources, such as online patient-doctor communication and consulting
services, disease management applications, social networks for medical professionals, and even &ldquo;internet hospitals&rdquo;
that provide remote diagnostics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">China&rsquo;s digital
healthcare market is expected to grow considerably in the next few years, with US$110 billion expected to be invested in 2020,
of which US$35 billion is expected to be invested in disease management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Digital Platform</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that
the non-invasive attributes of our technology will make it easier for a patient to monitor their glucose levels. Accordingly,
we anticipate having the potential to collect a greater amount of information from a larger proportion of patients. This increased
data flow, for both the patient and their health care professionals, would open significant opportunities to improve the way diabetes
is monitored, as highlighted below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tv506394_img03.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&#9;For illustrative
purposes only &ndash; device is not a Company product</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 72; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Specifically, with
the cloud-based application across web and mobile, we anticipate our holistic system would be used as a disease management tool
and address many of the systemic issues inherent in diabetes management in China through:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the storage and analysis of patient data generated by the biosensor and or the dietary and fitness inputs generated by the app and the output to the user;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the connectivity of patients and patient results with health care team or relatives (as per patient requirements);</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">reminder and flagging service for patients;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">a medium for pharmaceutical companies to implement patient support programs (as per regulatory restrictions); and</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">education services for lifestyle, diet and glucose management.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Regulatory/Clinical Development Framework</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not be permitted
to market the GBS System until we receive regulatory clearance. To date, we have not received regulatory clearance in any jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The research, design,
testing, manufacturing, labeling, selling, marketing and distribution of medical devices are subject to extensive regulation by
country-specific regulatory authorities, which regulations differ from country to country. We also will be subject to numerous
post-marketing regulatory requirements, which may include labeling regulations and medical device reporting regulations, which
may require us to report to different regulatory agencies if our device causes or contributes to a death or serious injury, or
malfunctions in a way that would likely cause or contribute to a death or serious injury. In addition, these regulatory requirements
may change in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have conducted
limited testing on the GBS System. While preliminary feasibility studies conducted by the University of Newcastle, Australia have
produced results we believe to be encouraging and indicative of the potential performance of the GBS System, data already obtained,
or in the future obtained, from clinical and performance testing may not necessarily predict the results that will be obtained
from later pre-clinical studies and clinical studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The completion of any
future clinical testing for the GBS System or other testing that we may be required to undertake in the future will be subject
to, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the conduct of performance testing in accordance with regulatory requirements;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the availability of patients participating in the testing; and</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the work of clinical investigators performing clinical trials on our anticipated schedule and consistent with regulatory standards and protocols.</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will be responsible
for obtaining requisite regulatory approvals in the jurisdictions of the China Region, initially engaging the China Food and Drug
Administration. We do not yet have the necessary regulatory approvals to put to service our biosensor systems or any other product
in the China Region. We plan initially to launch our products, once approved, in China first. We have not yet considered the subsequent
regulatory requirements and strategies in other jurisdictions in the China Region.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Distribution, Sales and Marketing</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We propose to enter
into arrangements with distributors to market and sell our products. We have entered into an agreement in principle with a medical
affairs specialty company to drive prelaunch activity for 18 months with the scope to create awareness and build share of voice
with local referring physicians, diabetes educators, patient associations, government organizations and general practitioners.
This agreement is our Medical Affairs Services Agreement with Clinical Research Corporation, which an affiliate controlled by LSBD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We seek local provincial
distributors in China that will stock, market and sell the product across the region. While a single licensee may seek exclusive
distribution rights to the device, it is anticipated there will be multiple distributors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 73; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial strategy
for distributor selection and appointment includes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">appointment of a global consulting firm to screen the top three distributors per province;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">determining selection criteria that include capability, capacity, volume of test strips currently sold and experience in sector;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">defining the time frame to implement a &ldquo;switch&rdquo; strategy for distributors to replace the conventional blood glucose testing devices; and</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">appointment of local provincial / regional distributors.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are looking for
and will depend in part on qualified distributors for the marketing and selling of our products. We will depend on these distributors&rsquo;
efforts to market our products, yet we will be unable to control their efforts completely. These distributors typically would sell
a variety of other, non-competing products and will be expected to devote certain resources to selling the GBS System. We expect
to devote suitable time and effort to recruiting and retaining qualified third-party distributors and training them in our technology
and product offering. To develop and expand our distribution, we intend to scale and improve our processes and procedures that
support our distributors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend, assuming
the completion of development and regulatory approval, to commercialize, market and distribute our GBS System in Mainland China,
Hong Kong, Vietnam and Bangladesh in that order of priority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Market Penetration</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to commence
our market penetration strategy initially in China. Our commercialization strategy will be to switch users from the current finger-lancing
capillary blood test product to our GBS System. The strategy for this market penetration will include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">developing an early stage website to generate market awareness and engage with future users;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">creating &ldquo;Share of Voice&rdquo; for the GBS System in the China Region;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">creating market awareness among patients through various promotions; and</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">partnering with patient diabetes associations and sponsor patient support groups in China.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This early strategy
is designed to be driven by patients and validated by the physicians and health care professionals through the generation of evidentiary
data. We expect that this data will demonstrate that patients will achieve better glycemic control when using the GBS System as
compared to conventional blood glucose testing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has
utilized for its benefit certain employees of its parent LSBD. The Company is not incurring or accruing any financial or other
obligations other than certain shared corporate overhead in connection with this utilization. The Company intends to continue
this utilization through completion of this Offering while employing its own employees as it deems necessary. Through its use
of parent employees, the Company is currently utilizing the following staff, in addition to the directors of the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Commercialization Director</FONT></P>
                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Commercialization Manager</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Medical Affairs Director</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Science Officer</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Finance Director and support team</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Head &ndash; Legal and Commercial Affairs</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently not
a party to any pending legal proceeding, nor is our property the subject of a pending legal proceeding, that we believe is not
ordinary routine litigation incidental to our business or otherwise material to the financial condition of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 74; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_008"></A>MANAGEMENT&rsquo;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION<BR>
AND RESULTS OF OPERATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Prospective
investors should read the following discussion and analysis of our financial condition and results of operations together with
our consolidated financial statements and the related notes and other financial information included elsewhere in this Offering
Circular. Some of the information contained in this discussion and analysis or set forth elsewhere in this Offering Circular,
including information with respect to our plans and strategy for our business, includes forward-looking statements that involve
risks and uncertainties. See &ldquo;Cautionary Note Regarding Forward-Looking Statements.&rdquo; You should review the &ldquo;Risk
Factors&rdquo; section of this Offering Circular for a discussion of important factors that could cause actual results to differ
materially from the results described in or implied by the forward-looking statements contained in the following discussion and
analysis. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>On
November 5, 2017, the Company effected a stock split of one to 90,000 shares resulting in 9,000,000 issued and outstanding
shares of common stock as of that date and the date hereof. On August 9, 2018, the Company effected a reverse stock split of
approximately one to 0.9167 shares that resulted in the Company having 8,250,000 issued and outstanding shares of common
stock.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>General</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a development
stage medical device company with licensed rights to commercialize a novel &ldquo;smart&rdquo; biosensor salivary glucose monitoring
system (the &ldquo;GBS System&rdquo;) in the China Region, comprised of Mainland China, Hong Kong, Vietnam and Bangladesh. We were
formed on December 5, 2016, as a Delaware corporation with headquarters in New York City.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently are a
wholly-owned subsidiary of Life Science Biosensor Diagnostics Pty Ltd (&ldquo;LSBD&rdquo;), an Australian company that owns the
worldwide intellectual property rights to the biosensor platform from University of Newcastle, Australia. LSBD is responsible for
the development of the biosensor platform and has licensed to us that technology for us to commercialize the GBS System in the
China Region.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated
financial statements show a loss of $5,020,383 from July 1, 2017 through June 30, 2018. The Company has funded its operations
to date with the net proceeds from private placements outside of the United States in the amount of $8,715,793 of Series A Preferred
Stock and $5,277,056 of convertible notes issued by our 98%-owned subsidiary GBS Pty Ltd. Net shareholder&rsquo;s equity was $(3,063,694)
as of June 30, 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our consolidated financial
statements are prepared using the accrual basis of accounting in accordance with Generally Accepted Accounting Principles in the
United States (&ldquo;US GAAP&rdquo;). Our fiscal year ends June 30.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations discuss our consolidated financial statements, which have
been prepared in accordance with US GAAP. The preparation of these consolidated financial statements requires making estimates
and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities
at the date of the consolidated financial statements, as well as the reported revenues and expenses for the reporting periods.
On an ongoing basis, we evaluate such estimates and judgments. We base our estimates on historical experience and on various other
factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about
the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ (perhaps
significantly) from these estimates under different assumptions or conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While all the accounting
policies impact the consolidated financial statements, certain policies may be viewed to be critical. Our management believes that
the accounting policies which involve more significant judgments and estimates used in the preparation of our consolidated financial
statements, include revenue recognition, inventories, liability related to certain warrants, and accounting for production lines
and its related useful life and impairment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Revenue Recognition</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not generated
any revenues to date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 75; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Revenues from product
sales would be recognized in accordance with ASC 605-10, &ldquo;Revenue Recognition&rdquo;, when delivery has occurred, persuasive
evidence of an agreement exists, the vendor&rsquo;s fee is fixed or determinable, no further obligation exists and collectability
is probable. We do not intend to grant a right of return. We will assess whether the fee is fixed or determinable based on the
nature of the fee charged for the products delivered, the existing contractual arrangements and the distributor&rsquo;s consistency
of payments. When evaluating collectability, we consider whether we have sufficient history to reliably estimate the distributor&rsquo;s
payment patterns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a sales arrangement
were to contain multiple elements, such as software and non-software components, we would allocate revenue to each element based
on a selling price hierarchy as required according to ASC 605-25, &ldquo;Multiple-Element Arrangements&rdquo;, or ASC 605-25. The
selling price for a deliverable will be based on its Vendor Specific Objective Evidence, or VSOE, or, if available, third party
evidence, or TPE, if VSOE is not available, or estimated selling price, or ESP, if neither VSOE nor TPE is available. The best
estimate of selling price is established considering several internal factors including, but not limited to, historical sales,
pricing practices and geographies in which we offer our products. The determination of ESP is judgmental.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Revenues from software
components in sales arrangements containing multiple elements will be recognized when all criteria outlined in ASC 985-605, &ldquo;Software
Revenue Recognition&rdquo;, or ASC 985-605, are met (when persuasive evidence of an arrangement exists, delivery of the product
has occurred or the services have been rendered, the fee is fixed or determinable and collectability is probable).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For multiple element
arrangements within ASC 985-605, revenues will be allocated to the different elements in the arrangement under the &ldquo;residual
method&rdquo; when VSOE of fair value exists for all undelivered elements and no VSOE exists for the delivered elements. Under
the residual method, at the outset of the arrangement with the customer, we will defer revenue for the fair value of its undelivered
elements and recognize revenue for the remainder of the arrangement fee attributable to the elements initially delivered in the
arrangement when the basic criteria in ASC 985-605 have been met. Any discount in the arrangement will be allocated to the delivered
element.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since VSOE does not
exist for undelivered elements, revenues will be recognized as one unit of accounting, on a straight-line basis over the term of
the last deliverable based on ASC 605-15 and ASC 985-605.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Liability Related to Certain Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value
of the liability for certain warrants issued to investors will be calculated after the closing of the proposed IPO when the events
have occurred to allow a fair value to be determined for these securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Fair
                                         value for each reporting period will be calculated based on the following assumptions:</FONT></P>
                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Risk-free interest
                                    rate&nbsp;&mdash;&nbsp;based on yield rates of non-index linked U.S. Federal Reserve treasury
                                    bonds.</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Expected volatility&nbsp;&mdash;&nbsp;was
                                    calculated based on actual historical stock price movements of the Company together with companies
                                    in the same industry over a term that is equivalent to the expected term of the option.</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Expected life&nbsp;&mdash;&nbsp;the
                                    expected life was based on the expiration date of the warrants.</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Expected dividend yield&nbsp;&mdash;&nbsp;the Company does
    not expect to pay dividends to its shareholders in the foreseeable future.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Capitalization of Costs</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Extended Transition Period for &ldquo;Emerging
Growth Companies&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have elected to
use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.
This election allows us to delay the adoption of new or revised accounting standards that have different effective dates for public
and private companies until those standards apply to private companies. As a result of this election, our financial statements
may not be comparable to companies that comply with public company effective dates. Because our financial statements may not be
comparable to companies that comply with public company effective dates, investors may have difficulty evaluating or comparing
our business, performance or prospects in comparison to other public companies, which may have a negative impact on the value and
liquidity of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of June 30,
2018, we had $418,420 in cash and cash equivalents.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 76; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have experienced
cumulative losses of $5,332,055 from inception through June 30, 2018, and have a stockholders&rsquo; equity position of $(3,063,694)
at June 30, 2018. In addition, we have not completed our efforts to establish a source of revenues sufficient to cover our operating
costs and expect to continue to generate losses for the foreseeable future. There is no assurance that we will be able to obtain
an adequate level of financing needed for our near-term requirements or the long-term development and commercialization of our
product. Due to these conditions, our ability to continue as a &ldquo;going concern&rdquo; depends in part on our ability to raise
sufficient capital. See Note 1 to Consolidated Financial Statements for the period from July 1, 2017&nbsp;through June 30, 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since inception,
we have financed our operations primarily through funding from affiliates, and a private placement of convertible notes of our
98%-owned subsidiary GBS Pty Ltd and our Series A Convertible Preferred Stock accompanied by warrants. The convertible notes bear
interest at 7% per annum and are convertible to Common Stock at a 15% discount to the price per Share in this Offering. The Series
A Convertible Preferred Stock are convertible into Common Stock at a one-to-one ratio upon completion of this Offering. One warrant
was issued along with each share of Series A Convertible Preferred Stock. Each warrant is exercisable at the price per Share in
this Offering during the one year period commencing on the second anniversary of the completion of this Offering, and the underlying
Common Stock must be held at the time of exercise.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to our
management&rsquo;s estimates, based on our budget and proposed schedules of development, approvals and organization, we believe,
although there can be no assurances, that if we raise the minimum amount of this Offering then we will have sufficient capital
resources to enable us to continue to implement our business plan and remain in operation for at least the next 12 months, but
there also can be no assurances how long after, if at all, such 12 months we might be able to continue as such without raising
additional capital. We do not anticipate generating any revenues for at least 24 months, if at all, from the date of this Offering.
We believe, although there can be no assurances, that raising more than the minimum and less than the maximum amount of this Offering
will enable us to continue to implement our business plan and remain in operation for an indeterminate amount of time longer than
just raising the minimum amount, with the amount raised in excess over that minimum amount generally allowing for more additional
time, but we will still be required to promptly seek and obtain additional sources of capital. Even if we raise the maximum amount
of this Offering, we will need additional capital before we are able to fully implement our business plan and commercialize our
products for public sale, as to which implementation and commercialization there can be no assurances as to success. In any event,
there can be assurances that we will ever be able to raise additional capital.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As such, we have a
significant present need for capital. If we are unable to scale up our development, approvals and organization efforts of the
GBS System or meet our commercialization targets (or if we are unable to generate any revenue at all), and if we are unable to
obtain additional capital resources in the near term, we may be unable to continue activities absent material alterations in our
business plans and our business might fail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, readers
are advised that available resources may be consumed more rapidly than currently anticipated, resulting in the need for additional
funding sooner than expected. Should this occur, we will need to seek additional capital earlier than anticipated in order to fund
(i) further development and, if needed, testing of our the GBS System and its related application and data storage components,
(ii) our efforts to obtain regulatory clearances or approvals necessary to be able to commercially launch the GBS System, (iii)
sales and marketing efforts and (iv) general working capital. Such funding may be unavailable to us on acceptable terms, or at
all. Our failure to obtain such funding when needed could create a negative impact on our stock price or could potentially lead
to the failure of our company. This would particularly be the case if we are unable to commercially launch the GBS System in the
jurisdictions and in the timeframes we seek.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We did not have during
the period presented, and we do not currently have, any off-balance sheet arrangements as defined under Securities and Exchange
Commission rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Contingencies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We account for our
contingent liabilities in accordance with ASC 450 &ldquo;Contingencies&rdquo;. A provision is recorded when it is both probable
that a liability has been incurred and the amount of the loss can be reasonably estimated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to legal
matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice
of legal counsel and other information and events pertaining to a particular matter. Currently, we are not a party to any ligation
that we believe could have a material adverse effect on our business, financial position, results of operations or cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 77; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_009"></A>MANAGEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All directors hold
office for one-year terms until the election and qualification of their successors. Officers are appointed by our Board of Directors
and serve at the discretion of our Board of Directors, subject to applicable employment agreements. The following table sets forth
information regarding our executive officers and the members of Board of Directors as of the date of this Offering Circular.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 31%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 6%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 61%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Position(s)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Jonathan S. Hurd</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">47</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chairman of the Board</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Harry Simeonidis</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">49</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">President and Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Dr. Jean-Claude Becker</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">69</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Operating Officer, Executive Vice President and Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Victoria Gavrilenko</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">37</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Operations Manager, Secretary, Treasurer and Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Dr. Yong-Jiang Hei</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">57</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Dr. John Caminis</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">59</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Executive Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Harry Simeonidis</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Harry Simeonidis
has been our President since 2017. Mr. Simeonidis has more than 25 years of experience in senior management roles in healthcare,
pharmaceutical and life sciences businesses in Australia, New Zealand and Asia. Since March 2017, he has been the General Manager
of Farmaforce Limited, an Australian company listed on the Australian Stock Exchange. FarmaForce is a contract sales organization
catering to the Australian Pharmaceutical Industry. FarmaForce is majority-owned by iQnovate Limited, which also owns a majority
of LSBD. iQnovate Limited is an Australian life sciences organization that provides intellectual property asset management services
and scientific advice to the biopharmaceutical industry. Mr. Simeonidis was General Manager Surgery Asia Pacific of GE Healthcare.
From 2003 to 2012, Mr. Simeonidis was the CEO of GE Healthcare ANZ, a healthcare company operating in Australia and New Zealand
and affiliated with General Electric Company.&nbsp;Mr. Simeonidis&rsquo; duties nominally will consist of the duties of President
contemplated by the Company&rsquo;s by-laws and will consist of formulating market entry strategy and public relations but will
not include general management of the Company&rsquo;s operations, which will be managed by Dr. Becker.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B><I>Dr. Jean-Claude
Becker</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">J.C. Becker, M.D.
is a Rheumatologist and global researcher with expertise in developing and positioning innovative products in autoimmune diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For more
than the last five years Dr. Becker has been an independent consultant in the pharmaceutical and biomedical industries. Prior
thereto, for 12 years Dr. Becker was Group Director Global Clinical Research in Immunology at
Bristol-Myers Squibb, where he has led the clinical development of Abatacept, leading to advancements in treating Rheumatoid
Arthritis and Lupus. Dr. Becker has significant experience conceiving and designing clinical development strategies for
biologics and drugs that treat autoimmune diseases such as Rheumatoid Arthritis and Lupus. He also has successfully
conducted clinical trials toward obtaining regulatory approvals as well as projects to position and profile biologics/drugs
with post-approval studies to achieve marketing and commercial objectives. He has collaborated and led on projects in global
markets including North America, Europe and Asia, specifically Japan, Korea, Taiwan and China as well as Australia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to his work
at Bristol-Myers Squibb, Dr. Becker held senior research positions at other large pharmaceutical companies, including Sandoz and
Pfizer as well as smaller biotechnology firms, such as Genetics Institute, Inc. and Texas Biotech. His experience encompasses
biologics to small molecules and ranges from early clinical development to medical affairs with marketing and international setup.
Prior to joining the pharmaceutical industry, he worked as a consultant in Rheumatology and was a senior lecturer in Immunology
at Hospital Universities in Paris.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Becker received
his M.D. from, and specialized in Rheumatology at, the Paris VI University in France. He has been widely published in major scientific
publications and medical journals and has reported at major international congresses for more than 25 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>The Becker Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In conjunction
with Dr. Becker&rsquo;s service in his executive officer positions and as a director of the Company, we have entered into an employment
agreement with Dr. Becker, dated September 24, 2018 (the &ldquo;Becker Agreement&rdquo;), pursuant to which he will perform his
duties to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Becker Agreement
requires that Dr. Becker perform for the Company the functions typically served by a chief operating officer/executive vice president,
with such customary responsibilities, duties and authority normally associated with such positions and consistent with the Company&rsquo;s
objective of obtaining regulatory approvals of its product, which approvals are the principal objectives of the Company in the
near term. Dr. Becker also will perform such other duties consistent with the foregoing as may from time to time be assigned to
him by the Company&rsquo;s Board of Directors or an authorized committee thereof. Dr. Becker will report directly to the Company&rsquo;s
Board unless and until a United States based chief executive officer is appointed. The Becker Agreement provides that he is expected
to select that staffing to support him in his duties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<!-- Field: Page; Sequence: 78; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Among other terms
of the Becker Agreement governing Dr. Becker&rsquo;s duties to the Company, Dr. Becker will supervise all personnel working for
the Company and as such will be responsible for the proper operation of the business of the Company. Those duties are expected
to include, but are not limited to, primary responsibility for directing clinical, medical affairs strategy, regulatory, pharmacovigilance
and other supervisory personnel responsibility for all activities that are pertinent to the regulatory and clinical process, responsibility
for coordinating staff and contractors for educating key opinion leaders and other stakeholders in the field of glucose monitoring
and diabetes, coordinating all staff and contractors, clinical, medical and regulatory matters, and the Company&rsquo;s publication
strategy, primary responsibility for directing, controlling and coordinating, the preparation and implementation of pre-launch
activities, market access, medical affairs operations, branding, distribution, and scientific due diligence as needed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For his
services under his employment agreement, Dr. Becker will receive as compensation an annual salary of $150,000 and will be
eligible for and the Company expects to grant compensation in the amount of 3,000 shares of common stock per year in the
discretion of the Board. The Becker Agreement has a term of one full year automatically renewable for successive one-year
terms, subject to notice of non-renewal at term-end by any party to the other delivered within 30 days of the end of such
term, unless terminated earlier for reasonable cause or by resignation at no further cost or without cause with a maximum
termination amount as full liquidated damages of the lesser of the remaining cost on such term or $50,000. The Becker
Agreement also contains confidentiality and ownership of intellectual property provisions.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Victoria Gavrilenko</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Victoria
Gavrilenko has been our Operations Managers&rsquo; Secretary and Treasurer and a director since July 2018. Ms. Gavrilenko is
based full-time at the Company&rsquo;s New York City headquarters and will report directly to Dr. Becker. From 2007 to 2009,
Ms. Gavrilenko was an executive assistant and contractor liaison at Southern California Steel Inc, a steel fabricator. From
2010 to 2013 she was an executive assistant to the CEO at John Carris Investments, LLC, a boutique investment banking firm
providing financial advisory services. From 2013-2015, Ms. Gavrilenko was a real estate agent at Centric New York, a boutique
agency. From 2016 until August 2018, Ms. Gavrilenko was the Office Manager at the New York City Offices of IQ Capital. Ms.
Gavrilenko graduated from California State University San Marcos.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-indent: 28.9pt">Ms. Gavrilenko&rsquo;s duties
will include, under Dr. Becker&rsquo;s ultimate authority:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-indent: 28.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Primarily
                                         directing all prelaunch and regulatory tactical steps, ensuring recruitment process and
                                         business plan are executed in accordance with the business plan</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Controlling
                                         employees, contractors and others to ensure effective and efficient tactical outcomes</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Primary
                                         responsible for upkeep of governance and compliance, coordination of board activities
                                         and input to the board agenda</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Informing
                                         stakeholders of relevant information</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Coordinating
                                         board meetings</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Responsibility for coordination of activities within the US as
    well as overseas business partners and contractors, all subject to her reporting to Dr. Becker and other senior executives</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<P STYLE="margin-top: 0; margin-bottom: 0"></P>





<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in">&nbsp;</TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Coordination
                                         of the Company&rsquo;s treasury functions</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business is
managed under the direction of our Board of Directors. Our Board of Directors currently consists of Messrs. Hurd and Simeonidis,
Ms. Gavrilenko and Drs. Becker, Caminis and Yong-Jiang Hei.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Jonathan S. Hurd</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Hurd joined
our Board in April 2018 and was appointed Chairman in August 2018. Mr. Hurd founded Asgard Regulatory Group in 2008, providing
broker-dealer and investment adviser compliance consulting services clients both domestic and abroad. Mr. Hurd has expertise in
broker-dealer and investment advisory regulations and is well versed in FINRA and SEC rules and regulations. Prior to starting
Asgard Regulatory Group, Mr. Hurd was the Chief Compliance Officer for several financial institutions. His experience involves
full-service broker-dealer, investment advisory services, bank-broker-dealers, and securitizations of mortgage-backed securities.
Jon also served on the Board of Directors for many of these companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to this,
Jon was a Supervisor of Examiners at FINRA, previously NASD, in the New York District Office. While with FINRA, he supervised
routine examinations of FINRA member firms, conducted large- scale enforcement cases jointly with the Justice Department and Federal
Bureau of Investigations. Mr. Hurd also assisted the District Office with its ongoing training of new examiners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 79; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, Mr.
Hurd was a Senior Adjunct Professor in the Townsend School of Business at Dowling College whereby he provided in-depth knowledge
and related work experience to MBA students as it related to the U.S. securities markets and financial institutions. He was responsible
for introducing students to the subjects of financial derivatives, foreign stock exchange, hedge transactions and risk management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Hurd earned
his BBA in Accounting and his MBA in Banking and Finance from Dowling College. Mr. Hurd is also a Certified Anti-Money Laundering
Specialist (CAMS) and holds the Series 7, 24, 27, 53, 55, 63, 66, 79 and 99 licenses as well as his NYS Life and Health Insurance
licenses.&nbsp;&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Dr. John Caminis</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Caminis
was our original sole director and served until August 2017. He rejoined our Board in April 2018. Dr. Caminis is a
pharmaceutical physician with a successful track record in clinical development, medical affairs and pharmacovigilance. He has wide-ranging
experience in the design and execution of clinical trials in diverse therapeutic areas including metabolic/metastatic bone
disease, oncology, gastroenterology, pain, immunology, infectious disease and dermatology. Dr. Caminis has made many
contributions in providing medical direction for new products and business development efforts. Dr. Caminis is currently the
Therapeutic Area Head (Gastroenterology &amp; Metabolism for Global Drug Safety) at Shire. His experience includes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.15pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 19px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Former CR&amp;MA head &ndash; Biosimilars, Baxalta (Shire)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 19px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Former Senior Medical Director, UCB</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 19px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Former Director Clinical Development &amp; Medical Affairs, Novartis</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 19px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Former Medical Science Leader, Roche</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Dr. Yong-Jiang Hei</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Yong-Jiang
Hei joined our Board in April 2018. Dr. Yong-Jiang Hei is a physician executive with leadership responsibility for product development
strategy and portfolio management in oncology. Expertise and hands-on experience in clinical strategy, clinical trial design and
conduct, and regulatory filings. Track record of success building and leading cross-functional project teams. US and global working
experience in large pharma as well as small biotech settings including setting up a clinical /medical group as the medical head
for Amgen China. Dr. Yong-Jiang Hei is currently Corporate VP and Chief Medical Officer, Qilu Pharmaceuticals, Shanghai, China.
His experience includes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Pharmaceutical product development, portfolio management, and corporate strategy</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Clinical trial design &amp; conduct including global phase III trials &amp; companion diagnostics</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Experience interacting with US &amp; global health authorities</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Regulatory filings (IND/NDA with FDA, EMA, PMDA (Japan), and cFDA (China)</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">US and global opinion leader network</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">US, global, and country affiliate level working experience</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There
                                         are no family relationships between any of our directors or executive officers to be
                                         reported</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Board Leadership Structure </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors
recognizes that one of its key responsibilities is to evaluate and determine its optimal leadership structure so as to provide
effective oversight of management. Our bylaws and corporate governance guidelines, which will become effective immediately prior
to the consummation of this offering, will provide our board of directors with flexibility to combine or separate the positions
of chairperson of the board of directors and chief executive officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Board Oversight of Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although management
is responsible for the day to day management of the risks we face, our Board of Directors and its committees will take an active
role in overseeing management of our risks and have the ultimate responsibility for the oversight of risk management. The Board
will regularly review information regarding our operational, financial, legal and strategic risks. Specifically, senior management
will attend periodic meetings of the Board, provides presentations on operations including significant risks, and is available
to address any questions or concerns raised by our Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 80; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scientific Advisory Board</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">We
have assembled a scientific advisory board with expertise in biology for medical applications. The members of our scientific advisory
board have made significant scientific contributions in their individual fields, have published in leading journals and have been
recognized with numerous awards and distinctions. Members of our scientific advisory board provide strategic advice to us in fields
pertinent to the GBS System and applicable technology and perform such other services as may be mutually determined by us and
the scientific advisory board member. Our scientific advisory board will meet on an as-needed basis, based on our need for advice
in their fields of expertise from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal"></FONT>&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Dr. George Syrmalis MD, PhD, FACNP, MAAPP</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Executive Chairman and CEO of The iQ Group Global</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Syrmalis is
trained in Nuclear Medicine-radiation immunology and established iQnovate, part of The iQ Group Global, in 2011. Previously, Dr.
Syrmalis founded and led as CEO and Chairman The Bionuclear Group SA, (1995-2005) incorporating Antisoma SA, Bionuclear Institute
of Diagnosis and Therapy SA, Bionuclear Research and Development SA and Vitalcheck SA. He developed a business model by addressing
unmet clinical needs and leveraging on synergies between Bionuclear Group companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Antisoma
                                         SA: focused on development of novel biologic compounds both radio diagnostic and radio
                                         therapeutic in the area of oncology.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Bionuclear
                                         Institute for Diagnosis and Therapy SA: expanded into medical centers-renal dialysis
                                         clinics and the development of Europe&rsquo;s most prominent reference pathology service.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Bionuclear
                                         Research and Development SA: novel and generic radiopharmaceutical production.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Vitalcheck
                                         SA: Research, development and commercialization of point of care tests for professional
                                         and layman use. From 2005 onwards George continued his career as advisor to the Biopharmaceutical
                                         industry, advising on translational clinical trials, biomarkers and strategy to commercialize
                                         novel biologic entities in the areas of oncology, epilepsy and autoimmune diseases.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Professor Paul Dastoor - Inventor</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>PhD, University of Cambridge, Bachelor of Arts (Honours),
University of Cambridge</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Paul Dastoor is
a Professor in Physics in the School of Mathematical and Physical Sciences and the director of the Centre for Organic Electronics
at the University of Newcastle in Australia. He received his B.A. degree in Natural Sciences from the University of Cambridge
in 1990 and his PhD in Surface Physics, also from the University of Cambridge, in 1995.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After completing
his doctorate, he joined the Surface Chemistry Department at British Steel in 1994 before taking up his present appointment at
the University of Newcastle in 1995. He was an EPSRC Visiting Research Fellow at Fitzwilliam College, Cambridge, UK in 2002 and
a Centre for the Central Laboratory Research Councils Visiting Research Fellow at the Daresbury Laboratory, Cheshire, UK in 2004-05.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">His expertise covers
surface analysis, electron spectroscopy, thin film growth, organic electronics, organosilane chemistry, polymer films, atom beam
optics and microscopy and medical devices. His research can be grouped in 3 main areas: (1) Helium Atom Microscopy, (2) Polymer
Adsorption on Metal Surfaces and (3) Organic Electronic Devices. Helium Atom Microscopy Atomic scattering from surfaces has matured
into a unique analytical technique for the study of formation of thin film structures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Principal Place of Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to Rule
251(b)(1) of Regulation A, under which the Offering is being made, having a &ldquo;principal place of business&rdquo; in the United
States or Canada is a condition to the availability of Regulation A. In general, an issuer will be considered to have its &ldquo;principal
place of business&rdquo; in the United States for purposes of determining issuer eligibility under Rule 251(b)(1) if its officers,
partners or managers primarily direct, control and coordinate the issuer&rsquo;s activities from the United States. The Company&rsquo;s
headquarters are now and are expected to remain in New York City. Currently, the Company&rsquo;s officers who primarily direct,
control and coordinate our activities are in the United States, and the Company expects that its officers will primarily direct,
control and coordinate our activities in the United States for the foreseeable future.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although certain
formational and capital-raising activities of the Company to date have occurred outside of the United States, as noted above,
the Company&rsquo;s principal place of business is its offices in New York City. Also as noted above, Dr. Becker is the executive
officer primarily directing, controlling and coordinating the operations of the Company in the United States. Further, Ms. Gavrilenko
works at the Company&rsquo;s dedicated offices in New York City and the Company intends to hire additional personnel there as
contemplated by the Becker Agreement. As noted under &ldquo;Executive Compensation&rdquo; below, until the recent hiring of Dr.
Becker and Ms. Gavrilenko, the persons providing organizational and capital-raising services to the Company have been employees
of the Company&rsquo;s parent entities. The bases for the conclusion that the Company&rsquo;s principal place of business is in
the United States for purposes of Rule 251(b)(1) include that each of Dr. Becker and Ms. Gavrilenko is a full-time employee subject
to a written employment agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 81; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we expect
that Board committees will assist the Board in fulfilling its oversight responsibilities regarding risk. The Audit Committee will
coordinate the Board&rsquo;s oversight of the Company&rsquo;s internal control over financial reporting, disclosure controls and
procedures, related party transactions and code of conduct and corporate governance guidelines and management will regularly report
to the Audit Committee on these areas. The Compensation Committee will assist the Board in fulfilling its oversight responsibilities
with respect to the management of risks arising from our compensation policies and programs. When any of the committees receives
a report related to material risk oversight, the chairperson of the relevant committee will report on the discussion to the full
Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Controlled Company Exception </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After giving effect
to this Offering, LSBD will continue to control a majority of the voting power of our outstanding common stock. As a result, under
our certificate of incorporation, LSBD will be able to nominate a majority of the total number of directors comprising our Board
and we will remain a &ldquo;controlled company&rdquo; within the meaning of the Nasdaq corporate governance standards. Under the
Nasdaq corporate governance standards, a company of which more than 50% of the voting power is held by an individual, group or
another company is a &ldquo;controlled company&rdquo; and may elect not to comply with certain corporate governance standards,
including (1) the requirement that a majority of the Board consist of independent directors, (2) the requirement that we have
a compensation committee that is composed entirely of independent directors with a written charter addressing the committee&rsquo;s
purpose and responsibilities, (3) the requirement that we have a nominating and corporate governance committee that is composed
entirely of independent directors with a written charter addressing the committee&rsquo;s purpose and responsibilities, and (4)
the requirement for an annual performance evaluation of the nominating and corporate governance and compensation committees. We
intend to utilize these exemptions if we achieve listing of our Common Stock on Nasdaq. As a result, we will not have a nominating
and corporate governance committee and our compensation committee may not be composed entirely of independent directors. Accordingly,
you would not have the same protections afforded to stockholders of companies that are subject to all of the Nasdaq corporate
governance requirements. In the event that we cease to be a &ldquo;controlled company,&rdquo; we would be required to comply with
these provisions within the transition periods specified in the Nasdaq corporate governance rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Board Committees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the initial
closing of this Offering, our Board of Directors will have two standing committees: an Audit Committee and a Compensation Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Audit
Committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the initial
closing of this Offering, our Audit Committee will be formed and comprised of independent directors, at least one of whom will
be an &ldquo;audit committee financial expert&rdquo; as defined in Item 407(d)(5)(ii) of Regulation S-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Audit Committee
will oversee our corporate accounting, financial reporting practices and the audits of financial statements. For this purpose,
the Audit Committee will have a charter (which will be reviewed annually) and performs several functions. The Audit Committee charter
will be available on our website. The Audit Committee also will:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">evaluate the independence and performance of, and assesses the qualifications of, our independent auditor and engage such independent auditor;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">approve the plan and fees for the annual audit, quarterly reviews, tax and other audit-related services and approve in advance any non-audit service to be provided by our independent auditor;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">monitor the independence of our independent auditor and the rotation of partners of the independent auditor on our engagement team as required by law;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">review the financial statements to be included in our filings with the SEC and reviews with management and our independent auditor the results of the annual audit and reviews of our quarterly financial statements; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 82; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">oversee all aspects our systems of internal accounting control and corporate governance functions on behalf of the board.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Compensation Committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the closing
of this Offering, our Compensation Committee will be formed and will have a written charter addressing the committee&rsquo;s purpose
and responsibilities, but it will not be composed entirely of independent directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Committee
will review or recommend the compensation arrangements for our management and employees and also assists our Board of Directors
in reviewing and approving matters such as company benefit and insurance plans, including monitoring the performance thereof. The
Compensation Committee will have a charter (which will be reviewed annually) and perform several functions. The Compensation Committee
charter will be available on our website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Committee
will have the authority to directly engage, at our expense, any compensation consultants or other advisers as it deems necessary
to carry out its responsibilities in determining the amount and form of employee, executive and director compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Code of Ethics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the closing
of this Offering, we will adopt a written code of business conduct and ethics that will apply to our directors, officers and employees,
including our principal executive officer, principal financial officer and principal accounting officer or controller, or persons
performing similar functions. Upon the listing of our Common Stock on Nasdaq, we will post on our website a current copy of the
code and all disclosures that are required by law or Nasdaq rules in regard to any amendments to, or waivers from, any provision
of the code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Limitation of Directors Liability and
Indemnification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Delaware General
Corporation Law authorizes corporations to limit or eliminate, subject to certain conditions, the personal liability of directors
to corporations and their stockholders for monetary damages for breach of their fiduciary duties. Our certificate of incorporation
limits the liability of our directors to the fullest extent permitted by Delaware law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We propose to purchase
director and officer liability insurance to cover liabilities our directors and officers may incur in connection with their services
to us, including matters arising under the Securities Act. Our certificate of incorporation and by-laws also provide that we will
indemnify our directors and officers who, by reason of the fact that he or she is one of our officers or directors, is involved
in a legal proceeding of any nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no pending
litigation or proceeding involving any of our directors, officers, employees or agents in which indemnification will be required
or permitted. We are not aware of any threatened litigation or proceedings that may result in a claim for such indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Section 16(a) Beneficial Ownership Reporting
Compliance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to this Offering
our Common Stock was not registered under Section 12 of the Exchange Act and our directors and executive officers and persons who
beneficially own more than 10% of our Common Stock were not required to file with the SEC various reports as to their ownership
of and activities relating to our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Executive Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Becker and
Ms. Gavrilenko, both of whom reside in the New York City metropolitan area, will perform their work for the Company based at the
Company&rsquo;s offices in New York City. Dr. Becker shall receive compensation pursuant to his employment agreement
at a salary of $150,000 per year. Each other director receives annual director fees of $30,000, and no other fees, except that
Ms. Gavrilenko receives $30,000 annually for her other services to be performed for the Company. In addition, the Company intends
to grant each current director 3,000 shares of Common Stock for serving on the Company&rsquo;s board of directors after completion
of agreed milestones. The Company intends to employ additional employees as it deems necessary, including those employees to be
selected by Dr. Becker for employment in the Company&rsquo;s New York City offices. The Company also plans to utilize where suitable
the services of employees of our parent Life Science Glucose Biosensors Diagnostics Pty Ltd. Besides the previous amounts, to
date we have not experienced material executive compensation expense directly to our executives. See &ldquo;Description of Business
 &ndash; Employees&rdquo; and &ldquo;Interests of Management and Others in Certain Transactions &ndash; Relationships with Affiliates.&rdquo;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 83; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Employment and Related Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In light of the
foregoing, other than the Becker Agreement, we currently have no written employment agreements directly with any of our officers,
each of whom serves on an &ldquo;at-will&rdquo; basis, and directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2017 Equity Incentive Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 29, 2017,
the Board of Directors approved the 2017 Equity Incentive Plan (the &ldquo;2017 Plan&rdquo;) and recommended that our stockholders
consider the 2017 Plan and approve its adoption, effective as of the date that the Company completes this Offering. We have reserved
500,000 shares of our Common Stock for issuance under the 2017 Plan. Participation in the 2017 Plan will continue until all of
the benefits to which the participants are entitled have been paid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purpose of our
2017 Plan is to attract and retain directors, officers, consultants, advisors and employees whose services are considered valuable,
to encourage a sense of proprietorship and to stimulate an active interest of such persons in our development and financial achievements.
The 2017 Plan will be administered by the Compensation Committee of our Board of Directors or by the full board, which may determine,
among other things, the (a) terms and conditions of any option or stock purchase right granted, including the exercise price and
the vesting schedule, (b) persons who are to receive options and stock purchase rights and (c) the number of shares to be subject
to each option and stock purchase right. The 2017 Plan will provide for the grant of (i) &ldquo;incentive&rdquo; options (qualified
under section 422 of the Internal Revenue Code of 1986, as amended) to employees of our company and (ii) non-qualified options
to directors and consultants of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the administration of our 2017 Plan, our Compensation Committee will:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">determine which employees and other persons will be granted awards under our 2017 Plan;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">grant the awards to those selected to participate;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">determine the exercise price for options; and</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">prescribe any limitations, restrictions and conditions upon any awards, including the vesting conditions of awards.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Compensation Committee
will: (i) interpret our 2017 Plan; and (ii) make all other determinations and take all other action that may be necessary or advisable
to implement and administer our 2017 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2017 Plan provides
that in the event of a change of control event, the Compensation Committee or our Board of Directors shall have the discretion
to determine whether and to what extent to accelerate the vesting, exercise or payment of an award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our Board
of Directors may amend our 2017 Plan at any time. However, without stockholder approval, our 2017 Plan may not be amended in a
manner that would:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">increase the number of shares that may be issued under our 2017 Plan;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">materially modify the requirements for eligibility for participation in our 2017 Plan;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">materially increase the benefits to participants provided by our 2017 Plan; or</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">otherwise disqualify our 2017 Plan for coverage under Rule 16b-3 promulgated under the Securities Exchange Act of 1934, as amended.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Awards previously granted
under our 2017 Plan may not be impaired or affected by any amendment of our 2017 Plan, without the consent of the affected grantees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Description of Awards under the 2017 Plan</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Awards to Company
Employees</U><I>.</I> Under the 2017 Plan, the compensation committee, which will administer the plan (the &ldquo;Committee&rdquo;),
may award to eligible employees incentive and nonqualified stock options, stock appreciation rights, restricted stock, restricted
stock units, performance units and performance shares.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Awards to Non-Employees</U><I>.</I>
The Committee may award to non-employees, including non-employee directors, non-qualified stock options, SARs, restricted stock
and restricted stock units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 84; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Stock Options</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Committee has discretion
to award incentive stock options (&ldquo;ISOs&rdquo;), which are intended to comply with Section 422 of the Code, or nonqualified
stock options (&ldquo;NQSOs&rdquo;), which are not intended to comply with Section 422 of the Code. The exercise price of an option
may not be less than the fair market value of the underlying shares of Common Stock on the date of grant. The 2017 Plan defines
 &ldquo;fair market value&rdquo; as the closing sale price at which shares of our Common Stock have been sold regular way on the
principal securities exchange on which the shares are traded or, if there is no such sale on the relevant date, then on the last
previous day on which there was such a sale. If an award of stock options is intended to qualify as performance-based compensation
under Section 162(m) of the Code, the maximum number of shares which may be subject to stock options granted in any calendar year
to any one participant who is a &ldquo;covered employee&rdquo; is 200,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Options granted to
employees under the 2017 Plan will expire at such times as the Committee determines at the time of the grant; provided, however,
that no option will be exercisable later than ten years after the date of grant. Each option award agreement will set forth the
extent to which the participant will have the right to exercise the option following termination of the participant&rsquo;s employment
with the Company. The termination provisions will be determined within the discretion of the Committee, might not be uniform among
all participants and might reflect distinctions based on the reasons for termination of employment. Notwithstanding the preceding
sentences, unless the terms of the award agreement otherwise provide for a shorter exercise period, ISOs must be exercised within
three months after an employee&rsquo;s termination of employment. However, if the termination is due to disability (as defined
under Code Section 22(e)(3)), the ISOs must be exercised within one year after an employee&rsquo;s termination of employment. If
the termination is due to death, the ISOs may be exercised at any time during the option term. Subject to the specific terms of
the 2017 Plan, the Committee will have discretion to set such additional limitations on such grants as it deems appropriate. The
award agreement will reflect these limitations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the exercise of
an option granted under the 2017 Plan, the option price is payable in full to the Company, either: (a) in cash or its equivalent,
(b) if permitted in the award agreement, by tendering shares having a fair market value at the time of exercise equal to the total
option price (provided that such shares have been held by the optionee for at least six months prior to their tender) or (c) by
any combination of the foregoing methods of payment. The Committee may also allow options granted under the 2017 Plan to be exercised
by a cashless exercise through a broker, as permitted under Federal Reserve Board Regulation T, or any other means the Committee
determines to be consistent with the 2017 Plan&rsquo;s purpose and applicable law, including by cashless exercise directly with
the Company whereby the Company, following its receipt of the participant&rsquo;s notice of exercise, would withhold the proper
number of Company shares which would have a fair market value on the date of exercise equal to the option exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Stock Appreciation Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Committee may award
stock appreciation rights (&ldquo;SARs&rdquo;) under the 2017 Plan upon such terms and conditions as it may establish. At the discretion
of the Committee, the payment upon SAR exercise may be in cash, in shares of Company Common Stock of equivalent value, or in some
combination thereof. The Committee&rsquo;s determination regarding the form of payment for the exercised SAR will be set forth
in the award agreement. The Committee may award either (i) freestanding SARs, which are SARs granted as an independent instrument
and are not granted in conjunction with any stock options, or (ii) SARs in tandem with stock options (a &ldquo;tandem SAR&rdquo;).
A tandem SAR entitles the participant to exercise it as an option or as an SAR. The election of one type of exercise prevents it
from being exercised as the other type. A tandem SAR may not be granted to a non-employee Director unless the related option is
a NQSO. The exercise price of a freestanding SAR will equal the fair market value of a share of Common Stock on the date of grant,
whereas the exercise price of a tandem SAR issued in connection with a stock option will equal the option price of the related
option. If an award of SARs is intended to qualify as performance-based compensation under Section 162(m) of the Code, the maximum
number of shares which may be subject to SARs awarded in any calendar year to any one participant who is a &ldquo;covered employee&rdquo;
is 200,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Committee will
determine in its discretion the term of an SAR granted under the 2017 Plan. Each award agreement will set forth the extent to which
the participant will have the right to exercise the SAR following termination of the participant&rsquo;s employment with the Company.
The termination provisions will be determined by the Committee in its sole discretion, need not be uniform among all participants
and may reflect distinctions based on the reasons for termination of employment. The term of an SAR may not exceed ten years from
the date of grant. Therefore, no SAR may be exercisable later than ten years after the date of award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 85; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise
limited by the 2017 Plan, freestanding SARs may be exercised upon whatever terms and conditions the Committee, in its sole discretion,
imposes upon them. The Committee will determine the number of shares of Common Stock covered by and the exercise period of the
SAR. Upon exercise of a freestanding SAR, the participant will receive an amount equal to the excess of the fair market value of
one share of Common Stock on the date of exercise over the grant price, multiplied by the number of shares of stock exercised under
the SAR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the case of a tandem
SAR, the Committee may determine the exercise period of the SAR, except that the exercise period may not exceed that of the related
option. The participant may exercise the tandem SAR when the option is exercisable and receive on exercise an amount equal to the
excess of the fair market value of one share of Common Stock on the date of exercise over the option purchase price, multiplied
by the number of shares of stock covered by the surrendered option. Upon exercise of an SAR awarded in tandem with a stock option,
the number of shares of our Common Stock for which the related option was exercisable will be reduced by the number of shares for
which the SAR was exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding any
other provision of this 2017 Plan to the contrary, with respect to a tandem SAR granted in connection with an ISO (i) the tandem
SAR will expire no later than the expiration of the underlying ISO; (ii) the value of the payout with respect to the tandem SAR
may be for no more than 100% of the difference between the option price of the underlying ISO and the fair market value of the
shares subject to the underlying ISO at the time the tandem SAR is exercised; and (iii) the tandem SAR may be exercised only when
the fair market value of the shares subject to the ISO exceeds the option price of the ISO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Restricted Stock</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Committee may impose
restrictions and conditions as to awards of shares of restricted stock as it deems advisable. As specified in the relevant award
agreement, restrictions may include a requirement that participants pay a stipulated purchase price for each share of restricted
stock, restrictions based upon the achievement of specific performance goals (Company-wide, divisional and/or individual), time-based
restrictions on vesting following the attainment of the performance goals and/or restrictions under applicable federal or state
securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may retain in our
possession the certificates representing shares of restricted stock until the time when all conditions and/or restrictions applicable
to those shares awarded under the 2017 Plan have been satisfied. Generally, shares of restricted stock covered by each restricted
stock grant made under the 2017 Plan will become freely transferable by the participant following the last day of the applicable
period of restriction. However, even after the satisfaction of the restrictions and conditions imposed by the 2017 Plan and the
particular award agreement, shares owned by an affiliate of the Company will be subject to restrictions on transfer under the Securities
Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I><U>Awards to
Employees</U>.</I> The Committee may choose to award shares of restricted stock under the 2017 Plan upon such terms and conditions
as it may establish. If an award of restricted stock is intended to qualify as performance-based compensation under Section 162(m)
of the Code, the maximum number of shares which may be granted in the form of restricted stock in any one calendar year to any
one participant who is a &ldquo;covered employee&rdquo; is 200,000. The award agreement will specify the period(s) of restriction,
the number of shares of restricted stock granted, requirements that a participant pay a stipulated purchase price for each share,
restrictions based upon the achievement of specific performance objectives, other restrictions governing the subject award and/or
restrictions under applicable federal or state securities laws. Recipients may have the right to vote these shares from the date
of grant, as determined by the Committee on the date of award. As determined by the Committee on the date of award, participants
may receive dividends on their shares of restricted stock. Dividends accrued on restricted stock will be paid only if the restricted
stock vests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each award agreement
for restricted stock will specify the extent to which the participant will have the right, if any, to retain unvested restricted
stock following termination of the participant&rsquo;s employment with the Company. In its sole discretion, the Committee will
make these determinations; these provisions need not be uniform among all awards of restricted stock issued under the 2017 Plan
and may reflect distinctions based on reasons for termination of employment. Except in the case of terminations by reason of
death or disability, restricted stock, which is intended to qualify for performance-based compensation under Section 162(m) and
which is held by &ldquo;covered employees&rdquo; under Section 162(m), will be forfeited by the participant to the Company upon
termination of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I><U>Awards to Non-Employee
Directors</U>.</I> Restricted stock awards to non-employee Directors will be subject to the restrictions for a period (the &ldquo;Restricted
Period&rdquo;), which will commence upon the date when the restricted stock is awarded and will end on the earliest of the first
to occur of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 86; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the retirement of the non-employee Director from the Board in compliance with the Board&rsquo;s retirement policy as then in effect;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the termination of the non-employee Director&rsquo;s service on the Board as a result of the non-employee Director&rsquo;s not being nominated for reelection by the Board;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the termination of the non-employee Director&rsquo;s service on the Board because of the non-employee Director&rsquo;s resignation or failure to stand for reelection with the consent of the Board (which means approval by at least 80% of the Directors voting, with the affected non-employee Director abstaining);</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the termination of the non-employee Director&rsquo;s service on the Board because the non-employee Director, although nominated for reelection by the Board, is not reelected by the stockholders;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the termination of the non-employee Director&rsquo;s service on the Board because of (i) the non-employee Director&rsquo;s resignation at the request of the Nominating and Governance Committee of the Board, (ii) the non-employee Director&rsquo;s removal by action of the stockholders or by the Board, or (iii) a change in control of the Company, as defined in the 2017 Plan;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">the termination of the non-employee Director&rsquo;s service on the Board because of disability or death; or</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the vesting of the award.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date specified
by the Committee, each non-employee Director will be awarded that number of shares of restricted stock as determined by the Board,
after consideration of the recommendations of the Committee. A non-employee Director who is first elected to the Board on a date
subsequent to the date so specified will be awarded that number of shares of restricted stock as determined by the Board, after
consideration of the recommendations of the Committee. The amount of the award for the upcoming 2017 Plan year will be disclosed
in the Company&rsquo;s proxy statement for the Company&rsquo;s annual meeting of stockholders. The 2017 Plan provides that non-employee
Directors receiving restricted stock may have, subject to the provisions of the 2017 Plan, all of the rights of a stockholder with
respect to the shares of restricted stock, including the right to vote the shares and receive cash dividends and other cash distributions
thereon. If a non-employee Director ceases to be a member of the Board for any other reason, including removal or resignation for
 &ldquo;Cause,&rdquo; as defined in the 2017 Plan, the non-employee Director will forfeit to the Company all restricted stock awarded
to him or her for which the Restricted Period has not ended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Restricted Stock Units</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Committee may award
restricted stock units (&ldquo;RSUs&rdquo;). Each RSU will have a value equal to the fair market value of a share of the Company&rsquo;s
Common Stock on the date of grant. The maximum aggregate award of RSUs to any one participant who is a &ldquo;covered employee&rdquo;
during any one fiscal year will be equal to the fair market value of 200,000 shares; provided, further, that the maximum aggregate
award of restricted stock and RSUs for any one fiscal year will be coordinated so that in no event will any one participant be
awarded more than the fair market value of 200,000 shares taking into account all such awards. In its discretion, the Committee
may impose conditions and restrictions on RSUs, as specified in the RSU award agreement, including restrictions based upon the
achievement of specific performance goals and time-based restrictions on vesting. As determined by the Committee at the time of
the award, settlement of vested RSUs may be made in the form of cash, shares of Company stock, or a combination of cash and Company
stock. Settlement of vested RSUs will be in a lump sum as soon as practicable after the vesting date. The amount of the settlement
will equal the fair market value of the RSUs on the vesting date. Each RSU will be credited with an amount equal to the dividends
paid on a share of Company stock between the date of award and the date the RSU is paid to the participant, if at all. Dividend
equivalents will vest, if at all, upon the same terms and conditions governing the vesting of the RSUs under the 2017 Plan. Payment
of the dividend equivalent will be paid at the same time as payment of the RSU. The holders of RSUs will have no voting rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each award agreement
for RSUs will specify the extent to which the participant will have the right, if any, to retain unvested RSUs following termination
of the participant&rsquo;s employment with the Company or, in the case of a non-employee Director, service with the Board. In
its sole discretion, the Committee will make these determinations; these provisions need not be uniform among all awards of RSUs
issued under the 2017 Plan and may reflect distinctions based on reasons for termination of employment or, in the case of a non-employee
Director, service with the Board. Except in the case of terminations by reason of death or disability, RSUs awarded to participants
who are &ldquo;covered employees&rdquo; and which are intended to qualify as performance-based compensation under Section 162(m),
will be forfeited by the participant to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 87; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Performance Units/Performance Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Committee has
the discretion to award performance units and performance shares under the 2017 Plan upon such terms and conditions as it may
establish, as evidenced in the relevant award agreement. If an award of performance units or performance shares is intended to
qualify as performance-based compensation under Section 162(m) of the Code, the maximum aggregate payout for awards of performance
shares which may be granted in any one calendar year to any one participant who is a &ldquo;covered employee&rdquo; will be the
fair market value of 200,000 shares, whereas the maximum aggregate payout for awards of performance units which may be granted
in any one calendar year to any one participant will be $1,500,000. Performance units will have an initial value as determined
by the Committee, whereas performance shares will have an initial value equal to one share of Common Stock on the date of award.
At the time of the award of the performance units or shares, the Committee in its discretion will establish performance goals
which, depending on the extent to which they are met, will determine the number and/or value of performance units or shares that
will be paid out to the participant. Under the terms of the 2017 Plan, after the applicable performance period has ended, the
holder of performance units or shares will be entitled to receive payout on the number and value of performance units or shares
earned by the participant over the performance period. The payout on the number and value of the performance units and performance
shares will be a function of the extent to which corresponding performance goals are met.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Payment of performance
shares and performance units will be made in a single lump sum following the close of the applicable performance period. Upon satisfaction
of the specified performance goals, the Committee will pay the earned performance shares in shares of Company Common Stock. In
its discretion, the Committee may pay earned performance units in cash, in shares of Company stock or in a combination of cash
and stock, which will have an aggregate fair market value equal to the value of the earned performance share or performance unit
at the close of the applicable performance period. Participants will not be entitled to dividend or voting rights with respect
to any performance shares or performance units earned but not yet distributed to a participant. Unless otherwise determined by
the Committee, in the case of death or disability during the performance period, the participant, or his or her estate, will not
be entitled to receive any payout of the performance shares or performance units. In the case of any other termination of the participant&rsquo;s
employment during the performance period, all performance shares and performance units intended to qualify as performance-based
compensation will be forfeited by the participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Adjustment and Amendments</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2017 Plan provides
for appropriate adjustments in the number of shares of Company stock subject to awards and available for future awards in the event
of changes in outstanding Common Stock by reason of a merger, stock split, stock dividend, or certain other events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2017 Plan may be
modified or amended by the board at any time and for any purpose which the Board deems appropriate. However, no such amendment
may adversely affect any outstanding awards without the affected holder&rsquo;s consent. No amendment may, without stockholder
approval, (i) materially increase the benefits earned by participants under the 2017 Plan, (ii) materially increase the number
of shares which may be issued under the 2017 Plan or (iii) materially modify the requirements for participation in the 2017 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Change in Control</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of a change
in control, as defined in the 2017 Plan, generally all options and SARs granted under the 2017 Plan will become immediately exercisable;
and restriction periods and other restrictions imposed on restricted stock and RSUs which are not intended to qualify as performance-based
compensation under Section 162(m) under the Code will lapse. Any award intended to qualify as performance-based under Section 162(m)
must be earned in accordance with the applicable award agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Non-transferability</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No award under the
2017 Plan may be sold, transferred, pledged, assigned or otherwise transferred in any manner by a participant except by will or
by the laws of descent and distribution; and any award will be exercisable during a participant&rsquo;s lifetime only by the participant
or by the participant&rsquo;s guardian or legal representative. These limitations may be waived by the Committee, subject to restrictions
imposed under the SEC&rsquo;s short-swing trading rules and federal tax requirements relating to incentive stock options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 88; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Duration of the 2017 Plan</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2017 Plan will
remain in effect until all shares subject to the 2017 Plan have been purchased or acquired under the terms of the 2017 Plan, and
all performance periods for performance-based awards granted under the 2017 Plan have been completed. However, no award is permitted
to be granted under the 2017 Plan on or after the day prior to the tenth anniversary of the date the board approved the 2017 Plan.
The board, upon recommendation of the Committee, may at any time amend, suspend or terminate the 2017 Plan in whole or in part
for any purpose the Committee deems appropriate, subject, however, to the limitations referenced in &ldquo;Adjustment and Amendments,&rdquo;
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date hereof,
there are no options, warrants or other rights outstanding under any equity compensation plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Director Remuneration Policy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Directors of the
Company are entitled to compensation of $30,000 (plus $10,000 for the Chairman of the Board and except that Dr. Becker will receive
$50,000 for his Board service and certain related duties) in cash per year of service on our Board of Directors, commencing on
the completion of this Offering and payable in full thereon for the ensuing year. We currently do not have any equity compensation
arrangements with our non-employee directors. Service as a member or chair of any of the committees of the Board do not entitle
our non-employee directors to any additional compensation. To date, none of our non-employee directors has been paid any amounts
as compensation for serving on our Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 89; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_010"></A>SECURITY
OWNERSHIP OF MANAGEMENT AND CERTAIN SECURITYHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
sets forth information regarding the beneficial ownership of our Common Stock as of the date hereof by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">each person known by us to be the beneficial owner of more than 5% of our outstanding shares of Common Stock;</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">each of our named executive officers and directors; and</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">all our executive officers and directors as a group.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Beneficial ownership
is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities. Except
as otherwise indicated, each person or entity named in the table has sole voting and investment power with respect to all shares
of our capital shown as beneficially owned, subject to applicable community property laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In computing the number
and percentage of shares beneficially owned by a person, shares that may be acquired by such person within 60 days of the date
hereof are counted as outstanding, while these shares are not counted as outstanding for computing the percentage ownership of
any other person. Unless otherwise indicated, the address of each person listed below is c/o the Company at 733 Third Ave, Floor
15, New York, NY 10017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Name of Beneficial Owner</B></P></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Shares of</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Common</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Stock</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Beneficially</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Owned</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percent of</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Common</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Stock</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Beneficially</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Owned</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%"><FONT STYLE="font-size: 10pt">Life Science Biosensor Diagnostics Pty Ltd*</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">8,250,000</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">100.0</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Jonathan S. Hurd</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Harry Simeonidis</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Dr. Jean-Claude Becker</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Victoria Gavrilenko</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Dr. John Caminis</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Dr. Yong-Jiang Hei</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><I>All Executive Officers and Directors as a group (6 persons)</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* Life Science Biosensor
Diagnostics Pty Ltd (&ldquo;LSBD&rdquo;) is an Australian company that is 81% owned by iQnovate Limited, which is an
Australian company that is 24% beneficially owned and controlled by Dr. George Syrmalis and whose shares are otherwise
publicly-owned and traded on the National Stock Exchange of Australia. Dr. Syrmalis is an Australian citizen and resident
having an address at Level 9, 85 Castlereagh Street, Sydney NSW 2000. In addition, the Board of Directors of iQnovate Limited
consists of the following persons, each of whom is an Australian resident having the same address as above: Dr. Syrmalis, Mr.
Con Tsigounis and Mr. Peter Simpson. Accordingly, Dr. Syrmalis may be deemed to have sole voting and dispositive power, and
the Board of Directors may be deemed to share voting and dispositive power, over the Common Stock held by LSBD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 90; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_011"></A>INTEREST
OF MANAGEMENT AND OTHERS IN CERTAIN TRANSACTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Relationships with Affiliates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has
entered into the License Agreement with LSBD pursuant to which it licenses the saliva glucose biosensor system for the China Region.
For a detailed description of the License Agreement and considerations relating thereto, see &ldquo;Description of Business &ndash;
License Agreement&rdquo; and &ldquo;Risk Factors &ndash; Risk Related to Our Intellectual Property &ndash; Our License Agreement
with our wholly-owning parent, LSBD, which relates to the Company&rsquo;s principle asset consisting of licensed intellectual
property, contains numerous significant performance, payment, liability, compliance, termination and intellectual property risks
that may threaten the Company&rsquo;s viability or otherwise have a material adverse effect on the Company, its business and its
prospects.&rdquo; The License Agreement requires, among many material provisions, that the Company pay to LSBD (i) a fixed fee
after all regulatory approvals in Mainland China are obtained, (ii) royalties equal to percentages of net sales of commercial
units and net sales of an optional dedicated reading device, and (iii) certain application fees. From August 5, 2016 to June 30,
2018, the Company paid LSBD a total of $7,561,321 under the License Agreement and $1,866,376 in relation to general administration
expenses. As of June 30, 2018, it had incurred $2,525,798 (including a trade creditors liability to LSBD of $466,275) in relation
to research and development and regulatory approval costs.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that a substantial
portion of the net proceeds used for the purposes described above will be paid to LSBD pursuant to the License Agreement, pursuant
to which LSBD will conduct a substantial portion of the activities that must be performed in the near term to advance our business
plan, including without limitation market data studies, delivery of a finalized field prototype biosensor, delivery of a manufacture-to-scale
plan, delivery of a global regulatory strategy plan, commencing scale manufacturing, commencement and confidential testing, submitting
and finalizing regulatory submissions through final approvals, delivery of a finalized product for sale, and many other services.
Not all of the services to be performed by LSBD under the License Agreement are expected to be completed within the first year
following this Offering. While the payments to LSBD for all such services would exceed net proceeds in the event only the minimum
amount of this Offering is received, the Company expects that it will use such net proceeds for purposes as are most timely and
appropriate in its judgment. See &ldquo;Use of Proceeds.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has entered
into a master services agreement (the &ldquo;MSA Agreement&rdquo;) with IQ3CORP LIMITED ACN 160 238 282 (&ldquo;IQ3&rdquo;), which
is an affiliate of the Company by virtue of being under common control. The MSA Agreement sets forth certain basic terms and provisions
applicable to services provided and to be provided by IQ3 to the Company pursuant to specific service acquisition orders entered
into by the parties from time to time. One outstanding such order from January 2016 covers the following services provided directly
or indirectly to the Company for the following costs: business plan preparation and review &ndash; $120,000; due diligence &ndash;
$40,000; private placement capital-raising assistance &ndash; $250,000 plus 8% of proceeds raised outside the United States (payable
in accordance with IQ3&rsquo;s Australian Financial Services License); investor relations services &ndash; $20,000 per month commencing
in July 2017; and certain other services. All of the foregoing amounts accrued to date have been paid in full. In addition, the
MSA Agreement provides that hourly rates are payable for corporate advisory services to the Company, which amounts will be payable
as accrued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2017, the
Company entered into a three-year Medical Affairs Services Agreement (the &ldquo;MAS Agreement&rdquo;) with Clinical Research Corporation
(&ldquo;CRC&rdquo;), a wholly-owned Australian subsidiary of iQnovate Limited, an Australian entity that is an affiliate of the
Company by virtue of being under common control. iQnovate Limited also majority-owns LSBD. The MAS Agreement provides certain master
terms pursuant to which CRC would be engaged in the future by the Company from time to time to perform certain medical affairs
services on behalf of the Company. The master terms include minimum professional indemnity insurance, liability insurance and products
liability insurance that will be required and indemnification by the Company of CRC, except where liability has resulted solely
from the negligence or willful misconduct of CRC. The MAS Agreement does not set forth specified projects, services or costs in
connection therewith, but provides general parameters pursuant to which such specific projects, services and costs would be detailed
in the future as procured. All of the specific projects, services, costs and related performance details will be set forth from
time to time in one or more &ldquo;statements of works&rdquo;. &nbsp;The Company and CRC have not entered into any material statements
of works as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Statement of Policy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since inception we
have been wholly-owned by LSBD. Since inception we have entered into transactions with LSBD that have not been negotiated, arranged
or otherwise implemented on an arms-length basis and that may favor LSBD. These transactions include in particular the License
Agreement and the employee sharing arrangements whereby the Company has not engaged its own exclusive employees. Nonetheless, since
inception all transactions (if any) between us and our officers or directors have been on terms no less favorable than could be
obtained from unaffiliated third parties and were unanimously approved by our directors. In the future, all transactions (if any)
between us and our officers or directors or five percent stockholders, and their respective affiliates, will be on terms no less
favorable than could be obtained from unaffiliated third parties and will be unanimously approved by our directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the best of our
knowledge, other than as set forth above, there were no material transactions, or series of similar transactions, or any currently
proposed transactions, or series of similar transactions, to which we were or are to be a party, in which the amount involved exceeds
the lesser of $120,000 or 1% of the average of our total assets at year end for the last two completed fiscal years, and in which
any director or executive officer, or any security holder who is known by us to own of record or beneficially more than 5% of any
class of our Common Stock, or any member of the immediate family of any of the foregoing persons, has an interest (other than compensation
to our officers and directors in the ordinary course of business).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 91; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_012"></A>DESCRIPTION
OF OUR SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Certificate of
Incorporation authorizes us to issue:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">20,000,000 shares
                                    of common stock, par value $0.01 per share; and</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">2,000,000 shares of preferred stock, par value $0.01 per
    share, of which 1,222,506 shares of our Series A Convertible Preferred Stock are issued and are outstanding as of the date
    hereof pursuant to a private placement prior to the date hereof.</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 5,
2017, we gave effect by the filing of an amendment to our Certificate of Incorporation to effect a one-to-90,000 stock
split pursuant to which each outstanding share of common stock was converted into 90,000 shares of Common Stock. The
outstanding preferred stock, convertible notes and warrants exercisable or convertible into Common Stock have been
proportionately adjusted in accordance therewith. In addition, on August 9, 2018 we filed an amendment to our
Certificate of&nbsp;Incorporation to effect a reverse stock split of approximately one to 0.9167 shares that resulted in the
Company having 8,250,000 issued and outstanding shares of common stock. Share and per share amounts set forth herein (except
in any historical financial information) give effect to the reverse split, unless indicated otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following description
summarizes the most important terms of our capital stock, as they are expected to be in effect upon the closing of this Offering.
We expect to adopt an amended and restated certificate of incorporation and amended and restated by-laws in connection with this
Offering, and this description summarizes the provisions that are expected to be included in such documents. Because it is only
a summary, it does not contain all the information that may be important to you. For a complete description of the matters set
forth in &ldquo;Description of Securities,&rdquo; you should refer to our amended and restated certificate of incorporation and
amended and restated by-laws, which are or will be included as exhibits to the Offering Statement relating to this Offering Circular,
and to the applicable provisions of Delaware law. Immediately following the closing of this Offering, our authorized capital stock
will consist of 22,000,000 shares of Common Stock, $0.01 par value per share, and 2,000,000 shares of Preferred Stock, $0.01 par
value per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date
hereof we have 8,250,000 shares of Common Stock issued and outstanding and owned by one stockholder. As of the date hereof, up
to 1,500,000 shares are reserved for issuance in connection with the conversion of our Series A Convertible Preferred Stock on
a one-to-one share basis, up to 600,000 shares are reserved for issuance in connection with the conversion of outstanding convertible
notes and 500,000 shares are reserved for issuance under the 2017 Plan. Upon the closing of this Offering, all shares of Series
A Convertible Preferred Stock will automatically convert into 1,222,506 shares of our Common Stock and all of the convertible
notes will automatically convert into 517,358 shares of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Voting Rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holders of our
Common Stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders, including
the election of directors, and do not have cumulative voting rights. Accordingly, the holders of a majority of the outstanding
shares of Common Stock entitled to vote in any election of directors can elect all of the directors standing for election, if they
so choose, other than any directors that holders of any Preferred Stock we may issue may be entitled to elect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Dividends</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to limitations
under Delaware law and preferences that may be applicable to any then outstanding Preferred Stock, holders of Common Stock are
entitled to receive ratably those dividends, if any, as may be declared by our Board of Directors out of legally available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Liquidation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of any
voluntary or involuntary liquidation, dissolution or winding up of our affairs, the holders of our Common Stock will be entitled
to share ratably in the net assets legally available for distribution to stockholders after the payment of or provision for all
of our debts and other liabilities, subject to the prior rights of any Preferred Stock then outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 92; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Rights and Preferences</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of Common Stock
have no preemptive or conversion rights or other subscription rights and there are no redemption or sinking funds provisions applicable
to the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fully Paid and Non-assessable</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All outstanding shares
of Common Stock are, and the Common Stock to be outstanding upon completion of this Offering will be, duly authorized, validly
issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Transfer Agent and Registrar</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have not
engaged an independent third party to act as the transfer agent for our Common Stock. We will engage prior to the qualification
of this Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Immediately prior
to the consummation of this Offering, all of the 1,222,506 outstanding shares of our Series A Convertible Preferred Stock will
be converted into shares of our Common Stock. Immediately after the consummation of this Offering, our amended and restated certificate
of incorporation will be amended and restated to delete all references to such shares of Series A Convertible Preferred Stock.
Our Board of Directors currently has the authority, without further action by our stockholders, to issue shares of preferred stock
in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges
could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms
and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights
of Common Stock. The issuance of preferred stock could adversely affect the voting power of holders of Common Stock and the likelihood
that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock
could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action. Immediately
after consummation of this Offering, no shares of preferred stock will be outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date hereof,
there are outstanding warrants issued in connection with the Series A Convertible Preferred Stock having an exercise price of $12.00
per share, which warrants are exercisable only during the one-year period commencing on the second anniversary of the closing of
this Offering. The warrants are not entitled to any adjustment in the number of shares or the exercise price in the event of any
adjustments in the number of outstanding shares of our capital stock for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition,
upon each closing of this Offering, we have agreed to issue warrants to the Placement Agent (&ldquo;Placement Agent&rsquo;s
Warrants&rdquo;) to purchase a number of shares of the Common Stock equal to 5.0% of the total Shares sold in such closing.
Accordingly, if the minimum number of shares are sold in this Offering then the Placement Agent&rsquo;s Warrants will be
exercisable for a total of 20,833 and if the maximum number of shares are sold in this Offering then the Placement Agent&rsquo;s
Warrants will be exercisable for a total of 104,166 shares. The Placement Agent&rsquo;s Warrants are exercisable commencing on
the date that the SEC initially qualifies the Offering Statement and will be exercisable for five years thereafter. The
Placement Agent&rsquo;s Warrants are not redeemable by us. The exercise price for the Placement Agent&rsquo;s Warrants will be 10% greater than the initial public offering price. The Placement Agent&rsquo;s Warrants
contain anti-dilution provisions that may be triggered by future events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Convertible Notes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our 98%-owned subsidiary,
GBS Pty Ltd, has issued convertible notes in the outstanding aggregate principal amount of $5,277,056 (including principal and
accrued interest) as of the date hereof, which notes will automatically convert into 517,358 shares of Common Stock at a price
per share equal to $10.20 in connection with this Offering. In the absence of the completion of this Offering and such automatic
conversion of the notes, the notes mature on December 31, 2019. These notes were issued along with ordinary shares of GBS Pty
Ltd in a private placement conducted in the first quarter of 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Registration Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no registration
rights held by any party with respect to any of our capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Anti-Takeover Effects of Provisions
of Our Certificate of Incorporation, Our By-laws and Delaware Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some provisions of
Delaware law, our Certificate of Incorporation and our By-laws contain provisions that could make the following transactions more
difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or otherwise; or the
removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish
or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including
transactions which provide for payment of a premium over the market price for our shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 93; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These provisions, summarized
below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed
to encourage persons seeking to acquire control of us to first negotiate with our Board of Directors. We believe that the benefits
of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to
acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could
result in an improvement of their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Undesignated Preferred Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ability of our
Board of Directors, without action by the stockholders, to issue undesignated shares of Preferred Stock with voting or other rights
or preferences as designated by our Board of Directors could impede the success of any attempt to change control of us. These and
other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Delaware Anti-Takeover Statute</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject
to Section 203 of the Delaware General Corporation Law, which prohibits persons deemed to be &ldquo;interested stockholders&rdquo;
from engaging in a &ldquo;business combination&rdquo; with a publicly held Delaware corporation for three years following the
date these persons become interested stockholders unless the business combination is, or the transaction in which the person became
an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &ldquo;interested
stockholder&rdquo; is a person who, together with affiliates and associates, owns, or within three years prior to the determination
of interested stockholder status did own, 15% or more of a corporation&rsquo;s voting stock. Generally, a &ldquo;business combination&rdquo;
includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The
existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the Board
of Directors. A Delaware corporation may &ldquo;opt out&rdquo; of these provisions with an express provision in its original certificate
of incorporation or an express provision in its certificate of incorporation or by-laws resulting from a stockholders' amendment
approved by at least a majority of the outstanding voting shares. We have not opted out of these provisions. As a result, mergers
or other takeover or change in control attempts of us may be discouraged or prevented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 94; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Amendment of Charter Provisions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The DGCL generally
provides that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation's
certificate of incorporation or by-laws, unless either a corporation's certificate of incorporation or by-laws requires a greater
percentage. Our certificate of incorporation and bylaws that will be in effect upon the closing of this Offering will provide
the following terms. A majority vote of our Board of Directors or the affirmative vote of holders of a majority of the total votes
of our outstanding shares of capital stock entitled to vote with respect thereto will be required to amend, alter, change or repeal
the by-laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Authorized but Unissued Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our authorized but
unissued shares of Common Stock and Preferred Stock will be available for future issuance without stockholder approval. These additional
shares may be utilized for a variety of corporate purposes, including future public offerings to raise additional capital and corporate
acquisitions. The existence of authorized but unissued shares of Common Stock and Preferred Stock could render more difficult or
discourage an attempt to obtain control of a majority of our Common Stock by means of a proxy contest, tender offer, merger or
otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The provisions of Delaware
law, our Certificate of Incorporation and our By-laws could have the effect of discouraging others from attempting hostile takeovers
and, as a consequence, they may also inhibit temporary fluctuations in the market price of our Common Stock that often result from
actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition
of our board and management. It is possible that these provisions could make it more difficult to accomplish transactions that
stockholders may otherwise deem to be in their best interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 95; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_013"></A>DIVIDEND
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our inception,
we have not paid any dividends on our Common Stock, and we currently expect that, for the foreseeable future, all earnings (if
any) will be retained for the development of our business and no dividends will be declared or paid. In the future, our Board of
Directors may decide, at their discretion, whether dividends may be declared and paid, taking into consideration, among other things,
our earnings (if any), operating results, financial condition and capital requirements, general business conditions and other pertinent
facts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_014"></A>SHARES
ELIGIBLE FOR FUTURE SALE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Future sales of substantial
amounts of our Common Stock in the public market, including shares issued upon exercise of outstanding warrants, or the anticipation
of these sales, could adversely affect prevailing market prices from time to time and could impair our ability to raise equity
capital in the future. Before this Offering, there has not been a public market for shares of our Common Stock. Future sales of
substantial amounts of shares of our Common Stock, including shares issued upon the exercise of outstanding warrants that were
issued in connection with the issuance of the preferred stock, in the public market after this Offering, or the possibility of
these sales occurring, could cause the prevailing market price for our Common Stock to fall or impair our ability to raise equity
capital in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date
of this Offering Circular, we have outstanding 8,250,000 shares of Common Stock currently held by our sole stockholder. In addition,
as of the date of this Offering Circular: (i) 1,222,506 shares of Common Stock are issuable upon the completion of this Offering
by mandatory conversion of outstanding shares of our Series A Convertible Preferred Stock on a one-to-one basis; (ii) 517,358
shares of Common Stock are issuable upon the completion of this Offering by mandatory conversion of $5,277,056 of notes issued
by our 98%-owned subsidiary GBS Pty Ltd at an effective conversion price at a 15% discount to the price per Share in this Offering;
(iii) 1,222,506 shares of Common Stock are issuable during the one year period commencing on the second anniversary of the completion
of this Offering by exercise of outstanding warrants; and (iv) up to 104,167 shares of Common Stock will be issuable pursuant
to warrants issuable to the Placement Agent in this Offering, the actual amount of such shares to be equal to 5.0% of the Shares
sold in this Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of the foregoing
shares that will be outstanding after this Offering, other than the Shares sold in this Offering, are or will be upon issuance
 &ldquo;restricted securities&rdquo; as that term is defined in Rule 144 under the Securities Act. These restricted securities are
eligible for public sale only if they are registered under the Securities Act or if they qualify for an exemption from registration
under Rule 144 under the Securities Act, which are summarized below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rule 144</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, a person
who has beneficially owned restricted shares of our Common Stock for at least twelve months, in the event we are a reporting company
under Regulation A, or at least six months, in the event we have been a reporting company under the Exchange Act for at least 90
days before the sale, would be entitled to sell such securities, provided that such person is not deemed to be an affiliate of
ours at the time of sale or to have been an affiliate of ours at any time during the 90 days preceding the sale. A person who is
an affiliate of ours at such time would be subject to additional restrictions, by which such person would be entitled to sell within
any three-month period only a number of shares that does not exceed the greater of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">1% of the number of shares of our Common Stock then outstanding; or</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the average weekly trading volume of our Common Stock during the four calendar weeks preceding the filing by such person of a notice on Form 144 with respect to the sale;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">provided that, in each case, we are subject
to the periodic reporting requirements of the Exchange Act for at least 90 days before the sale. Rule 144 trades must also comply
with the manner of sale, notice and other provisions of Rule 144, to the extent applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rule 701</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, although
not applicable to any of the shares that will be outstanding upon the closing of this Offering Rule 701 allows a stockholder who
purchased shares of our capital stock pursuant to a written compensatory plan or contract and who is not deemed to have been an
affiliate of ours during the immediately preceding 90 days to sell those shares in reliance upon Rule 144, but without being required
to comply with the public information, holding period, volume limitation or notice provisions of Rule 144. All holders of Rule
701 shares, however, are required to wait until 90 days after the date of this Offering Circular before selling shares pursuant
to Rule 701.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 96; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Lock-Up Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Our directors,
officers and more than 5% shareholders have agreed, or will agree, with the Placement Agent, subject to certain exceptions, that,
without the prior written consent of the Placement Agent, they will not, directly or indirectly, during the period ending one
year after the date of the Offering Circular (180 days for investors in our Series A Convertible Preferred Stock and the outstanding
notes convertible into shares of our Common Stock): </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp;&nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant for the sale of, or otherwise dispose of or transfer any shares of the Common Stock or any securities convertible into or exchangeable or exercisable for the Common Stock, whether now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition; or</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">enter into any swap or any other agreement or any transaction that transfers, in whole or in part, the economic consequence of ownership of the Common Stock, whether any such swap or transaction is to be settled by delivery of the Common Stock or other securities, in cash or otherwise.</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These agreements
do not apply, in our case, to securities issued pursuant to existing employee benefit plans or securities issued upon exercise
of options, and other exceptions, and in the case of our officers, directors and other holders of our securities, exercise of
stock options issued pursuant to a stock option or similar plans, and other exceptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Registration Statement on Form S-8</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date hereof,
no awards of any kind have been made under the 2017 Plan. We intend to file a registration statement on Form S-8 under the Securities
Act to register shares that may be issued pursuant to the 2017 Plan. The registration statement on Form S-8 is expected to become
effective immediately upon filing, and shares covered by the registration statement will then become eligible for sale in the public
market, subject to the Rule 144 limitations applicable to affiliates, vesting restrictions and any applicable lock-up agreements
and market standoff agreements. For a description of our equity incentive plans, see &quot;Management&mdash;2017 Equity Incentive
Plan.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 97; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_015"></A>DISQUALIFYING
EVENTS DISCLOSURE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Recent changes to Regulation
A promulgated under the Securities Act prohibit an issuer from claiming an exemption from registration of its securities under
such rule if the issuer, any of its predecessors, any affiliated issuer, any director, executive officer, other officer participating
in the offering of the interests, general partner or managing member of the issuer, any beneficial owner of 20% or more of the
voting power of the issuer&rsquo;s outstanding voting equity securities, any promoter connected with the issuer in any capacity
as of the date hereof, any investment manager of the issuer, any person that has been or will be paid (directly or indirectly)
remuneration for solicitation of purchasers in connection with such sale of the issuer&rsquo;s interests, any general partner or
managing member of any such investment manager or solicitor, or any director, executive officer or other officer participating
in the offering of any such investment manager or solicitor or general partner or managing member of such investment manager or
solicitor has been subject to certain &ldquo;Disqualifying Events&rdquo; described in Rule 506(d)(1) of Regulation D subsequent
to September 23, 2013, subject to certain limited exceptions. The Company is required to exercise reasonable care in conducting
an inquiry to determine whether any such persons have been subject to such Disqualifying Events and is required to disclose any
Disqualifying Events that occurred prior to September 23, 2013 to investors in the Company. The Company believes that it has exercised
reasonable care in conducting an inquiry into Disqualifying Events by the foregoing persons and is aware of the no such Disqualifying
Events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is possible that
(a) Disqualifying Events may exist of which the Company is not aware and (b) the SEC, a court or other finder of fact may determine
that the steps that the Company has taken to conduct its inquiry were inadequate and did not constitute reasonable care. If such
a finding were made, the Company may lose its ability to rely upon exemptions under Regulation A, and, depending on the circumstances,
may be required to register the Offering of the Company&rsquo;s Common Stock with the SEC and under applicable state securities
laws or to conduct a rescission offer with respect to the securities sold in the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_016"></A>ERISA
CONSIDERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Trustees and other
fiduciaries of qualified retirement plans or IRAs that are set up as part of a plan sponsored and maintained by an employer, as
well as trustees and fiduciaries of Keogh Plans under which employees, in addition to self-employed individuals, are participants
(together, &ldquo;ERISA Plans&rdquo;), are governed by the fiduciary responsibility provisions of Title 1 of the Employee Retirement
Income Security Act of 1974 (&ldquo;ERISA&rdquo;). An investment in the Shares by an ERISA Plan must be made in accordance with
the general obligation of fiduciaries under ERISA to discharge their duties (i) for the exclusive purpose of providing benefits
to participants and their beneficiaries; (ii) with the same standard of care that would be exercised by a prudent man familiar
with such matters acting under similar circumstances; (iii) in such a manner as to diversify the investments of the plan, unless
it is clearly prudent not do so; and (iv) in accordance with the documents establishing the plan. Fiduciaries considering an investment
in the Shares should accordingly consult their own legal advisors if they have any concern as to whether the investment would be
inconsistent with any of these criteria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Fiduciaries of certain
ERISA Plans which provide for individual accounts (for example, those which qualify under Section 401(k) of the Code, Keogh Plans
and IRAs) and which permit a beneficiary to exercise independent control over the assets in his individual account, will not be
liable for any investment loss or for any breach of the prudence or diversification obligations which results from the exercise
of such control by the beneficiary, nor will the beneficiary be deemed to be a fiduciary subject to the general fiduciary obligations
merely by virtue of his exercise of such control. On October 13, 1992, the Department of Labor issued regulations establishing
criteria for determining whether the extent of a beneficiary&rsquo;s independent control over the assets in his account is adequate
to relieve the ERISA Plan&rsquo;s fiduciaries of their obligations with respect to an investment directed by the beneficiary. Under
the regulations, the beneficiary must not only exercise actual, independent control in directing the particular investment transaction,
but also the ERISA Plan must give the participant or beneficiary a reasonable opportunity to exercise such control, and must permit
him to choose among a broad range of investment alternatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Trustees and other
fiduciaries making the investment decision for any qualified retirement plan, IRA or Keogh Plan (or beneficiaries exercising control
over their individual accounts) should also consider the application of the prohibited transactions provisions of ERISA and the
Code in making their investment decision. Sales and certain other transactions between a qualified retirement plan, IRA or Keogh
Plan and certain persons related to it (e.g., a plan sponsor, fiduciary, or service provider) are prohibited transactions. The
particular facts concerning the sponsorship, operations and other investments of a qualified retirement plan, IRA or Keogh Plan
may cause a wide range of persons to be treated as parties in interest or disqualified persons with respect to it. Any fiduciary,
participant or beneficiary considering an investment in Shares by a qualified retirement plan IRA or Keogh Plan should examine
the individual circumstances of that plan to determine that the investment will not be a prohibited transaction. Fiduciaries, participants
or beneficiaries considering an investment in the Shares should consult their own legal advisors if they have any concern as to
whether the investment would be a prohibited transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 98; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulations issued
on November 13, 1986, by the Department of Labor (the &ldquo;Final Plan Assets Regulations&rdquo;) provide that when an ERISA Plan
or any other plan covered by Code Section 4975 (e.g., an IRA or a Keogh Plan which covers only self-employed persons) makes an
investment in an equity interest of an entity that is neither a &ldquo;publicly offered security&rdquo; nor a security issued by
an investment company registered under the Investment Company Act of 1940, the underlying assets of the entity in which the investment
is made could be treated as assets of the investing plan (referred to in ERISA as &ldquo;plan assets&rdquo;). Programs which are
deemed to be operating companies or which do not issue more than 25% of their equity interests to ERISA Plans are exempt from being
designated as holding &ldquo;plan assets.&rdquo; Management anticipates that we would clearly be characterized as an &ldquo;operating
company&rdquo; for the purposes of the regulations, and that it would therefore not be deemed to be holding &ldquo;plan assets.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Classification of our
assets of as &ldquo;plan assets&rdquo; could adversely affect both the plan fiduciary and management. The term &ldquo;fiduciary&rdquo;
is defined generally to include any person who exercises any authority or control over the management or disposition of plan assets.
Thus, classification of our assets as plan assets could make the management a &ldquo;fiduciary&rdquo; of an investing plan. If
our assets are deemed to be plan assets of investor plans, transactions which may occur in the course of its operations may constitute
violations by the management of fiduciary duties under ERISA. Violation of fiduciary duties by management could result in liability
not only for management but also for the trustee or other fiduciary of an investing ERISA Plan. In addition, if our assets are
classified as &ldquo;plan assets,&rdquo; certain transactions that we might enter into in the ordinary course of our business might
constitute &ldquo;prohibited transactions&rdquo; under ERISA and the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Code Section
408(i), as amended by the Tax Reform Act of 1986, IRA trustees must report the fair market value of investments to IRA holders
by January 31 of each year. The Service has not yet promulgated regulations defining appropriate methods for the determination
of fair market value for this purpose. In addition, the assets of an ERISA Plan or Keogh Plan must be valued at their &ldquo;current
value&rdquo; as of the close of the plan&rsquo;s fiscal year in order to comply with certain reporting obligations under ERISA
and the Code. For purposes of such requirements, &ldquo;current value&rdquo; means fair market value where available. Otherwise,
current value means the fair value as determined in good faith under the terms of the plan by a trustee or other named fiduciary,
assuming an orderly liquidation at the time of the determination. We do not have an obligation under ERISA or the Code with respect
to such reports or valuation although management will use good faith efforts to assist fiduciaries with their valuation reports.
There can be no assurance, however, that any value so established (i) could or will actually be realized by the IRA, ERISA Plan
or Keogh Plan upon sale of the Shares or upon liquidation of us, or (ii) will comply with the ERISA or Code requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The income earned by
a qualified pension, profit sharing or stock bonus plan (collectively, &ldquo;Qualified Plan&rdquo;) and by an individual retirement
account (&ldquo;IRA&rdquo;) is generally exempt from taxation. However, if a Qualified Plan or IRA earns &ldquo;unrelated business
taxable income&rdquo; (&ldquo;UBTI&rdquo;), this income will be subject to tax to the extent it exceeds $1,000 during any fiscal
year. The amount of unrelated business taxable income in excess of $1,000 in any fiscal year will be taxed at rates up to 36%.
In addition, such unrelated business taxable income may result in a tax preference, which may be subject to the alternative minimum
tax. It is anticipated that income and gain from an investment in the Shares will not be taxed as UBTI to tax exempt shareholders,
because they are participating only as passive financing sources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_017"></A>INVESTOR
ELIGIBILITY STANDARDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Shares will be
sold only to a person who is not an accredited investor if the aggregate purchase price paid by such person is no more than 10%
of the greater of such person&rsquo;s annual income or net worth, not including the value of his primary residence, as calculated
under Rule 501 of Regulation D promulgated under Section 4(a)(2) of the Securities Act of 1933, as amended. In the case of sales
to fiduciary accounts (Keogh Plans, Individual Retirement Accounts (IRAs) and Qualified Pension/Profit Sharing Plans or Trusts),
the above suitability standards must be met by the fiduciary account, the beneficiary of the fiduciary account, or by the donor
who directly or indirectly supplies the funds for the purchase of Shares. Investor suitability standards in certain states may
be higher than those described in this Offering Circular. These standards represent minimum suitability requirements for prospective
investors, and the satisfaction of such standards does not necessarily mean that an investment in the Company is suitable for such
persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 99; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each investor must
represent in writing that he/she meets the applicable requirements set forth above and in the Subscription Agreement, including,
among other things, that (i) he/she is purchasing the Shares for his/her own account and (ii) he/she has such knowledge and experience
in financial and business matters that he/she is capable of evaluating without outside assistance the merits and risks of investing
in the Shares, or he/she and his/her purchaser representative together have such knowledge and experience that they are capable
of evaluating the merits and risks of investing in the Shares. Transferees of Shares will be required to meet the above suitability
standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_018"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain legal matters
with respect to the shares of Common Stock offered hereby will be passed upon by Hughes Hubbard &amp; Reed LLP, New York, New
York. Schiff Hardin LLP, Washington, DC, is acting as counsel to the Placement Agent in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_019"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The financial statements
of the Company appearing elsewhere in this Offering Circular have been included herein in reliance upon the report of BDO East
Coast Partnership, an independent registered public accounting firm, appearing elsewhere herein, and upon the authority of BDO
East Coast Partnership as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 100; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="partii_020"></A>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have filed with
the SEC a Regulation A Offering Statement on Form 1-A under the Securities Act with respect to the shares of Common Stock offered
hereby. This Offering Circular, which constitutes a part of the Offering Statement, does not contain all of the information set
forth in the Offering Statement or the exhibits and schedules filed therewith. For further information about us and the Common
Stock offered hereby, we refer you to the Offering Statement and the exhibits and schedules filed therewith. Statements contained
in this Offering Circular regarding the contents of any contract or other document that is filed as an exhibit to the Offering
Statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of
such contract or other document filed as an exhibit to the Offering Statement. Upon the completion of this Offering, we will be
required to file periodic reports, proxy statements, and other information with the SEC pursuant to the Exchange Act. You may
read and copy this information at the SEC&rsquo;s Public Reference Room, 100 F Street, N.E., Room 1580, Washington, D.C. 20549.
You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC also maintains
an Internet website that contains reports, proxy statements and other information about issuers, including us, that file electronically
with the SEC. The address of this site is <U>www.sec.gov</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 101; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="partii_021"></A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 18pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 18pt"><B>GLUCOSE
BIOSENSOR SYSTEMS</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(GREATER CHINA)
HOLDINGS, INC. AND</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUBSIDIARIES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE PERIOD FROM JULY 1, 2017 THROUGH<BR>

JUNE 30, 2018</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 102; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings, Inc. &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Audited Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Table of Contents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contents</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; font-weight: bold"><A HREF="#Fs_01">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</A></TD>
    <TD STYLE="width: 10%; text-align: right; font-weight: bold"><A HREF="#Fs_01">F-3</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: right; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><A HREF="#Fs_02">CONSOLIDATED BALANCE SHEETS</A></TD>
    <TD STYLE="text-align: right; font-weight: bold"><A HREF="#Fs_02">F-4</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: right; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><A HREF="#Fs_03">CONSOLIDATED STATEMENTS OF OPERATIONS</A></TD>
    <TD STYLE="text-align: right; font-weight: bold"><A HREF="#Fs_03">F-5</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: right; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><A HREF="#Fs_04">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&rsquo; EQUITY</A></TD>
    <TD STYLE="text-align: right; font-weight: bold"><A HREF="#Fs_04">F-6</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: right; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><A HREF="#Fs_06">CONSOLIDATED STATEMENTS OF CASH FLOWS</A></TD>
    <TD STYLE="text-align: right; font-weight: bold"><A HREF="#Fs_06">F-8</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: right; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><A HREF="#Fs_07">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</A></TD>
    <TD STYLE="text-align: right; font-weight: bold"><A HREF="#Fs_07">F-9</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD ROWSPAN="4" STYLE="width: 32%">&nbsp;<IMG SRC="tv506394_img07.jpg" ALT=""></TD>
    <TD STYLE="width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">Tel:
    +61 2 9251 4100</FONT></TD>
    <TD STYLE="width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">Level
    11, 1 Margaret St</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">Fax:
    +61 2 9240 9821</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">Sydney
    NSW 2000</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">www.bdo.com.au</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">Australia</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="Fs_01"></A>To the members of Glucose Biosensor
Systems (Greater China) Holdings Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #242A2D"> <B>Report on the Audit of the Financial
Statements</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #242A2D"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11.3pt 0pt 0"> <FONT STYLE="color: Black">We have audited the
accompanying consolidated balance sheet of Glucose Biosensor Systems (Greater China) Holdings Inc. which compromise the consolidated
balance sheets as at June 30, 2018 and 2017 and the related consolidated statement of operations, changes in stockholders' equity,
and cash flows for the year ended June 30, 2018 and the period from August 4, 2016 (inception) to June 20, 2017. These financial
statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial
statements based on our audit.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11.3pt 0pt 0"> <FONT STYLE="color: Black">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.9pt 0pt 0; text-indent: -0.25pt"> <FONT STYLE="color: Black">We
conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards
require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material
misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial
reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures
that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's
internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test
basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that
our audit provides a reasonable basis for our opinion.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.9pt 0pt 0; text-indent: -0.25pt"> <FONT STYLE="color: Black">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.1pt 0pt 0; text-indent: 0.1pt"> <FONT STYLE="color: Black">In
our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position
of Glucose Biosensor Systems (Greater China) Holdings Inc. at June 30, 2018, and 2017 and the results of its operations and its
cash flows for the year ended June 30, 2018 and the period from August 4, 2016 (inception) to June 20, 2017, in conformity with
accounting principles generally accepted in the United States of America.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.1pt 0pt 0; text-indent: 0.1pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="color: #383F44"><B>BDO </B></FONT><B><FONT STYLE="color: #242A2D">East
Coast Partnership</FONT></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> /s/ BDO </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 183.55pt 0pt 0; text-indent: 0.2pt; color: #242A2D"> We have
served as the Company's auditor since 2017. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.55in 0pt 0; color: #242A2D"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.55in 0pt 0; color: #242A2D"> Sydney, Australia </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.55in 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #242A2D"> November 7, 2018 </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="Fs_02"></A>Glucose Biosensor Systems (Greater China) Holdings, Inc. &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Audited Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CONSOLIDATED BALANCE SHEETS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">Note</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center">As of</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">June 30,<BR> 2018</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">June 30,<BR> 2017</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">(audited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">(audited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Assets</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Current Assets:</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left; padding-left: 0.25in">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">7</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">418,420</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">56,033</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Deferred charges</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,983,123</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">611,194</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Other current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">4</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">94,380</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Total current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,495,923</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">667,227</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Intangibles</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Licensing rights, net of accumulated amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">5</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,495,923</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">667,227</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Liabilities and shareholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">6</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">719,690</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">339,174</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Convertible Notes Payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,839,927</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,534,322</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Due to Life Science Biosensor Diagnostics Pty Ltd</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">10</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,706,241</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Total current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,559,617</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,579,737</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,559,617</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,579,737</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Commitments &amp; Contingencies</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Shareholders' Equity</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Common shares (9,000,000 shares issued and&nbsp;&nbsp;outstanding as of 6/30/2018 and 100&nbsp;&nbsp;shares issued and 19,999,900 outstanding as of 6/30/2017)</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Preferred shares <FONT STYLE="font-size: 10pt">(1,222,506 shares issued and outstanding as of 6/30/2018 and none&nbsp;&nbsp;shares issued and none outstanding as of 6/30/2017)</FONT></TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8,715,794</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(8,330,314</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(5,603,556</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Accumulated deficit</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(5,332,055</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(311,672</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Accumulated Other comprehensive income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">571,105</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,717</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total Consolidated Group Equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,375,469</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,912,510</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Non-controlling interests (1)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,3111,775</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Shareholders&rsquo; (deficit) equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,063,694</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,912,510</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total liabilities and shareholders&rsquo; equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,495,923</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">667,227</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">This relates to 2.04% of the ordinary shares in the subsidiary
Glucose Biosensor Systems (Greater China) Pty Ltd owned by non-controlling interests</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">These financial statements shall be read in conjunction with
the accompanying notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="Fs_03"></A>Glucose Biosensor Systems (Greater China) Holdings, Inc. &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Audited Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CONSOLIDATED STATEMENTS OF OPERATIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">12 Months to <BR> June 30, 2018</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">August 4, 2016 <BR> (inception) to <BR> June 30, 2017</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Revenue:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-bottom: 1pt; padding-left: 0.375in">Interest income</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">564</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">74</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.375in">Audit &amp; Accountancy Fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">105,725</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.375in">General &amp; Administrative Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,952,548</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">127,504</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.375in">Interest Expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">453,872</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">138,749</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.375in">Rent Expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">19,396</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">45,493</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.375in">Research &amp; Development Expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,525,798</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.375in">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,057,339</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">311,746</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Consolidated Net Profit / (Loss)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,056,775</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(311,672</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.375in">Less: Net Profit/ (Loss) attributable to non-controlling interest</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(36,392</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Profit/ (Loss) attributable to holding company &amp; subsidiaries</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(5,020,383</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(311,672</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Other Comprehensive Income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.375in">Foreign Currency Translation Gain</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">568,388</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,717</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Other Comprehensive income for the period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">568,388</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,717</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Comprehensive income/(loss) for the period</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(4,488,387</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(308,955</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"> June 30 2018 </TD><TD STYLE="font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"> June 30 2017 </TD><TD STYLE="font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left"> Loss per share based on Net Profit /(Loss)&nbsp;&nbsp;(note 14): </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 10%; text-align: right"> &nbsp; </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 10%; text-align: right"> &nbsp; </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.375in"> Basic and diluted net loss per share attributed
    to common shareholders of Glucose Biosensor Systems (Greater China) Holding Inc. </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (0.61 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (0.04 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.375in"> Weighted-average number of shares </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 8,250,000 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 8,250,000 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note: The weighted average number of shares used in calculating
the basic net loss per share in the comparatives was based upon the retroactive effect of the share consolidation to 8,250,000
on August 8 ,2018 as per note 12. This is shown retrospectively in the comparatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">These financial statements shall be read in conjunction with
the accompanying notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="Fs_04"></A>Glucose Biosensor Systems (Greater China) Holdings, Inc. &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Audited Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&rsquo; EQUITY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FOR THE PERIOD FROM AUGUST 4, 2016 (INCEPTION) THROUGH JUNE
30, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Common Shares</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Total Subscribed <BR> Value</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Additional paid-in <BR>
    capital</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">(Accumulated <BR> deficit)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Other <BR> comprehensive
    <BR> income</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Stockholders&rsquo; <BR>
    equity</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">At inception August 4, 2016</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 34%; text-align: left"><FONT STYLE="font-size: 8pt">Issuance of common stock</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">100</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">1</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">768</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">769</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Subscriptions to purchase ordinary shares of Glucose Biosensor Systems
    (Greater China) Pty Ltd</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2,126,476</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2,126,476</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Cost of issuance of convertible subordinated notes that have elected
    to convert to shares</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(169,479</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(169,479</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Deemed dividend in accordance with FASB ASC 805 for amounts incurred
    to parent to procure license</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(7,561,321</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(7,561,321</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Foreign currency translation</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2,717</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2,717</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Net Profit /(loss)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(311,672</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(311,672</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Balance at June 30,2017</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">100</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">1</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">(5,603,556</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">(311,672</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">2,717</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">(5,912,510</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">These we re-applied for convertible preference shares of
Glucose Biosensor Systems (Greater China) Holdings Inc</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">Refer to Note 3 for par values.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">These financial statements shall be read in conjunction with
the accompanying notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="Fs_05"></A>Glucose Biosensor Systems (Greater China) Holdings, Inc. &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Audited Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&rsquo; EQUITY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FOR THE PERIOD FROM July 1, 2017 to June 30, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="30" STYLE="font-weight: bold; text-align: center">Glucose Biosensor Systems (Greater China) Holdings Inc Shareholders</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="text-align: center"><B>Non-controlling Interests</B></TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Common <BR> Shares</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Total <BR> Subscribed <BR> Value</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">No of <BR> Preferred <BR> Shares (1)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Total Value</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Additional<BR>
paid-in <BR> capital</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">(Accumulated <BR> deficit)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Other <BR> comprehensive <BR> income</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Stockholders&rsquo; <BR> equity</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">No of <BR> Ordinary <BR> Shares in <BR> GBSGC Pty <BR> Ltd</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Total Value</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 20%; font-weight: bold">Balance at July 1, 2017</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">100</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">1</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">(5,603,556</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">(311,672</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">2,717</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">(5,912,510</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Subscriptions to purchase convertible preference shares of Glucose Biosensor Systems (Greater China) Holdings Inc</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6,596,530</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6,596,530</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Issuance of convertible preferred shares and ordinary shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,222,506</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,715,794</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(8,715,794</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,036,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,403,948</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Cost of issuance of ordinary shares and convertible preferred shares, the latter that may convert to common shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(641,483</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(641,483</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(55,781</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Additional Shares allotted due to Stock Split</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,999,900</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Foreign currency translation gain</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">568,388</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">568,388</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Net profit /(loss)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,020,383</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,020,383</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(36,392</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">Balance at June 30, 2018</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">9,000,000</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,222,506</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">8,715,794</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(8,330,014</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(5,332,055</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">571,105</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(4,375,469</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,036,000</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,3111,775</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Convertible Preference Shares are convertible at a potential
IPO to 1 ordinary share and one option exercisable at the IPO price between 2 &ndash; 3 years after the IPO providing the option
holder holds the underlying share.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">Refer to Note 3 for par values.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">These financial statements shall be read in conjunction with
the accompanying notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="Fs_06"></A>Glucose Biosensor Systems (Greater China) Holdings, Inc. &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Audited Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CONSOLIDATED STATEMENTS OF CASH FLOWS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">12 Months to <BR> June 30, 2018</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0">From August
4 2016 <BR> (inception) to</P>
                                                                         <P STYLE="margin-top: 0; margin-bottom: 0">June 30, 2017</P></TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Operating Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 9pt">Net Profit / (Loss)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(5,056,775</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(311,672</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0.125in; padding-left: 0.125in">Adjustments to reconcile net loss to net cash provided by operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Change in assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Accounts payable and accrued expenses &amp; deferred charges</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(327,880</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65,067</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,384,655</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(246,605</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Investing Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Net cash provided by investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Financing Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Cash proceeds from the issuance of convertible notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,428,463</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,848,593</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Cash received from subscribers for convertible preference shares convertible to common shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,715,794</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(1)&#9;2,127,245</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Cash paid for debt issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(122,864</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(314,271</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Cash paid to raise funds by the issuance of shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(697,264</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(169,479</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Cash paid for expenditures relating to the issuance of new shares &amp; preparation for listing costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,439,234</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(337,087</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Cash paid against liability to procure license</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,706,241</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,855,080</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,178,654</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">299,921</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Net Cash Provided / (Used) by Operational, Investing &amp; Finance Activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(206,001</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">53,316</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash at the beginning of the period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">56,033</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Exchange Rate Adjustment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">568,388</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,717</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash at the end of the period</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">418,420</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">56,033</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Supplemental disclosure of cash flow information</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Interest paid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">453,872</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">138,749</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">564</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">74</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">(1)</TD><TD>This includes $1,403,948 subscriptions received which became minority interests in the current financial year</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">These financial statements shall be read in conjunction with
the accompanying notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="Fs_07"></A>Glucose Biosensor Systems (Greater China) Holdings, Inc. &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Audited Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 1.</B></TD><TD STYLE="text-align: justify"><B><U>GOING CONCERN</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Financial Accounting Standards Board
(&ldquo;FASB&rdquo;) Accounting Standards Codification (&ldquo;ASC&rdquo;) Topic 205-40, <I>Presentation of Financial Statements
- Going Concern</I> (ASC 205-40) requires management to assess an entity&rsquo;s ability to continue as a going concern within
one year of the date of the financial statements are issued. In each reporting period, including interim periods, an entity is
required to assess conditions known and reasonably knowable as of the financial statement issuance date to determine whether it
is probable an entity will not meet its financial obligations within one year from the financial statement issuance date. Substantial
doubt about an entity&rsquo;s ability to continue as a going concern exists when conditions and events, considered in the aggregate,
indicate it is probable the entity will be unable to meet its financial obligations as they become due within one year after the
date the financial statements are issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is an early stage and emerging
growth company and has not generated any revenues to date. As such, the Company is subject to all of the risks associated with
early stage and emerging growth companies. Since inception, the Company has incurred losses and negative cash flows from operating
activities. The Company does not expect to generate positive cash flows from operating activities in the near future until such
time, if at all, the Company completes the development process of its products, including regulatory approvals, and thereafter,
begins to commercialize and achieve substantial acceptance in the marketplace for the first of a series of products in its medical
device portfolio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company incurred a net loss of $5,020,383
for the twelve months to June 30, 2018 (Net loss $311,672 for the period from August 4, 2016 (inception) through to June 30 2017).
At June 30, 2018, the Company had an accumulated deficit of $5,332,055, negative working capital of $3,063,694, $5,559,617, in
current liabilities of which $4,839,927 are convertible notes that will convert to equity upon the proposed IPO, and cash of $418,420
(at June 30, 2017, the Company had an accumulated deficit of $311,672, negative working capital of $5,912,510, $6,579,737, in current
liabilities of which $3,534,322 are convertible notes that will convert to equity upon the proposed IPO, and cash of $56,033).
In the near future, the Company anticipates incurring operating losses and does not expect to experience positive cash flows from
operating activities and may continue to incur operating losses until it completes the development of its products and seeks regulatory
approvals to market such products. These factors may raise doubt about the Company&rsquo;s ability to continue as a going concern
without sufficient capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s ability to fund its
operations is dependent upon management&rsquo;s plans, which include in addition to financial assistance where required from the
parent company, raising additional capital, including the Proposed Public Offering, obtaining regulatory approvals for its products
currently under development, commercializing and generating revenues from products currently under development, and continuing
to control expenses. However, there is no assurance the Company will be successful in these efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings, Inc. &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Audited Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 1.</B></TD><TD STYLE="text-align: justify"><B><U>GOING CONCERN (CONT.)</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A failure to raise sufficient capital,
obtain regulatory approvals for the Company&rsquo;s products, generate sufficient product revenues, or control expenditures, among
other factors, may adversely impact the Company&rsquo;s ability to meet its financial obligations as they become due</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and payable and to achieve its intended
business objectives, and therefore, raises substantial doubt of the Company&rsquo;s ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s consolidated financial
statements have been prepared on a going concern basis which contemplates the realization of assets and satisfaction of liabilities
and commitments in the normal course of business. The consolidated financial statements do not include any adjustments relating
to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities should the
Company be unable to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>STOCK SPLIT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective November 5, 2017, each share
of our issued and outstanding common stock became 90,000 shares of common stock and no fractional shares were issued. The accompanying
financial statements and related disclosures give retroactive effect to the stock split &amp; the reverse share split noted in
note 12 for all periods presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 2.</B></TD><TD STYLE="text-align: justify"><B><U>ORGANIZATION AND DESCRIPTION OF THE BUSINESS</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Glucose Biosensor Systems (Greater China)
Holdings, Inc. (&quot;Holdings&quot;) and its wholly owned subsidiary, Glucose Biosensor Systems (Greater China), Inc. are formed
under the laws of the state of Delaware, and were formed on December 5, 2016 (collectively, the &ldquo;Group&rdquo;) and Glucose
Biosensor Systems (Greater China) Pty Ltd (&quot;GBSPL&quot;), which was formed on August 4, 2016 under the laws of New South Wales,
Australia.&nbsp; These three companies (collectively, the &quot;Company&quot;) were formed to provide a noninvasive, pain free
innovation to make it easier for people to manage diabetes.&nbsp; As more fully described in Note 5,&nbsp;the Company purchased
the license rights relating to saliva glucose biosensor technology for the Greater China Region from Life Science Biosensor Diagnostics
Pty Ltd. (&quot;Life Science&quot;), the shareholder of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings, Inc. &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Audited Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 3.</B></TD><TD STYLE="text-align: justify"><B><U>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Basis of presentation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group prepares its consolidated financial
statements using the accrual basis of accounting in conformity with accounting principles generally accepted in the United States
of America (&quot;GAAP&quot;) and the rules and regulations of the Securities and Exchange Commission (&ldquo;SEC&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Principles of consolidation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 29, 2017, Life Science transferred
to Holdings, in a non-reciprocal transfer, its shares in GBSPL. These shares comprised its 100% ownership of GBSPL. As a result,
the accompanying consolidated financial statements include the accounts of the following entities, all of which are under common
control. All significant intercompany transactions and balances have been eliminated upon consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of the shares authorized and
issued of each company at June 30, 2018 and June 30, 2017 are listed below. (Refer to Note 12 for changes in capital structure
since 30 June 2018).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>At June 30, 2017:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold">Name of entity</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">Country of <BR> incorporation</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Shares <BR> authorized</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Shares issued</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">Par value per <BR> share</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left">Glucose Biosensor Systems (Greater China) Holdings, Inc.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: left">United States</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">100</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: right">USD$0.01</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Glucose Biosensor Systems (Greater China) Pty Ltd</TD><TD>&nbsp;</TD>
    <TD STYLE="text-indent: 12.25pt">Australia</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">N/A (1)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Glucose Biosensor Systems (Greater China), Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">United States</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">USD$0.01</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>At June 30, 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold">Name of entity</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">Country of <BR> incorporation</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Shares</B><BR>
<B>authorized</B></P></TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Shares issued <BR> (Common)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">Par value per <BR> share</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Shares <BR> Issued <BR> (Convertible<BR> Preference)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Par Value <BR> Per Share</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 22%; text-align: left">Glucose Biosensor Systems (Greater China) Holdings, Inc.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: left">United States</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">22,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">9,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: right">USD$0.01</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,222,506</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">US$.01</P></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Glucose Biosensor Systems (Greater China) Pty Ltd</TD><TD>&nbsp;</TD>
    <TD>Australia</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">99,800,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">99,800,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">N/A (1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Glucose Biosensor Systems (Greater China), Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">United States</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">USD$0.01</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>Australia does not have the concept of par value per share</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 29, 2017, in a nonreciprocal transfer,
Life Sciences transferred ownership of its 1,000 shares of Glucose Biosensor Systems (Greater China) Pty Ltd to Glucose Biosensor
Systems (Greater China) Holdings, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 30, 2017 the authorized capital
was increased to 22,000,000 with a par value of $0.01 each consisting of 20,000,000 shares of common stock and 2,000,000 shares
of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings, Inc. &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Audited Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 3.</B></TD><TD STYLE="text-align: justify"><B><U>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 5, 2017 the Company conducted
a stock split of one to 90,000 resulting in issued common stock of 9,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 8, 2018 a reverse share split
occurred whereas the total number of common issued stock has been consolidated from 9,000,000 to 8,250,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended 30<SUP>th</SUP> June
2018, the group received subscriptions of $1,428,463 regarding the issuance of notes that are convertible to equity at the completion
of an initial public offering (&quot;IPO&quot;) and $8,715,794 regarding the issuance of Convertible Preference Shares convertible
to common shares at the completion of an initial public offering (&quot;IPO&quot;) and ordinary shares. The Convertible Preference
Shares carry the same rights as common shares except the right to vote at general meetings of shareholders. Further particulars
are at Note 9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Equity offering costs</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group complies with the requirements
of Financial Accounting Standards Board (&ldquo;FASB&rdquo;) Accounting Standards Codification ASC 340 with regards to offering
costs. Prior to the completion of an offering, offering costs will be capitalized as deferred offering costs on the balance sheet.
The deferred offering costs will be charged to stockholders&rsquo; equity (deficit) upon the completion of an offering or to expense
if the offering is not completed.&nbsp; Offering costs amounting to $1,983,123 were capitalized as of June 30, 2018 (June 30, 2017:
$611,194). The Company anticipates significant offering costs in connection with the proposed&nbsp;offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Revenue recognition</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company shall recognize revenues when
there is persuasive evidence of an arrangement, delivery has occurred or services are rendered, the sales price is determinable,
and collectability is reasonably assured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Debt issuance cost</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Debt issuance costs are being amortized
using the effective interest rate method over the term of the loan and the amortization expense is recorded as part of interest
expense of the consolidated statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Income taxes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the provisions of Financial
Accounting Standards Board Accounting Standards Codification (&quot;FASB ASC&quot;) 740, Income Taxes, tax positions initially
need to be recognized in the consolidated financial statements when it is more likely than not that the positions will be sustained
upon examination by taxing authorities. It also provides guidance for de-recognition, classification, interest and penalties, accounting
in interim periods, disclosure, and transition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2018, the Group had no uncertain tax positions
that qualified for either recognition or disclosure in the consolidated financial statements. Additionally, the Group had no interest
and penalties related to income taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings, Inc. &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Audited Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 3.</B></TD><TD STYLE="text-align: justify"><B><U>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2017, the Group had no uncertain
tax positions that qualified for either recognition or disclosure in the consolidated financial statements. Additionally, the Group
had no interest and penalties related to income taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group accounts for current and deferred income taxes and,
when appropriate, deferred tax assets and liabilities are recorded with respect to temporary differences in the accounting treatment
of items for financial reporting purposes and for income tax purposes. Where, based on the weight of all available evidence, it
is more likely than not that some amount of the recorded deferred tax assets will not be realized, a valuation allowance is established
for that amount that, in management's judgment, is sufficient to reduce the deferred tax asset to an amount that is more likely
than not to be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Foreign currency translation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assets and liabilities of foreign subsidiaries
are translated from local (functional) currency to presentation currency (U.S. dollar) at the rate of exchange in effect on the
consolidated balance sheets date; income and expenses are translated at the average rate of exchange prevailing during the year.
Foreign currency movements resulted in a gain of $568,388 (June 30, 2017 foreign currency translation gain of $2,717).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Net Loss Per Share Attributable to Common
Stockholders (&ldquo;EPS&rdquo;)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company calculates earnings per share
attributable to common stockholders in accordance with ASC Topic 260, &ldquo;Earning Per Share.&rdquo; Basic net income (loss)
per share attributable to common stockholders is calculated by dividing net income (loss) attributable to common stockholders by
the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per common share is calculated
by dividing net income (loss) attributable to common stockholders by weighted-average common shares outstanding during the period
plus potentially dilutive common shares, such as stock warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Potentially dilutive common shares shall
be calculated in accordance with the treasury stock method, which assumes that proceeds from the exercise of all warrants are used
to repurchase common stock at market value. The amount of shares remaining after the proceeds are exhausted represents the potentially
dilutive effect of the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has incurred net losses during
the period ended 30 June 2018 and the conversion of the convertible notes payable or the effect of the completion of the issuance
of convertible preference shares in a private placement would be anti-dilutive, and thus is not included in loss per share calculation
(see Note 8&mdash;Convertible Notes Payable).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Use of estimates</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial
statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the
reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings, Inc. &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Audited Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 3.</B></TD><TD STYLE="text-align: justify"><B><U>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Subsequent events</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with FASB ASC 855, <I>Subsequent
Events</I>, management has evaluated subsequent events through October 19, 2018 the date on which these audited consolidated financial
statements were available to be issued. There were no material subsequent events that required recognition or additional disclosure
in these consolidated financial statements, except for a reverse stock split which occurred where the total number of common issued
stock has been consolidated to 8,250,000 from 9,000,000 as disclosed in Note 12.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Recently adopted accounting pronouncement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2014, the FASB issued ASU 2014-15,
Disclosure of Uncertainties about an Entity&rsquo;s Ability to Continue as a Going Concern, which amends FASB ASC 205, Presentation
of Financial Statements. This update requires management to assess an entity&rsquo;s ability to continue as a going concern by
incorporating and expanding upon certain principles that are currently in U.S. auditing standards. ASU 2014-15 is effective for
the Company&rsquo;s annual reporting period ending June 30, 2017. The adoption of FASB ASU 2014-15 did not have a material effect
on the Group&rsquo;s consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Recently issued but not yet effective</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2014, the FASB issued Accounting
Standards Update (&ldquo;ASU&rdquo;) No. 2014-09, Revenue from Contracts with Customers (&ldquo;ASU 2014-09&rdquo;), which requires
an entity to recognize revenue to depict the transfer of promised good or services to customers in an amount that reflects the
consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU will replace most existing
revenue recognition guidance in GAAP, including industry specific guidance, when it becomes effective. This new guidance is effective
for years beginning after December 15, 2017.&nbsp; The standard permits the use of either the retrospective or cumulative effect
transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and
related disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2016, the FASB issued ASU No.
2016-02, <I>Leases </I>(&ldquo;ASU 2016-02&rdquo;). This update requires all leases with a term greater than 12 months to be recognized
on the balance sheet through a right-of-use asset and a lease liability and the disclosure of key information pertaining to leasing
arrangements. This new guidance is effective for years beginning after December 15, 2019, with early adoption permitted. The Company
is evaluating the effect that ASU 2016-02 will have on its financial statements and related disclosures, but has not yet determined
the timing of adoption.</P>


<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings, Inc. &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Audited Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 4.</B></TD><TD STYLE="text-align: justify"><B><U>OTHER ASSETS</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center">As of</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">June 30, <BR>2018</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">June 30, <BR>2017</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Goods &amp; Services Tax Receivable</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">36,481</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Prepayments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,899</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Total</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">94,380</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 5.</B></TD><TD STYLE="text-align: justify"><B><U>LICENSING RIGHTS:</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Licensing rights consists of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center">As of</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">June 30, <BR>2018</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">June 30, <BR>2017</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Licensing rights:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 8.5pt">Amount incurred to procure license</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">7,561,321</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.5pt">Less charged to equity as per FASB ASC 805</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,561,321</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.5pt">Licensing rights net of amortization and charged to equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year, the Company paid its liability
in relation to outstanding license rights procurement costs to Life Science Biosensor Diagnostics Pty Ltd being $2,706,241 outstanding
from June 30, 2017 $(4,855,080 August 5, 2016 to June 30, 2017) in relation to the development and approval process technology
that is described in Notes 2 and 11.&nbsp; The Company shall pay royalties of sales &amp; milestone payments, as defined.&nbsp;
The agreement shall be for the term of the applicable patents.&nbsp; The licensing agreement has a twenty-five year term. No royalties
have been incurred through June 30, 2018 (June 30, 2017: nil).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The licensing rights are carried at Life Science&rsquo;s historical
cost of $nil, with the excess of the amount paid over historical cost reflected as a deemed dividend, given this was a transaction
between entities under common control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 6.</B></TD><TD STYLE="text-align: justify"><B><U>ACCOUNTS PAYABLE &amp; ACCRUED EXPENSES</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center">As of</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">June 30, <BR>
2018</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">June 30, <BR>
2017</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Trade Creditors</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">167,466</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">339,174</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Accruals</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">85,949</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Amounts payable to Life Science Biosensor Diagnostics Pty Ltd</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">466,275</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 8.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">719,690</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">339,174</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings, Inc. &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Audited Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 7.</B></TD><TD STYLE="text-align: justify"><B><U>CASH &amp; CASH EQUIVALENTS</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center">As of</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">June 30, <BR>2018</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">June 30, <BR>2017</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Cash at Bank</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">418,420</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">56,033</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company places its cash and cash equivalents,
which may at times be in excess of the Australia Financial Claims Scheme or the United States' Federal Deposit Insurance Corporation
insurance limits, with high credit quality financial institutions and attempts to limit the amount of credit exposure with any
one institution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 8.</B></TD><TD STYLE="text-align: justify"><B><U>CONVERTIBLE NOTES PAYABLE</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Convertible notes payable consists of the
following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-left: 0">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center">As of</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-left: 0">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">June 30, <BR>2018</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">June 30, <BR>2017</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-left: 0">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left; padding-left: 0">Convertible Notes Payable</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">5,277,056</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3,848,593</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0">Less unamortized debt issuance costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(437,129</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(314,271</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0">Debt less unamortized debt issuance costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,839,927</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,534,322</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investors have subscribed to a Glucose
Biosensor Systems (Greater China) 7% Convertible Note Issue during the periods in the above table.&nbsp; The Notes bear interest
at the rate of 7% per annum payable quarterly in arrears. &nbsp; The Notes are unsecured and mature on December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Notes also provide that there shall
be a 15% discount on the potential IPO Price on the offer document intended to be filed with an approved stock exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 9.</B></TD><TD STYLE="text-align: justify"><B><U>SUBSCRIPTIONS FOR CONVERTIBLE PREFERENCE SHARES OF
GLUCOSE BIOSENSOR SYSTEMS (GREATER CHINA) HOLDINGS INC</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has issued 1,222,506 convertible
preference shares. Together with the subsequent conversion of convertible notes payable and maximum raise from the IPO, the Company
estimates that a maximum of common 12,073,199 shares in Glucose Biosensor Systems Greater China (Holdings) Inc shall be on issue
upon the successful completion of the IPO.&nbsp; The 1,222,506 convertible preference shares and 8,250,000 common shares to date
and the amounts representing these subscriptions to purchase shares have been credited to additional paid-in-capital in the amount
of $8,715,794.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings, Inc. &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Audited Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 9.</B></TD><TD STYLE="text-align: justify"><B><U>SUBSCRIPTIONS FOR CONVERTIBLE PREFERENCE SHARES OF
OF GLUCOSE BIOSENSOR SYSTEMS (GREATER CHINA) HOLDINGS INC (CONT.)</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each convertible preference share converting
to one common share upon the successful completion of the IPO, will have one Loyalty Warrant Entitlement attached.&nbsp; The terms
of the Entitlement provide that the holder can exercise one warrant to purchase one common share at the IPO price during years
two through to year three following the IPO. At exercise date, the shareholder must hold for each warrant to be exercised, one
underlying common share to exercise the option The warrants are not transferable and apply to the number of shares that were subscribed
for.&nbsp; In addition, the warrants do not apply to the convertible note holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company will continue to maintain its
97.96% (97,764,000 shares) in its subsidiary Glucose Biosensor Systems (Greater China) Pty Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 10.</B></TD><TD STYLE="text-align: justify"><B><U>LOANS PAYABLE</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As at June 30, 2017 the company had a liability
to its parent Life Science of $2,706,241 as a result of procuring the license. This has been repaid during the period to June 30,
2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 11.</B></TD><TD STYLE="text-align: justify"><B><U>RELATED-PARTY TRANSACTIONS</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following transactions occurred with
Life Science Glucose Biosensor Diagnostics Pty Ltd during the period July 1, 2017 to June 30, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As more fully described in Note 5, the
Company has paid its liability in relation to license procurement of $2,706,241 (June 30, 2017 $4,855,080). Further payments in
relation to research &amp; development will be due upon the achievements of milestones.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company incurred a total of $2,525,798
towards the services in connection with development and regulatory approval pathway for the technology. There is a trade creditors
liability of $466,275 remaining on these transactions as at June 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company incurred a total of $1,820,883
towards overhead cost reimbursement which includes salaries, rents and other related overheads directly attributable to the company
which are included in General &amp; Administration Expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company paid rent last year to June
30, 2017 of $45,493. This financial year to date the rent has been paid to a third party as a result of moving premises. The third
party lease is a monthly tenancy at $2,009 per month with a 3 months&rsquo; notice period to terminate. There is no fixed term
lease agreement, rather it rolls month to month. The above transactions have been determined by directors to be on an arm&rsquo;s
length basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings, Inc. &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Audited Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 12.</B></TD><TD STYLE="text-align: justify"><B><U>SUBSEQUENT EVENTS</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since June 30, 2018, as at the date of
this report the following have occurred:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">On August 8, 2018 a reverse share split occurred whereas the total number of common issued stock
has been consolidated from 9,000,000 to 8,250,000.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 13.</B></TD><TD STYLE="text-align: justify"><B><U>NET OPERATING LOSSES</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company shall file its income tax returns
with the Internal Revenue Service and Australian Taxation Office.&nbsp; The Company has net operating loss carry forwards of $5,332,055
which are derived from its operations in Australia and the US and are available to reduce future taxable income. Such loss carryforwards
may be carried forward indefinitely, subject to compliance with tests of continuity and additional rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The net operating loss carried forward
give rise to a deferred tax asset of approximately $1,615,000. However, the Company has determined that a valuation allowance of
$1,615,000 against such deferred tax asset is necessary, as it cannot be determined that the carryforwards will be utilized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 14.</B></TD><TD STYLE="text-align: justify"><B><U>LOSS PER SHARE</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>12
                                         Months to</B> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>June
                                         30, 2018</B> </P></TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"> &nbsp; </TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"> From August 4, 2016
    <BR>
    (inception) to <BR> June 30, 2017 </TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left; padding-bottom: 1pt"> Total Loss </TD><TD STYLE="width: 1%; padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left"> $ </TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right"> (5,056,775 </TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left"> ) </TD><TD STYLE="width: 1%; padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left"> $ </TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right"> (311,672 </TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"> On November 5, 2017 a stock split occurred where the total number of
    common issued stock had been split to 9,000,000 from 90,000. Subsequent to the split, the revised loss per share was: </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"> Basic and diluted net loss per share attributed to common shareholders </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (0.56 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (0.04 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt"> Weighted-average number of shares </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 9,000,000 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 9,000,000 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"> On August 8<SUP>th</SUP>, 2018, a reverse stock split occurred where
    the total number of common issued stock had been consolidated to 8,250,000 from 9,000,000. Subsequent to the reverse split,
    the revised loss per share was: </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"> Basic and diluted net loss per share attributed to common shareholders </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (0.61 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (0.04 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"> Weighted-average number of shares used in calculating basic &amp; diluted
    net loss per share attributable to common shareholders </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 8,250,000 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 8,250,000 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<!-- Field: Page; Sequence: 119; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>GLUCOSE BIOSENSOR
SYSTEMS (GREATER</B><BR>
<B>CHINA) HOLDINGS, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FOR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>THE PERIOD
FROM AUGUST 4, 2016 (INCEPTION)</B><BR>
<B>THROUGH JUNE 30, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 120; Options: NewSection; Value: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings Inc &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Table of Contents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 89%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Page</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 8.5pt; text-indent: -8.5pt"><A HREF="#a_001"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Report
    of Independent Registered Public Accounting Firm</B></FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="#a_001">F-<FONT STYLE="font: 10pt Times New Roman, Times, Serif">21</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 8.5pt; text-indent: -8.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Consolidated
    Financial Statements&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.15in"><A HREF="#a_002"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Balance
    Sheet</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="#a_002">F-22</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.15in"><A HREF="#a_003"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Statement
    of Operations</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="#a_003"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-23</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.15in"><A HREF="#a_004"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Statement
    of Changes in Stockholders' Equity</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="#a_004"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-24</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.15in"><A HREF="#a_005"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Statement
    of Cash Flows</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="#a_005"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-26</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.15in"><A HREF="#a_006"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Notes
    to Consolidated Financial Statements</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="#a_006"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-26
    - F-33</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 121; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD ROWSPAN="4" STYLE="width: 32%">&nbsp;<IMG SRC="tv506394_img07.jpg" ALT=""></TD>
    <TD STYLE="width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">Tel:
    +61 2 9251 4100</FONT></TD>
    <TD STYLE="width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">Level
    11, 1 Margaret St</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">Fax:
    +61 2 9240 9821</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">Sydney
    NSW 2000</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">www.bdo.com.au</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">Australia</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the members of Glucose Biosensor Systems (Greater China)
Holdings Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_001"></A><B>Report on the Audit of the Financial
Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have audited the accompanying consolidated balance sheet
of Glucose Biosensor Systems (Greater China) Holdings Inc. as of June 30, 2017 and the related consolidated statement of operations,
changes in stockholders&rsquo; equity, and cash flows for the period from August 4, 2016 through June 30, 2017. These financial
statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on these financial
statements based on our audit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We conducted our audit in accordance with the standards
of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required
to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration
of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances,
but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s internal control over financial reporting.
Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management,
as well as evaluating the overall financial statement presentation. We believe that our audit provide a reasonable basis for our
opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In our opinion, the consolidated financial statements referred
to above present fairly, in all material respects, the financial position of Glucose Biosensor Systems (Greater China) Holdings
Inc. at June 30, 2017, and the results of its operations and its cash flows for the period from August 4, 2016 through June 30,
2017, in conformity with accounting principles generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>BDO East Coast Partnership </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ BDO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sydney, Australia</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">December 28, 2017, except for the effect of the stock split
described in Note 1 of the financial statements, as to which the date is June 7, 2018.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 122; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings Inc &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_002"></A><B>CONSOLIDATED
BALANCE SHEET</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>JUNE 30, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center"><U>ASSETS</U></TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; text-align: left; padding-left: 9pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">56,033</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Deferred charges (Note 3)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">611,194</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">667,227</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt; padding-bottom: 1pt">Licensing rights, net of accumulated amortization
    (Note 4)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in; padding-bottom: 1pt">Total other assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">TOTAL ASSETS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">667,227</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: center">LIABILITIES AND SHAREHOLDERS' EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">339,174</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Convertible notes payable (note 6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,534,322</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Due to Life Science Biosensor Diagnostics Pty Ltd
    (Note 8)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,706,241</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,579,737</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,579,737</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Commitments and contingencies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Shareholders' equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Common Shares ( 20,000,000 shares authorised and 9,000,000 issued)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,603,556</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accumulated deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(311,672</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other comprehensive income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,717</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total Shareholders&rsquo; (deficit) equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,912,510</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">667,227</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">These financial statements shall be
read in conjunction with the accompanying notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 123; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings Inc &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_003"></A><B>CONSOLIDATED
STATEMENT OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE PERIOD FROM AUGUST 4, 2016
(INCEPTION) THROUGH JUNE 30, 2017&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Revenue: </TD><TD> &nbsp; </TD>
    <TD COLSPAN="3"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 87%; text-align: left; padding-bottom: 1pt; padding-left: 9pt"> Interest income: </TD><TD STYLE="width: 1%; padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left"> $ </TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right"> 74 </TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Operating expenses: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt"> Interest expense </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 138,749 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt"> Rent expense </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 45,493 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt; padding-bottom: 1pt"> General and administrative expenses </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"> &nbsp; </TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"> 127,504 </TD><TD STYLE="text-align: left; padding-bottom: 1pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"> Total operating expenses </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 311,746 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt"> NET LOSS </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (311,672 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> Loss per share (Note 12): </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt"> Basic and diluted net loss per share attributable
    to common shareholders </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (0.03 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt"> Weighted-average number of shares </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 9,000,000 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">These financial statements shall be
read in conjunction with the accompanying notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 124; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings Inc &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_004"></A><B>CONSOLIDATED
STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE PERIOD FROM AUGUST 4, 2016
(INCEPTION) THROUGH JUNE 30, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Common Shares<BR>
    (1)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Par Value<BR> (2)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Additional<BR> Paid-In<BR>
    Capital</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Accumulated<BR> Deficit)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Other<BR> Comprehensive<BR>
    Income</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stockholders&rsquo;<BR>
    Equity</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Issuance of common stock</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">9,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">0.00001</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">768</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">769</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Subscriptions to purchase ordinary shares of
    Glucose Biosensor Systems (Greater China) Holdings Inc..</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,126,476</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,126,476</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: left"></P>
                                                                               <P STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Cost
                                         of issuance of convertible subordinated notes to be converted to shares</P></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(169,479</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(169,479</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Deemed dividend in accordance with FASB ASC
    805 for amounts incurred to parent to procure license</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,561,321</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,561,321</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Foreign currency translation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,717</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,717</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in">Net Profit /(loss)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(311,672</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(311,672</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in">BALANCE - JUNE 30, 2017</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,000.000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.00001</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,603,556</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(311,672</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,717</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,912,510</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>This gives a retroactive effect to the stock split
                                         as per Note 10 in relation to changes in share structure since year end</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>This reflects the retroactive effect on par value originally
                                         at $1 as a result of the share split as per Note 10</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">These financial statements shall be
read in conjunction with the accompanying notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 125; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings Inc &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_005"></A><B>CONSOLIDATED
STATEMENT OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE PERIOD FROM AUGUST 4, 2016
(INCEPTION) THROUGH JUNE 30, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Operating Activities:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 87%; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Net loss</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="width: 10%; padding-bottom: 1pt; text-align: right">(311,672</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in; text-indent: -0.125in">Adjustments to reconcile
    net loss to net cash provided by operating activities:</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other comprehensive income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">2,717</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Changes in assets and liabilities:</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.375in">Accounts payable and accrued expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">65,067</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(243,888</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Investing Activities:</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Net cash provided by investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Financing Activities:</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Cash proceeds from the issuance of convertible
    notes payable</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">3,848,593</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Cash proceeds from the issuance of shares</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">769</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Cash received from subscribers to ordinary shares</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">2,126,476</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Cash paid for debt issuance costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">(314,271</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Cash paid to raise funds by the issuance of shares</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">(169,479</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Cash paid for expenditures relating to the issuance
    of new shares and debt</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">(337,087</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Cash paid in to procure license</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,855,080</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">299,921</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-decoration: underline; padding-bottom: 1pt; padding-left: 0.25in">CASH &ndash; ENDING</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">56,033</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Supplemental disclosure of cash flow information:</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Interest paid</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">138,749</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">These financial statements shall be
read in conjunction with the accompanying notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 126; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings Inc &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_006"></A><B>NOTES TO AND FORMING PART OF THE
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 1.</B></TD><TD STYLE="text-align: justify"><B><U>GOING
                                         CONCERN</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Financial Accounting
Standards Board (&ldquo;FASB&rdquo;) Accounting Standards Codification (&ldquo;ASC&rdquo;) Topic 205-40, <I>Presentation of Financial
Statements - Going Concern</I> (ASC 205-40) requires management to assess an entity&rsquo;s ability to continue as a going concern
within one year of the date of the financial statements are issued. In each reporting period, including interim periods, an entity
is required to assess conditions known and reasonably knowable as of the financial statement issuance date to determine whether
it is probable an entity will not meet its financial obligations within one year from the financial statement issuance date. Substantial
doubt about an entity&rsquo;s ability to continue as a going concern exists when conditions and events, considered in the aggregate,
indicate it is probable the entity will be unable to meet its financial obligations as they become due within one year after the
date the financial statements are issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company is an early
stage and emerging growth company and has not generated any revenues to date. As such, the Company is subject to all of the risks
associated with early stage and emerging growth companies. Since inception, the Company has incurred losses and negative cash
flows from operating activities. The Company does not expect to generate positive cash flows from operating activities in the
near future until such time, if at all, the Company completes the development process of its products, including regulatory approvals,
and thereafter, begins to commercialize and achieve substantial acceptance in the marketplace for the first of a series of products
in its medical device portfolio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company incurred a net
loss of $311,672 for the period from August 4, 2016 (inception) through June 30, 2017. At June 30, 2017, the Company had an accumulated
deficit of $311,672, negative working capital of $5,912,510, $6,579,737, in current liabilities of which $3,534,322 are convertible
notes that will convert to equity upon the proposed IPO, and cash of $56,033. In the near future, the Company anticipates incurring
operating losses and does not expect to experience positive cash flows from operating activities and may continue to incur operating
losses until it completes the development of its products and seeks regulatory approvals to market such products. These factors
raise may raise doubt about the Company&rsquo;s ability to continue as a going concern without sufficient capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&rsquo;s ability
to fund its operations is dependent upon management&rsquo;s plans, which include raising additional capital, including the Proposed
Public Offering described in Note 3, obtaining regulatory approvals for its products currently under development, commercializing
and generating revenues from products currently under development, and continuing to control expenses. However, there is no assurance
the Company will be successful in these efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">A failure to raise sufficient
capital, obtain regulatory approvals for the Company&rsquo;s products, generate sufficient product revenues, or control expenditures,
among other factors, may adversely impact the Company&rsquo;s ability to meet its financial obligations as they become due and
payable and to achieve its intended business objectives, and therefore, raises substantial doubt of the Company&rsquo;s ability
to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 127; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings Inc &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 1.</B></TD><TD STYLE="text-align: justify"><B><U>GOING
                                         CONCERN (CONT.)</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&rsquo;s consolidated
financial statements have been prepared on a going concern basis which contemplates the realization of assets and satisfaction
of liabilities and commitments in the normal course of business. The consolidated financial statements do not include any adjustments
relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities should
the Company be unable to continue as a going concern.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"><B>STOCK
SPLIT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Effective November 5, 2017,
each share of our issued and outstanding common stock became 90,000 shares of common stock and no fractional shares were issued.
The accompanying financial statements and related disclosures give retroactive effect to the stock split for all periods presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 2.</B></TD><TD STYLE="text-align: justify"><B><U>ORGANIZATION
                                         AND DESCRIPTION OF THE BUSINESS</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Glucose Biosensor Systems
(Greater China) Holdings, Inc. (the &quot;Holdings&quot;) and its wholly owned subsidiary, Glucose Biosensor Systems (Greater
China), Inc. are formed under the laws of the state of Delaware, and were formed on December 5, 2016 (collectively, the &ldquo;Group&rdquo;)
and Glucose Biosensor Systems (Greater China) Pty Ltd (&quot;GBSPL&quot;), which was formed on August 4, 2016.&nbsp; These three
companies (collectively, the &quot;Company&quot;) were formed to provide a noninvasive, pain free innovation to make it easier
for people to manage diabetes.&nbsp; As more fully described in Note 4,&nbsp;the Company purchased the license rights relating
to saliva glucose biosensor technology for the Greater China Region from Life Science Biosensor Diagnostics Pty Ltd. (&quot;Life
Science&quot;), the shareholder of the Company.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 3.</B></TD><TD STYLE="text-align: justify"><B><U>SUMMARY
                                         OF SIGNIFICANT ACCOUNTING POLICIES</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in"><U>Basis of presentation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Group prepares its consolidated
financial statements using the accrual basis of accounting in conformity with accounting principles generally accepted in the
United States of America (&quot;GAAP&quot;) and the rules and regulations of the Securities and Exchange Commission (&ldquo;SEC&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in"><U>Principles of consolidation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On July 29, 2017, Life Science
transferred to Holdings, in a non-reciprocal transfer, its shares in GBSPL. These shares comprised its 100% ownership of GBSPL.
As a result, the accompanying consolidated financial statements include the accounts of the following entities, all of which are
under common control. All significant intercompany transactions and balances have been eliminated in consolidation. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">A summary of the shares
authorized and issued of each company at June 30, 2017 is listed below. (Refer to Note 10 for changes in capital structure since
year end)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 89%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Name&nbsp;of&nbsp;entity</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Country&nbsp;of</FONT><BR>
    <FONT STYLE="font-size: 10pt">incorporation</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Shares</FONT><BR>
    <FONT STYLE="font-size: 10pt">authorized</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Shares</FONT><BR>
    <FONT STYLE="font-size: 10pt">issued</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Par&nbsp;value&nbsp;per</FONT><BR>
    <FONT STYLE="font-size: 10pt">share</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 50%; text-align: left; text-indent: -5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Glucose
    Biosensor Systems (Greater China) Holdings, Inc.</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 12%; text-align: left"><FONT STYLE="font-size: 10pt">United States</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">1,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 2%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">USD$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">0.01</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Glucose Biosensor
    Systems (Greater China) Pty Ltd</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Australia</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">AUD$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Glucose Biosensor
    Systems (Greater China), Inc.</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">United States</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">USD$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.01</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 128; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings Inc &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 3.</B></TD><TD STYLE="text-align: justify"><B><U>SUMMARY
                                         OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">During the period ended
June 30, 2017, Glucose Biosensors Systems (Greater China) Pty Ltd. raised $3,848,593 $(5,013,800 Australian currency) through
the issuance of notes that are convertible to equity at the completion of an initial public offering (&quot;IPO&quot;).&nbsp;
Through June 30, 2017, the subscribers to a private placement of ordinary shares amounting to $2,126,476 $(2,770,000 Australian
currency) were received. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><U>Equity offering costs</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Group complies with
the requirements of Financial Accounting Standards Board (&ldquo;FASB&rdquo;) Accounting Standards Codification ASC 340 with regards
to offering costs. Prior to the completion of an offering, offering costs will be capitalized as deferred offering costs on the
balance sheet. The deferred offering costs will be charged to stockholders&rsquo; equity (deficit) upon the completion of an offering
or to expense if the offering is not completed.&nbsp; Offering costs amounting to $611,194 were capitalized as of June 30, 2017
The Company anticipates significant offering costs in connection with the proposed&nbsp;offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><U>Revenue recognition</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company shall recognize
revenues when there is persuasive evidence of an arrangement, delivery has occurred or services are rendered, the sales price
is determinable, and collectability is reasonably assured. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><U>Debt issuance cost</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Debt issuance costs are
being amortized using the effective interest rate method over the term of the loan and the amortization expense is recorded as
part of interest expense of the consolidated statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><U>Income taxes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In accordance with the provisions
of Financial Accounting Standards Board Accounting Standards Codification (&quot;FASB ASC&quot;) 740, Income Taxes, tax positions
initially need to be recognized in the consolidated financial statements when it is more likely than not that the positions will
be sustained upon examination by taxing authorities. It also provides guidance for de-recognition, classification, interest and
penalties, accounting in interim periods, disclosure, and transition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As of June 30, 2017, the
Group had no uncertain tax positions that qualified for either recognition or disclosure in the consolidated financial statements.
Additionally, the Group had no interest and penalties related to income taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Group accounts for current
and deferred income taxes and, when appropriate, deferred tax assets and liabilities are recorded with respect to temporary differences
in the accounting treatment of items for financial reporting purposes and for income tax purposes. Where, based on the weight
of all available evidence, it is more likely than not that some amount of the recorded deferred tax assets will not be realized,
a valuation allowance is established for that amount that, in management's judgment, is sufficient to reduce the deferred tax
asset to an amount that is more likely than not to be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 129; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings Inc &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 3.</B></TD><TD STYLE="text-align: justify"><B><U>SUMMARY
                                         OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in"><U>Foreign currency translation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Assets and liabilities of
foreign subsidiaries are translated from local (functional) currency to presentation currency (U.S. dollar) at the rate of exchange
in effect on the consolidated balance sheets date; income and expenses are translated at the average rate of exchange prevailing
during the year. Foreign currency translation adjustments resulted in a gain of $2,717, which is included in the &quot;other comprehensive
income&quot; line item on the consolidated statement of cashflows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><U>Net Loss Per Share Attributable
to Common Stockholders (&ldquo;EPS&rdquo;)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company calculates earnings
per share attributable to common stockholders in accordance with ASC Topic 260, &ldquo;Earning Per Share.&rdquo; Basic net income
(loss) per share attributable to common stockholders is calculated by dividing net income (loss) attributable to common stockholders
by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per common share is calculated
by dividing net income (loss) attributable to common stockholders by weighted-average common shares outstanding during the period
plus potentially dilutive common shares, such as stock warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Potentially dilutive common
shares shall be calculated in accordance with the treasury stock method, which assumes that proceeds from the exercise of all
warrants are used to repurchase common stock at market value. The amount of shares remaining after the proceeds are exhausted
represents the potentially dilutive effect of the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company has incurred
net losses during the period ended June 30, 2017 and the conversion of the convertible notes payable or the effect of the completion
of the issuance of the shares in a private placement would be anti-dilutive, and thus is not included in loss per share calculation
(see Note 6&mdash;Convertible Notes Payable).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><U>Use of estimates</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The preparation of consolidated
financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements,
and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><U>Subsequent events</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In accordance with FASB
ASC 855, <I>Subsequent Events</I>, management has evaluated subsequent events through December 28, , 2017, the date on which these
consolidated financial statements were available to be issued. There were no material subsequent events that required recognition
or additional disclosure in these consolidated financial statements, except as disclosed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 130; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings Inc &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 3.</B></TD><TD STYLE="text-align: justify"><B><U>SUMMARY
                                         OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><U>Recently adopted accounting
pronouncement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In August 2014, the FASB
issued ASU 2014-15, Disclosure of Uncertainties about an Entity&rsquo;s Ability to Continue as a Going Concern, which amends FASB
ASC 205, Presentation of Financial Statements. This update requires management to assess an entity&rsquo;s ability to continue
as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. ASU 2014-15
is effective for the Company&rsquo;s annual reporting period ending June 30, 2017. The adoption of FASB ASU 2014-15 did not have
a material effect on the Group&rsquo;s consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><U>Recently issued but not
yet effective accounting pronouncemen</U>t (continued)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In May 2014, the FASB issued
Accounting Standards Update (&ldquo;ASU&rdquo;) No. 2014-09, Revenue from Contracts with Customers (&ldquo;ASU 2014-09&rdquo;),
which requires an entity to recognize revenue to depict the transfer of promised good or services to customers in an amount that
reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU will replace
most existing revenue recognition guidance in GAAP, including industry specific guidance, when it becomes effective. This new
guidance is effective for years beginning after December 15, 2017.&nbsp; The standard permits the use of either the retrospective
or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial
statements and related disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In February 2016, the FASB
issued ASU No. 2016-02, <I>Leases </I>(&quot;ASU 2016-02&quot;). This update requires all leases with a term greater than 12 months
to be recognized on the balance sheet through a right-of-use asset and a lease liability and the disclosure of key information
pertaining to leasing arrangements. This new guidance is effective for years beginning after December 15, 2019, with early adoption
permitted. The Company is evaluating the effect that ASU 2016-02 will have on its financial statements and related disclosures,
but has not yet determined the timing of adoption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 131; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings Inc &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 4.</B></TD><TD STYLE="text-align: justify"><B><U>LICENSING
                                         RIGHTS:</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">At June 30, 2017, licensing
rights consists of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 89%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Licensing rights</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 85%; text-align: left; padding-left: 0.125in">Amount Incurred to procure license</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">7,561,321</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in; padding-bottom: 1pt">Less charged to equity as per&nbsp;&nbsp;FASB ASC
    805</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(7,561,321</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Licensing rights, net of amortization &amp; charged
    to equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">From August 5, 2016 to 30<SUP>th
</SUP>June 2017, the Company paid Life Science a total of $4,855,080 and has a liability of $2,706,241 to procure the right to
license and develop the technology that is described in Notes 2 and 9.&nbsp; The Company shall pay royalties of sales, as defined.&nbsp;
The agreement shall be for the term of the applicable patents.&nbsp; The licensing agreement has a twenty five year term. No royalties
have been incurred through June 30, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The licensing rights are
carried at Life Science&rsquo;s historical cost of $0, with the excess of the amount paid over historical cost reflected as a
deemed dividend, given this was a transaction between entities under common control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 5.</B></TD><TD STYLE="text-align: justify"><B><U>CONCENTRATION
                                         OF CREDIT RISK</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company places its cash
and cash equivalents, which may at times be in excess of the Australia Financial Claims Scheme or the United States' Federal Deposit
Insurance Corporation insurance limits, with high credit quality financial institutions and attempts to limit the amount of credit
exposure with any one institution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 6.</B></TD><TD STYLE="text-align: justify"><B><U>CONVERTIBLE
                                         NOTES PAYABLE</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">At June 30, 2017, convertible
notes payable consists of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 89%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 85%; text-align: left">Convertible Notes Payable</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">3,848,593</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less unamortized debt issuance costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(314,271</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Debt less unamortized debt issuance costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,534,322</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Investors have subscribed
to a Glucose Biosensor Systems (Greater China) 7% Convertible Note Issue during the period ended June 30, 2017.&nbsp; The Notes
bear interest at the rate of 7% per annum payable quarterly in arrears. The Notes are unsecured and mature on December 31, 2019.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Notes also provide that
there shall be a 15% discount on the IPO Price on the offer document intended to be filed with an approved stock exchange. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 132; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings Inc &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 7.</B></TD><TD STYLE="text-align: justify"><B><U>SUBSCRIPTIONS
                                         TO PURCHASE ORDINARY SHARES OF GLUCOSE BIOSENSOR SYSTEMS (GREATER CHINA) PTY LTD</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company has received
subscriptions to purchase ordinary shares of Glucose Biosensor Systems (Greater China) Pty Ltd&nbsp; and together with the subsequent
conversion of notes payable to shares, the Company estimates that a maximum of 12,083,333 shares shall be on issue upon the successful
completion of the IPO.&nbsp; The amounts representing these subscriptions to purchase ordinary shares are credited to additional
paid-in-capital in the amount of $2,126,476.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">With each subscription to
share capital there is a Loyalty Warrant Entitlement.&nbsp; The terms of the Entitlement provide that the holder can exercise
one warrant to purchase one common share at the IPO price during years two through to year three following the IPO. At exercise
date, the shareholder must hold for each warrant to be exercised, one underlying common share to exercise the warrant The warrants
are not transferable and apply to the number of shares that were subscribed for.&nbsp; In addition, the warrants do not apply
to the convertible note holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 8.</B></TD><TD STYLE="text-align: justify"><B><U>LOANS
                                         PAYABLE</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As at 30<SUP>th</SUP> June
2017 the company had a liability to its parent Life Science of $2,706,241 as a result of procuring the license. This is payable
as and when the Company raises capital for the purpose of paying this amount otherwise the amount will be converted to capital.
This liability is not interest bearing.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 9.</B></TD><TD STYLE="text-align: justify"><B><U>RELATED-PARTY
                                         TRANSACTIONS</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As more fully described
in Note 8, the Company has a liability of $2,706,241 to an affiliate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As more fully described
in Note 4, the Company paid Life Science a total of $4,855,080 and has a liability of $2,706,241 to procure the right to license
and develop the technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company rents office
space from Life Science on a month-to-month basis. Rent expense incurred during the period ended June 30, 2017 amounted to $45,493.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The above transactions have
been determined by directors to be on an arm&rsquo;s length basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 10.</B></TD><TD STYLE="text-align: justify"><B><U>SUBSEQUENT
                                         EVENTS</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On July 29, 2017, in a nonreciprocal
transfer, Life Sciences transferred ownership of its 1,000 shares of Glucose Biosensor Systems (Greater China) Pty Ltd to Glucose
Biosensor Systems (Greater China) Holdings, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On October 30, 2017 the
authorized capital was increased to 22,000,000 with a par value of $0.01 each consisting of 20,000,000 shares of common stock
and 2,000,000 shares of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On November 5, 2017 the
Company conducted a stock split of one to 90,000 resulting in issued common stock of 9,000,000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Since the end of the financial
year, as at the date of this report there has been an additional $1,371,407 received for the equivalent of 1,371,407 convertible
notes resulting in the total proceeds received for the convertible note offering reaching $5,220,000 and an additional $4,430,330
received for the equivalent of 590,710 ordinary shares resulting in the total share offering reaching $6,556,806.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 133; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glucose Biosensor Systems (Greater China) Holdings Inc &amp;
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 11.</B></TD><TD STYLE="text-align: justify"><B><U>NET
                                         OPERATING LOSSES</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company shall file its
income tax returns with the Internal Revenue Service and Australian Taxation Office.&nbsp; The Company has net operating loss
carry forwards of $311,672 which are derived from its operations in Australia and the US and are available to reduce future taxable
income. Such loss carryforwards may be carried forward indefinitely, subject to compliance with tests of continuity and additional
rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The net operating loss carried
forward give rise to a deferred tax asset of approximately $94,000. However, the Company has determined that a valuation allowance
of $ 94,000 against such deferred tax asset is necessary, as it cannot be determined that the carryforwards will be utilized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>NOTE 12.</B></TD><TD STYLE="text-align: justify"><B><U>LOSS
                                         PER SHARE</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On November 5, 2017 the
Company conducted a stock split of one to 90,000 resulting in issued common stock of 9,000,000. The loss per share as of 30<SUP>th
</SUP>June 2017 prior to the stock split was:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 89%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 85%; text-align: left; padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Basic
    and diluted net loss per share attributable to common stockholders based upon actual shares issued as at 30<SUP>th</SUP> June
    2017</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; text-align: right">(3,117</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Weighted-average
    number of shares used in calculating loss per share attributable to common stockholders, basic and diluted common shares based
    upon actual shares issued as at 30<SUP>th</SUP> June 2017</FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">100</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Subsequent to the split,
the revised loss per share was :</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 89%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Loss per share: </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 85%; text-align: left; padding-bottom: 1pt; padding-left: 0.125in"> Basic and diluted net loss per share
    attributable to common stockholders based upon retroactive effect of 90,000 to 1 stock split post year end </TD><TD STYLE="width: 1%; padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left"> $ </TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; text-align: right"> (0.03 </TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in"> Weighted-average number of shares used in calculating
    loss per share attributable to common stockholders, basic and diluted common shares based upon retroactive effect of 90,000
    to 1 stock split post year end </TD><TD STYLE="padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 9,000,000 </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 134; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PART III&mdash;EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Index to Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; width: 12%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT> </TD>
    <TD STYLE="width: 3%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center; width: 85%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    Description</B></FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418051347/filename9.htm" STYLE="-sec-extract: exhibit">1.1</A> </TD>
    <TD STYLE="width: 3%"> &nbsp; </TD>
    <TD STYLE="width: 85%; padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418051347/filename9.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form
    of Placement Agency Agreement between the Company and Cuttone &amp; Co., LLC (incorporated by reference to Exhibit 1.1 to the Company&rsquo;s DOS/A dated September 27, 2018 filed as Exhibit 15.6 of this Form 1-A)</FONT></A> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420417065823/filename3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">2.1</FONT></A> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420417065823/filename3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Certificate
    of Incorporation (incorporated by reference to Exhibit 2.1 to the Company&rsquo;s DOS dated
    December 29, 2017 filed as Exhibit 15.1 of this Form 1-A)</FONT></A> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420417065823/filename4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">2.2</FONT></A> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420417065823/filename4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Certificate
    of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit 2.2 to the
    Company&rsquo;s DOS dated December 29, 2017 filed as Exhibit 15.1 of this Form 1-A)</FONT></A> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420417065823/filename5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">2.3</FONT></A> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420417065823/filename5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Certificate
    of Designations of Series A Convertible Preferred Stock (incorporated by reference to Exhibit
    2.3 to the Company&rsquo;s DOS dated December 29, 2017 filed as Exhibit 15.1 of this Form 1-A)</FONT></A> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418044808/filename4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">2.4</FONT></A> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418044808/filename4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Certificate
    of Amendment to Certificate of Incorporation (reverse stock split) (incorporated by reference to Exhibit 2.4 to the Company&rsquo;s DOS/A dated August 14, 2018 filed as Exhibit 15.3 of this Form 1-A)</FONT></A> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420417065823/filename6.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">2.5</FONT></A> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420417065823/filename6.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Amended
    and Restated By-laws (incorporated by reference to Exhibit 2.4 to the Company&rsquo;s DOS dated
    December 29, 2017 filed as Exhibit 15.1 of this Form 1-A)</FONT></A> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420417065823/filename7.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">3.1</FONT></A> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420417065823/filename7.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form
    of Certificate of Series A Convertible Preferred Stock (incorporated by reference to Exhibit
    3.1 to the Company&rsquo;s DOS dated December 29, 2017 filed as Exhibit 15.1 of this Form 1-A)</FONT></A> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420417065823/filename8.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">3.2</FONT></A> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420417065823/filename8.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form
    of Warrant issued in connection with the&nbsp;&nbsp;Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.2 to the Company&rsquo;s DOS dated December 29, 2017 filed as Exhibit 15.1 of this Form
    1-A)</FONT></A> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418034681/filename3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">3.3</FONT></A> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418034681/filename3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form
    of Convertible Promissory Note (incorporated by reference to Exhibit 3.3 to the Company&rsquo;s
    DOS/A dated June 18, 2018 filed as Exhibit 15.2 of this Form 1-A)</FONT></A> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418044808/filename5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">3.4</FONT></A> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418044808/filename5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form
    of Placement Agent Warrant (incorporated by reference to  Exhibit 3.4 to the Company&rsquo;s
    DOS/A dated August 14, 2018 filed as Exhibit 15.3 of this Form 1-A)</FONT></A> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418048915/filename4.htm" STYLE="-sec-extract: exhibit"> <FONT STYLE="font-size: 10pt">4.1</FONT> </A></TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 5.75pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418048915/filename4.htm" STYLE="-sec-extract: exhibit"> <FONT STYLE="font-size: 10pt">Form
    of Subscription Agreement (incorporated by reference to  Exhibit 4.1 to the Company&rsquo;s DOS/A
    dated September 11, 2018 filed as Exhibit 15.4 of this Form 1-A)</FONT> </A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420417065823/filename10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">6.1</FONT></A> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420417065823/filename10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">2017
    Equity Incentive Plan (incorporated by reference to  Exhibit 6.1 to the Company&rsquo;s DOS
    dated December 29, 2017 filed     as Exhibit 15.1 of this Form 1-A)</FONT></A> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418048915/filename5.htm" STYLE="-sec-extract: exhibit"> <FONT STYLE="font-size: 10pt">6.2</FONT> </A></TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 5.75pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418048915/filename5.htm" STYLE="-sec-extract: exhibit"> <FONT STYLE="font-size: 10pt">Technology
    License Agreement between the Company and Life Science Biosensor Diagnostics Pty Ltd, dated August 25, 2017 (incorporated
    by reference to  Exhibit 6.2 to the Company&rsquo;s DOS/A dated September 11, 2018 filed as
    Exhibit     15.4     of this     Form     1-A)</FONT> </A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418048915/filename6.htm" STYLE="-sec-extract: exhibit"> <FONT STYLE="font-size: 10pt">6.3</FONT> </A></TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 5.75pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418048915/filename6.htm" STYLE="-sec-extract: exhibit"> <FONT STYLE="font-size: 10pt">Variation&nbsp;&nbsp;Agreement&nbsp;&nbsp;to&nbsp;&nbsp;Technology&nbsp;&nbsp;License&nbsp;&nbsp;Agreement&nbsp;&nbsp;between&nbsp;&nbsp;the&nbsp;&nbsp;Company&nbsp;&nbsp;and&nbsp;&nbsp;Life&nbsp;&nbsp;Science&nbsp;&nbsp;Biosensor&nbsp;&nbsp;Diagnostics&nbsp;&nbsp;Pty
    Ltd, dated December 8, 2017 (incorporated by reference to  Exhibit 6.3 to the Company&rsquo;s
    DOS/A dated September 11, 2018 filed as Exhibit 15.4 of this Form 1-A)</FONT> </A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418034681/filename4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">6.4</FONT></A> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418034681/filename4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Second
    Variation Agreement to Technology License Agreement between the Company and Life Science Biosensor Diagnostics Pty
    &nbsp;Ltd.,     dated April 2018 (incorporated by reference to  Exhibit 6.4 to the
    Company&rsquo;s DOS/A dated June 18, 2018 filed     as Exhibit 15.2 of this Form 1-A)</FONT></A> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418044808/filename7.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">6.5</FONT></A> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418044808/filename7.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Third
    Variation Agreement to Technology License Agreement dated July 10, 2018 (incorporated by reference to  Exhibit 6.5 to the Company&rsquo;s DOS/A dated August 14, 2018 filed as Exhibit 15.3 of this Form
    1-A)</FONT></A> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418054618/tv504161_ex6-6.htm" STYLE="-sec-extract: exhibit"> <FONT STYLE="font-size: 10pt">6.6</FONT> </A></TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 5.75pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418054618/tv504161_ex6-6.htm" STYLE="-sec-extract: exhibit"> <FONT STYLE="font-size: 10pt">Form
    of Lock-Up Agreement (previously filed as Exhibit 6.6 to the Company&rsquo;s Form 1-A dated October 19, 2018)</FONT> </A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418048915/filename7.htm" STYLE="-sec-extract: exhibit"> <FONT STYLE="font-size: 10pt">6.7</FONT> </A></TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 5.75pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418048915/filename7.htm" STYLE="-sec-extract: exhibit"> <FONT STYLE="font-size: 10pt">Master
    Services Agreement between the Company and iQ3 Corp Limited, an affiliated party (incorporated by reference to  Exhibit 6.7 to the Company&rsquo;s DOS/A dated September 11, 2018 filed as Exhibit 15.4 of this
    Form     1-A)</FONT> </A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418044808/filename10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">6.8</FONT></A> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418044808/filename10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Medical
    Affairs Services Agreement between the Company and Clinical Research Corporation, an affiliated party (incorporated by
    reference     to  Exhibit 6.8 to the Company&rsquo;s DOS/A dated August 14, 2018 filed as
    Exhibit     15.3 of     this     Form 1-A)</FONT></A> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418051347/filename10.htm" STYLE="-sec-extract: exhibit"> <FONT STYLE="font-size: 10pt">6.9</FONT> </A></TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 5.75pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418051347/filename10.htm" STYLE="-sec-extract: exhibit"> <FONT STYLE="font-size: 10pt">Employment
    Agreement between the Company and Dr. Jean-Claude Becker dated September 24, 2018 (incorporated by reference to  Exhibit 6.9 to the Company&rsquo;s DOS/A dated September 27, 2018 filed as Exhibit 15.6 of this
    Form     1-A)</FONT> </A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418054618/tv504161_ex6-10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">6.10</FONT></A> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418054618/tv504161_ex6-10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form
    of Technology Services Agreement with Prime Trust, LLC (previously filed as Exhibit 6.10 to the Company&rsquo;s Form 1-A
    dated October 19, 2018)</FONT></A> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418054618/tv504161_ex6-11.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">6.11</FONT></A> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418054618/tv504161_ex6-11.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Employment
    Agreement between the Company and Ms. Gavrilenko dated August 8, 2018 (previously filed as Exhibit 6.11 to the Company&rsquo;s Form 1-A
    dated October 19, 2018)</FONT></A> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418054618/tv504161_ex8-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">8.1</FONT></A> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418054618/tv504161_ex8-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form
    of Escrow Agreement with Prime Trust, LLC (previously filed as Exhibit 8.1 to the Company&rsquo;s Form 1-A
    dated October 19, 2018)</FONT></A> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"><A HREF="tv506394_ex11-1.htm" STYLE="-sec-extract: exhibit"> <FONT STYLE="font-size: 10pt">11.1*</FONT> </A></TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 5.75pt"><A HREF="tv506394_ex11-1.htm" STYLE="-sec-extract: exhibit"> <FONT STYLE="font-size: 10pt">Consent of BDO East Coast Partnership</FONT> </A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418048915/filename10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">11.2</FONT></A> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418048915/filename10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Consent
    of Hughes Hubbard &amp; Reed LLP (included in Exhibit 12.1)</FONT></A> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418048915/filename10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">12.1</FONT></A> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418048915/filename10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Opinion
    of Hughes Hubbard &amp; Reed LLP (incorporated by reference to  Exhibit 12.1 to the Company&rsquo;s
    DOS/A dated September 11, 2018 filed as Exhibit 15.4 of this Form 1-A)</FONT></A> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418051347/filename13.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">13.1</FONT></A> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418051347/filename13.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Testing
    the Waters materials (incorporated by reference to  Exhibit 13.1 to the Company&rsquo;s DOS/A
    dated September 27, 2018 filed as Exhibit 15.6 of this Form 1-A)</FONT></A> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418054618/tv504161_ex13-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">13.2</FONT></A> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418054618/tv504161_ex13-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Testing
    the Waters materials (previously filed as Exhibit 13.2 to the Company&rsquo;s Form 1-A
    dated October 19, 2018)</FONT></A> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420417065823/filename2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">15.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420417065823/filename2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Draft
    offering statement previously submitted pursuant to Rule 252(d) dated December 29, 2017 (incorporated by reference to the
    copy thereof previously made public pursuant to Rule 301 of Regulation S-T)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418034681/filename2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">15.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418034681/filename2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Draft
    amended offering statement previously submitted pursuant to Rule 252(d) dated June 18, 2018 (incorporated by reference to
    the copy thereof previously made public pursuant to Rule 301 of Regulation S-T)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418044808/filename2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">15.3</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418044808/filename2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Draft
    amended offering statement previously submitted pursuant to Rule 252(d) dated August 14, 2018 (incorporated by reference to
    the copy thereof previously made public pursuant to Rule 301 of Regulation S-T)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418048915/filename2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">15.4</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418048915/filename2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Draft
    amended offering statement previously submitted pursuant to Rule 252(d) dated September 11, 2018 (incorporated by reference
    to the copy thereof previously made public pursuant to Rule 301 of Regulation S-T)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418054618/tv504161_ex15-5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">15.5</FONT></A> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 5.75pt"> <A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418054618/tv504161_ex15-5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Correspondence
    by or on behalf of the issuer previously submitted pursuant to Rule 252(d) (previously filed as Exhibit 15.5 to the Company&rsquo;s Form 1-A
    dated October 19, 2018)</FONT></A> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418051347/filename2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">15.6</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1725430/000114420418051347/filename2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Draft
    amended offering statement previously submitted pursuant to Rule 252(d) dated September 27, 2018 (incorporated by reference
    to the copy thereof previously made public pursuant to Rule 301 of Regulation S-T)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt"> <A HREF="#poa"><FONT STYLE="font-size: 10pt">24.1*</FONT></A> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 5.75pt"> <A HREF="#poa"><FONT STYLE="font-size: 10pt">Power of Attorney (contained on the signature
    page hereto)</FONT></A> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> *&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Filed herewith </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 135; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">III-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="poa"></A>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Pursuant to the requirements of Regulation
A, the issuer certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form 1-A
and has duly caused this offering statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Sydney,
Australia, on November 6, 2018. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Glucose Biosensor Systems<BR>
 (Greater China) Holdings,
    Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Harry Simeonidis&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Name:</FONT>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Harry Simeonidis</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">President</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>KNOW ALL PERSONS BY THESE PRESENTS</B>,
that each person whose signature appears below constitutes and appoints Spiro Sakiris and George Syrmalis, or either of them,
his or her true and lawful attorney-in-fact and agent, with full power of substitution, for him or her and in his or her name,
place and stead, in any and all capacities, to sign any and all amendments to this Form 1-A offering statement, and to file the
same with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting
unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and ratifying
and confirming all that said attorney-in-fact and agent or his or her substitute or substitutes may lawfully do or cause to be
done by virtue hereof. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">This offering statement has been signed by the following persons
in the capacities and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Jonathan S. Hurd</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: November 6, 2018</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Jonathan S. Hurd</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman &amp; Director</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Harry Simeonidis&nbsp;</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:&nbsp; November 6,
    2018</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT> </TD>
    <TD STYLE="width: 45%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Harry Simeonidis</FONT> </TD>
    <TD STYLE="width: 5%"> &nbsp; </TD>
    <TD STYLE="width: 45%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Director (Principal Executive
    Officer, Principal Financial Officer and Principal Accounting Officer)</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Jean-Claude Becker&nbsp;</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: November 6, 2018</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Jean-Claude Becker</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Vice President, Chief Operating
    Officer &amp; Director&nbsp;</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Victoria Gavrilenko&nbsp;</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: November 6, 2018</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms. Victoria Gavrilenko</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treasurer, Secretary &amp; Director</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    John Caminis&nbsp;</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: November 6, 2018</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. John Caminis</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Yong Hei</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: November 6, 2018</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Yong Hei</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 136; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">III-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX1A-11 CONSENT
<SEQUENCE>3
<FILENAME>tv506394_ex11-1.htm
<DESCRIPTION>EXHIBIT 11.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5in; text-align: right">Exhibit 11.1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5in; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5in; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #384144"><U>Independent</U></FONT><U>
<FONT STYLE="color: #262B2D">Registered Public Accounting</FONT> <FONT STYLE="color: #384144">Firm's C</FONT><FONT STYLE="color: #262B2D">onsent</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.25pt 0pt 0"><FONT STYLE="color: #384144">We consent to the inclusion
in this </FONT><FONT STYLE="color: #262B2D">Offering </FONT><FONT STYLE="color: #384144">Statement </FONT><FONT STYLE="color: #262B2D">of
</FONT><FONT STYLE="color: #384144">Glucose </FONT><FONT STYLE="color: #262B2D">Biosensor Systems </FONT><FONT STYLE="color: #384144">(Greater
China) </FONT><FONT STYLE="color: #262B2D">Holdings, </FONT><FONT STYLE="color: #384144">Inc</FONT><FONT STYLE="color: #546469">.
(</FONT><FONT STYLE="color: #384144">the &quot;Company</FONT><FONT STYLE="color: #546469">'</FONT><FONT STYLE="color: #384144">')
on </FONT><FONT STYLE="color: #262B2D">Form </FONT><FONT STYLE="color: #384144">1</FONT><FONT STYLE="color: #0E0E0E">-</FONT><FONT STYLE="color: #262B2D">A
of our </FONT><FONT STYLE="color: #384144">report dated November 7</FONT><FONT STYLE="color: #546469">, </FONT><FONT STYLE="color: #384144">2018
with </FONT><FONT STYLE="color: #262B2D">respect </FONT><FONT STYLE="color: #384144">the financial statements of the Company which
appears in </FONT><FONT STYLE="color: #262B2D">such Offering Statement. </FONT><FONT STYLE="color: #384144">We also </FONT><FONT STYLE="color: #262B2D">consent
</FONT><FONT STYLE="color: #384144">to the </FONT><FONT STYLE="color: #262B2D">reference </FONT><FONT STYLE="color: #384144">to
</FONT><FONT STYLE="color: #262B2D">our Firm </FONT><FONT STYLE="color: #384144">under the heading </FONT><FONT STYLE="color: #546469">&quot;</FONT><FONT STYLE="color: #384144">Experts</FONT><FONT STYLE="color: #546469">&quot;
</FONT><FONT STYLE="color: #384144">in such </FONT><FONT STYLE="color: #262B2D">Offering Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>/s/ BDO&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #262B2D">BDO </FONT><FONT STYLE="color: #384144">East
Coast </FONT><FONT STYLE="color: #262B2D">Partnership </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #384144">Sydney, Australia</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #384144">November 7, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #384144">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tv506394_img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv506394_img01.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ Q0*1 P$1  (1 0,1 ?_$ -P   $$ @,! 0
M       &!P@)!0H" P0!"P$  00# 0$               ,$!08! @<("1
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M[E_Q-N+!W^\;O>,Z^RR?'J6(\I12N;1)QN6VE6Z5 C5M'?,VX+Z/=^'%N</
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M6:P_>YKG636"GKC+LSR*9N_.L9KKC[SAVW2A*$)J^\[UN._9S;AN<G7.0
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M?O#<?CIRF0J"W23]M)9.V[MD*4$A53X<?LI'?X*\@AY158W#KZ0ZI$@V4_W
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ML-5:]C[*\Y6XT26UJ1UZ]BBGI\.H(/QT D<*"JDW/&HZ<R^*'C'Y"1'XG-W
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M\Q\2\C<:V#;BD+1FF)W-(RXL*(*F;&9%17S I6Y[FGG ?7?TUE6*M<<:<I)
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MX>Y]*0=FY47D7&E<I\5MR_0$1.0>+78S!43LNU4$]5=;SL/_ )CVEN^SG62
M0YL8\#$_HS6]L<P)_H57-S_PN^8&>-%D+X[_ -=?4C^YX[#^E5BNJ-5CHT44
M:**-%%&BBJ[/"!/\<\N>>O/T@AY>=>44_A[')  4T<&\8<2HN+H;<5T?*8SF
M>_Q&_L.A<>6KJ2=7CN[_  >V;-LJZ>CMPG8?[S+=IC?S]/TA[ *KFQ_O\O<-
MP/\ >91C7^C HC_Z_6?MJ3WDOSMC/C/P1RCSIERFU4W'&)65\F&MY+*[FW2W
M]-C]!&6I21]5?7DB/$;VW(4]O\-421^A>H\+5:L/'DS,I<6,:L>/A_(5^=YB
M.29AY&^0.8<G9U*5=WV59599;DMLM?O?6V]W8.SGT-!1*6HM?N&F$#8)9;;1
MZ)&N==PY!E.AM7J+L["AQ-N'2G2 -/LJ_P!X(H&ZJLK4(;&RT-]NQ*5]J$=O
MS?V?B=]MSUU 8@O8<JL>Y91F15'ND>-3_P ?CM-U[:T-(<6[NE/:@(V2H;!)
M6X>TE 2>H'4ZL6/$O3< WKG^9E=<A(.@-=F3@_I)<#08*>UO8N$E1(("NWL2
MD>GPWTK)&VAY @UG;IV;(*"_45L/R51-]U'%;"WPM-_*@BYQB%&=QVTA(45/
MP8ULVR\J:B/VJ4X'%$$+;^="FTG;IN(/-UG,GX-*Z?VR(\Q &/O+U$>T#7V6
M%/']M;AV3@GA!C^-25J<N><\\QO $R_;4R])H9%JW$OY01T="/X<BW+ZOAL-
M]=.V0?X!".!%>:OJ+N FW>?U" BL0/OU_+6P*A*$ I:0&F@=FFDC9#;8&R$(
M Z!*$@ #T &I:N+-JQ/B:YZ*Q7 N,AYIA3S*7WTN+994XD/.H9"2\MMLD*<2
MP%@K[=^T*&_J-%8M7(I&^Q W'3T_#16:XK;;<2$N(0XD'N"5H2M(4.@4$J!
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M:<;\#Q9G)-]R7QSC.,9KF6597EU_53%Y%&O;:TA)M+<U+$QG':"80I$5(3\
M-2$6UX,3^HB?O/&JV.^NZ-SD,.9DM\N0;H/A/Z>?+PI5>,Z&K?)_)?DUW=:,
MGYM?P*C6@$E['^$\:I>/T-1QU[F%9BU=K !V[G%>IU(%BQN>-<RW/I^<8+[3
M46/)#[EE%Q-D?(5EA7'TGE?ACQE=@2/,3EVFN6X5!Q0JWLJVDKN.N-TF.[$Y
M6YMAS+EB=9TK3\:/65[:VWY");K3.D66[:<*;)BI( .$[$V!TN/&]>KQC\_.
M%_,#D#CSD+AVHY7J\$M(_(?'%3F/)6!.X/C.895'CT>2KH,1FRK28N]G1(=*
M_P"YV)2V%@MI6IQ*T)8R?\?%D8Q5S&A5EX@D\_(@??7,NXL:?9/J7L&5.P$&
M1@;EC1DBZKDR''R$UT/3(D#I(OXO<(X5:LP^W(:]Y*DH2$DK"U!/M[#<]Y.P
M2-AON=AMUU)Z<N%7PE7595%@X)M^J02K+]C CS%CSKUI2E2 M!#C2T)6AP;%
M"T*V*5H(W!2L'H0>HT5C4"W*DU*PO$YV45>;3,?JY&7TD"55U.1+C VL"MFA
M:9<%B4"%B*^'5;H.X!62-M]1N1LVU9>YX^]Y4"MO.'&R0S7LR*W$>>AMKI4#
MF=F=J[GW-A]ZYN!C/W5A*XCR0G3*H?0J"I%A;0V^+6_&HU\O^,^39EG-MR'Q
M=R?(XRR#,,4;P;/4*J1;1;_'FTAI+D1P/LR*ZP3%"6RI)]$#M4@[D\O[T^EV
MX;_W'D]Q=O[D,'(S,5<?(O[H>,+T]!M:X&MOOXUYN^L?_+IW!W5WO/W]]-^X
M)NWNY=PVR/#SXHH/57*QG8H\L(-_3D5!TFUB"#TD7-WIXWXCQ;C+C*DXLJ6/
MKJ"JKGH<IR:A ?MI4Y2WK6RE^V?DD3Y;JU_*?D':D'9(U?.W>TMJ[6[5B[8Q
M4]1(TZ>J_E:X)^^NU?3_ .EO:7T^^GV']-\?'AR]LV_&='EZ3&<V:4'U))4/
M!A?4\CP)K-0..L5I[.#:TM8*N;!81#;5"=4&WHC48Q$QY##WO-J!85LI2>UQ
M1 W5Z[R,&RX&,RF$-[I&O.IW:^S>VL/=(-QVF%<;,1?>0L>D :$GQ!%Z3?#!
M^H@<DSQV^Q8\S<C.PU#T6Q!L(E,XM)VZ@S*QP']HTTVD$RY$UP5FGZ58::*?
M@87M>_'SJM_2 _,;7NV7""N/+W'N<\<9.OI1R" F%^#>HT32]!]V4,2I#^[3
ML*]IL+>?6&V6D*<?<)V#;+:2MUPGX!"$DGX;#4Y&K,UEXUUZ9U2/J8V!T'MJ
M#U,[(E\%0[)\%-GS'EMEETE _O%,\AY=-R&.DCIUCXH\PSZDI0V!Z:DEZDC(
MT)M4^O2D(119K:^%7=<8X^UB^ 8C1M-ALP:* EU !';(D,IE21L?3_>'E:9$
MDFYK0DGC2[UBL4:**KT^Z$PY6>)%[RC#"Q;^/W)_!?D#4/-_WD97%?,&&W]X
MZE7]A*\138M+/I[;B@>A.KO]/6$G<R;<W]EFX^1C-Y^M ZK_ *_2?:*KO=(Z
M-H;*'QX\L4P_[N12?]6]6$-.-O-MO-+2XTZA#C:TG=*VUI"D+2?BE22"-4D@
M@V/$58@;BXX5JS?>DXL\D. >5ZCR2XTY^\BZ'@7EZ;!QG+L=Q3FSDZDQ_BCE
M?V0S5RHM96Y&S J,.Y)C,=K:&TH8B732T (3,90/4_T&S.R^XU/:W<VWX4FZ
M1*3#(T4?5(E^#'INS(3:YU*E3^%C7&/J5C]P;4PWG:,G(7"<V= [V1O$"^@;
MP&EP?$5C?L]_<.S3%.8U^+WD3R3E^<XIS19B3PSGG)&4VV67N,<HIBH:E\:V
M62Y%,F6;M%G<**'J=#KRDL6K*XS8WF("97Z]_27"V_ 3NGM?&2&"!>F>.-0H
MZ/\ :64 77\1M<H;D^YJS^FG>^1DY+;-O$K222&\;L23U?JW)O9N7[6@^*MJ
M[7D*NYUY9TQBNA3+"4L-QH,61,D.'T0Q%96^\L_L2V@G6R*7<(OQ$@#[:PS!
M5+'@!>H"_:UA/(\%^#,CFI[;/DR+G',MLX00Y)L.8^2LQY*=DO*(W6ZIK)VQ
MOOOL!\-M7/ZB.#WCF0)_9XYC@7R$$216_P!2J_VJI_@,$I^.4-(?;([/_P#B
MJD?^8W\L$.M\:>'6,6;:O85$YCY>:C2%)2D-F1 XSQJ=[1[TJ?F+?M%M*/4-
MQ5@'7.-QR5BC(770UUSLG:VDD.X.+L#8>'G5*_ASA+<9EJ8$J><GNAYQ78I1
M[UA*^SL.P!"B3T.N4;I.\L@OXUZ5VG'CBQ$+&VM[5L#\.TX170W78+W<A*.W
MN<0H(!'H&OAW ?$@Z>[?"P D/ <J@-]G0.>AK5,NM=89:9VJ]BEM0W4X$I "
M>A'<24[$_P#-JSQ#JCT%JYU+',')]0&Y\Z;O-ILJ1%5'86D%M?<$H*1N"KN/
M>DD[=J?VZ;RR "QJ?VPJD@8@W'_1I537W&(%Y;<78[3U$5Y3V7<D8)AT];()
M+42WG*=;G#L)#7TZHBFBH]"AT#UU7-Q$GJQ1)QD>WVW%=0[/F@Q,>5YSK''(
MW^D-/S59APK@T7'+O@/C:*TD0>)^*[C.[)"1LAN\R-EG",=+@'H\XQ8WSB3^
M+1V^.NPX<*X^)'C_ (T0!O;7C?O+/3+SIB"?>E8CV=53G2GTZ=!T]?P_KW]=
M+U2V!6P/&PKGV#]O^G]6BM:35YA]+D+S,F:W+9GQH[L:+95\V3"GQF'E)4\V
MP^PX"AMU24E:=ME;#?X;9"L1U 'IK(5F^$$TD#BG(--*CHQK,_KJP)91(C9<
MRJP?CB/\KA8DLH$J2N4VO8GO;#9;2?FZZP=" =">'G[/&B13"W1*.E_ Z'\M
M9!W)LKJ9,W]9Q29-K0\Y]%.H4,RW$1PZOK):;E..^U[';VJ4E#BE$CMVUD@C
MCI6H(;X2#;PKV5&?XK=2'H46Q4S8Q_9]^MG19,28T9#[$9G=#C9;6''Y*$@I
M4H$G?T!(T;X36:5[2DO-H=:4AQIQ/<VZVM+K:Q^*%M%:5#]H)&D:S0H$C;T.
M_P ?^C?117B=2/PZ]?C\>FBBF;YRRZ1@'#W)>70P3:4V&W:Z-M([EOY'.B+J
M\9C-@;GW).0SHS:1L25* TXQHQ))9N %:.MY(4_7EZ3[*DMXQ<;Q\.ON-./X
MX"H'!7"V/X^H[;[WTJMA5+TA?_Y\DMS7%$]25$_$ZS+?IZKGC:W*K;(SQ7QT
M8^D-+58& 0=]R?V:;WTIH%(;J)O7+6*WHT44:**@1]SVCF6O@KY"7%6V57?&
M^-4W-- ZC<O1KGA'+<?Y8@R&"G9274+Q @$?!1U<OI],L?>.#%)_93R- WFN
M0C0D?Z]0'=",^PY#I\<2B0>V)A(/^K2__P YW#W_ ,7B_P#\YO\ ]SIG_E3=
M/U3]U+_QO"\:TN^,KERWPF%DSLA/NY-=Y;D[JUJ[U/2+_-,@MBX""025R1OU
M[%CJ"?77,/KF;?5?<X1PA:&(>0CQH4M^2O5GT(A$/TFVMCQR8Y93[7R)3>EA
M,LXK[2P^MI)([1_=EKW'#VJ;4D)[F71MT[NFW](URH^-==%Q8^%-G827XDD2
M(CI9<:4IR.^T?S6%-D*#+A;[RX%]G>E.X/7IZ:=P9)"'V5+XVYJMC(-.=>5S
MD"#8,*K<A;86M3J&XUDAIMUYCM#@;=!D-J4VH>\3OT*T]"".FI3'R Z].ES5
MUVO.Q"HR%/O#@+Z?=6'F0GJ] G5%D;6)[;2&V&G6TNMD=Q3\J7.Z*TM*P VE
M1[5C;]U2=EGL5JW1;H,J/T]!S^[SKK.<2*A"&77T1DNJ4'MEJ:5.2M':5NR$
M*4%J*&P 4DJ0%$:1Z?*I5$29!<BX]E>L<COD6?T$LI;L66$/H,AYWMCQNC,=
MH.+4E/[@ Z]P2G;IOOHM;2M7QE++<@V\;:5CXF3 NJ<D274J#3[(7N$_(I,9
M:DN*[CN4EL=OHK?H3L=*IPK>98T(4%2+>5,5S7GS+M;)C19;KC<1EU/TZ'U1
MV_WI 9+C;?1U7N$$K5OMU'0$Z=XX]_SJM[]FC%Q&EN+ <;_GJ^#["?VNLMH9
MTOS=Y]IY5-(R+'K"!P'B]LPMJY1!R2.MBRY2M(DE =@,RJY?LTS2P''6WG)1
M"4*8*KWM&-Z*C(.A8<*\._5_O\;AE_P7:FO&K6F86()\ =1:W&WLJ<_GO5S_
M !_Y0X$\XJN*\EOA#*7.'_(5F(A7?:^.O*UI'J9]I+;0/SVN.\P>BVS:E=$)
M=6>@WU;,9E!^6%K/K?VUPY0,F!XT'NJ;#QL.'G4^LZQU>>8%EN+5.36N-NYA
MB5S34V9XM.<A7%$]=U3S%5DM!91E!QF3 =?;DLK0>H V]=)?V9ZK</T4W2W6
M+\+BJEOM(P/(KBO(?+/QI\H<YDY9R1QSF>"9Q6(O<HMLQO9F.9[CSZ3E=3>V
MCL@3L-NW:EA+:4.=\.P0^TM"21NOE3?,HC@6L;T\RABF_I@Z\/"GQ^XYBUM@
MM5Q%YRX)7O3,\\-LO3DN3PH:%&1EGC]EKK-)S!BKR6AWR$0ZJ1^I,)/RMJ9=
M5ZG6D(#2=)-@;UI'+UQ?)\CS]FOZ*N,X4SNDSS#*.ZQZR9MZ*XI:O(\9M&'$
MN,6>,7\-BRIYK*D[@H,:2D?]G<#UU'Y,'IS=7*F18K*8K<!3QZ0K:C111HHH
MT44:**-%%&BBC113?\LX^SEG%?)F+2&P\QDO'^98^^T1N'6;G'+*N=;(^(6B
M21_7I[MLYQMQQ\E=&CF1O]%@?T4WRXQ-BRQ'@T;#[P14=/MV9 ]E'@;X>W,A
MPNR'O''B*'(<425./U&$T]0\M1/7O4Y ._[=3O?,(Q^\MTB71?GYB/8TC-^F
MHWMR0R[!AN>/RT8^Y0/T5,AQMMUM;3J$.M.H4VXVXE*VW&UI*5H6A0*5H6DD
M$$;$:JP)!N.-31 (L>%:"GG)QIQ!P_YF>0G%G!%K'NN+*'(V90JHS'_E7'F:
MY$RY9YUQ'52"I;5I3XE92-V^S9->)1KU;KBJ.OI/]%-XW_?.Q<:?N",B0+TH
M['65!HKD?M#4^/Q<'%>2OJ#@;9MW<<L6UN.B]V4<$;B5!\C]W#B*V&OL(\G<
MPYGXPYI@^:5\NQXEX>SLX3P5R!82%*EW%#]*[.R3 6$.I+MC3\6W#B(4.?W%
MLM2/H4]8"MO)O_,#LW;^T][%]FD!R<A.N>,#1'T :_BXO<?L]?XZ[;],,_<\
MWMX+GJ?1B;IC<\67F+>"Z6/GT_AJW#R+N5X[X^<[9 TOVW*+AOD^Y;<WV[%U
M>$WDU"]_AVJ8WUQ_881D;YA0'@^7"OWR*/TU>MTD]+;<B4<5@D/W(36I)PGD
M=?B?"G$D2T2TRF)Q[@=:P#VH+BWL;J^O>?F4XZX_N2-RG<[;;:X_WYDKF]^;
MYDR_&V[9=B.8]=P/NX?97MOZ<[+)'V!LV"JVCCVG$8Z_K0(UQ[;WJ9^%W-%=
M16D.N(6RZVTGJX 64*"B!W+6"DCIZ[^H'P.H/'2!@"W/E3W<FR$8K"I!!I"\
MW^)O$//&/FESO&85[%9<6[62R51[BDD.(5_O]-=1BF57O;=%=A*%[;+2H;C6
M3B>F0\6FM].=(1;CEJ")5!!XWX6\*RGA=X.?;4X#M8'^,/ DK-\S:E!R#R3R
M=8R<_P 0:>]_O8+V$_30*6F2RDA)=>@STGM*E.(W(%FV3>=LC?T<U?3F)TN-
M/S5SGO? [WS@^9M62/DB+>DALP'A?^8@ULU8<</3CE2C!&L=:Q!,1 HVL3:K
MV<?1#2/RT5K%2ANN:80GT2V $^FP]-7V.2&2/J@(*^7Z*\[9:3I/Z6>)!E'B
M'O?3QO\ II5[ ? :V\Z3&F@X5]T456UYU9K74N5<5L63Q%3@./\ )G,UZUW
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MZN'X<&6X&;2[7+EH:0)"TLMH[E;'M2DL-MP=V3MK;H,![YMO?DG.H4_$03S
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M8YE>3M4=UP)P#)<9<9NLUM(M].?O;\!QJ%&864%)6V=:$6)%^!J1D]3$P&N
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M9+TM0>6V3W%PC2&?'V_&F'M&_0S8^WQ.9(7AT*N5-O5(XFYM?76H[N$?3?\
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M%);0$DI /<2=]AI>'-5Q8'G2$NW/"O2^IX_HK9*^PIPDS-Y[SOD]V.I4#CC
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M,&;0BD%'1(.K36HH_;YY*RC)N&+7AKE&8N3S?XHY?8>/G)ZI"S]5=-XDVW_
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ME4M[39%"BV-#:0K:',C-S([L)]+I<C...M(<+1['V@76'$$.(2I+C:TD!25
M:E5;C60Q'#C:WL!XV\+\[<:S:5=?B.T[$$$$;_L]1\=9 "J%711P%:*JH.E
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MB?X'- OQS%(A[975/S,:G[!A1ZV%#KHC8:B0(L>%%:&P#<>*RAAAL  #9#:
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M"QBJFP)L1"PVY(8<2RX=]FWP.^,X>WYMFWTI)VZ[#II*56:,JNK$:4[VJ:#
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M '+']H[+6"H !;+D]T*MM11 K1Q68&PX4^N*8Q!JH,)2&4)^8-1RU\SBE+!
M<*EA2Q[6R=_16Y/H0=1+%QHU-<B=E-U!*WKT*R!NFR=AV=,0BKFO-19<H=ZF
M(;BT(5'<W4 %*2X3[I[02@$>NL8N:V)N",38:58A@Q9^U- +^J5XT[$C(VTU
M%EV/-AZO0ZXTZVL=VS1[BV74?WC;B""A74*201ZZZ9'*LT8D7@:Y4=LF@S0E
MB6!U_D::V=RC%KZN5,>E)!^G7L7%]1NG]J@3M^WIIK/DE&*^%3 VCU#\-DYF
MHP>?WG7SA88)QMX]\,Y*,'BY-C(D<S<K0'HZLOI\68B,0_X;X]9D(=:BY)E2
M''FA:+2H04M*6W\_:O4E_'4;%Z(UO,OCXUSB3Z<Y^3O+9"%(8&<@/?BM]"![
M/RU:S]MC-_$63P3@G&7C++I\?I*&M?=7QO(=<3ET3(2AM_*+K(G9N]AE%Y:6
M?N/3K-:GS*>/>5[;)3/8.YXFY8Y,+A)EM=>=^8M7$.^NTMV[?RV&5^\A5F]X
M:BP.C7\QK]M68!H;?AN!Z#KMMT_U ZE*YZ"&%QP-8RU8L50)[50Y&1:F,XFO
M7+2I45$E2=FG)"4H6I;*2=U #<@;=-]]%!U%J;LY7GE#)91=X4]9P40T//W.
M+R3*>5+0P')$1%3V%X;.]$K4M""D;[[[@%((&Z@17;*ROC7+J^146TV/$_B"
MHL:)^//*Z2U%4^^E$V$W-CEIV"'WTI< 2ZE14$J]0-%.*0\GQKQ!4NRR/$\@
MRB!?64>0XJPD97=V3$RS<B7**Z5.G,3F[%<5B5>*E*:;<+;LAIMY:5K2>XK9
M+=6M/KA53:8]B>.T=Y:JO+>KJHT.QN%N2WC82FT[N2/=FN.RW020 IQ7<0.H
M'H"E9+=/F*50.XW^'_LT4A7!2NG0]?\ F_IT44E<SR./AN(97F$HI$;%,:O<
MC>[N@6BEJY5E[?J.KBHP2/VG61\0 XWH:[)Z9!,9853_ ,_9FQ$XFXS\<*U]
MV3DTNCQN^Y!>AO%*:XJ;%K*ARWFR2+&ZR22X^6SU#2.Y0^9.\1W+NGR4"XL9
M!G>]P#PTXUZ&^EW:L^;DKN,B$8D2"Q*D]6O#P'CK2SX*XMCU4)%G9_3AEMM4
MCOEI4?<D,I+JDA:$J<(<.ZE$>OPVU0L'",LIR<@DJ-=:[?O.[8\,0V_"C(D)
MUM4F^)<^;XXFYQ;1ZF5,NKNH^CQ^Z2RHP(5K*F$6#\A(/<D-L+!;*=PDM)2?
MQU9-L?&QG+Q O-)?7CY:_HJJ=X;:^\86$.M%7&>Y0D!CU:GI'/SI-2Y4B8ML
MON.//R'5+=4HJ<6M:U$K<62?F*RHG?X[ZR>N29@WQ7J+1!"[18X A JQGP^Q
MN>U6W^126RW 4ZW759((#KX0VY9.I"O5" AI&_\ UM_P.K)A)Z<(7PKCG>D\
M<V2L2D>LI)-OTTA/+P_XB>3?@+X^1U!YASF+*_*'-&4#W3'Q/QPPZ4O&U3&]
MODC3N6<^H V5="Y'.V_;KH?;'^!V#>M[.A^53$C\WRG'5;S$,<E_(URO>3\S
MNFW[>.'K-.W]&%=/OD=/NJQ?5&JQT:**-%%&BBC116L1]USC0<>>=W'_ "BS
M#]JC\C>'44TR:=DM*Y&X/M0VL+<.R4NS\!RV&D D%3=<H^B3LX[SQ/XS]-(,
MQ=<G9-T(;Q&/G)8'V+D1 >1D\ZNGTEW ;;W[E;4YM#NVW=:#QR,-KD>TP2,?
M9'29X]N1$CLQHJ7?<;:]QM/<E*PZ%=JFNX[==QL/A_5KC<#)8)?WO"NZY<$F
M0Q9-$'/E?PJ2F,SZLI4_)W8*]G$NJ0M*6U N%:7N[M!+.Y]#W!(U8<4J%XU6
MLGY@'TY3= =*S5K-W!*7@MH;J2$_,D=R>WY%?%I8(4.O3?3R]T.M(1Q&1M.5
M()PJ=>#C3NR6^XJ0".Y74CIO\3J%R+A_LJ=@CZ$LVIK,8O%%I<UT!2%!4F;'
M;4=M^]M+GO2-SMML6F]B/V:=[5CR9>6$4Z(;FHCN',^1VYB-.L$5(SA-K]9O
MN8<Z4 MFXST833.D=#0<5UK6-'V5>GM+R]ZY5\ORDG71].7"U>;=WG1YE@'Q
M@G[SK^FGC$VW19M0WZM#D!]4HBQCR/EBMM!U<=,AE25DNNMA'HH?,H].FVL5
M&&]S?C617V[]/V[^O_/HK%>=9!/3TVT45QT:\N-%E.C"Z^%<D;=W^O\ VZR6
M8BQ.E95BI\JZ9T-$Y@,J==84AYB0R^S[?NLOQW ZTZ@.H<;44J3L4J24J22#
MZZ0GA6=.AOL]M/,;/FQ9.N+2XL?,>%$*"Q!:4AKO6XXX7I$AY1<DR7B""Z^\
M=BM?;\HZ!*$@)2 !MK:*,016C_MO$\*QEYT^:W3*;8XX >?&OLN$Q-#0>]Q*
MF'/=8>8=7'D,.D=JG&'VB%MJ4@E*AU2I)((.^AXEELTALX&MJSA9V1B-TI(P
MQ_U; ZUYFJR!$5W1XK272%%<I:?=ENJ6=UEZ8[WRG2H_]91&VP]!K40] LI)
M'G6<O<<G,DZI2"+ #EH*CIY%I;R"NXMXO4KIRUS5Q[C%DWTV<Q7&;%SDW,5+
M]-HRL?P=QAT]1VR!OZZ>XPZ(V#<3PIOB@-D(JZA3K6NKY]^>3V>^5_(S>)/B
M138G:_X;XP6G26__ "241D,]E0) =F72S'"AU2W#3MMW'5'W[)/JJHX+H?(B
MO87TMV-EV81LD,AR)!(5(UZ6 (OIX58OX1>;?D)AL:@BR,VN\GQQCZ?W</RJ
M6NZJQ#5V%R%!DS [9594T=FRP\ VK;Y"-P:WB[UN2M:Y*@Z#[:NG>'TH[7SL
M$Y9A&/GF^L U+6TN!QUXULS<+\VX/SIB,;+L(G^\PM2F+"LD]K=E4SF7%,2H
M4QE*E;+CR&U([AT)3\/370,+.ASL<30,KL&LP!!*GF&MP(\Z\>[UL>X[!G'!
MW.-HWMI<$7\P3:_V4\6GM1%&BBC115<WELK_ !+\G_ SQ\C]K\9/+66>5&=L
M-GW%1L2\<<6>9Q-<Y !"8UAR]G]#[15T4Y$.W[G2\]L_X#M[>=\;1OEDPX_-
M\I_?MYB&.2_MJN;Q_B=TV_;AP]9IW_HPK[M_;(Z?=5C.J-5CJMO[L/!=ESAX
M6<B/8O7FQY!X8EU//G'\9M 7(F7/&"W[6[IHZ=O<<=R3!WK:N2VGJXY*2.NK
M3VBV)/N;['N3!=JW7&EPIB>"KD+T(_\ W<OIR7Y=-,<[*RML;'W_  !U9^V9
M467&/UC P9D_[R/K3^M6KCCN55UY65EY6267H5M70I\%Y"2I#T*4TR_&<?2E
M*5/*#+NQ.P6-O7<;Z\N;CMF;LVX3[3N2&/-Q9GBD!Y/&Q1ORC3RKWC@9F-NV
MWP;UALK;9EPI-&P-[I(H=?R,+TL(MPR25QU.J6VY[B]^Q[V5-I6E8#: @J6V
M4@!23Z#?;<:95(I\8]M*V)>NEQ;B7'"\$MJ[@YLZ5[A 6Z$*/O.*6D%)_? '
M])UBGOMK--6[;I!;=20%$/)=*DJ44$A*OG;4X%*5\2>FVBLDCD*[5V41'N!M
M;21W?VTE2D*4%=K8*@D!2U#KT^!Z:S2$QL!;C>FMRFQ:4X](5)84Z6U)9;96
MD)8]M).[A'<4)*C\P'Q)UO&I:0 <+TV:0)&;T_OVZ^'3SQY683 E1/>QW!9"
M>1LN4XDJ28.+RX[M/$=]?RK2^7'92#ZH"_@-7WMW ,DX+7*#6N/?43=DPMG9
M48?,2&P'D>?YZW"4C8;;[]2?]9W_ *M='TY5YM M]IO7+16:-%%&BBJRON/>
M/5YS!P?E,? C]%RKB$^IYLX.MVT[/5/,?%\E.1T<=EP;+0UD2([U<\E/1;,Y
M8.XT\QV/21X4OC6]0HWPOI[/.LEXY<UTOD;P7QES90H,6-GV,0[.RJU["1CV
M3QE+KLLQF8CHIB;CV20Y,1:%;*26AOI5C;7P-)R)Z?5?D1;SUJ&]6!XO_</N
M:%21!X@\_J-S*:57]W747E-Q?5-LY)7MIV2S'?Y-X_2W+ &QD389ZE6G+?O@
M'X6%+?\ $'K.EA4J?*K@BG\E?'OE+A>WD(KG,OQJ2K';Q2O9=QC-:52+G"\H
MCR/WHK]'DD".\7 04MA8WV)TW1SZH3@M]3X4DC^F_B/STA_M5^<>)^4O%-+3
M3LNI9_.&"4-7B?.^*0I@D2:;-Z279XTC)&W6P8L^GS9ZA<E1Y##CJ"7PE12>
MT'&=%8W7X0/OK$J%6ZU^%N7A5NQ6 =CMO^&XW_9\?CJ,'6>6E)=2C1B U?>_
M_IZCI_3UUDDCD36;CQ%?._KUVV_I_P!!K!9OU6K3K'58E;>VN7=\>FWX[_\
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M -IO:L[)CC.(]^A0+'\EJ3W;;X&ROG(M>HZ@<?&F=Y@Y@XTX1Q2VRC.<HC9
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M@7YCVUP3ZQX>))V1AYN2@7>H\GHZC;J>,7U]AXU?5J_UY<HT45P6OL Z;DD
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M/[1_GI;U7F=Y-5_MAZ[Q*[0#L19XI#;*SMT[UU;U>K?^C;KJ27O3>ND I"2
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M*]TCM*NH4@'9(;[NHW&VV_35?Q\9FLIUJ3WG.B#,N@4&E886X4V&.T]PV!(
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M+U'T:**KL\O^7<\S#),=\)O':\>JN>N:*:1:9_G]8E$O_+1X[N2359?RY8+
M]F+F^1A3M-A<192N3;NJE;AB$Z=7?M;;,/&QW[NWU VS8CVBC.GS63:Z0CQC
M71YV'!!T\7%5W><R>65=CVUK;A.MW<?W,/!I#^T?AC'-M>"FIG\2<58-P=QG
M@_$/&E*SCV"<>8[78QC54THN*8KZYD-^_+D* =G6<]\KD2Y+F[LJ4ZXZX2M:
MB:MN>Y9F[[A-N>>Y?,GD+N?,\@.0'!0-   -!4SAXD&#BQX>,O3!&H51Y#\Y
M/$GF=:<33&G-&BBC111HHIO>5^*\!YOXXS'B7E'&X&6X!GM'+Q_)Z"Q1W1YL
M"6 0MMQ)2]$GPI"$/Q9+2D/1I+3;K2DN(2H/MMW'-VC/BW+;I#%FPN&1AR(_
M(01HP.A!((()IOEXF/G8SXF4H?'D6S \Q^@CB"-0=1K7YNOW4_M@\J?;[YDD
M0(R)60\*Y@_8V'%/)*F>Q%] 969+F,W[J$?1U^=XY'6D2V![0F- 2V![:UH9
MZ)GX^+ON"_=';R]"#7,Q5)OC2'^]C'$XLAX'^Y8]#>[TFH[:MRGP9U[?WDAY
M#ICSFW[Y1^!S_MT&A_VB^\-;BH \1<]<G<6Y- R3"[7(\1M:Y3)5=XW9V%-:
M10P?E>BRZR5%EH6HIZCO[3^'PU5NM1[S@,#XZ\:L[J67I%7W^.?\P7YB<1M,
MUN8W5?SYC<3Z9(A<EU*F<A0R[MW-M9K2_06KSJ4#Y52TS2#Z[CIIO/MN/(.O
MX03RIL^//IZ>IJ^KQY_F"O%#DV-$B\OXUF'!UT\EA+LIT(SO$PXYL%+_ %*C
MCL7\5 4>H=K2$@CYSZED=HEZ2^.0RCCR/E_+2DS'*FDHL:N$XJ\D.!N<(K,K
MB/ES <^#R/<^CH,EKI%PRC8$F51.O-74,@'J'8Z"/PU&M')&>F06(HM3VZUK
M%&BBC111HHHT44$;C8^A]?VC\/Z]%%5?_<]\;87(_@[Y!U^/M3)61T>._P"(
M=&PLH>0E_"I[61S8S$=+0[BY2QI;:">Y0*AMJ,W?'.1@L@)!77[O^FK=V-NA
MVON?%F)]QY!&=>3D?I K14P//[+CFV%I%4"8\A#CC)4@^\WT'O-MJ04+6$*V
M4-MBD_ZN53X<.0I675D)(\_(U[9QV*QNER$8_D\JLZXN\Y\7DL,1)_T4*6DL
M=R%QV6"M2 $@@_*I/56HQ"T9*2(O2.&@^VF<FRQY +8\CG]8$GCY:U,.G\GL
M4M([;C;]<0M*5ALEE:4KV [@VK='=UZ[#?3I)TMJHX^ J#R-@GZ]';AXFO3+
MYSIY!*TR(B!T2"A2$ [;$'MW[4CIZ#24K!VN.'Y*>8VUO#$$8DL"=;UA'^<H
M/<H)F-A)^7N[NU6X!ZH[2!U ]-)>N4]T7L*5.UHQNP!8_>:2EES-.GRJFIQJ
MIN\RRS*+B)B^#X-BZ!*RC.,OL4J-;C=!%)]M+KO:7)4IW:+6PD.2I*D--DZL
MG9_96[=_;NVWP.N-MD">KDY+7$6/"#K(Y'$GA'&#U2/95'$BE=_=X;'].-B&
M?FH9]SG<ICXZV]2:4C1%\%'%W^%%N3R!V)/ ?PSD>-.+76?\I2ZO*O)GEN-6
M/\GY17]\BGQ&CK@X]CG#?'CTD?41L#PGZA?>[LAVYLUO3Y *G&D,]YWG<=N^
M5Q^W.W(V@[5P 1"C?'*Y_M,F<CXIIB+GB$3IC70:^.(_XCG9\^_[]()M_P P
M@R,/A11\$,5^$<8T'-FN[:G2P?5=IY1HHHT44:**-%%&BBC111HHHT44ROD'
MP'Q_Y+<59%Q+R/$F*IKDPK"IO::4JLRO",NI)3=EBF>X1>M RL>S+$;IAJ9
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M-9;<8T*7\M:MI"$ERCQF?'82H'O:?O+&(VXM0^"TQ:PI_H41JC=OQIZZS\5
M%6KO',:-OEA\)XU("3$;=3L4@[@#J >@_J/XZNR,P)]4*17.&",/>+#V4BLC
MPRER6!(J;RHK;JKE-J;DUES71+2MD-K!"T/P9S,B(ZE0]0I)!&M#%&1;A6L6
M5+#[J:ISO55GD!]E'[=GD JQF9'XY8OAN13^Y;V4\2/2N-+<O*Z_4+C8ZMJ@
ME.A7S'WH+@.W[3I-<=D8-%(5<<"1>ECF1..F6/J0\1XU2?SY_*W5&TNR\;/(
MRQKG@'5Q<7YAQQFQCJ&Q+<9.78@(LAM/P"W*QP_$Z6];.B]YY%F3]4"Q]NOA
M2=MNE]U4:)OUB;CV:7JE3GK['_W%N$1*E3>$G^2:*'WK7D/#]I$SN.6$;[/.
MT\7Z7*(_RC<@P21H.<.$ZB,<B>?EI61A]?\ PK"0\P.0\=;55?E_'688-8R*
MG+,>N\;N(JO;E5&15%A16;"T$I6AV!:1HTI"@H>A3K=)X9-4932,T4F.0)U*
M$\+\Z0ZDJ&_<E2#MMU'7H-*:-KH1208'@:$;I&P4?4[;'_FZZ295#7 %ZSU-
MR)M6:I,@O\:L6+G';FVH;>*XAV+;TMC,J+*.X@]R5Q["N>C3&5I5U!2L==*+
M-,FJ,P]A-(O%%(W5(JLWB1>K3O'K[V_W*/'CZ*!CODGD^<XW"]M",4YAC1.4
M:=;"" F.W*R-M[(HC?;N/R9S9'J#OIT,F(C]["COS8C4^9/,TQR=MCE7]PW0
MWERK;)^T-]SCF/[GO)TB?RWQ7@^$1/%'%[KD*=DN#3KP5659EF=9+PW&FGJ*
M[7.-._6UOZJ\GVY;H470 E(&^DIG@C7IB7I4ZTMM6U-%D?.RR74::ULD<9>$
MG O)-+0<L<FX8[DN99)%-C(5,N+2/7& 9LE5.W^GPI,5M24U_MJ)43W%9)]=
M5W(QH<J43SB\E6O$[GWG:L:3 P)>C&<ZCI%[^1M<5._$L(Q' ZEJBPS'*?&:
MAG;L@TT%B$RI0&W>][*$KD.[?VW"I9_'2J(L:]* !:@\K+RLV3U<J1Y)/$F]
M*C;_ $Z:VIO^:@D#;<@;^FY WZ;]/ZAHHJ'7E3Y1N\)L8MQWQMBK?+'D_P O
MNV%1P9PM&G&,JZE10A%KR!G\YI)7A_#F!-NB7>W#O:GVTB-']R4\T@V?MSMW
M^+M)G;A)\MV[BV;(G(OT@_#'&/QSR<(T'/WFLH)J'W;=?D0F-C)ZVZ37$4?C
MXNY_#&G%F^P:D5F/$_QF'CYC&37.990OD_R"Y@NVLX\@.9)D01)><YF8HBQ*
MNDA$K..\;X-7D5N-TS9#-?7M@[%]U]QS3N3N#^-Y$<6+'\OLF*GIXT -Q''>
MY+'\4LA]^5SJS'P  VVG:_X=$SS/ZNX3-U2R'BS<@!R11[J+P \R:E=JMU+4
M:**-%%&BBC111HHIEO(/Q[XE\H^*,HX7YKQ.%E^"97%]N5#D -3ZJQ92O]-R
M+';)*52:3)*5]?NQ)C)#C:MP>YM2T*E-FWG<-ASTW+;'Z,E+C475U.C(ZG1T
M<:,IT(IGG8.-N.,V+EKU1'7P*L.#*1JK*=58:@U^=[]T[[3/.?V]\S3D-?7S
MN1O'NZN7&<2Y4JHBF$(8D%QR/C.?18J5,8_F##0V0"40[()+D0]P=CL7]MNV
M_N7'?=NU4]/*12V1@7N\=OBEQKZRP<R@O)#P(9+-3'%WK,VN1=L[A?JA9@L6
M4=%?P2>VB2\@VB2>3:54>[;J/Y4-^0A]"NT02XXOLV'N-N.([B/F2?WMSMMJ
MI=2G6XM5FF! %+NDR\5K$54*XCLW$E"G9JI8+JW$I7VM(CI2"4K0H; G2R&P
MUX5K'SJ3F'\N6T)58X_;6%-<M2&TPK:*XNNM&^[;VEM38BV9;1/;N"E8.VL2
M6*V%*W .M6#8)]WSSN\=7JV!C'D':9?C;9:99I,_;B\AQ&6 $=L9)R-N5;,-
M]H[?R9;1!/0@ZCQCX[#]XK=7E29B#GJ!%JL[XF_F8N0Z]46-S+X[X9EK#@0R
M+/CK*+7$+9UU"4!QV33W\?)JY*W%*) 0^TGX=-:-MR.+QM8<KT@T;!B+&U3Z
MQS^8K\39\&._D_%/-V-S'P=X<*%A^1-H4!N4_4LY-7J/R]>K2>GPTD=JG_"5
M-:6-.+0?S!/@+<N^Q-_QIQYSW"@FSXY8D-IV]5J-1D5DYV_T))_9K!VO) T*
M_?2 F!-K&I+X%]WW[>'(9:;J_)'&*64Z=A#S*GRG$G4[>O>]<TD>"@)^)+P&
MFIP<M=2I(%+7%28J_,OQ(NHHF5ODWP)*8*"X5#EG!VE! ]26G[MIX;?@4@ZU
M^7R/U'^XT4TW)/W%? #&:NTJ<W\I>%'J^=!E5]K7UN5Q<L<DP)T=R+,CJAXL
MBZ?=0_'>4D@).X)&L'!R)U,01Q<'E;\]'J-"1.O%"#X\#6@9RSCV(Q^3,YK^
M.,BCYA@43,+UC!<HA,RX\6\Q VD@T$]MB<S%FLI?JBUWH>;0XA84"G7)LW&E
MP-PEQ)3[H%Q]]>X>U]V_C&R8FX,18P*OE<#A?QI#N\?6$@M.)@2@$]G:MD J
M .X[@I"DJ)^'0C;UU 3:-<U>(G0C0@_;2PA\=\B-LI_AN\LH[AV*8\EQ93_W
M4I7LH#IZ@Z92NX;W 2+4_@,#-Z<PX\Z[Y\?R4QQA17'<GLI2"A?NOE13TZ[H
M4K?8'^K3=\UX19U('B=*FH]FP9U$B.EFX"X_GK*<6I\J>6^1L4XMPO!KS)LP
MR^>J%08_4*7)M[93*MI4F.R^VQ&@55:C=<VPEN,U]>R"Z^ZD )5?>Q>R=Y[]
MR7R&=<3MK$L<C,E!]&%>2CG+,W]W"EW8^"^\.3?5GOWMKZ5X"?. 9G=N0/\
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M:FG2PU(U]E;\_P#+:<%R<"\">4.4EQ%,WWD3S&UCU(XI'YS^.X>W'QJN+2B
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M5&$/9UEDE*F@%E84>T]I*P/7UUM3D\*ZT93 FS6<8KOJ8DB"T"N5("]EC8I
M;4XH GIOTW&LD6%Z;E& O7R9%8;L8:9*928O4SUB7[B98'53W8D[%7X?'3>4
MED*@&]9B4EP!QKQ9$S7,'NHI:I->4I<;64NF1'=W&[:DNC=*>X;#TTW]-_"W
MMTIST,.(KYQU;64/.*O(G79#VSZ:^7':]SN76S]XS[;S*04E;?<' -^X*0#M
MTUID=K[KW+A28FU8TN5D6T6-2^I\2-![20*E-D[BP^V-VBS]PR8<;%!]]I'"
MZ#70'4^P"];"_B-X7^;GD$U 7QAP%?LXC**/;Y(Y9$CC'C=,1Q0;,Z+874->
M2Y3&0D]W;35LXJ']I(ZZK>+]'(L$*_?6YX^WHE[XV.5R\MN=BL;>A"?.66X_
M5-=-WG_F%VXHR=D;=/N.>UK9,X;%QH[<P7'JS"^ON1@']85L->-?V0N),1?K
M\M\KLL5Y$91'<8G,\;U\"3B7 %+-:(<0E[$!,DW7(JXSH&SM[*7#> W57H/I
M<]OW39.THCC=@8*X,AN&S)2)L][Z&TI4)C@_JXZ(1^N:XSW+W#WEWZ5_SUN4
MF7AJ;KB1WAPUUN+Q*;S$<FF9_)15WM3455!65])15E?2TU3$8KZNHJ84:NK*
MV!%;2S%A5\"&TS$AQ(S2 EMMM"4(2   -5V666>1IIF9Y6))9B223Q))U)/,
MFF"(D:".,!4 L !8 >  X"LAK2MJ-%%&BBC111HHHT44:**-%%&BBC111HHH
MT44:**-%%&BBC114(.>/ ;A?F3*I'+&+RLHX \@5,>TUSMPA81\4R^U]L*,>
M)R#3.1)F'<JTP60%QL@KYR@T.QEUG?N%LVGO#<MNQ!M68L6=L5_^'R 71?$Q
M-<20M^U$RZ\0:A<S8L3)G.;CE\;<O]K$>ECY.-5D'DZGRM40[Z!YT^/"EM\G
M\25?EMQ[#W2CE?QGC1\;Y8CP6U]B)68^.F56PBVT[V_F<.*74PK.Y1"1OVB4
M7 [/WL]>T9;;9FG^XS"7A)\(\I%NH\/6C'FYXTV7-W[;#;/@&9C#^\QQTR6\
M6@8V)_[-CY+7HXV\M_'GE2U<QK'>2JJJSN.HM6'&6?L3^,N4:N2DE+D2PX]S
MZ+C^3H>;6-C[4=ULG]U1TRW/M3N#:(_F,O&=L,\)HK30L/$2Q%T^\@^52&%O
MVTY[^CCS*,CG&]XY!Y%'Z6^X&G3Y)Q5G.,'S3"92U16,SQ#)<5>>6E2?;8R&
MFFU)>&_:5(0)?=Z[$:KH(/"IBY5E;P-,_P"/G)5-E>&P\2=>;K^0N-85?A/(
M&%3"F-?X_?8_":K5R'*Q1#[M'=,Q4RZ^:V%1I49Y)0LJ"DIV 8FR@D^5&1TI
M*23I3?<@Y/7\F^1W"O%V(2F;B;P[E4SFWENPKGDR8F#UT'#\GQ7!L:N9+"EQ
MXF39SD.4^XQ 4KZC]-@27UH2WV%>SQ21B\@ OROK2<;==RH/3XVTJ7RW$);"
MCMN$D'TWV_$?@ -)V%[\Z4OIY54-Y\>5<J+;*\=N,;!3-M,9:7RGD<%\MR*6
MJEM^XSAE;):/='M[:.X%S7$GN8C*#8(4X2FO;_G_ "N,8X6 F?S_ #UTSZ>]
MO#-RCN6<K+B(0%)'NL=;V]G.H.,8(T[+Q;+*R$AJ-20DU"F$-[*"E*]Y"N@W
M(=4HCK\=NNN794BLWO'K-KFWC7>ML*0RF%/?C/ *+6\ 2?T5*!%UA6!8C$R3
M/\PQS#8WOA:)V374"F9]M!"0&53WV%2AN-^QI*U$C8 G3G9=EWGN/-^5V/$R
M<J6]NB*-Y"/;T@@#S) \Z9[UW#MO;B/-ODV-A8/3>\LJH#_I$$GR%[U(7A[+
M.9.8FVV_%[QTSGE1B8DQD<L<C19G"O +#2UI2]/&89?7?Q9FL5I1"@C'*6P6
MXCH'$@[CL&!]+!MEI^]]P@VX#7Y:(KE9A\C'$WI1$_[Z5;<U/"N![[]8\'-Z
ML?M+!FSY+V$TEX,4>89QZD@\HXS?DU3JX^^UXSFT^'EGF]R6.>9C,ANPB<%8
M17SL \9J&4AQ3S35GC*9TC+.7G8CBNCV33G(3H]:Y'0"SX^_[3VVIA[%PAAS
M$6.9,1-FL.?2Y 3'!\(%5A_M#7,MSEWWN=@W=>8T^,#IBQ7BQ5\ R EIK>,K
M$?LBK7::EI\<J:ZAQZIK**CJ(;%?4TU- BU=35P(K8:C0:ZN@M,0X4..TD);
M::0E"$C8 #54EEEGE::=F>9C=F8DL2>)).I)\33A$2)!'& L:BP %@!X #0"
MLGI.MJ-%%&BBC111HHHT44:**-%%&BBC111HHHT44:**-%%&BBC113!<_P#B
M[P'Y18RQBO.G&>/9Y"@.*DT-I,:?KLKQ2>=MK3#LRIWZ_*<4LD* /O0)<=:M
M@%=R>FIG9NX-XV"8S;3.\1<6==&CD'ZLD; HZ^3*13#/VO W.,1YL:OTFZG4
M,I\58693Y@BJK<Q^W5Y8\%KD67BASTCF+#(X6Y'X@\AK:329O!CHV4B!C'->
M/UDVONE@$I:;R*D<5L![DXG=6K,N[]G[V?\ SC%DVS//&;#'5"3XOBNPZ?,P
MR+Y)RJ+&-W!MO_ S+F8H_N\@VD \%G4:^7J(?-JC/D?ESREP:ZNL\I.$>3.$
MW8SJ(RKC.L1DRL"L%GHZ:7F+CQ>4<:34I4-PJ4]"6I)!*$G<!P.R\O+0R=N9
M&+NL1%[0R!9@//'EZ)0?)0P\S6Z=TP8[=&Z1S8,G"\BWC/LE3J2WM(KW5O*'
MB_S?9,Y@W8RJW()\5J+(RKCW.+>DEVL1D!+4>UML"N89N&&!N$&2VM;8Z)4-
M5/+V[<-OE,.X1RX\P/PR(R'[F JPXNY0Y4?J8[09$9Y@JX^\$U+GB>IXIQ:O
MF0^-F:1A%K*1.N94>Q?M<BNK$->VB=D=O;2YF0V\U#/RI7+=6IM'RI"1TTB$
M)&K FG$DJM'<*JF_ :?;3S(=3W#?<'\#MOZ?TZSH-*:@]0O7I!!]"#\?76P4
MD7K-<T[#?NVZ^GH?3??TWTF>-9K(,09,E)<:BNK92 7) 97[#*/4N//=H;:0
MD DE2@ !K4<0.?Y?NK>XMU'@*;"I\S?&/B'E')6\LY,I\GSB+20,9Q#C/B6)
M9\V<I6KSS_U%FQ$P+BF'EU[ 4IV*RCOF(BM]RB%* 23J=Q>S.YMS3YJ/%>'!
MYS3D8\0'CZDQ13]ES4+E]Q;-BMZ#3K)D_P"SBO*]_P"C&&(^VU.6YS#YW^0!
M7%X-\?:;Q7PB:>S_ !>\N9#-UR$8:^UM4S%O&OCNZD2&+!M)*VAD^1U6QV]R
M(KJ@O!M79NR^]O&:^Y98_N,*ZQ7\'RI5 (\?2B?R;G3 YN_[AI@8ZXD!_O,C
M5[?LPH>/AUNOF*6_&G@/QK29E5<O<\Y9F?EKSM4.?5U')'.LBOM:7")RU>XX
MKB/B2JB0.+^*V4.]6G:ZM-HD?OS7#N2TW#O//FQ6VO9HHMLV=M&BQP0T@_WT
MQ)EF\PS='@@I?&V#&289F>[Y>>.#RV(4_P"[C%DC^Q>K]HU.O5/J>HT44:**
M-%%&BBC111HHHT44:**-%%&BBC111HHHT44:**CAY,?Y3OX&?_S<?X%?P![;
M_P#_ +I_!7Z+OV'W?T[^,?E^M[?W?IOS]_W>NVI_M[_,WSH_RO\ ._/?^']3
MJ^WHY>W2HS=/X1\O_P"<_+_+?[WIM]G5S]FM:EWF,/Y<!4B6G%'.<&K<K> =
M\46<DD8ZB;L>Y4-CF)^-@+K8/]FO<0R1^Z0-M=:C_P Y]/\ ]8?P(C_Q_I"?
M_P#Q;Y%_Z0O507^%=7_T[_%?_EO4]+_];]S;V:52]F>/?;@>8E/<6\O>;U?6
MF6HQZ_D3QSX4MXR7^X^RE5QCOE+1E:_^TF"D?LU%9<_: :TV+$7YG#RLL#[%
MRL-A_K5,8T?=A%UF8+X9$..3]I@G!_)43<JK.'&7713YKRE8M H[EO\ &&.T
MSI:[_P LNM0N7KY"4%>VX[SM^.HYCV,XX;O'[#C2?E(C/Y*EU_S>HU_ACGS]
M=/S=8I%3H7%R[A EY+G\>1_N_>JMPC'IJ@GLZE2)?(,!2D^FX"@/VZ15>R ?
M[3>F/]#%7_\ F-^:LNW=I4^YM@T_7G/_ . 4\6!8]X</R(AY$Y=\H*R/WJ);
MQOQSXSO'/WSW!IVS\I<>:W]>PE&WXC3N*;LI" ,?/D/C-D+&OVB#%D;[C341
M]XLX]*7#1O\ =Q%SPY>K,@^^K,O'^']B&'9QF^7\C\_LC3[[/U,J_P *XFPK
M$=]QN9M?QIG^?9G].1ZAF3WCX$G?4[&^&Z [%'VQ'/R&1)E227]N9%%!?[+5
M%9Z[\NF]MO38]]?16!8_NQG>6WVUM6>"'_HB^[6_Y//\LO\ &O\ NWT?\2[?
MXP_5[)[?I/\ &'_Y^^K]S][Z/Y.[TZ;:K/<O_P!S_E3_ !;YK^$?^'Z?E;?_
M "O[FWMK.T_Y0]?_  ?H_/\ ^]ZO7O\ ]]^\^ZKJ-<PJX4:**-%%&BBC111H
MHHT44:**-%%&BBC111HHHT44:**-%%&BBC111HHHT44:**-%%0W\O_\ (E_"
M:/\ .S_EV_A[V'/TK_&S^#?U7][K_"/ZW_\ ,GZA[G[GZ5_O/=^[UU:>V/\
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8%4E1HHHT44:**-%%&BBC111HHHT45__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>tv506394_img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv506394_img02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $G ?0# 2(  A$! Q$!_\0
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M_!13]M_3;B2YB_:)\6732-N,6H:-X)N(%. -L:0^%K5D7C@&1CZDU](?#_\
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M\W\DKM_),FHJ))5<[>C8S@D'CCT^HXJ6DFGJOR:_-+[]@[:-75]4T[/R:3_
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M&A3R^DN:E6JV]^ISTI6A*QXMY[DRJX#A?B#'8+)>#,/D^=\=^*=;%5_889<
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MK]@T9X.0/,"L#_>QQG K[P_X*KI:)^W%\3/LH 9_#'PXDOP !_Q-'\+P"\+
M$G>0L.XMASQN'2OFJ=18S@[$5*\7*K@N(:,\-)M?NZV9TL33S2%/2ZP=2."P
M=3#4[J4*JKRG'WTS]<Q$5E7T@<H]A[24>,?![.XXWG<(NO3X"XWP%;AO-\1"
MC:E/&2R_CSB+(*==Q=265T\+2G-RH1A3_.TG S[C!]#G@_0'!/M7[S_\$,?'
M=W9>)OCS\,IYE.GZAH?A'QYI\;;MXNM-E'A;4$3,GEY'GQ2S/]G^T20R6:SS
MR1P0JOX,$9&,XZ>OK[9//3@$^QZ5^M'_  1:GG7]KC7X@N(;OX,>*)KQ0QV+
M/'KO@SR5]"98ECD.<$[4(S@$]7 &(JT.+\E4)6C6KU*52.JO&=&HFM+;I:+:
MZ3:9\Y]++*J.<?1R\5*->G3?]G9+@\_PE:<4Y4<PR7-\JQ&'E'2Z<J.+Q5)-
M--.K)M\K9_5Q:R"1"P4#GD@=>WH.F/\ .<"S5:U4*K   ;@PQ_M*#C\,_P Z
MLU_54TE*2CHKMKYZ_FV?X'7O=VLG*34=/=CS2Y8Z::145IH%%%1R'&#D_09R
M>G3Z>]2OZ]>B^8G?HKO31>OZ;DE46(". "<NYP6V\#)(S@X'&2<=.@ZT2R[4
M9B2"N>"P7@#)))/0#))Z <GC)JKYS!2?+=@J.PD!1\,06V; X!/)558@GC)7
MG;2A+FC)6;CS7@IQ3;M[NDFKIO;3?;9VBHUS.":C4IQ=3VDK1Y(+EY_9N;C"
MI.46TE%SY+*4XI-7YC3/'WA#4?%FN^"=-\3:!?\ C'PUIMGJGB'PK97]O<:[
MHECJA TR\U;3XI)+ZPM;[!-L\\"[T7<0!\P[J-F;.[;QCD9&3DYRIY '12?O
M ;AP<#^:W]L_]ECXY?LA?'34?V[/V9]7UO5] N_$MSXD\?VIO[S6M>\&7NNW
MMHOB2TUK2YD6X\=_"O7PD=NWF7(U7PJS21"!H(].O--_6[]C7]L;P#^US\.H
M?%7AJ^71_&&BQVMCX]\!75X1JGAS6)H(9&N[:)W9-3\)ZA+)OT;7+-IHY;>5
M;>1+:^@N+2/YO \0>WS;%9'F5!Y=FT8SQ&6T*U2G[/-<%&[<\'6C'V:J86*M
MB:=5J:<N:$7&,DOW#B[P<EEGA_P[XJ\"YU6X_P##_,,/@L#Q7G&"PC6,\/N,
MZL5'%9!Q?@_KM2ME>#Q=>5-\/YNZ,\OS"B^3VT,16P<<7]TT56M"3;IDDD&1
M26+$G;*ZYRY+<XXR2,?=)7%6:^B^:?G%II^::T:?1K1K4_$T[I.TE?6TDHR7
ME)*4TFNJ4I)/[3W"BBB@"*;_ %4G('RGDC(!/0D#!QGKR/K7X)?\%R/'UY9_
M"_\ 9^^&5LS);>*_B'XF\>ZP5;$KCX>>&AHNEV%P@DVO9W5]\1_[64/"V=0\
M,V,L$T7V2>.X_>V< PR \@HV?ICVK^9G_@N9,[?%WX!P!<01_#;Q)<)C<%CE
ME\4B-E7LI>.!0^ &(B09PM?(<?UZN'X-SN="7)5GAXTW/7^'.I2C-76MVI-+
MI:_='],_0YRO#YK](_PZIXRG&K0R_$YQGL(22?-C,DX8XCQ^7V;:2=+,/JF)
M3=U^XM9MJWX?(Q.<GH% Z\#& ![#'?+YR68Y%/;.TX&2 2!G;DCD#=AL9/&=
MIQUP<5&F22>V!^/I^6#CV/'6EF0212QL[QK)&\;/& TB*ZE2Z*2-SH#N5<KE
M@!N&<U_*ME%*\N5*$&Y)-\JY(2E)+=N-Y222ULDE=G^\$O<DXS7L_9-TY<J;
MY50_=N45%QD]*3G%1E&3NDI1FU*/T'^SQ^R_\5_VF?$%SIGP_P!+@M_#.AMY
MGC;XD>(F;3? ?@C3X86NM0N=<UJ026DU[:6\;!=#M)6NYPT<L]S81EVC^O\
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MQTL"5)3'_":?":$NR@J6 /PA4L"P)!.20,YS7]$M94J%89B'9CEV))V\9*A
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M\#?MN^,-$^',7[&GC.R\&:M9>(-;N/B#)=:UX:TAM2T>2S@318XI?$?A?Q/
MQM+N-YMMG;VLI#MYTDBDK7Z%4U_N-_NM_(URXW"K&X:IAG7Q.&535U<'6^KX
MB+[PJ\L^1]+\KLFSWN%<^GPIQ'E/$=+*,BSZKE.(GB:>3\3Y;'.,@Q\YTYTW
M2S/+)5\-'&4/?4O9/$4X\T(.3:BT_P"=Z3X*?\%SP 6^.NG >B>-/A, #P.B
M?!]5P23[<<]JXKX@?#3_ (+*^%/!GBCQ%\3?VAO"&C?#W2=#OY_&&I>*_'/P
M=7PY!H;1-%>_VI]H^$+));7$;_9%MUC:ZNKB:&WLHWNI8EK^D*>3RP6$19O(
M."Q(!*IG:0.I., #GICGI_,O\<?$G[4/_!3']IC6OV;/#_A[7_A-\'_A7XLN
M+/Q-8:U!<QVOA[^QK^6W@\=>-(H([8:OK^J6L7VSP+X<CNVB1+RVO[*^6Z66
M[M_SO/<GH9-0ITX9YQIC<=F,)X7"9?3S)XBG7=:G*G4<ZO\ 9LZ5.GAX2E6J
M<\XN=.+4>5OFC_:7@]XH9SXE9SG%7'^'_P!%[A#@;@[!KB#CKB;,?"?AZCC,
MCRBA5CST\@RZ>?8;,,[SC%UJ=/"9)A,OJ\_]I5<+*I6ITU^]^7?^"9/A7]H?
MQ#^TS8ZU\"=3N=.T31[NV_X6YXC-L;CP%)X+N99KN[T;4$,0L;^[UU)H[[PW
MIT4:ZI%,UIJ<(MM/GD5_['UZ#J.!UX/3N/7UKY^^ GP!^''[-WPNT?X8_#72
M%TW1]+BDO-1U%X(6UGQ+X@G1?[4\3:_=I&K7NM:DR@-(^[[) D%C9&*TM;=$
M^@5^ZOT'4Y/3N>_U[U]'P;PY+AG):>"K5YU\35J2KUVYN4(N:O&,(NRBTI<M
M22252<>:R25_PWZ2/C10\<?$C$\4Y?D>%R?*,OP6'R+*:WU+ 4<ZS7!9>E2P
M^8Y_B\'AL+*OC*^'I49T,#4C7AE&$J4L##&8NK#$59+1117U9^ A52]!:!D7
M[SLJCIZY;KT^4,,]CZ=1;J&8D*N.\B@_0YS33DFG"W,FG&^UTT]?DG\[#5TT
MT[.+4EU^!J>WI!KYH_F>_P""X'A"^LOB1\"_'#VD@M=<\(>)_#$][@F$ZEH^
ML0:G;6:L1M\U[/4+B94!#,%)(.,C\-L$@D @'@Y4YPN5SMY(# [@<9(.X8/3
M^N#_ (*U_!"Y^+_[)VM:_H]NMWXF^"^LVOQ.TI88FFO;C1;2WO-*\6VENJRQ
MA1'HU\VN.2DID&@"V5%\\R1_R1Q[=F$/RC*J=XDSL^0MN&,Y96(& 5^XWS*:
M_FGQ/RZ>#XHQ6)O*-'.</1Q%)Q>ZI0C2Q"3L[+VJA9=+V['^W'T'N+L'Q-X!
M9-DBQ5.MC^!,=B^$\QP4I*558#ZY7X@R#,I0NFJ&88?,L9@XM)QG6RO$<L[\
MT5]O_P#!/'PO\!/%O[2?AK3OC_>P_P!FBV,WPY\/:U]GM/!/C#X@+<)#I^@>
M*]5('V'38YQ!=Z7IK>=!KEU<R+JT<QAAAD_1!_VA_CA\&O&'QW^*'[4/Q"T.
M?R_B+8_"_P"*?[%[-<Z5+_PI[Q!;WNE^$/%_P(G=[;^WQ:^'I;V_273)8X/$
MF@0:P_B"^L_$MM906_X&F-E#$,P9L,7BF>VE\^, 6LZ2QND4-S;MDQ7*0[Q(
M4D"[HP&_7#X9^/O"/_!1'X9:'^S=\:=7T_PO^U5X"TNYM_V>/C9J40>#X@Z;
MI4<&H/\ #[QF\)@N)[B1;!!,YN&N+^YM(/$%O#>:O!>Z=K67#.<S6%IY51C&
MGF%*O.MDN%IU)8:CGN/>'E2E@<?5IRIS^MPPDL5'*J.(Q$<NS.IBL5@L3"A-
M4\5'J\>O#:CC.(JG'_$,\3FGAWCL+E67^(T*E&>89AP%PWE&<8/.L5Q#P;AZ
M,:F-RW)YXC!91BN.<?P_17&/#>$RC)^,LHQF9Y/DW$7#U7Y?_:__ &6=+^!;
M^'OBM\)M:'Q!_94^*<-OJWPP^(=C.VJS:(;\2SCP7XDOHI'5=0T_"6>DWEY(
M)=7MX#97+OKUAJ"3<!^SE\=K7]GO6/&.HZS\"OAY\9O^$GT[2M*32OB5H;:G
M::%)I=[+<2WVE(L<L<,U]%.MM<!$),6G1$L2Z;?TO_X)=ZI^T=\$/B[\6/A-
MX[T$:'\$/AM)JOB7XTQ>.K[^S='^%/BNPL6O+3Q3X:U%K:6VNM7UZU@4W%II
M9AT[5--A;Q!#'"\<4;>+_$+_ (*T?M76?CCQAIWP[^*/A?Q/X M]=UFW\(>(
MM8^%'A_2-9U3PU;3*--O]0L()<6LMPLR0)]GEA\]8GN3!:M*;>/KE@<HH0R_
MB=8K/LDJYGB\3E]+#4^'\%B(Y?5PT:E.IC*>%Q%?#X;$9=3EAYT,//%X#$UE
M7PU2FL35=.%6MAAN)_$KB2MQAX*O)N#_ !>RG*<CRG'9CQK+Q)S3@NGQ7EG$
MV(IYYP3A\TJ\.<)YS]0X_H91&AF'$M?)LPPF*XAP%*/%F6T\!DF+Q^#Q5&#_
M (*3WVG3P7/PR_8I_9S\%_$-KB&T\&^)_#'@">^\1Z/X@OY4M-/NM"TN*S:?
M5-:26=?[*TV!);F^O_LUO;02SN@KT'2M*TS]A?2+K]IG]I"*'QS^V[\8X-8\
M0_"KX<:NT%R_@&YUAM]_\0O&MI;'RXM99;F& PS&.WT_[/)H^D&"Z;49+7Q_
M_A[?^W (5C7QSX)78"J$?#K0\HS1-&)5+R2MYD1;S8_-,Z&5$%Q'<6YGM9OS
M]\<>-_&'Q+\6Z[XY\>^)-3\5^+O$MPMWKFN:O<RSW=]*C,T,;A'BB@L[93Y=
MII]K'!864.Z"SMH("(1SXSB'#1IT\91Q><9[F."E3GE>-S7A_+<GRW*\8Y<E
M3-*& P-6E!9K4IN7LL34HUH0K2YO8KEBX].2^!.<8UXS)\1P1P1X6\&9S:AQ
MSA>#N->->.^+O$'!8:4*L>%\\XAXIR+(<RX2X*Q%6G*MF<,NK1I\6.53 4J6
M75L;7QQG^*O%/B/QWXEU_P :^+M6N?$7BGQ9K5_XDU[7+XH+R_U;5I3<W%U*
M(U2)' =8H[:"..VM((8[.T@@M8(8(\Q>@^G?J?<_7K41& 6)W.[.VXA0 68L
M0%4*JJ"=JJ!\J@#)(R9&. >0O7!(R-Q!V!O12^T.PR54E@"17P56I*M.=6>L
MZE2K5D]7:56<JM1)RE*34ZTZM9N<IR]I5J6ER<L(?UA2A1HTH4,+1AAL+2A1
MIT</1ITZ.$H4L-AL/@L-A\)0I0A3H8;!X/"8?!8:C!<M+"8?"X=7IX7#*E7N
MENG1HK*)IKR=3;6<*#<TEY/E;)%&"3(UX+=(@.3(R@<D5_>;\&/"2^!O@Y\*
M?!4$+PQ^$/AOX$\,I#+E9(ET;PII.GB-P?FW(\)5\C(8,#DYS_'M^P3\$I?V
M@?VJOA1X.GL9+KP_H6K1_$7QJ7C+VL7A;P3<V^H313R1-F)-4UHZ3I-F\H7S
M9;L2>6_E-&?[5(G5D4RR!9/,(=,+@/YK; N#PKH$*<XVLG!X _<O![+Y4,+G
M.;24O]HQ&'PU"UW&4*,'&JW!?$U5DES726RUO?\ RH_:+<88;%Y[X=>'^%KQ
MKXK*,+G'%V91IR7^QU<WIY?E.59=66J6(Q&$RG&YJDVI5,)4IVARQ51Z\9RB
M'_9'\J*(\;$P<C:N#ZC Y_'K17[%:UTMDVE\FT?YPW3U3NGJGW3U3^::?S(9
M;2"8$.A.1C*O(AQN#=49>ZCW(&T\$BOR[_X*E_L>W'[1GP5M_%_@+3&N_BS\
M'HM5U_PY8V^3>>*_#$D:7?BSP=;%Y%234KVVM%U+P]%(P6?6[&WL \27S2)^
MIM4+Y6<1!,;LO@D$G[AP%PR@'=M.3T -<.9Y;A<XP&(RW&QY\/B8M25KN%2Z
ME"K'25I1J0IR<K;)IZ-V^JX&XSSWP[XMR+C3AFO'#9SD&/CC,*YJ3P^(IU%"
MCC\!C(TW&;P&:8%5L!CU!J7U:K[2%JF'HRC_ )\!9LL"'C=/DEBD5DDAE7*2
M1312?O(90X):WE"S6Y/D3#SHWIJR8V2!YB%>*=3%*ZR_N62> 0OOCV+%*B3V
M\:R)%%<JLZA) &']!'_!2?\ X)J:C=ZCK?[17[.?AV?4;NX2YU;XF_##2+02
M7%S=),D]WXP\%:9!"/M1,?VJXUSPVC7&IW,OE76CR0CSK=_Y\X2"B11I+N3=
M;O$Z2&>&2!=DL%S$T4<T,\+HT,R3PPNERCP.B7"F(?RGQ)PUCN&L36PF.C)N
M=9U,'C.2<<)*DGS1A&O)1IJM&/*ZE-5%4A&SE%1M)_[Y^$_C+P;XR\*4.+N%
ML?1J8RC+ SS+A^K+#TL?P[B*RAA\QP&9TXU&XX;^TXXJ>0YQ['ZMCLGG1I5:
M]3,(8FA#]-?AO^W/X(^('@72?@K^W;\-)OCCX%T6'[!X8^*6D2+%\7? L+;5
MD"7RS65UXBALD$;C6H;^QU"\D*1ZB-:>VBK>'[%'[(/Q:NCJ'[//[??@G3K>
M\2-[3PI\;]*;0=>L9G^>2TU!]1E\&ZR7B4HHG.AW$32*S+).FV6ORO.$;:R,
MD@Y59$>)RRXPR!U5FVAN'0%5R2#G.4D2.90LR),A_@F02K][!.'##GD]#D$\
MBNJ'%+KT:.'SC*\DS=4L/3H0JU*V:X;-?8TURTXK,<OBZ<J4(\RI1J5:E2"<
M^:2O$QK^![R3%X_'^%O&''_A54S#%8C,<=E67UN%N)> L;5QWM*F(JX;A/BG
M*,?A<N>+J5\14Q5;AG,^'I8J=255^RKI5X_JG=_\$Z_@KX#9;_XW?M]_ 7PY
MH\3B6XM_ L0UW7[F(*&7^S/^)V]T[D_P+H&H)\Q4K)_%H']K']E']E#2M0TC
M]ACX;:EXW^*M]9RZ=<_M,_%W2Y)+RPM+<R"4^"M'U/3;>2VMKJ=X[J*Q%CX>
MMKU]\FJ:;J)C29?R7BM;:WQY-M;P ,"/)ACAQQW**!R<G.!Q[ YG/4D]2=Q+
M=25[G/4@''.<9]35/B.E@U-9'P_A,EJUJ<J4L95Q4LUQBC.+@I83%8F=7$4)
MI2YJ53EC6C+DE+DFF<J\%,?Q'A(X7Q.\1>+N/<@HQHM<,X.AE7 ? ;J8:K2Q
M,*6:\-\)X#Z_GZAB*-.=;"Y[Q;F66XNI"3QF&Q<*U55M[Q3XH\1>./$>M>,?
M&.OZIXI\5^(KV?4M;\1:Y<M=:OJFH74WVF>YGFRRV\7GYC@LH76*VA1((H8H
M55*PB3G@^H+="QWDEF.<LQ)(+,23QSP*#]V0XVI#$\\[G"1001E%DN+B0[8K
M:WC=XD>>9HXEEEAC:3S)8E;V_P#9\_9V^*/[3_Q%LOAO\+=!EO;]FM9_$GB*
M[AN$\+^"M!NI1YFM>*K[RWCB!A$DFCZ/$\&HZO*N^WCFM\RCY^C3QF9XRI##
M*>-S+'SC"=2:GB:E6LG:G4Q4K5)S5*\O>JNT.9W:YFW^K9ACN'^"^'OK6.QF
M7\,\)9%@%4QV)Q2PV7X3 Y;A*,(*IAJ,GA*#]C2I4*<,-A8QQ53!JOA\KH3Q
MM3"TJGJ'[$O[*^N_M9_&[0O!*VE[!\/=!>T\2?%/Q(@'D:9X7M+Q%71;:8?*
MVM^*KKR-'L; JURUI/J&LQ-';:3<M7]I>B:)8:/86>C:7:I8Z3I6GV^E:?80
M9B@M+"SC2*QM8!NYM[&S,=E"R$@>4P)R,M\Z?LK_ ++G@']E/X7Z5\.? \4]
MW>.UIJGC+Q?>V]O'K?C/Q*57[3JVI&/B&T5VE@TC35,D.DZ8T=HKRW*SW4WU
M7AMN0,-C&<<XR.G<<9..F1D =_Z<X*X5CPUECCB%1GFF,4)9A.$8M12C:.'I
MS2NZ&\YP3Y'53E:]I'^%_P!)[Q]K^.?'2KY:\3AN".''B\%PE@*T)T*E6.)J
MP>.XEQF'O[*CC\_>%PM6E0A%++,JH8++Z?(Y8RFR*,1@@9^8Y.222?7G^7&,
M=*EJ./(!!!'/&?3 _J*DK[-[].EK;6225O1)+Y'\U1@H)16J5]>]VY/OUDPH
MHHI%!4;1(X((.""" Q7KSD8((.>01@CM4E%*RNG;57L^JOO8'JFGJFFFNZ>Z
M]&9?]B:3]KFOQIUH+^X6%+B^6%%O;E+9'CMX[F\4"YN([=)95ACFE=(EED"*
MH8U.FGVD>-L;'  P\LL@VC("X=V&W!VD8Y4!3E54"[15<S:Y;OEUTOIKJ]--
MWOM<7*M+J[3I--MR:="#IT'>4I.]&G)PI:_NX/E@HI1Y6JH10HS@# R23CTR
M<G Z#T' XIU%%(>^KW84444 13@&&0,,KL.1SR/3CD?7M6%=6\.V3<GF;I0C
M*Y<QS1W1 >-U.Y1&76,O@*,1D%@AD#;\@RC#:6R"-HXSGMDU7*DD@PDKM&,[
M221G /)Y&>#P.O.31=)2<K\CA*'N_&G+1N*5VFXMIM+:R=TK&52+DI1M=SCR
MT6KWA5YHRE=JSC3JTZ<:=1W2E%*+>B/XW?\ @HO^R;JG[,WQSU?4-%TQE^$?
MQ/U*^\4^ -5$;FWTF_NUDU'7O!-\RG-M/I]^+R31T=03H\]FBD>4U?&7PZ\?
M:[\+?&WAWXA>%8-*N->\.7OVZPM?$.C6^OZ'()+<1O;ZII-P4BNHY@3)#,ZR
MF(IF*2)B2/[>/V@_@)\/OVC?AKXA^%?Q)T>:[T+7+-S::I9M##KOA;6%26/3
MO$?AR^</]BUK2IV2YMF:.:TN51[+4+>YM+B6)OX[_P!JO]DWXJ_LC^/(O"'Q
M&LCJ&A:P]R/ GQ$TZU-MX9\:V4;@GYE+#1/$ME T,E]X=GG:0&:633EN+2,.
MG\Y\=\'5^'L7+.,IH<V38FM.OB84J+E6PE:<E.U&$(2E"FZKE4LDDW.=[N5W
M_L[]%3Z0^1^+W!M+PRX^Q-)\>91@Z6#_ +-Q^(IK#>(&24,/+#5*E+'UZ])U
M\Y6'5.GGF%A6EFWU?"X>OD=)>VQDJ?T=<?\ !5W]J>[,1N]%^ ][]FMTL[07
MOPD6\2RLXD5([.QCNM=FCL;- BE;2S6"W!4,8RPS4S_\%9?VL)9;6:;3/@;-
M+81QQ:?)+\*6E?3HH9/.@BT]I-?8V,5O-F:WCM#"EO*S20"-V9C^9A SRH!*
MEP"NTL@<1EU4@%DWD#>H*GJ"0<T;0."!GTP*^3?%W$OO3EGF+M^[4INA6M^Z
M:]E>3C;]VU'V>MX-+D<79G[[#Z/O@,X4XP\)^!G"$J\Z48Y9F#C">*=:6)E3
MC'BAJ$L3*O7E7<8Q=9UJSJ<[JU'/]+YO^"L'[55Q=-?7.C_ BYO'F2YDN[CX
M2B>YENHCNBO))Y==>22\C(!2\=FNE(XF&35E?^"MG[6RWLVHK8_! :A<K(ES
M?#X5N+VX2:,13)-=#Q!Y\B31 13(\C++'A) Z@ ?F/M'' Y]A_G_ #Z4;0 "
M0,' ' ZGG'Z?@>#S4KC#B..JS[$I\ZJW5*JG[2/-:I=17[Q<\[5+\ZYY)3M)
MIJ7T?_ 6+C2GX4<"Q;@Z<*<LKS"_LVJ7-3C!\2NU-JC0YH6C3?LJ-X/V=-P_
M2F'_ (*M_M56<J7.GZ9\#--NXUGBANK#X3Q6]XL-T(Q<V=JYULN([H0PK-:P
M26R/$C%B8_,CD^&/BE\2O$_Q>\=:]\1?&,&A6_B/Q#+#+J<'AK0;;PWH\;P1
M+!$MKI-I#%!%^[ ,DBF=I)"S27,D@9J\^4G(" Y<E0$!R_REMH Y?A20H#="
M0, D-=XX4=I7$*QQ2W#B3]VT=M  ;BZ>)]LBVMJI\R[N2@@LXB)KN2"$^97#
MC.(,RS*C#!X_,,1BL/&<ITXU'*&']I)R<G3I2481J<TI<\HZN<W*2<FY/Z;A
MKPM\-^!L?B,\X0X'R/AO'XC#4<MQ6:Y4W34,-&M+$4,-6PU7,\RKTZ?MZDZ\
M%5FJ=6M.=6DH.52-0=@$E+;=H5MV95A7&.2TK8CB !(\QB%3&]NG/]1G_!(W
M]CJY^#_@2Z^/7Q&T>XL?B/\ %RRA@\+Z;?1RVUSX:^%LD<VHZ8+O39A#+I^K
M^-9MFOZC:7T#:EI-A#I.ES26TYU*WF^+?^";W_!-74_B->Z%\?\ ]H/P[>:9
M\/;&XM]8^'_P_P!9MOLVH>/IXT@GT_Q-X@LYA'/9^"[='1]-TBY7[3K\J+JC
M-;6,J6\G],=I:O$ZNX8L6#$D!50)%+$D:1J=L:(C!5 SR3T!&W]>\-N"986W
M$><0E&K4</[.P;IR2@I)^PQ;HN*4'*E.-15>6+?M'.Z4DS_//Z;/TDL#F]'%
M>#/ >:4<9@Z&)_XSK.<'[-PQ6)I58*MPO@\RPDZE.OAJ&*HU,5Q!4P]>IAZ^
M+A@\DIRGA\-FU*%P6=NJE0AVD 8WOC 8MQ\W')R3U/ )P *G550848&2>I/)
M))Z^YIU%?M;;;;;;;M=MZNRLK][+1=C_ #048Q^&*C:,8*R2M"%^2&GV8W?*
MME=VW"BBBD,*" 00>A&#]#111OH]4]'Z/1@0M;Q,02&.""/G?&5Z'&[KZGJ<
M\DU2CT;2HI;N>*PM8;B_V?;[B*%(I[[RT$<9O9457NS'$HBC:X:0QQ#RD(3Y
M:TZ*%HHI:*&D$OLZ<ONZ>[[NFC6FFP[R_FEJHIVE))J$E.*:4HJ2C-*45)22
MDE))-)JJUG PP1(!L9 %FF4!7&"!MD&#CH>J_P )&!BT!@8].***'JVWJWN^
MKMMJ2HI6LDN6*A&W2"E*2BNT5*4I6[R;N[A1110,*AF!*C:=I#J<^P//4$9(
MX'\QUJ:HY=VWY5WG(P/3WZCI^--.S3#WOL\O-TYOAOMKY6;_  .;U72K.^M;
MS3[R"&[L]2L;O3+NSNBTEG<V5X/*N[2[A+$RP7$+R13;1D0M*)'$9 /\7W[<
M?[*>M_LH?'+Q#X6M;'4&^&'BV]O?%7PEUZXVM]I\/:E(-3U7PS>W.YXXO$/@
MS4+F\TB2TN ;G5=/@M]6C"_:A'#_ &OF('=E-V5(R1V;@XST)'!QQC/09KY@
M_:D_9G\ ?M4?"_6_AAXYLKBV<NMWX6\4Z?%;-KO@[Q,(]]CK^E2S(R%8Y&CB
MO[)OW6H63W%M+M+(Z_(\9\+QXFRUJBJ*S#!IU<OJ5(4T[^SJ*6%E.7O+#U9-
M5)4E[LJU.G4FKQNOZ*^C'XZU/ GCVCC,='%8G@C/X87*.+L-2G6K5J%"EBX5
MLOSO"9?":CC\1D%6I7K4\.J525;+:^:8&FE#%U&_X>@6!SN)P.X!QQC."."<
MY!(R"0P .*=;S75G<6=_8W5[9:AI]U;WECJMA=3VVIZ9>V=Q'=V>HV=Y#(EY
M!<V-[#!>Q30S))#<6\%PC"2&-E]V_:/_ &;?BC^R[\16^'GQ1T>6VGNEO;OP
MGXFLXIAX;\;Z-9O&G]J>&;MPT,^/,1M>T.4MJOAHO;2SO%;7*,W@V3C*_,H8
MIO4EDW# ="Z'8#R6"9!=<.@,9#5_+V(P>.RO%2CC(U<-C\-.=*I%1G1]^5D_
MJ^D&Z=2'*FZ5TW=*7?\ W2R3.\DXJRNAG>08[!9UE>;8/ZY1S'#XC#8W XW+
M\71Q&'>8X6C3GB</@*V(P^+Q>%Q.5J"JX"53%Y;BL)3;KX8^U?CK^WQ\>OC_
M /"[PI\+?&&L+8Z;I-M /'6KZ%.++4_BIJFGPBUTJ\\3&PM[-KE;:T2!I(9Y
M'@DN8Q<R1M* Z_%*@XY)SE2>21E/,<(.@,:LS$( 8S\IP=JX7CGH,>_<8!SD
M]L'I_P#6"C  ''/;ICTP>F<>@XQR.M&-QN*S.K[7,<37Q=6-*G12Q=6I5G3H
MTN5TZ-JDURP@XQE&/*GS/G;E*;E+DX6X(X5X(R>ME?".1X?)<JQ->MBO9X7+
MHX'#REB,1];K3G*G1AS.55.4/:5ZBHTJ=+#X=8;"4J>#@_8/7T].P[?Y-+M'
MJ>_IWX].GH.GM0'4X]^.AZ\\<?0_D:"ZJK.Q"1K]^:0B*!.N!)<2E($8X.U7
MD5FP2 0":XO9PG54U!2K)2:E9RJ)<KYVO>;2Y;\SM9*]VEJ?2Q<>53@X\DDH
M*4&E&2;M&%XR49)O2,7SJ]N5)V8A7 /)X!/7KQW]N*A?)4H6.9#Y2C/S,TI$
M2H@ .97,BI$I(#2/&"ZJ2].>X@2/S#*C(Q"*T;+,'E;<4@C\KS!+<2*CR16J
M!YYH5::.)X07K]Z/^";W_!-#5M2U#P[^T%^T9X<N;/2K*>#6/AO\+M7@$=SJ
METTD-YI_C;QI87(\^PL+/+#0/#;[9KJ9%U#4\6L5E8+[N0</8[B?&PP>7\RE
M"I3E7Q'+*6&H4N9N:Q%1+V<)3C"2I1G.,JDE*-.,FI6_,?%KQ=X.\'.#L1Q9
MQ7F3H4*$ZZRG*L$\/B,VX@S+#TY.EE&3X"4G.K.>-JX%9MC:N'J9=EF5RQ=;
M&U:6(J8"-;[9_P""4?[']Y\ /A;J'Q(\?:1+IOQ4^+]EINHW=A<$Q7GA?P5"
M3<^'=!NH4,9M-1OUD&MZK8RPI<V,DMI87BI>64Z+^L']FV8"@1,-A0J?-F)_
M=DE,DR$M@D_>)R, Y  J*QA,<DCF,H75F)))RSRNS;@Q)#$X;KC! ["M.OZP
MRO+,)DF"HY=@(^SHT8QY^5*+J5W:5:K+E23<ZO-)/6R:2DTDS_ 7CSCKB#Q+
MXOSSC?B?$4Z^<9YF-3&U*="52>#RVE357#Y?E>6NK.<XX#*<OG3P&";E=4?;
M7NZDVVJJHJHHPJ@ #). .!R22?J2313J*[CY!))))))))):)))))+HDDDET2
M05')_#TZGD]N#_GUQGWK*\1:U:>&] UKQ%J$ABT_0=*U#6M0E$-S<M%8:7:2
MWU[(MO9PW%W<-';02NL%K;SW,S*(X(9)&5#\@^$?V_?V3O'^F_LI:MX1^,^@
M>*-(_;6L_'E_^S3KFAZ7X@N-"^(L7PQ\$:I\0/B!!=ZHFFO9>"=1\(^&M \0
MS>(-*\<W'AZ_TC5M#U?PY?6\>NZ9<V 3<DGRVYNE]OZL.R>C;BGNX[V[>CV?
MDV?8$EOO9I<8 VE53*MN7;B0E6!,H"D1RDJ8T8J5<-BOS'_:V_X)>_!3]I>Y
MU?QGX>*?";XLZE)<7=WXH\/6,4^@^);YY7G,WB[PVKP+->32.[7.K:5+97\M
MS)+>7JZDQDMY>O\ V>_^"K7[!G[5'QBNO@7\"_VA-"\9_$.XA\63>#;&?PKX
M]\)>'/BW'X#DF3QE=? KXB^,/"VA_#_XZ67AF-%OM=N_A1XA\76^G:&8_$,D
MCZ)*U]#VWP^_X*&_L@?%KPW^RIXM^&GQCTGQIX9_;4\2^*O!G[.6LZ+X<\67
MEMXW\6^!?"7B[QIXT\.:P5T59_A_K?AC1? _B9-;T_Q]!X<N;+6M)N=!FC76
M&2SKDQ^79=FN'>&S'"4L52ES.U1<WLY."BY4[ZJ3^'FBT[+7W;(^JX+XYXR\
M.\^PG$W!'$N;<,9O@91="KE5:$(5(1FINEC:%:-3"8[#S:O+#8K#UJ<92E.*
MC4DZA_-9\9O^":7[7?P3NIQ-\/&^)/AJ$R06GBGX73R^)K26*WD=_M=]H#06
M_B'0Y9U)CE@^PW<"R0L6G53&6^'M7T;6O#\TD'B#1=8T&6%BDR:OI.I:8T3@
MG*O'?6EO*-I!4ML '3'%?W"?&+]I;X+? 3Q5\(?!WQ4\677A_P 2_'76?&WA
MOX66EEX7\2^('\3:]\/_ (>^(_BMXIL7F\.:)J-KI$UAX \*:UK,#ZS=64>I
MS6PTS39+O4WAM9_FCXA?\%)?^"?FA^ _@+\1?%7Q+T;Q?X(_:@^#GQH^._P,
MUCP_\*O''Q1D\=?##]GGX<Q_%?XQ:['I_AOP;X@U72[[P/X*NH+W5O#'B#3]
M,\2MJJ7GARUTV?Q%97^EVGYCF'A+E]:K*IEN;8C 4Y6M0EAHU80>MW&?-&36
MUDU=+9[G]P\)?M!^+,%3<>.?#GA;B;%33>+SK(<5/AO.,PJM)2Q.*^MY;GF!
MIXFHUS57AHT<,Y-NGAJ*<HR_CWBO[2X<16]U#=RM\PAM";B8\YY1%!4CKDG@
M>I!%>P?#_P"!'QL^*MZEC\.?A-\0?%TKM$AGTOPMJJZ?&)0?*DFU2^@L].MX
MGPP\RYNH(U"DLZJ17]@>D_&7]D&?XG?!;X3>&(_ 6L?$;]HCX3ZW\=/A-IWA
M7X;#4[;7?A-H5EH-W<>/M4\1Z3X4ET3PEX?OSXFT6T\/7OBO4-*'B._NWT_1
M(]0N[.^BMZ%]^WK^R!HO[,7BK]L!_C7X4'[-/@C5_%?A?7OB38:9JTVGP^)O
M!7C_ %3X8:OX6T;PYIFAW?B7Q'X@?QYITGAC0M"\/Z1J6I^)]0DLCX>M]0M=
M4L)IN3#>$,(RB\5Q!7K033E&G@XQ<E?5<TINVEU?I>Z5['T.=_M$JU;"*EPY
MX09;AL3!WIU^*^)EG7LIQ3]G5HRR7AS)JU.5.7+*/+6A--)QJ1E[Q^.7[.G_
M  1?^)GB.\T;Q!^T=XLTOP#H"36^I/X%\'3#7_&DLD2R".&_UZ>S7P[X=F\F
MX:![O2&UK4;02W=O;3QK.TK_ +^?![X(_#+X$^"K;P'\)_"VD>"O#-M=37,M
MMID=Q)>ZI?R")9]6UO4[II-0UK5KH(HN+V^GG=T$<<1A@C2-?CBY_P""L7[$
M&E_#WX5_%+5OB!\3-%\+?&VT_:'OOA;!KG[-W[1.D>,?%EC^RKX#\1?$WXZ7
MEIX!U?X60>.K&W\&^#/"^O:K;RZIH.FVWB/^RKK3?"ZZKJWEV4O:_''_ (*9
M_L4?L[>%?"?C/XF_'"TL?#/CCX%>(_VG/#6L^'?!OCOXB6MS\!/#%WX"T_4/
MB;?K\/O#/B.YT'P[>:G\3?!FD>'Y=;AL+GQ-JFHW5CH%MJ,VCZTNF_H^2<+Y
M'P_3C]0PD)XE6YL352]M/6[;E)223:C[JT;BFT[)+^+_ !9\=O$[QIQ<O]=\
M_P 1+*$XNAPYD'LN'^&\.J?-[&4\JP4Y/,L72YY1IYEF=7$8V*E.2=.56HW]
M\0J0RL =N8T0<Y"+_$V?Y\GKSSSH5\7_ +*7[<G[/7[:B^.)O@'K/Q,U2'X9
M7^AV'C%/B+\ _CK\"KFRO_$"ZF^F6VGP_&SX=^ I/$! TB^&HQZ#'J!T@K;#
M4VM&O[%;C[0KWW9MSZRMS+6T;*R2;W5M=$M;GY$DM&O=7+""IK54XTX\D(\W
MV[Q2;?1Z!1112&%%%% !1110 4444 %%%% !1110 4444 5+@%CL YV!@2,@
ME6)VG_\ 5S7G'Q(^&G@?XO>%-8\#?$?PYI7B[PEK$!2]T+6;;SH!(B$QW5NX
M/GVM_:OF2RO[22"YLY,20ON SZ<8PS%MS#Y=N 1M'.<@$'G]/:FF%3W;.,;O
MEW8XXSM_7K[XQA5:5#$498?$4E6I5$U4A-)Q::LTU).Z>VG>]FKHUPF*Q> Q
M.'QN"Q6+PF-P.)CCLOQF Q53 XO"8J#C*$J5>E.%2$X3A&<*L)1E&23BTU[W
M\W?[2'_!%;Q':7NH>)/V7_&6FZMIT\LETGPS^(-T^FZCIYGE$KV_A[Q<EA=V
MNHG86$::Y;V%].0([C6;EI'!_(3XD_LW_'WX/74MK\2_@_X_\*["ZM>3^'KO
M5-*G,;A2]KJ^AC4],N8L,C%Q=(T8DC,B*'Q7]W9LX#C<&;:VX;FW8;(/!8$C
MH  " !TQQB.73K688D0LISE"04;/]Y6!##N P(]L<5^9YKX4\-YC56(PD\7E
M5:*?+[&?MZ*D]+NC.2BTXMK?W7:45=']K^'WT\_&#A++Z&4\4X3*O$3 47'V
M>+S3V.4\5T$I*5Y<387!XI9NWK"?]N99B6Z;E*G*%?V=6'^>M<WEK9.$N[B*
MV<DCR[J6*UDSSE62Y>$HP'!#[3@$GWOZ7I]]K,GE:%I6IZQ,[HHCT72KO57D
MDD8*JJ=,AN@[.S85026)& <BO[\+OX9_#V_9I+[P/X0O)')9Y+OPOH%W([GJ
M[/<Z;*6<YY)Z]\UJ:9X/\+:*-NC^'M$TK'(.FZ3IUBX(Z%7M;6)D(SE2A4J?
MNXKYZ/@[-5'S<1U'2NO=C@ES:-WT<[7MM>^I^V5OVD:5&4\)X68^&.=)PC*M
MQW3H8.4U&T?K5+*.&<OQ&*IW>D'5;A>3ARRG)O\ C,^$'_!.[]KOXTW5NFC?
M"J^\$:+/MW^*OBF6\&:1 K/#^]MK&[C?Q#J;>7*;B-+#22LL<$B_:$;8K_NY
M^R9_P2?^#?P,O=*\;_%"\M_C/\2=+N+34+/^T[%8/A_X=UNT57AU#2_#$JNF
MMW]A>*+G2-4\2QW,NG3I#>:?86=_%'=+^MTMC%*\+M)+F%MRC<A!]B6C9@>W
MF(RRA2R"0(\BN]+.*/A<@;S)C9"!D]>%B&![C#$DDL2:^TX>\.^'\AJ+%N$L
MQS.*?+B\7"+H[OV<88/WJ<'26GM'S2FY<SUBC^8?%3Z8_C+XGX+%Y'2QV"X%
MX9QD9TJ^3\(2QM#$XVC5BUBJ>;9_C*LLZQ&'QC=ZF P-3!X.JE*.*<E.2<<,
M4A2.7<C2E%W,RNI;&,#EF\M< %E11N8 GUJ]2*H4!1G Z9.3^=+7W2VU27E'
M2*\HK2T5LET21_*BO97:;MJTE%-]6HIM13>R3:6R;M=E%%% PHHHH **** "
MBBB@ HHHH **** "BBB@ JA.K-(Q4<I(C8Q][Y$Y'J>-OMCZU?J%X%?=EY%W
M$'Y6 Q@!<+E3@'&3U))Z],-:2C+K%W2[NSC9^5I/]-1-RBU.*4I0NU!V2GS1
M<''F=^2\9-\UGM;J>._%GX,?#7XZ>$+_ ,!_%7PMH_C+PSJ$B3MIVK0.[65Z
M@58M2TRZ1H[O3-4M "UK>V4D4BN2)1*N0?P"_:+_ ."*OCW0;S4/$7[-GC#3
MO&FC,+F:V\ ^/+Q=%\6VL2,7AT_2?%26LVD^(C&IVQ3>('T:\)$<;W,Y?S!_
M2\;=<8#,,X!;$98XQU+(1SCT]Q@U#+803%3)O;8Y=1E0N203N4*%D&0"/,#E
M2,H5.2?G<\X6R+B126:8!.I[/DAB:-3DK4[.37*X*+:N^:TDUO;E=[_L7A/X
M]>*/@OB(/@;B2O0REUIXC$\-9W2I9_P[B:M91C7J0RO&U*<<#BZM.,:,LRRO
M%Y3F/LH0B\5B(TX4H_P;^/\ X!?''X5W\VG_ !$^$?Q"\*30/Y;OJ'A;4;BS
M\Q&<,%U/34OM*GC4*66XM+VYMF&=LQ?>B>-3WUE:2"*[NH;67)VQW,B0.V#P
M"DSQLA.!N5URA.UADD5_H3/I,$ADW2.4E9FDB:&QDC8L K;EDLWW!E 5MQ.1
MP37,S?#'X=73&2\\#>#[R5CN:6Z\,:%-(S$Y8DMI^"6)))QDDDY&:_.,5X.T
M>9O 9]7H4F_<HU<,JDZ<=/<=522J-+F7.TF[K31']G9'^T4Q%'!^RXC\),KK
M8II.>(X5XEJ9-.I6U<JU2>;Y!FM5N=3WW'GE*"?*JE1TZ<Y_P,:-I6K>(IH+
M?P_I&K:[/=3);P1:+I&IZLTMQ*2(XH_[.L[H2,S (!$9'+%0B')Q]O?!;_@F
MS^UW\:KZSEL/AO+\.-%8*9?%?Q4DN?"ME!#/E!+;:0MO<>*=4\I5:;['#I-J
MKY3-RC2**_LAT[PGX=T8!=#T;2=$0 J$TC2-)L% /;$%BN.G8X/?-7UTJ!7:
M0R2O(R,C.RVX)1OO*RI;I&X..-Z-MYVXR:Z<'X099"49YEFN*Q]--.6&HTEA
M'-WNG+$7E)1A*TY0BOWJ7(VDW?QN+OVBG&^.PCP_!7 ?#_#^(<.2GFW$&;8[
MBK,\(W=2JT*#R?)<KQ-6UE"GCE+"MN]:G5BN1_F!^R3_ ,$NO@O^SK>:3XW\
M7W*_&#XK:=MGLO$7B;3$A\/^&;\0H)+KPMX9NKC488[R"X!:SUO5I;Z]A$4%
MQ9P:9=0QR1_J(D(4F4$G<?F())D.!G<S D@'&Q<JBC<<>KELHT&$>15";%4>
M40@ZG86B+#).=N=@Z*H4 "QY:X"Y. ,=N1P.< =AVQU./;]3R_+<#E.'AA,O
MHTJ&&@H*,:=)0J/E5KU:B7-6E:R4IR;7O;)G\)<:<=<9^(O$.+XEXYXCS+B7
M.<<K5\PS"LVHT(N4J&"PF!I^SPF6X3#\THT\)E]"C@X14.3VC3D)&<EN .F,
M?4YZ\^G)]?3%2TQ4"L6!))&"#C''IP/YT^NUVOIY'RD;VUBH:M*,6FN5/1W2
M6K6K[,****11PGQ2TZ_U?X9_$32=+M)+_4]4\"^+M.TZPB(66^OKWP_J-M9V
M<;%)-LES<2Q0H?+DPS@[&'!_CO\ V<_^"/?[8/@GX??\$L='\-:3XD^'WPSU
M;]G+]JK0_P!H_P"%GBV=[CQ'^R7^U[\=OV!/BU\!=2^,'AZ9]6O;W1_AK\7O
M$=WH.I?$?P9H=U>6VA?&:1/'6@:-8M\1_%<>D?VET4 ?R[?LY?"7]K3XXZI_
MP2-_9I\??L)?$?\ 9+T__@E=XPTGQQ\;OV@_'%_\,+_X;>,KWX4_ OQ9\!_"
M_P ./V6[OP;XJU3Q+X^\(?'/5O%5QXN\9:YK&F^"+;P/H?A3PZ+[2?&MYJD$
MNE?(/_!.3_@E7^VM^S]X;_X(Q?$*S\,^+_AUI'A'XJ?M,>-_VMO@?X\TZSUZ
M_P#@7\>?%7P=_:I^%_P]_:'MM+;Q3:N?"OC?0M?\ Z)\1?".B:Q##J-Y9^ -
M7M6THZAK<]E_:/10!_/3^TG^RS^W9JGQ!_X)V7OQ7^(UG^V=XB^%/[1_[6OC
M7QE\4/A1^SQ9?L\:%\/OASXS_8=^+?PV\#^'M>\$'XI?%"*[O9_B=J\NF6/B
MJ/7(3JC^*-)TNZT6(Z2VJZM^>W["O_!(W]I#X&?$K_@AQXD\2>!?$TO[.'@K
MX%?M1:;^U#\#_&?]F7>N?LW_ +0'[1?[&O\ PA/Q/NKMQJMW?3_"CXV^(? N
MGQW/ABT6[M/!GQ9UW5KFXEMS\1[/2]'_ +'Z* /Y$/@G^Q?_ ,%$_P!D#]G#
M_@H9J^A^#O&/Q7_:6\.>$=/_ ."6'_!+JYT V-AJ7@[]D6#Q1JUW\,OC[JNN
M7)OK32;'P*WQA7Q'XJU6^LX[0#X"Z1H*6<D'V:]NV_ +]C']I#]F;X _MG_L
M*?MQ?L.3_'3]F;Q5X1_9V_:!^!.A_P#!,75/&^L6&F_$SPU_PBOP?^(/A[P1
MXP^-_B/X0^*/!_QMCU[X7> ?VFYWAOM/T:+4M=^(/B/2=8O=5U>'0A_7C10!
M_*7^S[^SG^WY\3OC5_P27\5?M8?#KX\>-/AM\'?VE/\ @J59P^(?VA7^'WB#
MX\^"OV,/BO\ LC^*/AW^S9!^V-J'P[NI/"Y^,OBN]U2]\)ZX=(&LK=S2Z=%K
M&I2:E)))<?,?B'_@E!^V1H7[ O\ P5L\*^*?!OB3XK_%70/A)X>_X)V_\$\?
M"&B6&FIKWB']BCX3?%VU^,WAC7M*<:A*U_?^,]>^(]UI&L_VA!HLKV?P8TN"
MVM5LH[&Z;^U"B@#\N?\ @F3XMU:^^'WC?X?7WP&_X*5?"BP\&^,$\0Z=XH_X
M*5>,/#GC[XE>-G\;'4[BZM/!WBW1?BY\6]4O?#WA,Z5%%?:5KFH:9#I+:_8G
M3I-8DN+^2S_4:BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *CE.V*
M0@$D1N<*2&.%)P"H8@GH"%8YZ GBI*1CA6.,X!...<#..<#GW./6@#Y&N_VU
MOV8+#X=?%+XKW_QS\&1_#OX'_&RY_9O^+?C-+C4)-(\!?'.S\=^&/A?>?#G7
MX8M*:Y@\1Q>/_&GASPS);1+<VL6H:SI;I?-:33W=IR_C?_@H;^Q5\,?A;XO^
M-_Q"_:B^%'A#X4^ OBOXF^!?BSQKXC\10Z3INE_&'P=J1T;Q7\-XK2[VZGK'
MC3P]J,,T5]HVAZ7J=Q#;VMW=2@VEO?ZA;?RX_%/_ ()Z_M@^(/@!_P %.?B5
MIGC+]MC3;+7?^"W>O_$+PE^PYH/PRL+SX8_'?X:7?[>W[.NO0?'*QT*[^&&J
M_%_7_"R>&6U3XE0>+?"/B^U\#RV/PWA\0K&?#6F:XUY[%\.OA9\>?V;?CU\.
M_P!LKXH?L7_'WXX? OX*?\%"O^"P;^(?A_X(^#FN^.?C)X&OOVD_BC\/-4^
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M^(? VK2VMMH5Z_AFTBA:POM0\PT+]CW]O?XA-\7_ -BO5?V4-=^%WPB\9_\
M!9[XE?\ !0+4_P!L3X@?$[X1ZSX*;X"^'_VKK#X[^$],^%/@#P3XW\2?%+_A
M9_C]?#^@6FE:3XJ\-^%M-TO0M9\37>KWUGJ$(TH '[,_M6_\%4/V2/V,OB[I
M_P $OCAKWQ8L_&DOPM@^./B"Y\!? OXN_$[PSX"^#W]N>(O#5_\ $SXC>)/
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M^(_QD\9_%F[^*'[/=MKGPR\$3_&SPC\)M)\!ZA\*M7OOB'JO@_X5Z;X^EN_
MOBC5;KP%I(!^N'Q6_P""K?P"^#_[1'[8W[+_ (GT'Q%'\8_V3OV1F_;.L?#C
MZIHUL?CI\/M-\'^(O%OC71?AS/+,L=MXH\%IX<TJ#5['6Q%<W5CKC:WI<%SH
MFC>(KS3O)[O_ (+!WNMWOA#P[^S)^P[^TG^U;XH;]G3X(_M._'?0_AMJGPXT
MF']GGPG^T!X'TKX@?#[P/J>J>*-8T6U^(OQ*OO"MW<ZI;>#? *:UK%Y8V<-V
M9G74+<KX)\3O^"0'Q@_:VA_;'\0?M6>-/A;X2^+?[27[*7[$OP_^'OQ7^"'B
M?QQXEU_X-_M1?L^_#?\ :2\#?%;XAZ3/XF^'GPTO(/A?X_C^/-UX5FT/3M2;
M6?&OPS\0>.?#WB73_#KZC97+4?!7[!__  57_9)OX?$_[$7Q%_82U"Z^-/[)
M_P"R9\,/V@/#?[2ES\<)=)^&?QY_9<^ _A;X%Z7\4?@%XB^'?P\O[CXD^$-=
MT+1]/U!?#WQ)\/> IVG\.Z3=3Z;92Z_JUGHP!]8_"/\ X*O^,OCI^UQ\5?V:
M?A=^Q9X\\2^#_@G^U!XX_9A^)?QP/QY_9\TBS\/:Q\.[/PYJ?BKQNGP@UKQC
MI_QAUCPE8:7XM\/WJWNA^%=2M[EKRYT^WO9=3TO5+.S_ &1K^;_]EW_@G-^V
M_P#LQ_\ !0C]H/\ :3LOA#_P2Z\=> OVB/VQ_BA\;-7_ &@?%EQ\<U_;D\#_
M  4^*>G>"]$U3X8_#_5+;X)GPOHUM96_A>X\1V/@2]^(NL>&$UWQ/KMA)XEN
MH))-7F_I H **** "BBB@ HHHH **** "BBB@ HHHH ^9OVN_P!J#P-^QS^S
M;\9OVF/B5IVLZQX/^#G@V\\3ZEH/A> 7GB7Q)>R7UOHOAOPMX?MI&B@?6O%/
MB/4=&\/:>;F>"U@O=3CFNIX[6)Y*_$;XI?\ !:;]H#]GGX+_ +8WC?\ :$_9
MX_9.\*?&S]F_X%> ?CYHG[*O@?\ ;:/Q'^-$.@>.O&OP[T3^S/C?X1M_A'I$
MO@.>Q\._$3PYXEL];\.#Q3I5Q<8TP/:Z?JMGJUQ^U?[7_P"S5X)_;(_9P^,G
M[,7Q'U+7=#\(?%_PQ=^&;_7O"MP+?Q1X:O[>]L=;\->+M!OGM[JTL]=\)>)M
M,T/Q'I+WEM=V33V-O:WD2J\@'X??&W_@AY^TK^U9X0^,UO\ M5_\%#_#'Q0^
M)?C']D&']CKX>>/_  =^Q]HGPWCT?PMJ?Q>^&GQ4\3>,/BMHME\;=:OOBEXV
MOY_A)H.E:*=)\0_#G0]!FU?5M4EM=5MKE+&W /U@_;1_;"_X8?USX"^/?B?X
M8T&V_9$\:^.[OX9_'OX_7OBG4M/U']G'Q!XETB_?X1^.?%7AT>';OP[>?";Q
M-XNT^+X>>+?%VI^(]$F\'^)O%7@RZ73M9@U2^DL_@S3/^"J?[5?Q</P(\#_L
MZ_L*Z%XP^-?[37AOXM_M-?#'PE\5OC5?_"+PIX!_82\*^,(_"/P8^,OQP\0)
M\/O%6I^%OBU\?#>Z%KGAKX/^'-"\30>&=-\06Z:]XMMM1T;5]/LO<?BM^PY^
MV/\ M.?L6_M<?LF_M:_MH_"#XH:C^T1X3TOPGX ^(?@+]D&X^&6F?">S6^_M
M+6I=;\%R_'SQA+\24U2YL=&72XH_$/A>]TB6&YF^UZH)=MCTG[3?[!GQF^('
MQI^!?[4?[)O[56G_ ++_ .T=\(_@[XD_9W\8:YXE^"%C\=?AA\5?@WK=WINN
MP:%XH^'=QXY^'NIZ?KGASQGH]CXE\%ZYIWC2^BTYK_6])FT[6+>_?48@#XG\
M>?\ !8+]JO1/VP=._8IT_P#9V_8M\!?'F?X5_LL^*[_X>_M$_MU:I\-/%NN_
M$C]H'POKFJ>)_AC\'K32/@GXOLOBE<?#77O"E]HFJ:OHUWH\E_'JW@Z^_LO[
M1KQL[+T[]JW_ (+@_"O]FJ#_ (*EV&I^ +'Q#KG_  3;TW]FCS-+C\820#XG
MZK^TY+X9\/Z;8W*VVA27OAS3_"?C7Q79V.M2V\7B"YNM(L;[4_LUO-"8((K#
M_@FE^WEX)_:,\2_M*>!/^"A?P*N_BG\4/@U^RQ\./C#XF^*O[!-CX_U;Q;XE
M_9KT/Q=IK^-O"<FG?M"^$;'X:GX@ZG\0?%&H7VBZ!HVH1Z;8QZ/%+JNH7VCM
MJNHX>K?\$,? 'CGXP>(_C7\3_BUIGBK7O'?[0O[9GQU^(FAQ?#%=*\/^/;3]
MHWX8ZI\+O@/X*\66M_XZ\2?VAI?[,-EKA\3^&]662XFU?QK'I^M6VF^$S'-&
M #I?B1_P6,O_  ]\5OVI/@K\,/V=3\9O'W@OXV?L3_ #]E#2--^(\NA1_'_Q
MU^V3^S;:_M#V6M^/[^]\+2:?\'_AW\-?#+7]SKOB&T_X3">[TC3+F]CTZ#5[
MQ+.7]+OV;_B7^T/XA^%/BKQA^V+\%? W[.WQ$\&^(_$MCJ6A_#[XL3_&#P/J
MO@+P]IUMJ]C\0]#\5WOA/P??+:7L=[KMK=:3JWA>RU2WN]'E:9_+>VQ^07@_
M_@A[X\\/V?CCQ7'^VI)!^T:OBG]@'XE?!'XU^'_@/;6<'PS^,/["W[*VF?LM
M:AKWCGP5KGQ0\0Z?\4/ GQP\/PWU]XI\$6^I^#Y],L=;?3TUW4+FTBU>'];O
MV</@[^T)X6^&?COPC^UY^T=H'[5OBWQ[XF\1W5WK/A;X)Z/\"_!^A?#_ %OP
MYI7A^+X>:)X-L/&/CC59-,MA9ZI?7.KZYXKUC4;K4?$L\:FTL+2T\D _/+X4
M?\%2/V@?&WPL\<?MQ>-_V+M.\!?\$U]$^!W[0/Q\\(_&+_A>5CJ/[1^J> O@
MKH6LZUH&K:W\!KWPMH.BZ%+\;;70=7?P%I%A\2;_ %6*&\T27Q--83W354\&
M?\%0?VI/#'B3P5X=_:Z_8E\*_ >7]HK]G3XY?'?]DFY\&?M"2?%$:WK7P-^%
M2?&+Q%\'/CM';?#GPQ>_"OQQ+\/;K3]6M=1\+CQGX>DGT_Q38VTUY=Z?$)Z_
MPV_X)-_'[PK\(O$7[%OCS]OBZ\>_\$WY_@W\??@7X=^ $W[.G@VS^.-I\,OC
M-X;\4>&/!&F>)?VC=0\:^)K77[_X%+XB75/A]K6D?##0-4O+WPUX<CU>WN$A
MDM9]OP+_ ,$L_P!HC6?$OA+Q3^UQ^W/:?M+W_P !?V=/C+^S]^R9;:3^S=I'
MPBM/A]J/QN^'_P#PJKQ;\9?B_-I?Q)\6:A\7OB++X%TW1?#UI)IES\/]"MX+
MCQ9>6>E?;_$#7FD@'FOPA_X+7Z[^U;X1_8,D_98_9_\ !OBKXJ_ME?"K]I+5
M]?\ AU\5/BIK'PZ;X*_'GX"?!CP-\7K;X4:U?:?\/_$6J3>&/B78>-]/\1^"
MOB'?Z-I$?B/X6:]X2\?:=HL^E^)OL.F^.ZM_P6:_;P\%?LQ_MR_M7_$G]@W]
MG71OAG^P]XX^)'P<\;KX2_;"\9^)O$/B/XT_#SQ;\-?"-[HFBV2? '1XF\&W
M0^(7VRU\6'4!<0MHL\;Z+;&6"X/V-\$?^".WPW^"OQO_ .";?[2/A_QW:R?&
M/]A;]D_1?V3/B1K6G>"[G1]%_:@\%^'OV=K#X(>%?%>KZ:/$-R/ 7C;PQ>VD
M6JZ9?W-WXYENO",C^ [ZXDCM=!UKPU0^)_\ P20U[XA_L,_\%&?V,7_:#T;1
MIOV^_P!ISXJ?M$VGQ%MOA-J#P?"73_B3XU^%WBB'P/>>#C\2Y&\>7FFK\/+[
M2KWQ/;>,/!\5P^N0WJ>%XHK%[>[ /'-"_P""TWQ'M_#OQ=^'/B+]EOX=^(OV
MR?"G[4_P#_8_^%GPN^!?[2VE_$[]G_XL_%+]I+X>^(OBAX*FU#X[S>"/#[>#
MM%\#>!?!?C#7/BP=2\"W^K>&QHMC8VEG<WVNP6T76>-O^"N7QG^"O@OXW^#?
MVA/V3/"G@#]JCX ?%7]BGP]XA^'6@_&?4_&/P?\ &GPB_;9^,^E_"7P9\7OA
MI\5F^'>A^(]07PIJ4OBK0/$7A_5?!&E7%AXK\&WMAID]QH[Q7XE\2_\ !%]=
M"M?&G@G]F+X_Z#^S)\-O"W[4?@3]NC]CWP-X3^ MIK=G^RS^U3X=T75/"_C1
MK2.#Q?X8\,?$']GGXI>%_$/B33-5^"5UX;\.S^'I->D/A_QO'I5M9:-%2^)/
M_!'WXR?&CX6_M":G\3OVR]*\4_MH?M$_$']DWQ?J_P"T7+^SE::5\,/ /A7]
MC'XKZ=\4?A#\,/A_^SS8?%9-0LO#$^I6>H:KXREUGXJZA>:OXI\1:UJSRQD0
M^']. /Z!$78JJ"2% &3@$X&,D*%7)[X 'H!17R3^SAX(_:V\ >"]:TG]J']I
MGX9_'_Q[>^+[W5=$\7> _P!G4_!#1=&\&S:)X?LK#PI)X4'Q=\?R:C?V>NV'
MB+69O$4VNK+=P:[;:8;&!-(26X* /KBBBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "@@'J ?KS110 F!Z#\OQ_GS1@>
M@_(=NG\A^5+10 FU?[H_(=NGY9/YT8'H._8=^OY]_6EHH :$08 50!D#"C@$
M8(''<  ^H%+M7KM&?7 I:* $P/0=CT'4=#^';THP.#@9'0X'';CTX 'X4M%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIJ%RRG[Z_+\_MY=D&:9DHNC@ZE-.[_?R]E&UFTG.44O.Z5GHDW='Y?Q;XO\
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M+AZE7#<29[AL5[#$XC$TX1G/*,KQN'JPJX##TZ=1.OF]&M"G.K#$83VR=*M
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MFCQAV_L?7;61Q?VD;F-?-MI7!NK.=-RW%O)&Q;>I4>^B1&Q@_>&1P0<8SR"
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MHDCO?MPN&L[FZBBOK:(F_BLQI-X&M_@:,A@65MRDD!@"H(5W7.UOF'3 W8)
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M [OQY[$^_KU'\^<O2XGL);>]MG=;FSN(+NV>,[72XM)DN(&5ADJXDC4J_5&
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M>767M;?4#!9ZQ"(6=%O1&6\SX1^.H?\ X7=\6VEV^:WQ!\3[RHP2%OV500.
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M>MEU',,KJ.O6P'UO+81=/'8.K[6&)II/V=#$<\::I2I1C**E3NY<]W%)6?\
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M)<OP6\-KIFNKK?COQIKES>^+=QT^5+2PT>"YC\U#<D1Q74H9PT$D\@.8\O\
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MNPHHHH CEW"-R@!<*=H/0GMFOC;]MSX8W'Q+^ /B>*SLS=ZQX*U'3O'N@11
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M/MG@FO2?B5\8OB)\6=0M+[QSK8O8=.CFBT?1K*SATG2-,,V$!L='M%CMK4O
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MEO<P"YTC6+<JFH^']<M][V&KV,A(V26LP1FC.8[F,O!,#$Y!_GE^+_P=\<?
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M*?@[JWPZT#XL^';OX@^%+;6_AGKGQ>MK6]^%.C^/-,FU5+SPGJ?Q*M+ZRN?
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MK#QAX>O+/6_#%WI=G=0:_I5Y:WVEO=6US#(_N_B/XI?#'P=XM^'O@#Q9X_\
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M98X8D>1@IEZMONW^9HKV5[)VUY5:-^O*GJE?9=%8^_J*\+T?]I_]F[Q#X?\
MA1XLT'X^?!W6O"_QW\47G@CX)^(M*^)'A&_T3XN>,M/_ +>^W^%?AMJEKJ\M
MEXU\0V?_  B_B076C^'9M1OX#H.L"6!3IUV(O<E974,C!E/0J00>W44@'444
M4 %%%% !1110 4444 %%%% !1110 45P7Q*^(/@KX3^"O%/Q,^)7B[P_X ^'
M?@30-1\4>-?&WBO6+'0/#?ACP]I$+7>HZSK6L:C/;VEAIUC;QR3W,LT@#JJQ
M(&DD4#\Z? 7_  67_P"";7Q*^"'Q?_:*\*_M1:*OP@^!-WX5T[XF^)O%/P]^
M,WP]U71M0\;P7MSX#L-$\ _$'X>>%OB)\0+[Q\+#4+/P%8_#KPIXLO/&FKZ?
M>Z-X?35-4M;BUA /U/F&8V!!(X) ZX!S_2JLD09.=P#*1L5BA&".IR,#(]LY
MZY/'YRZ/_P %8/\ @GOX@_9;\5_MG:;^TQX9G_9V\#^+(?A[XM\5S^'OB59>
M)M ^(<E_IVEV7PYU/X/7W@RR^-MI\1=5N=9TJ\T?P2/AW)XGUO1]2M-;TS2;
MW19X+^3Q#XB?\%VO^"7OPAT#X<^*_B3^TCXO\,^'/C#X/LOB%\.M4O/V6OVP
M[N+6_"^H>*=<\$V6HR06/[/]_+X>NKKQ/X=U;2].\.^(H],UF^N;>WNHM,>R
MU73)KA/F>G,XQZ\NDOD]E^8))-R2Y9M<OM%9RY;WY?>35KZ['ZYWVGV.HJ;?
M4;&VO[<KM,%[;6E_"01C!6ZCDYQG(  !/0DDG@KKX(?!^_<SW?PO\ 7$C,TA
MDG\)Z27+,VXLS+;G+,QR3U)ZU\P+_P %%_V,C^Q^W[>M[\:H-#_96D.L06_Q
M*\5^ ?BKX1U&^O\ 3/&VH?#J70=/^&7B?P-HWQCU'Q%/XZTR]\.Z!H.G> +K
M7_$,J6L_AS3M6M+NUGEZ+P_^WO\ LF>)_P!EF/\ ;;L_BLVA_LPHTD4WQ0\:
M^!OBI\.(+8KXQMO JRW7@SX@^!?"WCZW2X\6O:Z-97L_A6WM[F.<ZC8M<:6[
M7+;4ZU6DK0K5HV5DE-I+32]I)LX,3E>78W_?L%@,>KW2QV597B;=4^:IA)S;
M3UO)MO2^R/I?2?ASX'\.(!H/@[PMHJJ<JVD^'=,M6!^]D/' C*1@$,&!!Z<X
MKJ8H0-R,"ZD@!92B8VJ1A5#$%<'YNX('45XE)^T+\)8OC_8_LQR>-A#\<]8^
M$T7QWTKP5/X?\6"UUCX46GC"U\#:IXET3QI-X?7P)KLND^(KFRMO$'A_2?$5
MSXIT33=2TO5=7T/2=$U;3];G^3] _P""LO\ P3O\2VFMZK8?M*:3;Z+X9T#P
M5XKUOQ'KWP^^,'A/PY;>$_'WQU\2_LS>"O%MKXC\3?#S1= O_"?B3XU^$]=\
M):?XDT[4;S0C#9VOC&:^_P"$*UG2/$5X2K5*D6JM2K-NVO.TU;:S=Y?^36:T
MLU=/;#X3#X2/)@Z.&P%.]^3 9?EV$5UJO>I8:$DK[\MKK1NQ^ET<(C3"@E22
M>6SC+;B"W7J<C/;@<8S<'0=N!QZ5\B>*_P!L_P#9D^'_ (P^._@CXA?&GPQX
M#UW]ESX:^"/B]\>7\9+K_A;PW\//AW\3;KQ);> /$^I^-]=T33O!NIP^);SP
MAK]A'I>@^(-7UJTNK>VL-1TZUOM3TJ*[^8/#G_!:'_@FGXK^ OQ+_:;TO]IZ
MWB^#WPF\4>!? _C;5]?^$GQ\\*^++;Q9\3+R2V\#Z+X;^%OBCX6Z+\5_'\GC
M.1+B/PW-X!\"^)+>^3P]XIN+:X:'POXC?2<V[I+73N[OYM[G2VVW*3YI.R<V
MO>DEMS6T\]$MV?JW17B_[/\ \=_AA^TM\*/!GQM^#6O:KXG^&OQ!TJ35O"GB
M#6/"'C?P'?:M86U_=:9+=2>%?B-X>\)^,M,47MI<PQ_VMX=T]KA8S+&)(RCG
MVBD 4444 ?PZ?MB_LN?M;ZMXF_X+5_%SX*:+\0?&O@SXE_M^_LZ^ /CE\!=2
M\/Z]/IGB;X,>"-&_9#^)7@[]I3X"0V6FP7=_\0_A?XITGQCX/\=6^G6OB+1O
M&GPO\5:M+=FUUOX:Z+/J?4?M">&M!TKP-_P5K_8I^*W[(_Q@^,?_  4E_;$_
M;1^+/C[]D7XHV/P0\9>*(O%'@WXHW/@<_L?_ !B\-_M066GZCX;^$_@/]F'0
M_"6F-?\ AN7QUX<A\ I\+]7TR/P_<WNK:K;ZA_:R+7 &)9,@  D[@FT.JF)6
MW+$P1RA9%!<<.6'% M<+M\Z7&"/OL<DALLV20S,9)&?<"&8IQ^ZCV@'\1WQZ
M_9^^-\W[:7[8_CWXG^"]+OOV2/!__!2'_@G1XE_:0^+?A_\ 9\\;^*/VM/#=
MM\-_@M\'-;T_XU? KXBK*^F'X&VGQ4\+^&M&^.T7ACP/XP\7Z+X8U7Q=XDTK
M[,D&I6+?/7Q4^&O[=WQG^'_[97Q3^'NC?$V'X._M5_M!_M4_\%;/#FL7/@+Q
MCIOBWPWH?_!.;XN>)/"7[-_P9@\+ZW;#6&\2_'_1?!7P9\7^&].OM)BU)].\
M+V%UHF@M8>2UO_?FUH[/N6ZG0!0H0;,8!0C)V[R1AP<. =_((4"G"U. &FD;
M!!R<;LJJJIR<DD%2VXY<EL;@ , '\0GQUM?".O\ P:_X*F_LQ_$W]CKXM_$[
M_@H-_P % OVE?%'QR_8Q\66_[/OC/QA>:Q\-?CAX0^%3_LI?$NR_:'D\/WNF
M?![P[^S@WA+4],U3PIJ?CCP[??#J]^'7B&Q'APZEJ]W9W'I/[;.J^*/V9/B#
M_P %6--\??#WXFVO[;O[0<G[/'CC]A#]J?2?V*8?VZ?"WQ,\*?#SX5>"O#%I
M\ O#-CXT\%_$+X=_#F_NOB-X7^(GA+Q7:>,[+PW!I ^+"?%.P@UC4;.&&V_L
MS%JH#CS)=LDID90YP05"M&0<C8X&7P%9G)D)\QG=HS9,2H-U<!5;(2-_*&W8
MR+&3%L9E4%<9).5+?>*L@!_,C^P?^U_X1_9O_;>_;:^#O[3GA;XY:!\;_P!J
M?]I#]BI/"TMI^SC\5M<\$ZYXP\6_L8?LQ?"_7'U7Q[X$\!2_"KPCI.E_%5M;
MT;Q!+-J6D:'X;M+:\EN!#HD&^+P.R_8%^+]_-_P6N^%'P.NOB9?ZK^S-\)/&
M_P"S7_P3"\!:YI3>#_"WP?\  ?[7'A"+]HSXY^$_@9XVO;:*YN]3\5>+]4A^
M$/A_Q1!KLA\#^!/#7ASX>P3V7AL1Z/9?UV&T)(S<W!4%24+Y1MK!B&X#E6QA
MEW[64[6#+D%KV$3@ L<HKK$2J-Y0D51($W _*[*'9#E2P QM&V@#^+#]K;XL
M?L9_'+_@DS\=OA=^QG^R#\8_@5\7?AA\$/\ @G7HWQ&U2;]AOQ;X:\7>!/#W
M@K]M_P#9P^U_"G4[3Q-X'AO_ (V>,/AG=Z1XH\7W_AS3E\9^&O$%KINM:G>Z
MKJD$TUS+V/QAMO&7[7G[('[(7[+/[%7Q/\??$'XRWO[:GC[XF>)?VD_$_P"P
MY+^Q)9S_ !:_92^"'B3]HSX(ZEXP^&WA[X=_"OP/I/AO4/BJWP$^&I\8G27.
MHV*ZE]FU"3Q1HC11_P!CSV1=<?:9]P<R1NS;FB?8(P8S\I4  Y&26$DR,2DA
M4#6(*R+]HN&62,(%DD>41E1^[=-S9#HQ+^86,S/M8RYCCV '\*K0?M&>+/'G
MB3XF?%GX<?%G2%_;?_;L_P""47_!47PUX.D^'/C#5+'X"_"O5OV@/B7\,9O
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MJW4442PJ%4D@*BY)))"+M!+,2Q.T 9))P!S4M !1110 4444 %%%% !1110
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M!X9FM[R3P4/"P=]-M=7\UK/R3X\?L^6/["'[9'[ ?@7X@?%#XE_#KP'\*O\
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M'_#;Q1XKMT\5^+/&,S]?\2?"'QB_:K\4?MD?&+XY_ W_ (+7Z7^RY?\ B?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/%%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tv506394_img03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv506394_img03.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ Y (B P$1  (1 0,1 ?_$ /8  0 !! (# 0
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MRQ7]<GC>H'_>WAS_ (;S7_(&E=Z?-Q?\:?\ U4\O[LOZW??[+%?UR>-Z@?\
M>WAS_AO-?\@:5WI\W%_QI_\ 53R_NR_K=]_LL5_7*!GJ5J\PAXAW\N4V7'9&
MBFFJ($XIC63R8ZM(%^<H88\$$;-$LX@6@RH( N)S@8$]^T!-L&H=OP[G^S,W
MUB+$6?/'S>492_VVT]MH;2M*^A;(_=-9T,'7#&'9TFZ7;C]WO/)%_'8-M_\
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M2661'N0770,/:/<@LJB?W1[BCW)'(;<INH=>@]=6($C4$A95?'&\<LC6N'I
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M[,RK2#!U*A,YJR[1L-5ET*,C(1C8(]A9+\T</3>+XA&2:IDR*J 1,Y%>X3%
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MJS;"'CTRF1Q[25)]LV;,T$FK1N@U;($!-%NV230013+T*1))(I4TR%#V
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M>9\3?#'-RLF:WP\Y: !)WBMDW$]TY5\<HRB<;J?A^70R2=ZXLE?R!DFUO7S
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ME1:V4(H^]O7CV8(M&#QS/B9XC0-0XMR=PL45E'E=8X[-.0H]R64K=);MG#;
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M]Z6XL9TO=#QA=L"9UQG=;_9Z]38,8<U7R37E+!9I1K#QB"CI@]KLXDU4?NR
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MU3&$1,([B(CN(B([ZQ,'R7MPYU21S56TLXALK-D4(Y0UM*#AP696O0:(,VH
M11( ']8%@ .W8=C%+U(&VW4!-L&^K_;VS&M#G#Q*$7F2>Z0LTHK19PG']5I-
MTE629G#V*@))Q'(D)W"H]\JIY0NQ!,';XP )A]G: ZZW4<D;2X<*55UQ4PG<
MWR?:%%AC].K,?(;-O)7)5TY!9*M.2XOCU2YN;J[J9DW2U?38HQ+IK"%B8@BA
M(6+79MW!FXE003\,Z9BAT'K)]M3RWH$D[B3&-!V*%]1<5C,!#&VQC#)' EY[
M7%VI+CVD'AW+9AQG 'K>/*5". $KUC6HKXGO^L,N[;E?S!SB(=PG4E7:QAWZ
M[CJ8&I-3Q*UAE>))WN'SBJY O:(& QBB780$!V$!#V" AU 0UP@>0*:47@2#
MT >X"AW" #L  81][IL ;B/M'[=%YKXJM4U>T1$Y3%+V )>P0$@CW=AB*$.0
MP ;J'3<!]FBY0J!4B]I.X>IC&$YNXQS&'<QSF']8XC_HVUXO]I<JFY&!7=/F
MKU-_*-@:+JK^68ODV["1*N1$IVDTU506%TV)X0 3L$# 41 ! 1'75%V1FH@@
M5(3"82$(3NW .XQ"@'=U 1 !VWT1=:L*+4BCAVIX;=LDHY<J&$.U-L@05%U#
M".W0B11$?X-=PT%[&G@XT*\IWEL>G8K%XTX[R_(_"F-J3\SA3#V)A,Y\MLHI
M%&E%U%LHW26M,;'$9^:8D*Z-&2R!0,H< *1OML/V>69M6Y&S= PEC7/%:]O+
MIIZZ+*&Q-S#9F3CR[(A/,R M9K1H+Q4U[:@E3AP;P0Q#AETPEEEI>]3\88JS
M)]8_*IQK1V00$KMK"-$_+"X(<.XAESKB0=A#80WU:+/!V=I1Q)?)3MI0>FG>
MK_NCJINC=#76\KA;VCN(C)J1PH22=/@"FZ ;!M]VKRL; 4%.*\Z+E=!:H"+M
M=;GJM.-DWL'9H>2KTTS6 !2=Q$TR7C9)L<! 2B5=FY.4=^FPZ\IX([F!]M,*
MPR,+7#O#A0CXBJ_%92]PF4MLUC7F/(V=Q'/$\<6R1/$C'#TAS05&?A#/RTAQ
MZK=/LCE1W;,+S=MP/:%U]Q76D,1V)_3HYXN(^\964K4>P>"8>IO,;_;OJ/[2
MFD?A([6<UN;1[[=_KA<6 _"T-=\*R]]X3&V5MU/N\[BF!F$S]O;9BW X!F2@
M9=/:/1'.^:*@X<E.Q2WU)5A)-$31$T11UY:Y#DL7<<<M6Z!$WS06K+UVFE(;
MM54NUU=-:;32(@'O'5"RSS40 O4=M6/<E[)C\'<W,/\ O'E\K/Z20AC/Y3@L
MI=$]KVF\.JF$PF2_^#F\$]U7@+2T:ZZNB>X>1#(*GO5PL.XYC,0XIQUB^'*0
M&%"IM>JZ:A $/-+1$8W:O)!01ZF7DGI%'"IAZF44,(^W5;B[&/&8Z#'Q>Q#$
MUGKY0 3\)J3Z2HQOO=5WOC>F5WA?$^\Y*_GN"#\D2R.<U@[A&TM8T=C6@*Y&
MJ]11>IC%(4QSF*0A"B8YS"!2E*4-S&,8=@*4H!N(C[-$5CZ5R=XW9)N+W'F/
M,_X7O5]CA<@^I=0R?2[):6PL@.9YXL##S3R4+Y,J9A5_"_"[1[MMAT17RT1-
M$6O_ .K%P:Y#Y4SE$<L<-6K!4?5X+BK;N.F0HK,LCDN)4A6=COGS,QN%?-C:
MD7R0FE/$DQ;':&:IBF) /N8IA[+KB<J_$RR2QL#S)$6:DB@/;HH!U"V!:]0;
M&RL;NYDMFV5_'= L:UQ>Z,$!A#B* UU(U6$JO<3>2]>-112R]PC<C1>-DGQN
M; J\YBD^(1,D-=$]J<=G&0?!E$OETFS<FZ(^*;WN@:NT6ZIX_+I"P^7:F#VC
MJ#R^+UZ<."Q_>] <7>^^<V2N6^^9YN4-(V'E>WS?HAKJP^8?$?%H-%&#D'Z6
M&?N0-5P'597D7PYK2&!,:HXVBWD:ERW?+6-HBA"H!*R*;OC0F1DZ,$*4?#2$
MQ/Q!Z] U:<EE7Y*&WA>P-%O%R @D\PTU/=P60-E;!M=EY',Y&WN9)WYF_-T]
MKFM:(G$O/(T@^(>,ZG711C_H%LR_YW'$_P#P1RJ_[MVK4I^JBJWHB\D:-+DL
M%*YO<;JC.IMG3).9K7YN(64(S?)"@]:E?1_'1NY!N[1'M4)W=IP]H= UZPS3
M6[_,@>YDE*5:2#0\=0J'(8S&Y>V-EE;>&YLRX.Y)6-D9S--6GE<"*@Z@TJ%P
MI+T-N0LM$,8*2YK<9GL/$^</%1KY#EN\CXD[\QE'R[%DKQS.DW.X.83J=@ 8
MX[[CN.J-EK;13ONHXV-N9:<[PT!SJ<.9W$T]*D=UGLW?8NUP=[>74N%L>;W>
MW?*]T,'.:O\ )B)+(^8\>0"JVU/33]77A-.OJWZ<U:O<_(Y+XSXDHN+J=;9.
MI3-<A.2<QBO'$5&WI'$L#--VMI2L,?-0[M%I"2;5K)R2*8*M4U=S$)[JU+'Q
MPS2Y ^K1ZQ\+ZED=B5_A'BUQ1^.XKKDC>F+]C9[NM7XB_5MM608+B0%KV29N
MSEY-E1#R4 BBFR445=_KD6SCR[Y>X-X0X3LV=\^VQ"MU.!3%O&1J(IN;+=+(
MNF<8JGTV&\0CB;L4NJ3M33)LFBF!UESI()J*$(M;JE>NOZL.9:\VR5@[TA[)
M>\36=U).:+;(QME.:9S$$B_<-FBQ9B.@V\7*+)D2 BR[4OECK%-X8B7;1%+K
MB)ZF_JN9IY)8GQ;G;TL+3@[$=RGGD=>,L/HG);=I28Q""EI!O)K+3,<E%D*O
M),T&WXQ@+NN&W7;1%L4:(H6Y5*&.N8''3):/[/%Y@KMXXY7%7M $59)LQ7RI
MBU98P!U<HR%=FV:0CU_N@)0]HAJ*Y'^P[GL;\:1W3)+9_K \Z+X:MD:/SEGW
M9A^U70W=.TY/%>8*ZM,Y:CM$;GC'9 #\DLGM)7 ?J:G@II:E2P$FB)HB:(FB
M)HBQZ<_.=]<X>4QI&0S9C9\TW-FX4I54<J&%A%,4SF;+7&UE043<IP3-P D0
M0(8BL@Y**1#%(195*$[SWA!MBU$<0$F5E!\MAX <.=_;R@\!Q<=!H"1L_P#=
MI^[CE>NF>?=W[Y+/8%A(T7=PT>.1Y',+6WJ"TS.;J]Y!;"PA[@7.C8_4ERCE
M;(N:KE(Y RG;I>Z6R3.<59.67[DV;<QQ.G&0S!,",(2';;[)-&J:2) _B[[B
M.MN0R-]E;IU[D972W+NT]@[FC@UH[   OMGL_9FUM@8&+;.S;&#'X2$"D<8U
M<ZE#)*\U?+*[BZ21SGD]M*!6^U1*3+QN'W^SVZ(O.B*;?#KG5EOB'96:<.]>
M6W$SU\12UXKDGIQBUFZQR@\E*BJN)R5BS$3W,51( ;.C% KE,X=IR2S:^[\E
MMF<"(F7&D^.$G2G:6?,?Z1H?E \1K[UU^[ILGKAB7NOXX[+>L<9%MD8V#S X
M#PQW(%#<0$Z%KJR1@DQ.::M=N X@RY1,Z8ZK&4L;S!)NI6I@5XQ<"4$7C-<A
MA1?Q$LS$QSQ\S$O"';ND#"(IK$$ $Q=C#LUC,E9Y>QCR%@[GMI!4'M'>TCL<
M#H1V%?#7?.R-Q].MTWFSMUP&WS=E)RO'%K@=62QNT#XI&D/C>/::1H#4"Y6J
M]1-8%N4F=,L8!Y<\[+SAMY5$K^MA_P!&7&M8'(45+V2DQ9L[\V^2N&K!+2=>
MAYZMR#T6L%<55BE;O6JBBJ"8"H   @14_?.5'/O$)^8#R7SOAZ]0W ;.G&^K
M322O'P:Y-<C:?R$A<&W*=A+0[89)=QN-'M%@LLN&,,^A&RIW3IJBY?)J$!1N
MJ158XYH<N65KR+F)3)&(G6(L9^J56> 27'5+%+A&UWBBWW+>+<4M[6QR>.0%
MI4<N54V4/CC=JWBB1;J*B5D5VPG6\\W(NO@>8/-FR8FQ[D!WE7"5;?<L.>E]
MX/X?42PZ_/6^/U=QGF_E#4'N5K>ZD\BJKY8R5D.M8*;P\+%]\%"-[#)L>Y-V
M!ED5R*K(+GOG'#<[92<B;OC*V8:XP\T9_B;R5S]!49S4(N5J>0..=%S'A3*S
MAJWM$Q"TBQ4')5UCZ)=&"!G#)9[))/$"L]A9I$4=K=S[]3RVO*'0</8?5=YI
M5X;5OFR]I-5Q9CBR-K'(9SRGEEOA+ -Z-ECD3AF2HE.I="HT?"V^R02<Y*C8
MI SDI&*+<C1^1=5ZD>:>2&>\#>HS$GNE"PUB?BU)<7<8VO \G14+CD&_6')<
M%QTS5:+!.Y'"XQ2559,7F4$Z_6ABX]RT=N85XZ7,\*X2;M2+9?T1-$31$T10
MHXGOF#HW*7+DFZ0;MKER3RBH:8=*$1;I5/$S*#Q?&**KJ;%39LD*4Y5$1'M)
MWF'IUWB^V?I3D,@>,^0E /Y,0;"W_0*SOUQ)Q[=H;0;HW&;/L7.9W3Y!TV1E
M/K/O3!ZFCT+2'Y3<@)/G#SXOF7CJ"ZI064\/CUFOW@5ECRK*K0E.*DD(@0AY
M5J@I(K 4.T7#XYO:.^K5N2\:^K:BE%=>GN'=90M:6U>2#V<::K-3QM@REA&"
M8 *:;;PQ$4TE#F$=@  [@]T.T-M^HAJ*8J(O=0Z:J9Y^Z%N3RT)(HLB+-%FB
MP+MYA4R*(=HK(B1/?H(]QC=>WITV]FIEY?*P$:MIQ6,))9I9220'5X=JL7?C
MJR:LBEV FDJU $E"&3,"9R&#8QBF'M.!>@B'L,7</MU1WCJ,+AK0'\2E.%>U
ME&N-"2.&G<L?_ ?%"\95\Y2LG!_ 93,G(YOC<D>5L+8R->B;BZ7G2E()"?LK
MB CGJP& O:HD)3?;OJ][/92SDD=H\OX>A1SKM?V\N0@M;73R[7Q4[#04KZ5G
MO* "(F^\QA /L#<=]OX WU+UK(T@C1>P%#?</;_4Z;?=IQT7;U:E6L>L*JQG
M&=6B;V_KEJE6[YY%UUK/C(+*IMNZ1?/CP#TSTQ6OOB90Y_#*;OV*;N$-4TE[
M:17;;%\C!=N!(;6I(&I.E=!VJPS;HVW;Y^VVK/?VC=RWC7NAM3*WSGMC;SO/
ME@\S0UOB//RZ4[PNS:!/^*+:*NM>LCN+3,WEF+M%F5T1P=93L,[3AECJQRB1
M!*0"F('<).O41'7JV:%[N1CV.?6E X'4^HE5]IE,=?SRVMC/%/=0DA\<;@^1
MI%2:L;5W8>S6E!4KGA)VUIYD92I$6*B4IDCP,JB[5=^XH(D(R?),3HG Q"AN
M8XE]_<1]NO2@Y2[0@<:$'\2N'*ZG-3P4!KV:BHUX>L5J#H:$$+M(F5"6\T4(
MN:C5&9DB+)R['R7>94O=^S'\11-TF3V&.0PE =>/*[N1=B=/]']3ITZ>T-<$
M$<45C\^/G<;B.^DC1,$O.0@4Z%[1$%!G+V]9TJ'!+M]X5 D+ F8 #[M>L/M<
MW8W\"Y8PO(8!5QE90>@<5+C -UQ75KK<\>'M\!&62&3IU*@J^^>(LG1X*K0"
M31@FR,N)&ZZBYU3CX)#"KL0![>NO&ZO+;WKW4O'GAM>7T<:]RFQPN5]R&39;
MR_5KG.Y7AOAT)!X<*>H!3; 0'V>W^#8=*45H:6GAQ7G1=DT1>! !#80 0^X0
MW#_3T10TX_A\M\DN:-"3$4V#NY8JS'&MQZ 4V2\<M8*=63+[.U:?QRN<P_:<
MXC[=]1;#?V?/96R'L&6&<#^EB#7?RHBL\]2S];=)]@[E?K<LL,CBY'?]@OG3
M0@^J&^8!Z .RBF9J4K R:(FB)HBAIRW+\PV'B?C3M\5*[<GZ;-2C80[DW,'B
M>NVO*SE-9/V'1^+5-B([]/9^C46W+]//C;#LER#'$=[86OF/X6-6>>B1^J\7
MO3=G!^/VA=11N[6RY*>VQS2#V'R[F6BF7J4K R:(L)O[PG9LXU3TMLYR.#%Y
MUB]<2E*B\ER=;,Y2F(S#TE.I-KRY3=LA*^81RY#-F\@LD)1)&KN.X03$X@1:
M<^=(#TV,;<9.!V1/3CREE1[ZCI[9CYS<HV#>6U6SM;BM'%4G"RD2JQ;PU=F6
M.1A;,8!K"F%.28*G!4KE,16T1;%[>_\ [U4=NW..&.(NYVZ!Q\Q(8Y2<;G2(
M8?,I%R84B3C<?Q"@  4^X   &VB*V]]]27UT^ <_C;+?J"\9<4V[C!-VYM3[
MN.#V$/+6B+/+^&BP7;2U6N5B3@YDZQ]XU*1;D92K@@M 52543.!%4WJMYAO6
M6>6.((BI9:Y'8LQ4\]."V\CZW3*?>\H<?IQ&^R60E6,=-7BOP;ZKV/XXQ@44
M6JD?*%,#4Q3E A1,<32+;>/M<C<3QW;2YK+=SQ0D>($4.GXEAGK5O'/[,Q&*
MN]O2LBGNLS#;R%S&R5B>UQ<T!X(!-!XAJ%BGI3[*\T;$(2'*7F:K\V\$Y[.,
M[V<N<^)>9R0Q-2 ;3"7AW@/+,R!-N-V9-FX]X;E]T-2.#;V*D\GF8[QX\RGQ
M.]L<NO'AJ=."PSENL6_[3ZS\BZB'NV\(["/Z"(TM7>?5AJW5W@;XSXM..I6/
M_FER(Y2X;QWPWL./^7_,"*E<P8(:WF^KNN4&:I4DI9%6=56.\:HO[DLE&(BI
M*+#X* $3]X.G0-1S.X^UL;:QEMFD/GMP]]235U&ZZ\.)T"S/TJWCG]TYO=%E
MFI626V,S#K>W 8UG)$'3#E): 7FC&^)U3IZ5 3^D YY?Y[/+3_WA\L?\Z]1U
M9E5\N._(3U&.2>24<8U+GWR!J\PM 3MB"4O?*'+,%">4@&R;ARV(Z)8W2RSY
M<%0[$R$'8@'4,($3,(7#&XZ7*77ND+HV/Y2ZKS0:?N__ *J([WWEC]B8([@R
M4%U<6PFCBY+>/S)*R$@&E0 T4U)/&C14D!=#=^4?J)T2@T[(+[GMR)>L+J\G
MF48R@>4>5)&7CG%?<+MUG#U)*S@D#=51N)DU$CG*&Y -L)@#47M,U;WF7N\-
M''*VXL^7F<6TC=S?,=77\%1J-%G;<'3',;<Z=;?ZEW=WCY<1N/S?(@CFYKN'
MRN/O,/*/+)IJ 7&-U&/HX@*]?JX6BQM^4_&7-3":?Q67+OP2X+YQM618=7X3
M:IG,<CC5N_?Y-=R<>5NH-S>R$2V<*O@V5471*<PB.XC>%C=;H?#OUL<$!Z25
M4YO\B9*)@+G49.=Q)DJEU)@R9S61>1D*5:3<LJA HF22-,948N4;(LH?PV[4
MC]PLL<J:)SZ(L>_%+AUR0]='/,-S]]19A)TKAM5WSA;C5QB1</X^,NL"+D%F
MR@)&\H\"D// 2-+SAR)OK4J3P6HH1Q"[$6X)#0T17(B+K]?BXZ#@H2/9Q,-"
MQ#)O'143%Q[=-HPC8V/9IHM&+!DU2*FDDD0J:9"@4H   &B+LM$31%#7G648
MO!T=D5'H]PWF#"656B@!N9-&NY-K;*=$/N*I5YA^F??IX9S /346W?\ 1XAM
M\/;M;J"8?P96AW\ASEGC[N9%YU#EVL__ '?/8++8YP[S/83OA^*XBA(]("F5
MJ4K Z:(FB)HB:(J=M]IAJ-5+-=+&Z!E7ZE 2]EFW8[#Y:*@V#B2?K 41*!C)
MM6QA -_>'IKPN;B*TMI+J<TAB8YSCW!H)/X KI@\/?[BS5I@,4SS,G>W,4$3
M?G22O;&P?"YPU[%HMY\S5:>1&7KQF&WJJC)7"76<L8\ZAU$:_7&YC-ZY6V0'
M$?#:0L25-+8/UU>]0=SG,(ZB9G*W&;R<V3N3])*ZH'S6CV6CT-%!ZZGB5^BO
MIKL##]+MCX[8N#:/=+& ->\  S3NUGG?3BZ63F=Z&\K!X6@*O>)^"B\BK_<L
M=-F+Z3L9<.9&LU%CV,FWB/.7V"9Q_P KH/GCH/+!%F>O!\P4XD*9/VF#;59M
MS#_7E[+8M!=/[K*^, AM9&@<E2=*5.JC?6CJ,>ENVK#=,LD<.*.=L;>\>^-T
MG+9S.?[P6-;XO,Y&^ @$@\!JKBVJ,P1QB62K;O%SWD;DY RB,S=<CDN5+P(Q
ME6@@20B\=5.-&O63)C2+<CX:LM(/F[)R(=R+7PS%,-=<1X? 'R'6YOL@/:DE
MYV6X(XB)@Y72@'0O<X-/8VBBV&N^H_5V,Y6',1[5VBZABM+$VMUF'QNU9)?7
M,GGP6#I&^)MM#"^6/A)-S@@4C^:B'D0*RM/%3BA-P( *?PR&QO+4.311,/4&
M5LJ%I86!NX*7]5511<0'J(&]FJ;[11/\%QCL:^'N;$8S\#V/#@?225>_\F[Z
MU)N,/O/>EODN/F2WT=Y&3^7;7-N^%S>]K6L]!"^\UB3%V8*C8\A<:/F.%L%+
MBG%BR-QVN$DE8[+#5EKL:3NN*[>@V9+9 I\(!N^09NFR4S&H?C'\PD!CAS+C
M<?D[:2]P/F,FB:72VSSS.:P<9(7T'F,;\II >T:GF&J\\?O;>&QLW:[8ZM>Z
MW&,OYA!8YNUC,$$L[OT=KD;8N>+*ZEX0RQO=:SO\#?*>0TQ# 0$ $! 0$ $!
M =P$!Z@("'00$-1I9O((-#Q69CT;>2DAC_-3[C[.R"AJ1F%%Y(5QLX6'R\-D
MF$CS/"*-"G$2HEM-?8JMUBEV\1RU;?;OOE'I=GGV65.%F=_9+H$M!X-E:*Z?
MGM!![R&K0W[]_2>VW-L"/J=CHA]H<$YK)W-'BEL97\I#J<?=YGM>TGV623=E
M*;1^MA%\>5:ZQX1P];Y>=G[5C"BV*;M!<:%L<M,UB(D9&=+AFVOK[B4)5VZ:
MJ+O@QM=I-Q+0GB";X;(+G70[%#"82+Q,X/PY8D\AI3V+Z',)9;E*S-Y13DJO
M$/"9!F*8Q@HRI2=P*NT.%@?5J.J\:@Q5=>(=LDQ0*F)02( $4/\ CYZ<F#L1
MYAS'R"N=$Q=D7-M_Y-9<SY2<H.Z#'I7+'\9DIG#QK"NMIE^I(.5YNNQ;%PT2
ME$Q26(T=JHH^$DHH0Y%*F>XXX#M&*9G!EBPYC>9PY8)*:FIG&;^H0J],?3=B
MM[[(,U.J0)VGD"3K^^2:\V9Z0A71994SLJ@./Q-$73Q_%'C/%X0>\:F6!L4$
MX_RA'!9C#RM'K[O'LX=Y,IV)\ZGJR[8KQLY(2%A2*_<N79%G#AZ'CJ',K[^B
M+XYOXE<9N2B]8=YYP9C3*K^E$>HU.4N%7CI.7K[*4%L:6BHN7,D22:PDP+)
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M3(\%K@1I0J:VL/-[0H3Q518IC$WMQH+!-( 0@VM^R$_,0H !WZR,91H-5;M
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MY6%5OD-&7> CBC]I(V.L!&Y?LV2#5?N.SBL,W<6]N*6W.'L'<R1HD:/@#J?
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M3H"N@O-)QS!X^J-@K.2VMOM,ZZL#:S5-&(<QZE;9L%G"48_.JX,*@EDT$R'
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MUZZ)^1CFR2_E:K:(>5E3%,BD50"I0J3DX[#^J4?LU#=_V#)]IW?E,'/&&OT
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MVD[N]!*QVA!SBK%S5<I>B;OP']C>I@;8=FI3 &WMBM]_;MTV=D-8K.)]R_\
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MK)_-J3=PEL(+(5T&T?4BG X=Q3&8'.0=MC:D^+Z>;8Q;Q*(3/,.#ICST/YM
MS^2L&;[^^+UUWU;OL'9-F)QD@(='CH_=BYI[#/S/N:4T($P![0LAJ**+9%)N
MW220;H))HH((IE21112*!$DDDB 4B:29"@!2@   !L&IL &@-:*-"U>DDDED
M=+*XNE<222:DDZDDG4DG4D\5]=<KHFB)HB:(FB)HB:(FB)HB:(FB)HB:(@@
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M7BLI.*_4:X#YQ;0K+$G-;!DE*$\JF#"PW")KEEDR"* *(O(NZC6)07JB1#%
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MQ/('.49@ZGM9!**<W#(5OE$JCB;&D4H0)[(E\D$SC&PK$H[^4BF92BZE)!0
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M=A6P3PF]7EA?I6%Q9RC3AJK:)-9",K^68U,D749R06,5%JQN,:)A;U22>K&
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M 0="%<64P9R3KJ:AV*>/<@(I@)@(PD7U6E' $#< !&234C/'. ;  JE+N/M
M.NJOSXSWJU@T4?,CQV36Z*1+7C+-U#<QJP.VULHK%"T,FIQ3,"B3PT6WFH>4
M8F(<0.B[:*%WZD$H]=>S3S-JV4#3AW+MS,^:"?A5"TZ6QXM8F-FMF1IJU6B%
M!TWA"WAHUK#.L+/FYFC]:*K3&%@HMM-NV2AD5':X+NRH'.F0Z:9SE-TI(11S
MW$? NXD8W5K&@]^JDVQEHV2("C!^Q>$$.X#-':#D!#V[_@G-L&O8&HIW+R.I
MJNPW#7*X7-(7J'L ! 1#J'W#M]OVCKQ7JKQ8)8+35YE)M-+OAZ?!J0:#H0W*
MI89QRD\?I-C& "B=E'-R@MMOL*Q0U3W%*#O75RF"(@4!$1V /:.J9=%:?+.;
M\981@$K+DFVQM;CG2PLHMHJ#A[8+)*G[0;0M2K4<DZG;5-.CG I&K%NNL81]
M@!N.K?DLKC\1![QD)6QL)HT<7//S6,%7/<>P-!*F.RM@;OZAY0XG:%C+=W#&
M\TKQ1D,$8XRW,\A;#;Q-H2Z25[&COKHHOJ57-_+HQOJ&QLW'?C6[.8Q\:I2!
MHO.V9(TP !4,C2T4Y4^DU'D4NBT)'KGFWB1C)NW+4IA1&.FWR^YO]^$EC@3_
M #5:7$X_VI!^AC/;&T^8X:.<W@LQ,R_3SH?KM>2TW3U9;_QY9YF'Q<@[;&.1
MH^L;MAU;=S,%K$X!T,4Q D$VJM5JW2*[#5&GP456:O7F"$7!P$(R;QT5%1[8
MO8@T9,FI$T$$2!]@!U$1$=Q$1U++>W@M(&6UJQL=NQM&M:   .P +7[,9G+;
MARD^;SMS-=YBZE,DTTKR^21[M2Y[W$DD^DZ#0:!=_KV5M31$T1-$31$T1-$3
M1$T1-$7!DXR-FHY]#S,>REHF4:.(^3BY)J@^CY%@[2,@Z9/F3I-5L[:.4#F(
MHFH4Q#E$0$! ==)(XY6&*5H=&X$$$5!!X@@Z$'M"J+2\N\?=1WUA+)!>PO:^
M.2-Q8]CVFK7L>TAS7-(!:X$$$5!4&?IAF'B<LI(\>6+W+N @56=2?&R5ETTK
MCCMN<YEG+CC]:YIP#9U#)=QCEJ4LL1N40[8]VW[@0U$?J_*;;//A ;G#5J;4
MN\<0[3;/<:%O^Q>:=C'-X+8K[7[%ZTQBUZH21X/J5RAL>=CB)M;UP%&MS5M$
MWF;*= <E;,+S[5S#+0R*1^'L_8MSI&OG= L7CR\&L#.VTF<9NJ[D"CR@; K$
MW.ES";6?K[Y%01( K(@BL("9%10FQAON+S./R\9=9/K*PT?&X%LD9[GQNHYI
M]8H>PD+%6^NFF\>G5U'#N6UY;&X;S6UW"YL]E=Q]DEK=1%T,S"-?"[F;P>UK
MJA7EU=% DT1-$31$T1-$31$T1>IC%(4QSF*0A"B8QC"!2E*4-S&,8=@ H '4
M=.&IX+D N(:T5<5#"U\J)&[SLGC3B36F&:;W'NC1EDR$Z=.&F <5NMQ(L>X7
MMB14MJG67ZP0$ +M^H("5=1H "<(K<[B?=S.L-M1B[O&FCI"2+>$_ER#VW#]
M7'5W>6\5GS"]&[7;V.AW;UMNY,!MR5GF0636M=F<BWB!:V;R/=X7\/?+SRX0
M#6-LQHTUWA;CA&XXG)+)U\LLAE[/EG9 RL^6+*U0;+,HPRGCA3\=UU RL;CR
MA-%AW3CV0BHX,'B.UG"NQPK,5@H[&9V0O)'7.9D%'S.%*#YD3>$<8[&MU/%Q
M<=5'-_=5KO=6.BVAMNTBP?36SDY[?&P.+@^2E/>;Z<TDO;QP]J:7PL'@@CB9
MX3U&<\"S\U96.=L$2T=2.1%6C2QR3Q^58M-R[5&QS.38PRPS:;*/X-RH(C'R
M1 %_!NC LW,)/$24\LOAII9QF,.YL.<C;2I]B9@U\J8#BT_)=[49U&E0:[IU
MU)QEAB9.G/4>&7(=+;R7G+64-UC;EPY?K#&N=HR9H_30$B&[C!CD =RO;6F"
M,]P&;H>80-$R-&R71WR<#E3$]E,B2UX_LGA>)Y=T5(?!EZ]*D 5XF7;=S*4:
M""B1@,"B:=7A\S#EHG#E=#?PGEFA=[<;NX_.:>+'CPO;J.T"/]1^FN3Z?7T$
M@FBR.TLC&9L=D8*FVO8*TYFUUBGC/@N;:2DMO)5CQ3E<Z_.KPL;IHB:(FB)H
MB:(FB+4)]37F/)\E<RR5'J\LI]%<43#Z%K+-HL8&-MM#!15A.7IZ4INQX47!
M5&L7W )4F1!5( '<J:UGW]NB3/91UI;N_P#"K9Q:P#@]XT=(>_6H9W-U^45]
MP_NC]";3I-L.+<.8A'V_S4#);AS@.>VMW@/ALV=K?#RR7%-72D,-1$U8S]0)
M;:J_F#^.-]S\C=WE/EL?U^*QXRA)"U3F1[K'46"8-[$_<1D3_=>53,R\1R^;
MBF!3G)N8Q0#<3 &KQB<'>9D2NM70LC@#2]TL@C: XD#Q'34BBQMU"ZJ;;Z:2
M8^#.09.YO,I)*RWAL;5]W,]T#&R2?11GGHUC@ZH!T!)H 2KU-. .49!VU8,,
MP<2WKY\Y;LF3)IR3HCEV\>.U2-VK1JV1.=9PY<KJ%(FF0HG.<P  "(@&KLW9
MF0>X,9=8TO)  %U&22=  .TGL6/Y_O+[/M8'W-S@M[1VT;'/>]V"O&M:UH)<
MYSB &M: 222  "2:*(5XITWCRZ6V@V5-LE8J58YBK3J3-P#MHG+P3Y:.D"-7
M0$3!R@5R@8"'[2]P==@U&;NUELKJ2SGH)XGN8ZAJ.9IH:'MU6<=O9W'[HP%E
MN7$E[L7D+6*XA+F\KC%,P/87-J>4\I%14T*I4Q0, E, &*8!*8I@ 0, AL("
M ]! 0U3*\@D&HT(6SAZ07,F4RC5I#C=DF86DKICF&3E,>S4BX%9_8<>-E$&*
M\(Z<+'%9Y)4IPN@FF<1,HK'KI@/^YSF-G[IENB3(6[L%?N+KN!M8W$ZNC&G*
M3VF,T [VD?-*^1?WX^@]GL_,Q=5]J0-BP&5G,=[$QM&07K@7B5K0*-CNFA[G
M 4#9V/I^E:!FWUEA?/I:W7J#TO,.5>?>?ZIC3CYE#DC*T_T]<%67'T?1^:=L
MXD)X>R-8\M\L&#2[Q+B$N-9:R]@GE:VP$[DI5%4"0J1#B)#E+HBX[#U5>3'T
M^PG5^,]!MG+*;H7 ;B=R*R!<G/&K-MVMO**Z9@C;/'?*$:KC"495SC/-6=MB
MJ9?&GK$E8&(3,@DV38':-'3LQ%YSKGWU'H;'GKIVVMYVQ!7(;CA&GE,.-%\8
MW\MWQ6P=\/L-9A8,JO*!E@T/%3S"O65P=V9PQ>HFN:R[XA",!+&E(KV<B.?G
M-S"=II_'NDXWJ>9\_5KB83D_D.8QUQHY$Y,I^29*Q7RWT_%N&JG6J%>Y6=PV
MXM:5"D22=RL$I-L6+PR!D(IPF=8C<BEYQXY.<E.0'*O-5"7I6,\68-P%&X5-
M;8*TQUQE>0$Q:LW\=*7EU"I+&;S<52*4.-[%9U&T@Z4;RJDF0GEDVS(Z0O%R
M+))HB:(FB)HB:(FB)HB:(FB)HBZ^5B8J=C7T-.1D?,P\FV59245*LVTC&R#-
M<HD7:/F+Q-9J[;+$$0.FH4Q3 .PAKI)''-&8IFM?$X4((!!'<0="/6JJRO;S
M&W<=_CII8+Z%X?')&YS)&.&H<Q[2'-<#J""".PJ&JO$^QXK<+R_$?*;_  \@
M=4[M?#=N9NL@\?Y)8YO%51C:J[D&ECQL+I3?N/79%JU)O_N,^VPQ8[<GQSC+
MMJX-JVM?(>#);'U,)#HJ]\3@/R2L[LZT8G><3;+K=AH\[*&AHREL]MEFF :
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M.HEFD[LSQDW<JNTFI^T"FW[@VZCJ]XO 9'+P27-IY(@B<UKG22,C +@2!5Y
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M,I ,)S.G<_'MVY2 7WNX5E"[;==6"U:Y]U$QGMF5@'K+@ LNYZ>&UP-_<W!
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M1WK!E]TOV9TUZW;".R+:XM#?SY=EP#=WEPV5L6/+XP67$\K1RN)(+0#7B=%
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MO/(5YY'UT%'$8Q2DQ/*GV<JD78SF59R0K7*BO\?_ % %%N&%&RAP[DJ3R Y
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M/G)/I\22;./C(F4N%(R76<$UJ0O_ )LQI!"!M,2G@MJY:MP1=M/'>F\0#D2
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MOXWF_#\CY?X!TW\CX'7P=$60ZS?T>WYFB_./Y._SB>'1O#^9OHQ^8_;ST?\
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D:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tv506394_img04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv506394_img04.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ XP"8 P$1  (1 0,1 ?_$ -D  0 " @(# 0$
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M6MALV9.<DT]E2&'#$,P;SYTPX8AF# '#$,P8 X8AF# '#$,P8#$K^@? >^&
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MQ&3.6 ;$9,Y8!L1DSE@&QR#BXRS]KP+0=)9GN1U:WO04;NV\6$X"F@-8">/
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M&I#*T @'"22'!LEOI*R53";DWHL6^D[-R5G6=;4I$DY=$S$5:DFB A2%Q1"
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M 8 P!@(LKC]#-5OT>7P]X9Y@,>W9_H&IC^3</VW-L!.C & , 8 P!@# & ,
M8 P!@# & , 8 P$65Q^AFJWZ/+X>\,\P'4RC?PP\5]S/<WZR?N?[D_L3X&>(
MOX+;'PN9U?<3X6?&;P![]3P[]D.\U@<P$F?'[[77W:F ?'[[77W:F ?'[[77
MW:F ?'[[77W:F ?'[[77W:F ?'[[77W:F ?'[[77W:F ?'[[77W:F ?'[[77
MW:F ?'[[77W:F ?'[[77W:F ?'[[77W:F ?'[[77W:F ?'[[77W:F ?'[[77
MW:F ?'[[77W:F ?'[[77W:F P:IWPT\7-^_#?K0>!_!&\'A7PD\0/P?\']S)
9G;>[?N!_+ON5J/\ "/ OV5LM;9=VY@/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tv506394_img06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv506394_img06.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ Y0#; P$1  (1 0,1 ?_$ ,$   $$ @,!
M      < !@@)! 4" PH! 0 !!0$! 0$              @,$!08!!P@)$  "
M 0,# P$&! ,%!04##0 ! @,1! 4 (08Q$@<305%A(A0(<8$R%9$6":&QP5(C
MT>%",Q?Q8D,D&%,T5/!R@F-S)35%)C9&6!D1  $# @0$! ,&!0(& @,   $
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M44 :;>0<EJXHVQ1")H  Y)K%10[#H?9\/PTT7!N:42!FL1U/7:E/\= ((J$
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MKAC\'8JQK7U<"M#*YJ5KTJ#TI^6GV^X>:$U,W012?'<_E0:DKC_:4 N42_J
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MT[#*16C,@8GWZGQ&"U:61"@XJB[FC=NY8\&L\3JMX4/.@P* 7G*UO+*[FO\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tv506394_img07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv506394_img07.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ *P!L P$1  (1 0,1 ?_$ ,L   (#  ,
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M95[#MB-/HG$A*'##0A24$ZE*, 7JB[QVWG4R]:;2U$PVB(X1[Y)B4CG!(&L
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M 'T<P$]%SII+:XQ(/20JX1B-.KU:RK5O5TVXIR5:<P+;)Q)PW=)!-Z;CB$(
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MZQ-N =%+;0,2 (A"$]% )4M<2I1@4U,US.]4&R;Q%-R4B.S:2=)4H\NLF\Z
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%?_1M_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
